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  SUMMARY XI
Summary
Heterotrophic marine bacteria are challenged by versatile and dynamic nutrient conditions, 
which fluctuate seasonally, as a result of bloom and collapse of algae populations. Due to such 
conditions, the Roseobacter clade is one of the most abundant and metabolically active bacteria 
clades in marine environments. 
In this thesis, mainly GC-MS-based metabolomic analyses were applied to study how the 
metabolism of Phaeobacter inhibens DSM 17395 is adapted to the nutrient conditions in marine 
habitats. Collected data were statistically evaluated and interpreted in the context of collaborative 
performed complementary analyses.
Phenotypic microarray analysis revealed a broad substrate range for carbon and nitrogen 
sources. Accordingly, cultivation in complex medium led to depletion of most of the provided 
substrates. Under these cultivation conditions, high abundance of catabolic enzymes and the 
corresponding intermediates were observed, which revealed simultaneous utilisation of different 
substrates, especially amino acids. To analyse their utilisation in a detailed study, a defined 
casamino acid medium was used for a time-dynamic resolution. Although different amino acids 
were utilised simultaneously, a specific uptake preference was observed. Further, even though 
sufficient amino acids were still available, cells entered stationary phase. In contrast to this, strains 
cured from the 262 kbp plasmid showed enhanced growth. Thus, either regulatory factors or the 
tropodithietic acid biosynthesis, which are encoded on this plasmid, are responsible for growth  
inhibition.
Based on the original genome annotation, some amino acid (Phe, Lys, His, Met, Leu, Ile, Val,  
Thr and Trp) and carbohydrate degradation pathways (N-acetyl-glucosamine, mannitol, sucrose and 
xylose) remained unclear. Metabolomic and proteomic analyses, which were conducted in this 
study, allowed reconstruction of these pathways. Further, these analyses showed that P. inhibens 
DSM 17395 is well adapted to catabolise efficiently single substrates. But replenishment of the 
TCA cycle for anabolism lacked efficiency, because of usage of the complex ethylmalonyl-CoA 
pathway. This pathway is widely distributed in the Roseobacter clade and could completely be 
reconstructed by proteomic and LC-MS-based coenzyme A analysis. 
Overall, this thesis revealed many new metabolic features, which explain the adaptation of 
P. inhibens DSM 17395 to marine habitats and improve our understanding of marine bacteria.
XII   ZUSAMMENFASSUNG
Zusammenfassung
Heterotrophe Meeresbakterien müssen vielseitige und dynamische Nährstoffbedingungen 
bewältigen, die jahreszeitlichen Veränderungen unterliegen, infolge von Blühen und Zusammen-
bruch von Algenpopulationen. Aufgrund solcher Bedingungen ist die Roseobacter Klade eine der 
zahlreichsten  und metabolisch aktivsten Bakteriengruppen im Meer.
In dieser Arbeit wurde hauptsächlich mittels GC-MS-basierten Metabolomanalysen untersucht, 
wie der Stoffwechsel von Phaeobacter inhibens DSM 17395 an Nährstoffbedingungen in marinen 
Lebensräumen angepasst ist. Die erhaltenen Daten wurden statistisch ausgewertet und im Kontext  
von kollaborativ durchgeführten ergänzenden Analysen interpretiert.
Mittels phänotypischer Microarray Analysen wurde ein breites Substrat Spektrum für 
Kohlenstoff- und Stickstoffquellen festgestellt. Daher führte die Kultivierung im Komplexmedium 
auch zum Verbrauch der meisten Substrate. Die Fülle an detektierten katabolischen Enzymen und 
entsprechenden Intermediaten unter diesen Bedingungen zeigte eine gleichzeitige Verwertung 
verschiedener Substrate, insbesondere von Aminosäuren. Um deren Verwertung genauer zu 
untersuchen, wurde ein definiertes Medium mit Casaminosäuren für eine Zeit-dynamische 
Auflösung verwendet. Obwohl verschiedene Aminosäuren gleichzeitig verwendet wurden, wurde 
eine spezifische Aufnahmepräferenz beobachtet. Trotz noch ausreichend verfügbaren Aminosäuren, 
traten die Zellen in die stationäre Phase ein. Im Gegensatz dazu wurde bei Stämmen, denen das 262 
kbp Plasmid entfernt wurde, erhöhtes Wachstum festgestellt. Daher sind entweder regulatorische 
Faktoren oder die Biosynthese der Tropodithiensäure, die auf diesem Plasmid kodiert sind, 
verantwortlich für die Wachstumshemmung.
Basierend auf der Original Genomannotation, blieben einige Aminosäure- (Phe, Lys, His, Met, 
Leu, Ile, Val, Thr und Trp) und Kohlenhydratabbauwege (N-acetyl-glucosamin, Mannitol, Sucrose 
und Xylose) unklar. Mithilfe von metabolomischen und proteomischen Analysen konnten diese 
Abbauwege rekonstruiert werden. Weiterhin konnte dabei gezeigt werden, dass P. inhibens DSM 
17395 gut angepasst ist um individuelle Substrate effizient abzubauen. Allerdings wurde der 
Citratzyklus für anabolische Zwecke nicht effizient nachgefüllt, wegen der Verwendung des 
aufwendigen Ethylmalonyl-CoA Stoffwechselwegs. Dieser Stoffwechselweg ist weitverbreitet in 
der Roseobacter Klade und konnte durch proteomische und LC-MS basierte Coenzym A Analysen 
rekonstruiert werden. 
Insgesamt wurden in dieser Arbeit viele neue metabolische Besonderheiten aufgedeckt, die die  
Anpassung von P. inhibens DSM 17395 an marine Lebensräume erklären und unser Verständnis 
von Meeresbakterien erweitern.
1  INTRODUCTION 1
1 Introduction
1.1 Marine environment as habitat (for bacteria)
The marine environment is the largest and one of the most important ecosystems on 
earth; it comprises an area of about 3.6 × 108 km2, which corresponds to more than ⅔ of 
earth's surface and 97% of available water on earth. Therefore, it contributes to global 
climate and plays an important role as source for human nutrition. Presently, 239000 
different species are known inhabiting this ecosystem; amongst these are 208000 animals, 
7600 plants, 1000 different fungi and 1700 bacterial species. Their absolute number, 
especially for bacteria species, is considerably underestimated (Appeltans et al., 2012). 
Current estimations assume about 3.6 × 1029 bacterial cells, inhabiting all kinds of different 
marine environments (Whitman et al., 1998). 
These habitats are differentiated first by their distance to coastal regions, second by 
vertical axis (i.e. sea layers), and third by latitude (e.g. tropic, temperate or polar regions). 
This results in extreme differences, in regard to temperature, light, pressure, pH, nutrient 
content and concentration of essential trace elements. However; bacteria are quite adaptive 
and thus have specialised to the various marine environments. Marine microbial 
communities are very diverse and complex, showing regional diversity and seasonal 
dynamics in their composition (Ladau et al., 2013; Sintes et al., 2013; Sogin et al., 2006). 
Due to high numbers and metabolic activity, marine bacteria contribute to the conversion 
of dissolved organic matter, and play a major ecological role. Further, secondary 
metabolites produced by marine bacteria are of particular interest, e.g. as antibiotics or 
functional foods (Dewapriya and Kim, 2014; Eom et al., 2013; Imhoff et al., 2011). Marine 
bacteria are also regarded as potential candidates for bioremediation, because of their 
genetic versatility and adaptivity (Dash et al., 2013). 
1.1.1 Characteristics of seawater
Seawater comprises high varieties of physical and chemical parameters, which can be 
challenging for bacteria. One of the main difficulties for bacteria is the high salinity of 
seawater, which is in average about 3.5% (w/v), with major regional and monthly 
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variations on the surface (Maes and O’Kane, 2014; Reul et al., 2014; Subrahmanyam et al., 
2013). As protection against osmotic stress, bacteria either accumulate ions (e.g. potassium 
ions) or compatible solutes, including distinct amino acids (especially glutamate or 
alanine), sugars (e.g. trehalose), or carboxylates (e.g. ectoine) (Costa et al., 1998). These 
compatible solutes can interact with protein surfaces and stabilise them. However, such 
mechanisms are extremely energy-demanding (Vauclare et al., 2014). Seawater is slightly 
alkaline, with a pH range from about 7.7 to 8.6, in average about 8 in the upper sea layer (0 
to 15 m depth). Still, pH can fluctuate daily up to 0.1, and even up to 0.5 in a larger time 
scale (Duarte et al., 2013). The solubility of organic and inorganic compounds, including 
trace elements, is influenced by salinity, pH and temperature and thus affects directly the 
primary production, which is limited to the euphotic zone, i.e. the upper 200 m of the water 
column. Beneath that zone, light for photosynthesis is not available. 
The three most important elements for primary production are nitrogen, phosphor and 
iron. In oceans, gaseous N2 is fixed by selected heterotrophic bacteria, or cyanobacteria, 
especially by cyanobacterium Trichodesmium spp. (Karl et al., 1997). The resulting 
product, nitrate (NO3-) is the main inorganic nitrogen source for phytoplankton and 
bacterioplankton in upper sea layers, whereas ammonium (NH4+) is strongly limited and 
more abundant in deep sea layers; the nitrogen cycle in the ocean is simplified in figure 1. 
Figure 1: Overview of the oceanic nitrogen cycle. Bold arrows represent mixing of water 
columns. Nitrogen fixation is mainly limited by low phosphor and iron concentrations; the primary 
production is limited by nitrogen and iron. Figure was adapted from Gruber and Galloway (2008).
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The overall N:P molar ratio for organic matter production in algae is about 16:1 (Karl et  
al., 1997), indicating higher relevance of nitrogen. But, as phosphor cannot be fixed from 
atmosphere sources and enters the ocean mainly by rivers, oceanic phosphor 
concentrations are significantly lower than nitrogen and thus are strongly limited (Tyrrell, 
1999). As Mills et al. (2004) have shown, primary productivity is nitrogen limited; 
whereas N2-fixation is co-limited by iron and phosphor. Iron as a key element for many 
molecular processes is essential for phytoplankton growth and production of biomass, 
serving as carbon source for heterotrophs (Sunda and Huntsman, 1997). Photosynthesis is 
only possible in the euphotic zone. This is why this zone is inhabited by cyanobacteria and 
algae and is generally rich in nutrients. Organisms inhabiting deeper sea layers have to 
generate energy from dead cell material, that sank from upper sea layers, and have to 
sustain higher pressure. 
Further, bacterial growth is dependent on temperature (Apple et al., 2006; Kirchman et  
al., 2009; Nedwell, 1999). In most cases, there is a positive correlation between 
temperature and bacterial growth. However, also factors like substrate availability have an 
influence on bacterial growth. Especially the uptake of inorganic compounds is dependent 
on temperature. For instance, there is a strongly reduced uptake of nitrate at lower 
temperatures in algae and bacteria, resulting in a preference for ammonium, despite lower 
concentrations of ammonium compared to nitrate (Reay et al., 1999). 
1.1.2 Dissolved organic matter
Besides chemical and physical conditions of seawater, heterotrophic marine bacteria are 
mainly challenged by complex and changing nutrient conditions. Although sometimes high 
amounts of dissolved organic matter (DOM) are available, its utilisation is difficult because 
of chemical diversity, low concentration of individual compounds and seasonal  
fluctuations during bloom and collapse of algae populations. DOM represents a major pool 
of organic matter in the oceanic and global carbon cycle, which is summarised in figure 2. 
The amount of marine DOM of (at least) 700 × 101 5 g carbon corresponds roughly to the 
amount of atmospheric CO2, which is 750 × 1015 g carbon (Koch et al., 2005). It comprises 
a broad variety of molecules, ranging from simple amino acids, lipids and sugars to larger 
polysaccharides, proteins and complex polymers. Due to the complexity of DOM, its 
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molecular structure currently remains unclear, as established molecular approaches for 
characterisation only target operationally-defined subunits (Dittmar and Paeng, 2009). The 
molecular size comprises a broad range from 100 to 100 000 Da, mostly smaller than 
2000 Da. This corresponds to a broad variability of chemical characteristics, already in 
respect to potential molecular elemental composition. 
Although only a small fraction (< 5%) of marine DOM is considered to be terrestrial 
origin, which can be provided by rivers at estuaries, comparison of marine DOM with 
terrestrial DOM showed large similarity regarding molecular elemental composition (Koch 
et al., 2005). Most of marine DOM is produced by photosynthetic plankton in the euphotic 
zone of the ocean and is either released actively or via natural decay after death, before it 
can serve as source for carbon, nitrogen and phosphor (Hansell et al., 2009; Nebbioso and 
Piccolo, 2013). Within hours or days, released DOM can be converted by bacteria, whereas 
a small fraction remains non-degraded. It is unclear whether this refractory DOM is formed 
within months or whether it is comprised by released fossil compounds. Extreme 
conditions in the deep sea, such as geothermal heat and elevated pressure might catalyse 
Figure 2: Overview of the global carbon cycle. Movement of carbon is represented by arrows; 
yellow numbers are natural fluxes, red are human impact and white numbers indicate stored  
carbon, readings in gigatons (= 109 t = 1015 g) per year. Source of this figure: National Aeronautics 
and Space Administration (NASA): http://earthobservatory.nasa.gov/Features/CarbonCycle/
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chemical reactions that result in the formation of polycyclic aromatic compounds resistant 
to biodegradation (Dittmar and Paeng, 2009). 
1.1.3 Seasonal and regional variations of dissolved organic matter
Both oceanic streams and transportation of organic matter by organisms contribute to 
horizontal and vertical distribution of dissolved organic matter (DOM) within the ocean. 
Generally, warmer regions (e.g. the Mediterranean Sea or tropic regions) comprise higher 
concentrations of about 70 to 80 µM dissolved organic carbon, compared to polar regions 
with about 40 to 50 µM dissolved organic carbon (Hansell et al., 2009). Quantitative data 
in publications of the last decade differ, depending on sampling time, sampling location, 
sampling method and analytical approaches (Pettine et al., 2001).
Higher temperatures in summer favour growth of phytoplankton, resulting in seasonal 
algae blooms that can be observed in coastal and oceanic regions. Thus, DOM 
concentration fluctuates with the seasons, reaching higher concentrations in summer than 
in winter. Furthermore, the composition of DOM may also change, even during an algae 
bloom, as shown e.g. by Ittekkot (1982). The concentration of dissolved sugars remained 
relatively constant during bloom, about 320 to 410 µg/l, whereas concentration of 
dissolved amino acids decreased from 350 µg/l in the early stages of bloom, to less than 
150 µg/l towards the end of bloom (Ittekkot, 1982). However; the higher amount of DOM 
in the summer is not only a result of algae bloom. Especially in coastal regions there is a 
higher input of organic compounds through rivers. Further, inability of bacteria to consume 
all of the produced compounds keeps the amount of DOM temporarily on those high levels 
(Pettine et al., 1999, 2001). 
The most abundant small compounds utilisable by bacteria are carbohydrates and amino 
acids, in which the concentrations of carbohydrates are 10 to 20-fold higher than those of 
amino acids. Most dominant during algae blooms are glucose, fructose, galactose, mannose 
and xylose, plus particular amino acids, like glutamate, serine, glycine, histidine, aspartate, 
threonine and lysine (Ittekkot, 1982; Pettine et al., 1999). However, as Sarmento et al. 
(2013) have shown, the released amino acids differ strongly depending on algae species. 
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1.2 The Roseobacter clade and Phaeobacter inhibens
1.2.1 The Roseobacter clade
The marine ecosystem comprises many different bacterial clades, some which only 
inhabit very specific environments, others which are more globally distributed, like 
Cyanobacteria, Planctobacteria, marine Actinobacteria, Bacteroidetes and Proteobacteria 
(Giovannoni and Stingl, 2005). Amongst the latter, the Roseobacter clade, which comprises 
a high variability of physiologically diverse isolates (Brinkhoff et al., 2008), is one of the 
most abundant and worldwide distributed heterotrophic bacterial groups. Its members are 
classified as Alphaproteobacteria, belonging to the family of Rhodobacteraceae and were 
first described by Shiba in 1991. The name Roseobacter refers to the pink photosynthesis 
carotenoids of the first isolates of this clade.
Members of the Roseobacter clade are physiologically versatile, inhabiting a broad 
range of marine environments. Besides coastal regions, members of the Roseobacter clade 
could be isolated from temperate and polar regions, sediments, macroalgae and 
invertebrates (Wagner-Döbler and Biebl, 2006; Brinkhoff et al., 2008). This also correlates 
to the metabolic versatility of the Roseobacter clade, comprising denitrifying species, like 
Roseobacter denitrificans, or strains which can produce bacteriochlorophyl α, like 
Dinoroseobacter shibae and Janaschia spp. This bacteriochlorophyl capacitates to perform 
aerobic anoxygenic photosynthesis, which produces energy without synthesis of organic 
carbon, and thus can be useful in case of nutrient shortage. Others, e.g. Oceanibulbus  
indolifex or Phaeobacter spp. produce antibiotics (Wagner-Döbler et al., 2004; Brinkhoff 
et al., 2004). Other important compounds, produced by many members of the Roseobacter 
clade, are acylated homoserine lactones, which function as quorum sensing molecules and 
regulate many metabolic processes (Neumann et al., 2013; Patzelt et al., 2013; Zan et al., 
2014). Many of these metabolic features of the Roseobacter clade are encoded by genes 
located on extrachromosomal elements. Most members of the Roseobacter possess several 
plasmids, up to 12 different, as in case of Marinovum algicola DG 898 (Pradella et al., 
2010). As these plasmids contain ecologically relevant genes and can be transferred via 
horizontal gene-transfer, they might be a reason for the ecological and evolutionary success 
of the Roseobacter clade (Petersen et al., 2013). 
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Despite their global distribution, members of the Roseobacter clade are not the only 
dominant and omnipresent bacterial groups in marine environments, but rather dominate 
distinct, but ecologically relevant niches. They are the most common primary surface-
colonising bacterial group in temperate coastal waters. Potential surfaces range from 
stones or particles to algae, invertebrates or even animals. Surface colonisation can be 
beneficial, e.g. as a protection against adverse environments, or to enhance metabolic 
cooperation under nutrient-rich conditions, or to facilitate horizontal gene transfer (Dang et  
al., 2007). 
In regard to surface-colonisation, many members of the Roseobacter clade were isolated 
from algae, like D. shibae from Prorocentrum lima (Biebl et al., 2005) or P. inhibens 2.10 
from Ulva australis (Martens et al., 2006). This indicates symbiotic lifestyle between 
members of the Roseobacter clade and phytoplankton, as described by Geng and Belas 
(2010a) and Seyedsayamdost et al. (2011). As a matter of fact, many microalgae cannot 
grow normally without bacterial symbionts; therefore bacterial colonisation might be 
beneficial, in which cases these symbiotic mechanism are not well understood. Antibiotics 
produced by members of the Roseobacter clade, e.g. tropodithietic acid, can suppress 
growth of potential parasites and produced auxins might enhance growth. In return, algae 
provide nutrients or vitamins (Rao et al., 2007). Observations that the Roseobacter clade is 
the unique predominant subgroup in the decay-phytoplankton bloom period (Liu et al., 
2013) underlines this assumption. Furthermore, Alonso-Sáez and coworkers (2007) 
showed that the Roseobacter clade is not only one of the most abundant bacterial clade 
upon seasonal collapse of algae blooms, but also one of the most active (Alonso-Sáez et  
al., 2007; Alonso-Sáez and Gasol, 2007). A possible explanation for these observations, 
could be the metabolic and nutritional versatility of the Roseobacter clade, which favours 
growth under nutrient-rich conditions, like seasonal bloom periods of phytoplankton. Thus, 
this clade also contributes strongly to conversion of organic matter and to the marine 
carbon cycle. Particular members of the Roseobacter clade, e.g. Silicibacter pomeroyi 
might also play an important role for sulfur cycling in the ocean by degrading the algal 
osmolyte 3-dimethylsulfoniopropanoate, yielding dimethylsulfide and other carbon and 
sulfur compounds (Wagner-Döbler and Biebl, 2006).  
The number of isolates and sequenced genomes of the Roseobacter clade is 
continuously growing, due to simple cultivation in the laboratory and due to their 
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ecological relevance. Currently, the Roseobacter clade comprises at least 54 described 
genera and 135 species reflecting physiological and genetic diversity of this bacterial clade 
(Breider et al., 2014).
1.2.2 The genus Phaeobacter and the strain P. inhibens DSM 17395
Presently, the genus Phaeobacter comprises six species, which were isolated from 
different marine environments (Table 1). The first Phaeobacter strain was isolated 1998 
from larval of the scallop Pecten maximus, in Galicia, Spain, and was first named 
Roseobacter gallaeciensis (Ruiz-Ponte et al., 1998), which was 2006 reclassified as 
Phaeobacter gallaeciensis BS107 (Martens et al., 2006). The name Phaeobacter was given 
because of the brown pigmentation, which is true for all Phaeobacter, except for 
P. caeruleus, which is blue pigmented (Vandecandelaere et al., 2009). However this 
clustering is ambiguous, as shown recently through the analysis of genome-scale data and 
phenotypic characteristics. For this reason it was suggested that only P. inhibens and 
P. gallaeciensis compose the Phaeobacter cluster, and the others should be regrouped 
(Breider et al., 2014). 
Table 1: Available Phaeobacter isolates (as listed by the DSMZ).
Species Comments References
P. arcticus 
DSM 23566
From marine sediment, Arctic ocean. (Zhang et al., 2008)
P. caeruleus 
DSM 24564
From marine biofilm on stainless steel electrode, Italy, 
Genoa harbour. Bacteria form blue pigmented colonies.
(Vandecandelaere et al., 
2009)
P. daeponensis 
DSM 23529
From tidal flat sediment, Korea, Daepo Beach. (Vandecandelaere et al., 
2008; Yoon et al., 2007)
P. gallaeciensis 
DSM 26640 
(= CIP 105210)
From larval cultures of scallop Pecten maximus, Spain, 
Galicia. Deposited as P. gallaeciensis BS107.
(Martens et al., 2006; 
Ruiz-Ponte et al., 1998)
P. inhibens 
DSM 16374
From German Wadden Sea. Deposited as P. inhibens T5. (Martens et al., 2006)
P. inhibens 
DSM 17395
Alleged type strains, deposited as CIP 105210 and 
DSM 17395 are not identical.
(Martens et al., 2006; 
Buddruhs et al., 2013)
P. inhibens 
DSM 24588
From surface of green macroalga Ulva australis. 
Originally deposited as P. gallaeciensis 2.10.
(Martens et al., 2006; 
Buddruhs et al., 2013)
P. leonis 
DSM 25627
From marine sediment beneath the sea floor, France, 
Mediterranean Sea, Gulf of Lions.
(Gaboyer et al., 2013)
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Phaeobacter species are strictly aerobic and chemoheterotrophic bacteria that form 
ovoid rods and are motile by means of polar flagella. Generally, growth conditions of this 
genus comprise an NaCl concentration range from 0.01 to 1.5 M, a pH range from 6.0 to 
9.5, and a temperature range from 4 to 37 °C. Although Phaeobacter is nitrate reductase, 
amylase, tweenase and gelatinase negative, it employs a broad range of substrates, ranging 
from amino acids, sugars and disaccharides to carboxylates (Martens et al., 2006).
The strain used in this study, P. inhibens DSM 17395, was originally deposited as 
P. gallaeciensis DSM 17395, which should correspond to the P. gallaeciensis strain BS107 
(= CIP 105210), as described by Ruiz-Ponte et al. (1998) and Martens et al. (2006). As 
recently shown, the alleged identical type strains are not identical in respect to genetic and 
phenotypic analyses. Whereas the type strain CIP 105210 corresponds most likely to the 
original P. gallaeciensis type strain BS107; strain DSM 17395 is closer related to 
P. inhibens DSM 16374 and was thus reallocated to the species P. inhibens (Buddruhs et  
al., 2013). 
The genome of P. inhibens DSM 17395 comprises a 3.8 million basepairs (bp) long 
chromosome and three plasmids of the size 65 kbp, 78 kbp and 262 kbp. The largest 
plasmid contains important genes required for biosynthesis of the antimicrobial compound 
tropodithietic acid. This antibiotic inhibits growth of competitors, especially the fish 
pathogen Vibrio spp. (D’Alvise et al., 2012; 2013), but showed also strong antibacterial 
effect on human pathogens, e.g. Staphylococcus aureus (Porsby et al., 2011). Biosynthesis 
of tropodithietic acid is regulated by quorum-sensing and co-occurs with formation of the 
brown pigment (Berger et al., 2011).  
First metabolomic and proteomic analyses of P. inhibens DSM 17395 were conducted 
2009, using glucose-containing minimal medium and a time-course experiment setup 
(Zech et al., 2009). These analyses revealed that abundance of enzymes and metabolites of 
the central metabolism remained relatively constant upon entry into the stationary growth 
phase, contrary to model organisms like Escherichia coli and Bacillus subtilis. The authors 
stated that this “stand-by” operation is more beneficial than energy-consuming adaptation 
of proteome accessory, as cells can utilise newly provided substrates faster without 
requiring a lag-phase. 
Another characteristic of P. inhibens and other members of the Roseobacter clade is the 
absence of the phosphofructokinase. Thus, glucose is not degraded via Embden-Meyerhof-
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Parnas pathway (also known as glycolysis), but via the phosphorylative Entner-Doudoroff 
pathway. This was verified for P. inhibens DSM 17395 and D. shibae DFL 12T (= DSM 
16493T) by flux analysis using isotopic labelled [1-13C] glucose (Fürch et al., 2009). 
1.3 Systems biology
Systems biology intends to study the whole structure, composition and dynamics of a 
biological system, in this case a bacterial cell. As cellular processes are strongly 
interconnected, several “omics-approaches”, like genomics, transcriptomics, proteomics 
and metabolomics are combined to improve the understanding of the nature of a cell. In 
addition to quantitative experimentations, mathematical simulation and modelling in an 
iterative process are included. This allows to draw and test new hypotheses and improve 
the understanding of the investigated system (Kell, 2004). 
An overview of the output obtained by the 
“omics-approaches” is shown in figure 3. 
Precise and reliable genome information that 
provide the potentials and limitations of an 
organisms to distinct treatment, are the basis 
of the systems biological approach and 
essential for data interpretation. Consecutive 
“omics-analyses” reveal the actual responses, 
such as transcription of particular genes, 
which can be detected within minutes or a 
few hours after treatment. An overview about 
the methods applied in transcriptomics, from 
RNA ext rac t ion to sequenc ing and 
consecutive data analysis is provided e.g. by 
Sorek and Cossart (2010). Both transcript-
omic and subsequent proteomic analyses 
benefit from the uniform chemistry of their 
analytes, capacitates to cover almost the 
whole transcriptome and proteome. 
Figure 3: The "Omics" cascade of systems 
biological approaches. I t c o m p r i s e s 
complex datasets that, if integrated, enables 
an entire description of a cell's response to 
the tested treatment. Amongst these, the 
metabolome is the most predictive. This 
figure was adapted from Dettmer et al. 
(2007).
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Conducting proteomic analyses automatically takes into account the regulation at 
posttranscriptional and posttranslational level. The complexity of the proteome requires at 
least one preliminary separation step, which is often performed by one- or two-dimensional 
gel-electrophoresis. Proteins are typically digested, preferably by sequence-specific 
enzymes, yielding peptides, i.e. low molecular weight molecules that are easier to be 
separated and analysed by liquid chromatography – mass spectrometry (LC-MS) than an 
intact protein (Cox and Mann, 2011). Further methods, principal quantitative approaches 
and recent advances in mass spectrometry on the field of proteomics are provided e.g. by 
Bantscheff et al., 2012; Righetti et al., 2004. 
The metabolome, the final level of the “Omics” cascade, amplifies changes in the 
proteome (Kell, 2006). It is not only closest to phenotype and therefore most predictive to 
phenotype, but also the most dynamic, which responds to a treatment within seconds, i.e. 
even before any gene-regulatory mechanisms are applied. Further, it comprises the highest 
versatility of analytes, in regard to chemical characteristics and concentration ranges 
(Dettmer et al., 2007). 
This study investigates the impact of nutrient compositions on the metabolism of 
P. inhibens DSM 17395 by applying mainly metabolomic analyses, which is described in 
detail in the following section.
1.4 Metabolomic analyses
1.4.1 Introduction to Metabolomics
The overall aim of metabolomic analyses is to obtain a qualitative and quantitative 
overview of the whole metabolome by analysing all metabolic intermediates in a given 
scenario, which is challenging due to the complexity and diversity of analytes. 
Metabolomic approaches were first conducted in plant research, as the plant kingdom 
provides a high variety of secondary metabolites, which is estimated to be around 200 000 
different metabolite species (Hall, 2006; Weckwerth, 2003). So far, organisms studied via 
metabolomic analyses comprise microorganisms up to tissues of animals and humans. It 
must be noted that none of these studies really cover the whole metabolome. Instead, 
metabolic profiling is performed, which refers to the quantitative analysis of selected 
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metabolites, e.g. in the context of a distinct pathway or specific class of compounds. 
However, applying different methods allows to cover a broader range of metabolites and 
therefore fits better to the concept of an “omics-technique”. Another possibility reducing 
complexity of the metabolome often used is metabolic fingerprinting, which intends not to 
identify each metabolite but rather to compare patterns (i.e. fingerprints) of metabolites 
that change in response to the treatment. In addition to that, the impact of the environment, 
i.e. imported or exported compounds in the medium, is often analysed, which is described 
by the term metabolic footprinting (Fiehn, 2002; Dettmer et al., 2007). Without compound 
identification, though, any metabolically interesting pattern remains meaningless.  
Identification requires high-resolution mass spectrometry, software and supportive 
databases (Scalbert et al., 2009). 
1.4.2  Sample preparation techniques for bacterial metabolomics
Sample acquisition is primarily driven by the experimental design and the experimental 
type. When sampling biological samples, special care has to be taken to minimise the 
formation or degradation of metabolites after sampling due to remaining enzymatic activity 
or oxidation processes. Therefore, the metabolism has to be stopped immediately. In case 
of plants or cell tissues, a quenching method for this purpose is easily applied using liquid 
nitrogen, whereas it is more complicated to stop metabolism when handling aqueous cell 
suspensions. 
As a matter of fact, cells have to be separated from the medium first, by centrifugation,  
(e.g. Börner et al., 2007) or filtration (e.g. Bolten et al., 2007), followed by washing of the 
obtained cell pellet. Alternatively it is also possible to mix the culture broth with a cold 
solvent, e.g. -40 °C methanol, to stop metabolism immediately without any prior 
separation step. (Bertini et al., 2013). Such quenching methods often result in loss of 
membrane integrity, i.e. leakage of cells, loss of metabolites and less reliable  
quantification. Significant loss of metabolites can also occur when washing solution with 
insufficient ionic strength is applied, especially in case of gram negative bacteria (Bolten 
et al., 2007). Once metabolism is stopped, an extraction procedure is conducted, which is 
mainly driven by the target metabolites. Most methods are based on liquid-liquid extraction 
or solid phase extraction and often include pre-concentration steps to improve detection of 
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low abundant metabolites. Matrixes like proteins or salts have to be removed, as these 
interfere with separation and ionisation (Dettmer et al., 2007).
1.4.3 Gas chromatography – mass spectrometry
Gas chromatography coupled to mass spectrometry (GC-MS) along with liquid 
chromatography – mass spectrometry (LC-MS) is one of the most commonly used analysis 
method in metabolomics. Volatile compounds can be analysed directly via headspace with 
a GC instrument. Less volatile compounds have to be derivatised first, and are then 
vaporised in an injector and separated via the column containing silicone as stationary 
phase, the mobile phase, which is an inert gas (e.g. helium) and a temperature gradient. 
To make compounds volatile, functional chemical groups are silylated, using common 
agents, like MSTFA (N-methyl-N-(trimethylsilyl)-trifluoro-acetamide) or BSTFA (N,O- 
bis(trimethylsilyl)-trifluoroacetamide). The derivatisation agents differ in regard to 
specificity and volatility of formed analytes. In case of MSTFA, which is applied in this 
study (Figure 4), modification targets are hydroxy-groups, carboxylates, amines, amides 
and thiols. Of these, carbohydrates have the highest specificity due to the high number of 
hydroxy-groups. Methoximation is usually applied prior to silylation (Figure 4A). This 
stabilises alpha-keto acids and keeps sugars in the open-ring conformation, slightly 
Figure 4: Conducted derivatisation reaction in this study. (A) First, aldehyde and keto-
functions are methoximated. This also keeps sugars in the open ring structure, reducing the number 
of formed sugar analytes. (B) Next, compounds are silylated, using N-methyl-N-(trimethylsilyl)-
trifluoro-acetamide (MSTFA). By silylation of target functions, compounds are thermally stabilised 
and become volatile. In most cases, silylation yields more than one analyte per metabolite.
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reducing the number of obtained derivatives per sugar species. 
Silylation is sensitive to moisture, thus samples and agents have to be completely free of 
water. Otherwise compounds can be degraded or derivatisation is less effective (Dettmer et  
al., 2007). Special care has to be taken for data analysis and data correction, as 
derivatisation yields several derivatives per compound. Those distribution patterns can or 
might probably not correlate to each other (Kanani and Klapa, 2007). Moreover, 
conversions caused by derivatisation, e.g. arginine to ornithine, have to be taken into 
account (Halket et al., 2005). 
The key advantages of GC-MS are high inter-instrument reproducibility and the 
standardised electron ionisation with an electron energy of 70 eV. Several open and 
commercial mass spectrometry libraries are available that allow easy and confident 
identification. GC provides an excellent chromatographic separation for complex samples, 
which can even be improved by GC × GC (Górecki et al., 2006) or alternatively by 
advanced TOF-MS spectrometer and improved data analysis to separate compounds 
computationally (Kell, 2004). Overall GC-MS provides high metabolite resolution, and 
quantification of metabolites, as well as reliable identification and can even be used for 
structural elucidation and annotation of unknown compounds (Strehmel et al., 2013). 
1.4.4 Liquid chromatography – mass spectrometry
Liquid chromatography (LC-MS) is another powerful analytical tool for separation and 
detection of metabolites. It is suitable for larger molecules, like the metabolic relevant 
coenzyme A intermediates, which cannot be analysed with GC-MS. By applying different 
columns, and elution buffers, a broad range of chemically different compounds can be 
analysed. These systems are often combined with electrospray ionisation (ESI), which 
vaporises the elute to fine drops that are then converted to gas. Small molecules 
(< 1000 Da) can be charged without degradation. Depending on the applied voltage either 
[M+H]+ or [M-H]- can be analysed, which broadens the range of detectable compounds. A 
disadvantage of LC-MS is the lack of standardisation, which complicates comparison of 
retention time, ionisation and mass spectra between instruments and laboratories. 
Confident and well applicable and universal LC-MS databases for compound identification 
are still missing, despite recent efforts, e.g. NIST or MassBank (Dettmer et al., 2007).
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1.5 Objectives
Marine bacteria have been subject of many recent studies and reviews, which focused 
mainly on genomic analyses and phylogenetic classifications. Due to the abundance, 
metabolic activity and contribution to the carbon cycle, bacteria play a major role for 
marine ecosystems. Amongst marine bacteria, the Roseobacter clade represents one of the 
most active and metabolic versatile bacterial clade. This study focuses on the  
characterisation of the metabolism of Phaeobacter inhibens DSM 17395 as model 
organism of the Roseobacter clade and of heterotrophic marine bacteria. Of particular 
interest in this study were metabolic abilities and limitations in regard to different nutrient 
conditions. 
First, substrate range for carbon and nitrogen sources were determined using phenotypic 
microarray analysis. Further, the standard repertoire of synthesised metabolites was defined 
using [U-13C] glucose. These analyses, along with the published genome sequence (Thole 
et al., 2012) formed the basis for consecutive detailed metabolomic and proteomic 
analyses. Combined “omics-experiments” were accomplished in close cooperation with the 
research group of Prof. Ralf Rabus (ICBM), who conducted cultivation and proteomic 
analyses, whereas I performed whole GC-MS-based metabolomic analyses, from sample 
preparation to data processing and detailed statistical analysis. Following six scenarios 
were studied: (1) Complex medium and glucose-containing minimal medium were used to 
mimic nutrient-rich conditions during an algae bloom, respectively nutrient poor 
conditions. (2) In a time-dynamic experiment, uptake and utilisation of casamino acids 
were investigated. (3) Influence of plasmids on growth and amino acid uptake were studied 
using selected plasmid-cured strains. (4) Single amino acids and (5) carbohydrates as 
single carbon sources were used to study and to refine complex catabolic networks, which 
remained unclear or incomplete in the original genome annotation. (6) Metabolic responses 
to limited ammonium content were studied over a whole growth curve.
Through theses experiments a general understanding of the metabolic properties of the 
bacterium was generated, which contributes to the understanding of its adaptation 
strategies and success of P. inhibens DSM 17395 in marine environments.
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2 Material and methods
Particular experiments were conducted in close cooperation with the research group of 
Prof. Ralf Rabus (Institute for Chemistry and Biology of the Marine Environment (ICBM) 
of the Carl von Ossietzky Universität Oldenburg, Department General and Molecular 
Microbiology), who conducted proteomic analyses, as well as cultivation and sampling for 
the main experiments. 
2.1 Equipment and instruments
All instrument used in this study are listed in table 2. Instruments present at the Institute 
for Chemistry and Biology of the Marine Environment are marked with ICBM.
Table 2: Equipment and instruments used in this study.
Equipment Manufacturer
GC-MS systems
(1) Leco
MPS 2 XL autosampler Gerstel (Mülheim a.d. Ruhr, Germany)
7890 Agilent GC Agilent (Santa Clara, USA)
Leco Pegasus 4D mass spectrometer Leco Instruments (Mönchengladbach, Germany)
(2) Jeol
MPS 2 Twister autosampler Gerstel (Mülheim a.d. Ruhr, Germany)
6890N Agilent GC Agilent (Santa Clara, USA)
Accu TOF GC JMS-T100GC JEOL (Germany) GmbH (Eching, Germany)
(3) DSQ II
Autosampler 3000 Thermo Fisher Scientific (Dreieich, Germany)
Thermo GC Ultra Thermo Fisher Scientific (Dreieich, Germany)
DSQII Thermo Fisher Scientific (Dreieich, Germany)
LC-MS system
Ultimate 3000 Dionex (München, Germany)
Bruker MicroQTOF II MS Bruker Daltonik (Bremen, Germany)
Equipment for proteomic analyses (ICBM)
Typhoon 9400 scanner GE Healthcare (München, Germany)
Proteineer spII and dp systems Bruker Daltonik (Bremen, Germany)
UltraflexIII MALDI-TOF/TOF MS Bruker Daltonik (Bremen, Germany)
Ultimate 3000 nanoLC Dionex (München, Germany)
AmaZon ETD Bruker Daltonik (Bremen, Germany)
Incubator
Certomat BS-1 (orbit:50 mm) Sartorius (Göttingen, Germany)
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Table 2: Equipment and instruments used in this study. (Continued)
Equipment Manufacturer
Incubator BD 53 Binder (Tuttlingen, Germany)
CH-4103 (ICBM) Infors AG (Bottmingen, Switzerland)
Bioreactor Labfors II (ICBM) Infors AG (Bottmingen, Switzerland)
Photometer
Genesys 6 spectrophotometer Thermo Fisher Scientific (Dreieich, Germany)
UV-Vis spectrophotometer UV-1800 (ICBM) Shimadzu (Duisburg, Germany)
UV 1240 mini (ICBM) Shimadzu (Duisburg, Germany)
Centrifuges
Centrifuge 5424 Eppendorf (Hamburg, Germany)
Centrifuge 5810R (rotors: F34-6-38, F45-30-11) Eppendorf (Hamburg, Germany)
Avanti J-E (rotors: JLA-10.500, JA-14) Beckman Coulter (Krefeld, Germany)
Vacuum Dryer
Speed Vac Concentrator 5301 Eppendorf (Hamburg, Germany)
CentriVap Centrifugal Labconco (Kansas City, USA)
Others
Autoclave Varioklav 25T and 135S H+P Labortechnik (Oberschleißheim, Germany)
Balance Discovery DV214C OHAUS (Gießen, Germany)
Incubator (80 °C) Melag Medizintechnik (Berlin, Germany)
Incubator ED400 Binder (Tuttlingen, Germany)
Microscope Axiostar (ICBM) Zeiss AG (Göttingen, Germany)
Microscope Axiostar plus Zeiss AG (Göttingen, Germany)
Microwave HMT 842C 1300W Bosch (Gerlingen-Schillerhöhe, Germany)
Mix Mate Eppendorf (Hamburg, Germany)
OmniLog-Incubator/Reader Biolog (Hayward, CA, USA)
Precellys24 homogenizer Peqlab (Erlangen, Germany)
Precision Balance Adventurer Pro AV2102C OHAUS (Gießen, Germany)
Sanyo MDF-U53V -86 °C Ewald Innovationstechnik (Nenndorf, Germany)
Sterile bench HERAsafe KS 12 and KS 18 Thermo Fisher Scientific (Dreieich, Germany)
Turbidimeter Biolog (Hayward, CA, USA)
Ultra pure water system Arium Sartorius (Göttingen, Germany)
Ultrasonic bath Sonorex Digitec DT 255 H Bandelin electronic (Berlin, Germany)
Vacuum pump Laboport SCC840 KNF Neuberger (Freiburg, Germany)
2.2 Consumables
Table 3: Consumables used in this study.
Material Manufacturer
GC-MS equipment
CIS 4 glass liner (71 × 1 mm), filled with 
silanized glass wool
Gerstel (Mülheim a.d. Ruhr, Germany)
Crimp glass vials and crimp caps Chromatographie Zubehör Trott (Kriftel, 
Germany)
DB-5MS (30 m × 0.25 mm × 0.25 μm) Agilent (Santa Clara, USA)
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Table 3: Consumables used in this study. (Continued)
Material Manufacturer
Glass vials with cap CS (Langerwehe, Germany)
Microinlets for glass vials CS (Langerwehe, Germany)
Silicon septae Chromacol (Welywyn Garden City, UK)
Syringes CS (Langerwehe, Germany),
Restek (Bad Homburg, Germany) or
Thermo Fisher Scientific (Dreieich, Germany)
Trace 2000 Liner (2 mm × 2.75 mm × 120 mm) Restek (Bad Homburg, Germany)
ZB-5MS + 5 m Guardian column (30 m ×  
0.25 mm inner diameter)
Phenomenex (Aschaffenburg, Germany)
Others
Cuvettes, Polystyrol, 1.5 ml Sarstedt (Nürnbrecht, Germany)
Erlenmeyer flasks with 3 or 4 baffles, 100, 300, 
500 and 1000 ml
W. O. Schmidt Laboratoriumsbedarf, 
(Braunschweig, Germany)
Glass beads, 70-110 µm Kuhmichel GmbH (Ratingen, Germany)
Phenotypic Microarrays: PM1, PM2A, PM3B AES Chemunex (Bruchsal, Germany)
Pipette tips, 10, 200, 1000, 1200, 5000, 10000 µl Eppendorf (Hamburg, Germany) or
Sarstedt (Nürnbrecht, Germany)
Polypropylen reaction tubes, 1.5 ml and 2 ml Eppendorf (Hamburg, Germany)
Polypropylen tubes, 15 ml, 50 ml Greiner Bio-One GmbH (Frickenhausen, 
Germany)
Precellys tubes, 2 ml and caps Peqlab (Erlangen, Germany)
Sterile filters, Filtropur 0.2 µm Sarstedt (Nürnbrecht, Germany)
2.3 Chemicals
If not indicated otherwise, chemicals and reagents of highest quality marked with the 
term “purest” or “for analytical purpose” were utilised. The substances were purchased 
from the manufacturers Carl Roth (Karlsruhe, Germany), CS GmbH (Langerwehe, 
Germany), Euriso-Top GmbH (Saarbrücken, Germany), Fisher Scientific (Schwerte, 
Germany) and Sigma-Aldrich (Steinheim, Germany). 
2.4 Organism
Table 4: Strains of Phaeobacter inhibens DSM 17395 used in this study. Strains were 
maintained in glycerol stocks at -80 °C.
Strain Description Reference
DSM 17395 Wild-type strain (Buddruhs et al., 2013), obtained from 
the DSMZ
Δ65kb DSM 17395, cured from 65 kbp plasmid J. Petersen (DSMZ)
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Table 4: Strains of Phaeobacter inhibens DSM 17395 used in this study. (Continued)
Strain Description Reference
Δ262kb DSM 17395, cured from 262 kbp plasmid J. Petersen (DSMZ)
Δ65kbΔ262kb DSM 17395, cured from 65 kbp and 
262 kbp plasmid
J. Petersen (DSMZ)
“M3” Natural isolate, which lacks the 262 kbp 
plasmid
(Petersen et al., 2011), provided 
by T. Brinkhoff (ICBM)
2.5 Media and supplements
All water-based media and solutions were prepared with salt-free, particle filtered and 
sterile filtered ultra pure water from an ultra pure water system (Arium, Sartorius). 
Autoclavation for sterilisation of media was conducted for 20 min at 121 °C and 1 bar 
overpressure. 
2.5.1 Salt water medium (minimal medium)
The media was essentially prepared as described previously (Zech et al., 2009) with 
some minor modifications. It consist of four components: Basic A (salt solution), Basic B 
(NaHCO3), 1 ml/l of a trace element stock solution (1000x) and a carbon source, which 
was provided as individual solution or was included to Basic A. The concentration of the 
corresponding stock solutions was adapted individually to meet the requirements of 
substrate solubility and final medium volume. Therefore only final concentrations of the 
respective compounds are provided here.
Basic A – final concentration in the medium:
Na2SO4 4.0 g/l
KH2PO4 0.2 g/l
NH4Cl 0.25 g/l
NaCl 20.0 g/l
MgCl2 × 6 H2O 3.0 g/l
KCl 0.5 g/l
CaCl2 × 2 H2O 0.15 g/l
Filled up with ultra pure water and autoclaved for sterilisation. Due to the high salt content, 
maximum concentration was 7.5x, used for Biolog Phenotypic Microarray Analysis.
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Basic B – final concentration in the medium:
NaHCO3 0.19 g/l
Filled up with ultra pure water and autoclaved for sterilisation. Maximum concentration of 
this stock solution was 100x.
Trace element stock solution (1000x) – 1 ml/l medium
H2O 25 ml
Fe(II)SO4 × 7H2O 1.05 g
HCl, 25% (w/v) 6.5 ml
Tritiplex III (Na2EDTA) 2.6 g
Dissolved and adjusted pH to 6.0 to 6.5 before adding the next components
H3BO3 15 mg
MnCl2 × 4 H2O 50 mg
CoCl2 × 6 H2O 95 mg
NiCl2 × 6 H2O 12 mg
CuCl2 × 2H2O 1 mg
ZnSO4 × 7H2O 72 mg
Na2MoO4 × 2H2O 18 mg
Filled up to 500 ml with ultra pure water and sterile filtrated
Carbon sources – final concentration in the medium:
Glucose 5 mM, respectively 11 mM in “adaptation to 
growth with complex medium” experiment 
(Section 2.13.1)
[U-13C] glucose 5 mM
Casamino acids / Caseinhydrolysate 
(A157, Carl Roth)
10 g/l. This amino acid mixture was provided 
together with low concentrated Basic A (1.11x) 
and was autoclaved for sterilisation. 
Succinate 20 mM
L-tryptophan 5 mM
L-phenylalanine 5 mM
L-methionine 20 mM
L-leucine 15 mM
L-isoleucine 15 mM
L-valine 15 mM
L-histidine 15 mM
L-lysine 15 mM
L-threonine 15 mM
N-acetyl-glucosamine 5 mM
Mannitol 5 mM
Sucrose 2.5 mM
Xylose 5 mM
If necessary, pH was adjusted to 7. If not mentioned otherwise, carbon sources were sterile 
filtrated.
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2.5.2 Bacto Marine Broth (complex medium)
For complex medium, ready compositions were used: either 37.1 g/l DIFCO 2216 
(DIFCO, Lawrence, KS, USA) or 40.1 g/l Marine Bouillon CP73.1 (Carl Roth, Karlsruhe, 
Germany). For solid medium, 15 g/l agar was added prior to autoclaving.
2.5.3 Biolog-inoculum solutions
Biolog-inoculum solution 1
IF-0a GN/GP (1.2x) 
(Biolog, Hayward, CA, USA)
5.0 ml 
Basic A (7.5x) 0.6 ml
Basic B (100x) 0.05 ml
Ultra pure water (sterile) 0.35 ml
Biolog-inoculum solution 2
IF-0a GN/GP (1.2x) 
(Biolog, Hayward, CA, USA)
8.33 ml
Basic A (7.5x) 1.2 ml
Basic B (100x) 0.1 ml
Trace Element stock solution (1000x) 0.012 ml
Ultra pure water (sterile) 0.238 ml
Redox Dye Mix D (100x) 
(Biolog, Hayward, CA, USA)
0.12 ml
2.5.4 Solutions for GC-MS analysis
Ribitol stock solution
0.05 g ribitol were dissolved in 0.25 l ultra pure water. The solution was sterile filtered, 
aliquoted and stored at -20 °C.
Methoxyamine/pyridine solution
Methoxyamine hydrochloride was dissolved 20 mg/ml in pyridine prior to usage.
Alkane time standard (retention index calibration mix)
Decane, C10H22 12.5 mg, respectively 17.1 µl 
Dodecane, C12H26 12.5 mg, respectively 16.7 µl
Pentadecane, C15H32 12.5 mg, respectively 16.2 µl
Nonadecane, C19H40 12.5 mg
Docosane, C22H46 12.5 mg
Octacosane, C28H58 12.5 mg
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Dotriacontane, C32H66 12.5 mg
Hexatriacontane, C36H74 12.5 mg
The alkanes were dissolved in 25 ml cyclohexane and aliquoted, resulting in a 
concentration of 0.5 g/l for each alkane. For GC-MS measurement 6 µl of this stock 
solution were added to 48 µl cyclohexane.
2.6 Software
Table 5: Software used in this study.
Software Description
ChemSketch (Freeware Version 12.01)
(Advanced Chemistry Development, Inc.)
Program for sketching molecules
ChemBioDraw (Version 13.0.2.3020 for Mac OS X)
(Cambridgesoft)
Program for sketching molecules
ChromaTOF (Version 4.24)
(Leco Instruments)
Vendor software for GC-MS data acquisition and 
evaluation 
DataAnalysis software (Version 4.0 SP5, Build 283)
(Bruker Daltonic)
Vendor software for LC-MS data acquisition and 
analysis
EnzymeDetector (Quester and Schomburg, 2011)
(http://edbs.tu-bs.de) 
Program for comparative pathway prediction 
based on genome annotation from different 
sources
Hystar (Version 3.2, Build 44)
(Bruker Daltonic)
Vendor software for controlling and synchronis-
ing all components of the LC-MS system
itool Internal Python/MySQL-based script for GC-MS 
data. Sums analytes of metabolite and calculates 
mean values and errors for each sample group 
and metabolite.
Maestro (Versions 1.2.3.5 and 1.4.24.2)
(Gerstel)
Vendor software for controlling and 
synchronising the Gerstel autosampler with GC-
MS system
MassCenterMain (Version 2.3.0.1)
(Jeol) 
Vendor software for GC-MS data acquisition and 
evaluation
MetaboliteDetector (Hiller et al., 2009), 
TU-BS branch
(various developmental versions released 2012 to 2013)
(http://md.tu-bs.de) 
Program for GC-MS analysis 
MultiExperiment Viewer (Saeed et al., 2003)
(Version 4.7.3)
Program for statistical analysis and visualisation 
of scientific data
OmniLog – OL PM FM and OL PM Par
(both version 1.20.02) (Biolog)
Program for data evaluation and visualisation of 
kinetic respiration plots
OmniLog – PM DC (Version 1.30.01)
(Biolog)
Administration software of the OmniLog 
Incubator/Reader
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Table 5: Software used in this study. (Continued)
Software Description
OriginPro (64-bit Academic Versions: 8.6.0 and 9.0.0G)
(OriginLab)
Program for visualisation of scientific data
R (Version 3.1.1 for Windows7, and 3.1.0 for MacOS X)
(R Foundation for Statistical Computing)
Program for statistical analysis and visualisation 
of scientific data
Xcalibur (Version 2.0.7) 
(Thermo Fisher Scientific)
Vendor software for GC-MS data acquisition and 
evaluation
XCMS  (Smith et al., 2006; Tautenhahn et al., 
2008; Benton et al., 2010) 
R package for LC-MS data analysis
2.7 Databases
Table 6: Databases used in this study.
Database Description
BRENDA (Schomburg et al., 2012)
(http://www.brenda-enzymes.org) 
Database for enzymes and ligands
Chemspider
(http://www.chemspider.  com)
Chemical database
Golm Metabolome Database
(http://gmd.mpimp-golm.mpg.de)
Open source mass spectral library
KEGG (Kanehisa et al., 2014)
(http://www.genome.jp/kegg)
Database for pathways and compounds
MASCOT
(http://www.matrixscience.com)
Database for identification and characterisation of 
proteins
MassBank (Horai et al., 2010)
(http://  www.massbank.jp)
Open source mass spectral library
MetaCyc (Caspi et al., 2014)
(http://www.metacyc.org)
Database of experimentally elucidated metabolic 
pathways and compounds
MD Library, Version: 2014-03-31 In-house library of EI mass spectra and retention 
indices. Contains 1531 entries from 1031 
chemical standards; and 1087 entries of 
unidentified compounds.
NCBI
(http://www.ncbi.nlm.nih.gov/)
National Center for Biotechnology Information 
that provides amongst others biomedical and 
genomic information
NIST08 Mass Spectral Database
(http://www.nist.gov/) 
Commercial EI mass spectral library
UniProtKB/Swiss-Prot
(http://www.uniprot.org/)
Manually curated protein database
24 2  MATERIAL AND METHODS
2.8 Microbial techniques
2.8.1 Biolog phenotypic microarray analysis
Wild-type stock cultures were streaked onto MB agar plates and incubated for 48 h at 
28 °C, transferred once to a fresh agar plate and incubated for another 24 h. Obtained 
colonies were picked with a sterile cotton stick and resuspended into a reaction tube 
containing 6 ml of Biolog-inoculum solution 1 until a turbidity of 42% was reached. Then, 
2 ml of it were transferred to 10 ml Biolog-inoculum solution 2. For PM3B plate (test for 
nitrogen substrate range), Basic A contained no NH4C l ; instead of sterile H2O, 1 M 
succinate was used as carbon source in the Biolog-inoculum solution 2. The resulting 
mixture was used to inoculate the Biolog phenotypic microarrays with 100 µl per well. 
Each well contained one single dried substrate, which were either carbon sources (PM1 
and PM2A) or nitrogen sources (PM3B). 
The microarrays were incubated for 72 h at 28 °C in the OmniLog-Incubator/Reader; 
every 15 minutes pictures of the plates were taken automatically to record colouring of the 
wells. Data were analysed with the vendor software OmniLog-PM FM and OmniLog-PM 
Par.  Each plate was analysed in duplicate. 
2.8.2 Isotope labelling
Stock cultures were streaked onto MB agar plates and incubated for 48 h at 28 °C. A 
single colony was picked to inoculate 20 ml minimal medium (in a 100 ml Erlenmeyer 
flask with three baffles) containing 5 mM glucose as carbon source. The pre-culture was 
incubated at 28 °C in a shaker (150 rpm, BS-1, Sartorius) and then used to incubate fresh 
medium containing either glucose or [U-13C] glucose to OD600 nm = 0.01. After another 48 h, 
main cultures (200 ml medium in 1 l Erlenmeyer flasks with three baffles) supplied with 
either glucose or [U-13C] glucose were inoculated and incubated under same conditions as 
pre-cultures. Cells were harvested at ¾ ODmax by centrifugation (30100 × g, 5 min, 4 °C). 
Obtained cell pellets were resuspended in 3.7% (w/v) NaCl solution and distributed to 
50 ml polypropylene tubes, centrifuged (10414 × g, 3 min, 4 °C), the obtained cell pellets 
were washed again and immediately prepared for GC-MS-based metabolomic analysis. 
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Metabolite extraction and derivatisation for GC-MS analysis was performed essentially as 
described in section 2.11. Cell pellets were resuspended in 1.5 ml ethanol containing 
22.5 µl of a 0.2 mg/ml ribitol solution. After phase separation, 1 ml of the polar phase were 
transferred to a 2 ml reaction tube and dried in a vacuum concentrator overnight. 
2.8.3 Study of coenzyme A derivatives linked with tryptophan degradation
To analyse tryptophan-degradation specific coenzyme A derivatives, cells were grown 
on 5 mM L-tryptophan, or 20 mM succinate (reference condition) in a Certomat BS-1 
(150 rpm, Sartorius). Two adaptation cycles, transferring actively grown cells to fresh 
medium, were conducted before inoculating main cultures. Samples were harvested at 
½ ODmax by centrifugation (10414 × g, 4 °C, 5 min). Supernatants were removed and the 
remaining cell pellets, approximately 20 mg dry mass each, were immediately frozen in 
liquid nitrogen and stored at -80 °C until further analysis with LC-MS. 
2.8.4 Cultivation conditions for main experiments
Erlenmeyer flasks with three baffles, were filled 1/5 – 1/4 to their maximum volume 
capacity with medium. Then, flasks were inoculated with stock culture (or substrate-
adapted cells stored at -80 °C in glycerol-containing medium) diluted 10-1 to 10-4. For the 
consecutive adaptation steps and up-scaling, flasks were inoculated with 2% (v/v) to 5% 
(v/v) of actively growing culture at half-maximal optical density (½ ODmax) . Incubation 
was done at 28 °C in a shaker (100 rpm, CH-4103, Infors). 
Cells for GC-MS-based metabolomic and proteomic analyses were harvested at 
½ ODmax by centrifugation (14300 × g, 20 min, 4 °C). The obtained cell pellets were 
washed in Tris/HCl buffer (100 mM + 5 mM MgCl2 × 6H2O, pH 7.5), 0.9% or 3.7% (w/v) 
NaCl and centrifuged again. The washed cell pellets were resuspended in wash solution, 
distributed into 2 ml reaction tubes and centrifuged (16000 × g, 3 min, 4 °C). The wet mass 
of the resulting cell pellets were determined and then directly frozen in liquid N2 and stored 
at -80 °C. For exometabolomic analysis 1.5 ml – 1.8 ml of the culture supernatant obtained 
by centrifugation and/or filtration (0.2 µm, Minisart, Sartorius, Göttingen) were 
immediately frozen at -80 °C. 
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2.9 Proteomic analyses
Proteomic analyses, comprising differentiation of extracellular proteins, as well as 
soluble and membrane-enriched fraction of intracellular proteins, were conducted by 
cooperation partners from the ICBM in Oldenburg (research group of Prof. Ralf Rabus). 
Proteins were analysed using 2D DIGE with cyano dyes for quantification, SDS-PAGE, 
MALDI-TOF-MS and shotgun nano LC-MS. Identification of peptide sequences was 
performed on a MASCOT server searching against the genome of P. inhibens DSM 17395 
(Thole et al., 2012). Only results, required for interpretation of metabolomic data are 
included in the corresponding chapters. Details of the methods and results are provided in 
the corresponding joint publications (Zech et al., 2013a; Zech et al., 2013b; Drüppel et al., 
2014; Wiegmann et al., 2014).
2.10 Analysis of coenzyme A derivatives
2.10.1 Extraction of coenzyme A derivatives
Cells were resuspended in 1 ml methanol, containing 0.2 µg/ml biochanin A as internal 
standard, and transferred to cryo tubes with 600 mg glass beads (70 – 110 µm). Cell lysis 
was conducted using a Precellys24 homogenizer at -10 °C and 6800 rpm shaking speed for 
3 × 30 seconds, with equivalent short breaks between the three shaking cycles. Cell lysates 
were transferred to 10 ml ice cold 25 mM ammonium acetate (pH 6) and centrifuged 
(5 min, 10000 × g, 4 °C). 
Extraction of coenzyme A derivatives was performed on Strata XL-AW solid phase 
extraction columns (Phenomenex, Aschaffenburg, Germany). Before application of the 
supernatant, the solid phase extraction columns were pretreated sequentially with 1 ml 
methanol, 1 ml methanol: ultra pure water: formic acid (50:45:5) and 1 ml ultra pure water. 
After passing the ammonium acetate supernatant through the columns with a vacuum of 
900-800 mbar for approximately 5 min, the column were rinsed with 1 ml ammonium 
acetate (pH 7.2) and 1 ml methanol, and were then dried at 700 mbar vacuum for 3 min. 
Analytes were eluted by 2 × 500 µl methanol containing 2% (v/v) ammonia solution (27% 
ammonia in water) and then dried in a centrifugal-vacuum concentrator at 14 °C. For 
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analysis samples were dissolved in 200 µl sample buffer (25 mM ammonium formate, 
pH 3.5, 2% v/v methanol).
2.10.2 Liquid chromatography – mass spectrometry analysis
Coenzyme A derivatives were analysed with a Dionex Ultimate 3000 system, coupled to 
a Bruker MicroTOF QII mass spectrometer with an electrospray ionisation interface. 50 µl 
of the samples were injected into the LC system and separated essentially as described 
previously by Peyraud et al. (2009). Separation was done with a C18 analytical column 
(Gemini 150 × 2.0 mm, particle size 3 µm, Phenomemex, Aschaffenburg, Germany) at a 
flow rate of 220 µl/min and 35 °C. Solvent A was 50 mM formic acid adjusted to pH 8.1 
with NH4OH and solvent B was methanol. The following gradient of B was applied: 0 min, 
5%; 1 min, 5%; 19 min, 30%; 26 min, 95%, 30 min, 95%. The mass spectrometer was 
operated in ESI+ mode with a rate of 3 Hz for data acquisition and automated MS2 
acquisition. Mass range was set to 90-1178 m/z with an end plate offset of -500 V, capillary 
voltage of 4500 V, 1.2 bar nebulizer pressure, 8 l/min dry gas and 200 °C dry temperature. 
A detailed list of the applied MS and MS2 settings is provided in Table 7.
Table 7: Mass spectrometry settings for analysis of coenzyme A derivatives. The MicroTOF 
QII mass spectrometer was operated in ESI+ mode, using the following settings for MS, MS2, and 
MS2 fragmentation.
MS settings
Transfer Funnel 1 RF 200 Vpp (Volts peak to peak)
Transfer Funnel 2 RF 200 Vpp
Transfer ISCID Energy 0 eV
Transfer Hexapole RF 150 Vpp
Quadrupol Ion energy 5 eV
Quadrupol Low mass 100 m/z
Collision Cell Collision Energy 7 eV
Collision Cell Collision RF 150 Vpp
Collision Cell Transfer Time 80 µs
Collision Cell Pre Pulse Storage 5 µs
MS2 settings
Threshold (cts) 2000
Smart Exclusion 2
Active Exclusion on
Exclude after (spectra) 2
Release after (min) 0.2
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Table 7:  Mass spectrometry settings for analysis of coenzyme A derivatives. (Continued)
MS2 fragmentation
Isolation mass Isolation width Collision Energy Charge state
500 8 35 1
25 2
20 3
1000 10 50 1
40 2
35 3
2000 15 75 1
50 2
45 3
2.10.3 Data processing and peak identification
Internal mass calibration with sodium formate cluster and data export to MZXML 
format was realised with DataAnalysis software (Bruker Daltonic). Processing of the peak 
data was then conducted with the R package XCMS under R version 3.0.3, parameters are 
provided in table 8.
Table 8: Settings for LC-MS data processing, using the R package XCMS.
Parameter Value
peakwidth c(5,24)
snthresh 1
prefilter c(1,200)
mzCenterFun “wMeanApex3”
integrate 1
mzdiff 0.4
fitgauss TRUE
scanrange c(700, 5000)
noise 0
Peak alignment and retention time were performed with XCMS methods group and retcor in two 
iterations with these parameters:
method “nearest”
mzVsRTbalance 15
mzCheck 0.2
rtCheck 20
kNN 15 (for the first iteration); 
10 (for the second grouping)
missing 3
extra 2
smooth “loess”
span 0.2
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Table 8: Settings for LC-MS data processing, using the R package XCMS. (Continued)
Parameter Value
family “symmetric”
plottype “mdevden” with missing = 1
extra 1 (for the second iteration of retcor)
A final grouping step was conducted with the same group parameters as the second iteration. 
Missing values were calculated by the fillPeaks methods. Peak data were exported as csv-table.
Peak identification was carried out via the accurate masses of [M+2H]2+ ions and 
retention times of synthetic standards. For substances with no chemical standards 
available, both the calculation of the molecular masses from [M+2H]2+ and [M+H]+ ions 
and the prediction of sum formulas from accurate masses and isotopic patterns using the 
DataAnalysis software, were applied for their identification. MS2 fragmentation was used 
to confirm the coenzyme A moiety when possible. Identification of isomers was partially 
possible in the biological context but not based on LC-MS2 data alone.
2.11 Sample preparation for GC-MS analysis
Samples were prepared according to the recently described method (Zech et al., 2013a). 
This procedure involves the extraction of metabolites from the cell-pellets and removal 
from any water-based solvent and derivatisation of the samples. Details and modifications 
for the main experiments are provided in sections 2.13 and 2.14.
2.11.1 Extraction of intracellular metabolites
Cell pellets were resuspended in 1.5 ml ethanol, containing 30 or 60 µl of a 0.2 mg/ml 
ribitol solution. For cell lysis, cell suspensions were incubated in an ultrasonic bath for 
15 min at 70 °C. Samples were cooled on ice, followed by addition of 1.5 ml water and 
mixing. Then, 1 ml chloroform was added and samples were shaken vigorously for 
chloroform extraction of hydrophobic compounds from the aqueous phase. After phase 
separation by centrifugation (3900 × g, 5 min, 4 °C), 500 μl or 1 ml of the polar phase were 
transferred to a 2 ml reaction tube or alternatively to a 1.3 ml crimp glass vial in case of 
automated derivatisation. Samples were dried in a vacuum concentrator overnight and 
stored at -20 °C until further processing. 
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2.11.2 Preparation of culture supernatants 
An appropriate amount of the culture supernatants were spiked with a polar solvent and 
a 0.2 mg/ml ribitol solution and then dried in a vacuum concentrator overnight and stored 
at -20 °C until further processing. The used volume of the supernatants were adapted to 
their corresponding concentration, to detect low concentrated compounds without detector 
saturation by the high concentrated substrates.
2.11.3 Derivatisation reaction
The two-step derivatisation reaction (methoximation using a methoxyamine 
hydrochloride solution with a concentration of 20 mg/ml in pyridine followed by silylation 
applying MSTFA) was performed as follows: 40 μl methoxyamine/pyridine were added to 
the dried sample and incubated for 90 min at 30 °C with constant mixing. Then 60 μl 
MSTFA were added and samples were incubated for 30 min at 37 °C followed by 2 h at 
25 °C with constant agitation. The samples were centrifuged at 14000 × g for 5 min and the 
supernatants were transferred into glass vials for GC-MS analysis. In case of automated 
derivatisation, a MPS 2 XL autosampler coupled to the Leco Pegasus 4d GC × GC TOF 
MS system was used. Here, the final incubation time was reduced from 2 h to 1 h.
2.12 Gas chromatography – mass spectrometry analysis
For metabolomic analyses three different GC-MS systems were available, whereas most 
samples were analysed with the Leco Pegasus 4d GC × GC TOF MS. The Jeol JMS-
T100GC was used for the exometabolomic analysis of “carbohydrate degradation” 
(Section 2.13.5) and “ammonium limited growth condition” experiments (Section 2.13.6), 
using a splitless and split (1:15) injection method. Further, it was used for an additional 
intracellular metabolome analysis of “carbohydrate degradation” (Section 2.13.5) and 
“isotope labelling” experiments (Section 2.8.2), both using splitless injection. The DSQ II 
GC-MS was used for the analysis of the supernatants derived from the “dynamics of amino 
acid utilisation” experiment (Section 2.13.2). As time standard, every 20 measurements, an 
alkane mix (Section 2.5.4) was analysed to allow reproducibility of the measurements. 
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2.12.1 Leco Pegasus 4 d GC × GC TOF MS
Samples were analysed using a Leco Pegasus 4d GC × GC TOF MS, operated in GC-
TOF mode, and equipped with a MPS 2 XL autosampler. Calibration of the mass 
spectrometer was conducted according to the manufacturer with perfluorotributylamine. 
Samples (1 μL) were injected in splitless mode into a programmed temperature vaporising 
(PTV) injector (Gerstel), which was equipped with a 71 × 1 mm CIS 4 glass liner, filled 
with silanized glass wool. After an initial time of 0.02 min at 70 °C the temperature was 
increased with 12 K/s to 330 °C, which was then held constant for 5 min. Gas 
chromatography was performed with a 7890 Agilent GC, equipped with a ZB-5MS column 
(Phenomenex) or with the identically constructed DB-5MS column (Agilent). The helium 
flow was set to constant at 1.2 ml/min, respectively 1.0 ml/min in case of the experiment 
“adaptation to growth with complex nutrients” (Section 2.13.1).  After 1 min at 70 °C the 
GC oven temperature was increased by 10 K/min to 330 °C, which was then held constant 
for 3 to 8 min, depending on deterioration of the column. The transfer line was set to 
275 °C, the ion source temperature was 250 °C and the detector voltage was adjusted 
according to the sample concentration and the daily performance of the instrument. Overall 
the detector voltage was set 200 V higher than the output of the automatic tuning. Solvent 
delay was adjusted according to the deterioration of the column; around 300 s. After 
solvent delay time, full mass spectra were collected from 45 to 600 m/z at 8 scans/s, or 
20 scans/s, with the ChromaTOF software. 
2.12.2 Jeol JMS-T100GC Accu TOF MS
Samples were analysed using the Accu TOF GC JMS-T100GC, equipped with a MPS 2 
Twister autosampler. Tuning with Perflourorokerosene (MasCom, Bremen, Germany) was 
conducted according to the manufacturer's instructions. Samples (1 µl) were injected in 
splitless or in split mode (1:15) into a programmed temperature vaporising (PTV) injector 
(Gerstel), equipped with a 71 x 1 mm CIS 4 glass liner, filled with silanized glass wool. 
After an initial time of 0.02 min at 70 °C the temperature was increased with 12 K/s to 
330 °C, followed by 330 °C for 5 min. Gas chromatography was performed with a 6890N 
Agilent GC, equipped with a ZB-5MS column. Helium flow was set to constant 
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1.2 ml/min. After 1 min at 70 °C the GC oven temperature was increased to 330 °C at 
10 K/min, followed by an additional constant temperature period at 330 °C for 3 min. The 
transfer line temperature was set to 250 °C. Electron impact mode at 70 eV was used for 
ionisation; ion source temperature was set to 200 °C, the detector voltage was adjusted 
according to sample concentration and daily performance of mass spectrometer, which was 
a value of about 2400 V. The emission current was set to 300 µA. Solvent delay was 
adjusted according to deterioration of the column. After solvent delay time, full scan mass 
spectra were collected from 45 to 600 m/z at 5 scans/s with the MassCenter Main Software. 
2.12.3 DSQ II GC-MS
Determination of the amino acid depletion profile was performed on a Thermo GC Ultra 
coupled to a DSQ II mass spectrometer equipped with an AS3000 autosampler. In 
summary, 1 µl of the derivatised sample was injected in split mode (1:25) into a PTV 
injector (Thermo Fisher Scientific). After an initial time of 0.2 min at 70 °C, temperature 
was increased to 330 °C at a rate of 14 K/min, followed by an additional constant 
temperature period at 330 °C for 5 min. GC was performed over 60 min on a ZB-5MS 
column. Helium flow was set to 1.2 ml/min. After 1 min at 70 °C, temperature was 
increased to 76 °C with 1 K/min and then to 325 °C with 6 K/min, followed by a constant 
temperature period at 325 °C for 10 min. The transfer line temperature was set to 275 °C. 
Ion source temperature was set to 220 °C. After 5.8 min (solvent delay time), full-scan 
mass spectra were collected from 40 to 460 m/z at 2.5 scans/s using the Xcalibur software.
2.13 Setup of main experiments
To exclude potential misleading results due to minor variations of cultivation 
procedures; all samples of the joint experiments combining proteomic and metabolomic 
analyses originate from the same biological replicates and were generated by the research 
group of Prof. Ralf Rabus (ICBM, Oldenburg, Germany). Cultivation and sampling were 
conducted in Oldenburg as described in section 2.8.4, details and modifications are 
provided in section 2.14. Washed cell-pellets (around 100 mg wet mass) and cell-free 
supernatants for GC-MS-based metabolomic analyses were delivered on dry ice.
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2.13.1 Adaptation to growth with complex medium
To study the adaptation of P. inhibens DSM 17395 to seasonally fluctuating nutrient 
conditions, medium mimicking nutrient depleted or nutrient-rich conditions during algae 
bloom, were used for cultivation. Minimal medium contained 2 g/l (≈ 11 mM) glucose as 
carbon source (GM medium), complex medium (MB medium) contained 5 g/l peptone and 
1 g/l yeast extract as carbon source. In addition to Erlenmeyer flask cultures, cells were 
cultivated in process-controlled fermenter, for which phosphate concentration in the 
minimal medium was reduced to 0.15 M, and one fermenter (1500 ml medium) was used 
as inoculum for four fermenter cultures operated in parallel. Details of the fermenter setup 
are provided in (Zech et al., 2013a). Reference state were cultures grown in Erlenmeyer 
flasks with glucose. Contrary to this publication, here metabolomic data was only 
compared between samples derived from bioreactors, using cultures grown in glucose as 
reference state for statistical data analysis.
2.13.2 Dynamics of amino acid utilisation
In this time-dynamic experiment, uptake and utilisation of casamino acids were 
investigated. Minimal medium contained 10 g/l casamino acids (A157, Carl Roth, 
Karlsruhe, Germany). Sampling points were 10, 15, 20, 25, 30 and 35 h after inoculation. 
Reference state was the first sampling point, 10 h, respectively 0 h (uninoculated medium) 
in case of supernatants.
2.13.3 Casamino acid consumption by plasmid-cured strains
The impact of the smallest and the largest plasmid on growth and casamino acid 
utilisation was studied using the following plasmid-cured strains: Δ65kb, Δ262kb, 
Δ65kbΔ262kb, the natural isolate “M3” lacking the 262 kbp plasmid, plus the wild-type 
strain DSM 17395 as reference (see table 4 for details). Cells were cultivated in minimal 
medium containing 10 g/l casamino acids (A157, Carl Roth, Karlsruhe, Germany). Here, 
only samples for exometabolomic analyses were taken, in particular 18, 24 and 36 h after 
inoculation; reference state was t0 (uninoculated medium).
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2.13.4 Amino acid degradation
Single amino acids were used to study and to refine complex catabolic networks, which 
were unclear in regard to the original genome annotation. Minimal medium contained one 
of nine selected amino acids or succinate (20 mM) as reference condition. The selected 
amino acids were: L-tryptophan (5 mM), L-phenylalanine (5 mM), L-methionine (20 mM), 
L-leucine (15 mM), L-isoleucine (15 mM), L-valine (15 mM), L-histidine (15 mM), L-
lysine (15 mM), and L-threonine (15 mM). Sampling was performed at ½ ODmax, plus t0 for 
exometabolomic analysis.
2.13.5 Carbohydrate degradation
Single carbohydrates were used to study and to refine complex catabolic networks, 
which were unclear in regard to the original genome annotation. Minimal medium 
contained one of five selected carbohydrates or succinate (20 mM) as reference condition. 
The selected carbohydrates were: N-acetyl-glucosamine (5 mM), mannitol (5 mM), sucrose 
(2.5 mM), glucose (5 mM) and xylose (5 mM). Sampling was performed at ½ ODmax, plus 
t0 for exometabolomic analysis.
2.13.6 Metabolic responses to ammonium limited growth condition 
The metabolic responses of P. inhibens DSM 17395 to limited ammonium content were 
studied using minimal medium with only 1 mM NH4Cl concentration (instead of 4.7 mM). 
5 mM glucose were provided as carbon source. Sampling was performed 15, 20, 25, 30, 
40, 50, 60, 75 and 90 h after inoculation, plus t0 for exometabolomic analysis. Reference 
state was t30 (½ ODmax). 
2.14 Details and modifications of main experiments
Harvesting, sample preparation and GC-MS analysis of conducted main experiments 
(Section 2.13) were essentially performed as described in sections 2.8.4, 2.11 and 2.12. 
Details and modifications are listed in table 9.
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Table 9: Overview of sample preparation modifications for GC-MS analysis of main 
experiments, conducted in cooperation with the ICBM (see Section 2.13). (1) Adaptation to 
growth with complex nutrients; (2) Dynamics of amino acid utilisation; (3) Casamino acid 
consumption by plasmid-cured strains; (4) Amino acid degradation; (5) Carbohydrate degradation; 
(6) Metabolic responses to ammonium limited growth condition.* MSTFA was spiked 10% (v/v) 
with alkane mix; a, sum of biological and technical replicates.
(1) (2) (3) (4) (5) (6)
Intracellular metabolomic analysis
Number of replicatesa 3 or 12 12 12 12 5-6
Washing solution for 
cell pellets
Tris/HCl 
buffer
Tris/HCl 
buffer
0.9% (w/v) 
NaCl
3.7% (w/v) 
NaCl
3.7% (w/v) 
NaCl
Ribitol content (µl) 
per 1.5 ml ethanol 60 60 60 30 30
Volume of polar 
phase dried for 
analysis (µl)
500 500 500 1000 1000
Derivatisation manual manual automatic manual manual
Methoxyamine (µl) 40 40 20 40 40
MSTFA (µl)    70 * 60 35 60 60
GC-MS instruments Leco Leco Leco LecoJeol Leco
Injection method splitless splitless splitless splitless splitless
Scans per second 20 8 8 8 (Leco)5 (Jeol) 8
Exometabolomic analysis
Number of replicatesa 3-6 4 4 4 4 4
Harvesting procedure 
for supernatants
centri-
fugation
centri-
fugation & 
filtration
centri-
fugation & 
filtration
filtration filtration filtration
Volume of 
supernatant used for 
analysis (µl)
90 (of MB 
medium)
25 (of 
minimal 
medium)
100 20 50 50 150
Added solvent  H2O ethanol ethanol  H2O  H2O  H2O
Volume of solvent 
added (µl)
110 (for MB 
medium)
175 (for 
minimal 
medium)
500 180 100 100 100
Volume of ribitol 
solution (µl) 8 20 14.4 8 8 40
Derivatisation manual manual automatic automatic manual manual
Methoxyamine (µl) 40 40 40 40 40 40
MSTFA (µl)    60 * 60 70 60 60 60
GC-MS instrument Leco DSQ Leco Leco Jeol Jeol
Injection methods splitless split 1:25 splitless splitless splitless,split 1:15 
splitless,
split 1:15 
Scans per second 20 2.5 8 8 5 5
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2.15 GC-MS data processing
Raw data obtained from the GC-MS instruments were exported as NetCDF (network 
common data format) files without data smoothing, except for data obtained from the Jeol 
JMS-T100GC Accu TOF MS, where noise was removed using a filter-treshold of 20%. 
Data was processed using the correspondent latest releases of TU-BS branch of the 
MetaboliteDetector software (Hiller et al., 2009), which was under development from 2011 
to 2013 by Christian Nieke (TU Braunschweig). This software automatically deconvolutes 
all mass spectra from a chromatogram and calculates the retention indices based on the 
formula 1 using a retention index (RI) marker, in this case an alkane mix (Section 2.5.4). 
RI (T )=100⋅[( y−x)⋅(
log (t i)−log (t x)
log (t y)−log (tx)
)+ x] (Formula 1)
with RI(T) = retention index in a temperature gradient,
x = number of carbon atoms of the alkane eluting before the analyte,
y = number of carbon atoms of the alkane eluting after the analyte,
ti  = retention time of the analyte,
tx = retention time of the alkane eluting before the analyte,
ty = retention time of the alkane eluting after the analyte.
 
Additionally, the retention indices were aligned to the internal standard ribitol (RI = 
1727.1), by moving the chromatograms in average about 2 RI units forward or backward. 
Compounds were automatically identified by comparison of mass spectra and retention 
indices with a defined spectra-library (MD-Library 2014-03-31) as described by Hiller et  
al. (2009), using a cut-off score of 70% similarity. For most metabolites, one appropriate 
fragment ion for quantification (in regard to specificity and intensity) was defined in the 
library. Otherwise, one unique fragment ion was selected by the software for each 
individual metabolite. If necessary, quantification ions were curated manually.
Reproducible compounds (detectable in at least 50% of all samples belonging to one 
sample group) that could not be identified were added to the library and regarded to be 
formed specifically under tested conditions. Unidentified compounds are termed 
“Unknown” and possess an identifier created by retention index, an acronym of the 
organism and experimentalist, and a consecutive number, e.g. “Unknown#1361.3-pin-
mhe_010”. Unknowns, originating from the Golm Metabolome Database are mostly 
named with “NA” and a consecutive number.
To reduce the number of zero-values for compounds of low abundance, an extended 
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single ion chromatogram scan was performed. Here, chromatograms are searched in a user-
defined retention range (maximal 5 RI units, respectively 2 in case of sugar compounds) 
for the selected quantification ion; the outcome of this scan was checked manually. Data 
were normalised by the internal standard ribitol and blank was deduced. Then, data were 
normalised to the exact cell wet mass and finally by a central normalisation to the 
reference state (Figure 5). Next, all methoximated and/or silylated derivatives originating 
from one single compound were summed, using itool. 
2.16 Statistical data analysis
2.16.1 Significance tests
Due to the limited sample numbers in metabolomics and related “omics experiments”, 
conducting proper statistical data analysis is challenging and requires correct assumptions 
and selection of appropriate tests to avoid false discoveries. The applied procedure here is 
based on recommendations of Broadhurst and Kell (2006) and was performed as follows.
For each sample-group, each metabolite was tested on normal distribution, using the 
Shapiro-Wilk test, which possesses high power and is still reliable for sample numbers, 
n < 50 (Shapiro and Wilk, 1965). Null hypothesis is that quantification via GC-MS result 
Figure 5: Procedure for central normalisation to deduce influence of sample concentrations.
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in normal distributed data, which is not necessarily the case, especially for overloaded or 
weak signals. If the p-value was < 0.1, the null hypothesis was rejected, meaning that the 
corresponding metabolite was not normal distributed in that specific sample group. 
However, as higher p-values do not necessarily validate normal distribution, the null 
hypothesis was also rejected, if the variances were high, e.g. in case of individual outliers.
ANOVA (Analysis of Variance) with Holm-Bonferroni correction (Holm, 1979) and the 
non-parametric Kruskal-Wallis test (Kruskal and Wallis, 1952) with false discovery rate 
control (Benjamini and Hochberg, 1995) were used to recognise metabolites with altered 
abundances between sample groups; p-values < 10-4 were considered to be significant. For 
detailed elucidation of these differences, each test condition was tested against the 
reference condition, and in case of time-course experiments also two sequent sampling 
points were tested against each other. If both conditions to be compared, were normal 
distributed, a both sided t-test, assuming equal variances, with Holm-Bonferroni correction 
was used; otherwise the non-parametric Wilcoxon-Mann-Whitney test (Wilcoxon, 1945; 
Mann and Whitney, 1947) with false discovery rate control was used. If not indicated 
otherwise, for both tests p-values < 10-3 were regarded to be significant. 
Further, fold changes of metabolite abundances (quotient of the mean values 'test state' 
and 'reference state') were included into the analysis; fold changes > 2, or < 0.5 were 
considered to be significant, depending on variances. Errors of fold changes were 
calculated using propagation of uncertainty (Formula 2). 
(Formula 2)
with t = test state,
r = reference state,
, n = number of replicates.
2.16.2 Visualisation of datasets
For intuitive understanding of the complex datasets, obtained by metabolomic analyses, 
visualisation was of special importance. Visualisation was conducted with the softwares 
OriginPro, R and MultiExperiment Viewer (Section 2.6) on basis of post-processed result 
tables obtained from MetaboliteDetector (Section 2.15).
SE=standard error = standard deviation
√(n)
error of fold change=√(( (SE (t ))(mean(t )))2+( (SE (r ))(mean(r )) )2)⋅( mean(t )mean(r) )
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Hierarchical clustering was applied to recognise correlation between sample groups and 
between metabolites. Metabolites and samples are clustered according to their similarity, 
which is represented by the euclidean distances of a dendrogram. Correlation analyses 
were mostly based on Spearman's rank correlation. Alternatively, Pearson coefficient or 
Kendall's (τ) coefficient were used. Heatmaps were applied to visualise metabolite 
abundances, or correlation, on basis of colouring, for this data had to be log2-transformed 
first. Scatterplots were used to directly compare the metabolite abundances between two 
states by plotting normalised peak areas on a double logarithmic scale. Further, for better 
visualisation of the differences, a bisecting line was inserted.
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3 Results
3.1 Biolog phenotypic microarray analysis
For determination of substrate-uptake and utilisation capabilities of Phaeobacter  
inhibens DSM 17395, phenotypic microarray analysis was applied. 190 carbon sources 
(PM1 and PM2), and 95 nitrogen sources (PM3) were tested. The procedure of this 
analysis is described in detail in section 2.8.1.
In this assay, the respiratory activity of the bacterium was measured by monitoring 
colour changes of the tetrazolium dye. The dye is colourless and turns purple when reduced 
by electrons, here by reduction equivalents like NADH or NADPH (Bochner, 2009). The 
colour change was monitored over 72 h, resulting in kinetic plots for each substrate. To 
evaluate the bacterial response to specific substrates, area, height and slope of the obtained 
curves were taken into account. However, a positive response is actually only an indicator 
of transport capabilities and presence of required catabolic enzymes, but does not 
necessarily prove usability of the substrate for anabolic purposes, whereas negative spots 
clearly indicate missing transporter and/or catabolic enzymes. 
Overall 81 carbon sources (Figure 6) and 72 nitrogen sources (Figure 7) were clearly 
positive in regard to respiratory activity.
3.1.1 Carbon sources
The strongest responses for carbon sources were observed for amino acids and 
monosaccharides (Figure 6). All tested L-amino acids were clearly positive, with the 
exception of L-valine (P4), which gave only a weak response and L-pyroglutamate (P3), 
which was negative. Also amino acid derivatives (O3, O8) and dipeptides (F1, G1, G6, H1) 
were clearly positive, whereas of tested D-amino acids (A9, B1, D2, F4) only D-alanine 
was positive. Similar strong responses as for amino acids were observed for carboxylates, 
like pyruvate (H8), L-lactate (B9), acetate (C8), butanoates derivatives (D7, E7, L10, L12, 
M8), and TCA cycle intermediates (A5, D6, F2, F5, G11). 
Common natural sugars, like N-acetyl-glucosamine (A3), D-galactose (A6), D-fructose 
(C7), D-glucose (C9), D-xylose (D8) and D-mannitol (B11) were positive, whereas other 
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Figure 6: Phenotypic microarray analysis of carbon sources. The curves represent the amount of 
reduced tetrazolium dye as indicator for respiratory activity; which was monitored over 72 h in 
PM1 (lines A – H) and PM2A (lines I - P); the orthogonal scale was set to a maximum of 500.
  
A2
L-Arabinose
A3
N-Acetyl-D-
glucosamine
A4
D-
Saccharate
A5
Succinate
A6
D-Galactose
A7
L-Aspartate
A8
L-Proline
A9
D-Alanine
A10
D-Trehalose
A11
D-Mannose
A12
Galactitol
B3
Glycerol
C3
D,L-Malate
D3
D-Glucos-
aminate
E3
D-Glucose-
1-phosphate
F3
myo-Inositol
G3
L-Serine
H3
3-Hydroxy-
phenyl-
acetate
B2
D-Sorbitol
C2
D-
Galactonate
-γ-lactone
B1
D-Serine
B4
L-Fucose
C4
D-Ribose
B5
D-
Glucuronate
B6
D-Gluconate
B7
D,L-α-
Glycerol-
phosphate
B8
D-Xylose
B9
L-Lactate
B10
Formic acid
B11
D-Mannitol
B12
L-Glutamate
C1
D-Glucose-
6-phosphate
D2
D-Aspartate
E2
meso-
Tartrate
F2
Citrate
G2
Tricarbal-
lylate
H2
4-Hydroxy-
phenyl-
acetate
D4
1,2-
Propanediol
E4
D-Fructose-
6-phosphate
D1
L-
Asparagine
E1
L-Glutamine
F1
Gly-Asp
G1
Gly-Glu
H1
Gly-Pro
C5
Tween ® 20
D5
Tween ® 40
C6
L-
Rhamnose
C7
D-Fructose
C8
Acetate
D6
2-Oxo-
glutarate
F4
D-Threonine
G4
L-Threonine
H4
Tyramine
E5
Tween ® 80
F5
Fumarate
G5
L-Alanine
H5
D-Psicose
C9
α-D-Glucose
E6
α-Hydroxy-
glutarate-γ-
lactone
F6
Bromo-
succinate
G6
Ala-Gly
H6
L-Lyxose
C10
Maltose
C11
D-Melibiose
C12
Thymidine
D8
α-Methyl-D-
galactoside
D9
α-D-Lactose
D10
Lactulose
D11
Sucrose
D12
Uridine
E8
α-Methyl-D-
glucoside
E9
Ribitol
E10
Maltotriose
E11
2'-Deoxy-
adenosine
E12
Adenosine
F8
Galactarate
F9
Glycolate
F10
Glyoxylate
F11
D-
Cellobiose
F12
Inosine
G8
N-Acetyl-β-
D-mannos-
amine
G9
Mono-
methyl-
succinate
G10
Methyl-
pyruvate
G11
D-Malate
G12
L-Malate
H8
Pyruvate
H9
L-Galacto-
nate-γ-
lactone
H10
D-Galactu-
ronate
H11
β-Phenyl-
ethylamine
H12
Ethanol-
amine
D7
2-Oxo-
butanoate
E7
2-Hydroxy-
butanoate
F7
Propanoate
G7
Aceto-
acetate
H7
Glucuron-
amide
PM1
A1 -Control
I1 -Control I2
Chondroitin
Sulfate C
I3
α-Cyclo-
dextrin
I4
β-Cyclo-
dextrin
I5
γ-Cyclo-
dextrin
I6
Dextrin
I7
Gelatin
I8
Glycogen
I9
Inulin
I10
Laminarin
I11
Mannan
I12
Pectin
J3
β-D-Allose
K3
D-Lactitol
L3
Sedoheptu-
losan
M3
Methyl-
maleate
N3
Melibionate
O3
N-Acetyl-L-
glutamate
P3
L-Pyro-
glutamate
J2
N-Acetyl-
neuraminate
K2
L-Glucose
J1
N-Acetyl-D-
galactos-
amine
J4
Amygdalin
K4
D-
Melezitose
J5
D-Arabinose
J6
D-Arabitol
J7
L-Arabitol
J8
Arbutin
J9
2'-Deoxy-D-
ribose
J10
i-Erythritol
J11
D-Fucose
J12
3-O-β-D-
Galactopy-
ranosyl-D-
arabinose
K1
Gentiobiose
L2
Salicin
M2
Hexanoate
N2
Malonate
O2
L-Alanin-
amide
P2
L-Phenyl-
alanine
L4
L-Sorbose
M4
D,L-Citra-
malate
L1
D-Raffinose
M1
Decanoate
N1
D-Lactate-
methylester
O1
Acetamide
P1
L-Ornithine
K5
Maltitol
L5
Stachyose
K6
α-Methyl-D-
glucoside
K7
β-Methyl-D-
galactoside
K8
3-O-Methyl-
glucose
L6
D-Tagatose
N4
Oxalate
O4
L-Arginine
P4
L-Valine
M5
D-Glucos-
amine
N5
Oxalomalate
O5
Glycine
P5
D,L-
Carnitine
K9
β-Methyl-D-
glucuronate
M6
2-Hydroxy-
benzoate
N6
Quinate
O6
L-Histidine
P6
Butylamine 
(sec)
K10
α-Methyl-D-
mannoside
K11
β-Methyl-D-
xyloside
K12
Palatinose
L8
Xylitol
L9
N-Acetyl-D-
glucos-
aminitol
L10
4-Amino-
butanoate
L11
5-Amino-
pentanoate
L12
Butanoate
M8
3-Hydroxy-
butanoate
M9
4-Hydroxy-
butanoate
M10
2-Oxo-
pentanoate
M11
Itaconate
M12
5-Oxo-D-
gluconate
N8
Decane-
dioate
N9
2,4-Hexa-
dienoate
N10
Succin-
amate
N11
D-Tartrate
N12
L-Tartrate
O8
4-Hydroxy-
L-proline
O9
L-Isoleucine
O10
L-Leucine
O11
L-Lysine
O12
L-
Methionine
P8
Putrescine
P9
Dihydroxy-
acetone
P10
2,3-
Butanediol
P11
2,3-
Butanone
P12
3-Hydroxy-
2-butanone
L7
Turanose
M7
4-Hydroxy-
benzoate
N7
D-Ribono-
1,4-lactone
O7
L-Homo-
serine
P7
D,L-
Octopamine
PM2
Legend Standard monosaccharides
Modified carbohydrates
Di-/oligo-/polysaccharides
Alcohols
Carboxylates
(Modified) alkanoates
Amino acids, peptides
Aromates
Nucleosides, nucleobases
42 3  RESULTS
monosaccharides and especially sugar-derivatives, like acidic monosaccharides (A4, B5, 
B6, F8, H10), phosphorylated sugars (C1, E3, E4), or methylated sugars (K6 – K11), were 
negative. Otherwise, some of the tested disaccharides showed strong responses (e.g. A10, 
C10, C11, D11, F11), whereas oligo- and polysaccharides were negative (Q2 – Q12), with 
the exception of dextrin (Q6) and glycogen (Q8), which might probably be positive. 
The range of utilisable carbon sources also includes some nucleosides (C12, D12, E12, 
F12), some amines, like ethanolamine (H12), tyramine (H4) or putrescine (P8), plus 
modified short-chain fatty acids, like 2-oxopentanoate (M10) and propanoate (F7). Simple 
short-chain fatty acids were weakly positive, whereas longer chains, like decanoate (M1) 
or hexanoate (M2) gave no response at all, which was also true for aromatic compounds, 
e.g. hydroxyphenlyacetate (H2, H3), β-phenylethylamine (H11) and hydroxybenzoate 
(M6, M7).
3.1.2 Nitrogen sources
P. inhibens DSM 17395 utilises several substrates as nitrogen sources (Figure 7). 
Ammonia was the only one of tested inorganic nitrogen sources (Q2 – Q4) that gave a 
positive response. Urea (Q5) was negative, as well as the structurally similar compound 
biuret (Q6). Of the remaining tested N sources almost all were positive, with similar strong 
responses. All tested L- and D- amino acids were positive (Q7 – S12) with the exception of 
D-lysine (S7) and L-pyroglutamate (T3). Most of amines and amides, derived from sugars 
or simple carboxylates were positive (T4 – V1). Nucleosides, nucleobases and associated 
catabolic intermediates (V2 – W6), aminated short-chain fatty acids (W7 – W12) and all 
tested dipeptides (X1 – X12) can also serve as nitrogen source for P. inhibens DSM 17395.
3.1.3 Substrates tested as carbon and nitrogen sources
Some of the substrates were tested both as carbon and nitrogen source. Most were 
positive or negative in both tests. Four had specific single usability as carbon or nitrogen 
source. Tyramine (H4, U3) was only positive as carbon source, whereas 5-amino-
pentanoate (L11, W11), D-aspartate (D2, S5) and D-serine (B1, S8) were only positive as 
nitrogen sources. Butylamine, β-phenylethylamine, N-acetyl-galactosamine and N-acetyl-
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mannosamine could neither be used as carbon nor as nitrogen source. L-amino acids 
(except for pyroglutamate), the nucleosides thymidine, adenosine, uridine and inosine, the 
dipeptides Ala-Gly and Gly-Glu, as well as 4-aminobutanoate, ethanolamine, putrescine, 
D-glucosamine and N-acetyl-glucosamine were positive under both test conditions. 
3.2 Isotope labelling
P. inhibens DSM 17395 was supplied with standard glucose or [U-13C] glucose, cells 
were harvested at ¾ ODmax, intracellular metabolites extracted from cells were analysed via 
GC-MS. By comparison of spectra derived from cells cultivated with isotopic labelled or 
unlabelled glucose, m/z shifts could be observed as a result of integration of 13C instead of 
12C atoms into biomolecules. This enabled determination of compounds of biological 
origin. Still, whether such compounds were indeed synthesised by P. inhibens DSM 17395 
or were formed from labelled compounds during sampling procedure might be ambiguous.
Figure 7: Phenotypic microarray analysis of nitrogen sources. The curves represent the amount 
of reduced tetrazolium dye as indicator for respiratory activity; which was monitored over 72 h in 
PM3B (lines Q - W); the orthogonal scale was set to a maximum of 500.
  
Legend Alcohols
Aromates
Amino acids, peptides
Nucleosides, nucleobases
Q1 -Control Q2
Ammonia
(NH3)
Q3
Nitrite
(NO2
-)
Q4
Nitrate
(NO3
-)
Q5
Urea
Q6
Biuret
Q7
L-Alanine
Q8
L-Arginine
Q9
L-
Asparagine
Q10
L-Aspartate
Q11
L-Cysteine
Q12
L-Glutamate
R3
L-Histidine
S3
D-Alanine
T3
L-Pyro-
glutamate
U3
Tyramine
V3
Adenosine
W3
Urate
X3
Ala-Glu
R2
Glycine
S2
L-Valine
R1
L-Glutamine
R4
L-Isoleucine
S4
D-
Asparagine
R5
L-Leucine
R6
L-Lysine
R7
L-
Methionine
R8
L-Phenyl-
alanine
R9
L-Proline
R10
L-Serine
R11
L-Threonine
R12
L-
Tryptophan
S1
L-Tyrosine
T2
2-Phthal-
imido-
glutarate
U2
β-Phenyl-
ethylamine
V2
Adenine
W2
Xanthosine
X2
Ala-Gln
T4
Hydroxyl-
amine
U4
Acetamide
T1
N-Acetyl-
D,L-
glutamate
U1
Histamine
V1
N-acetyl-D-
mannos-
amine
W1
Xanthine
X1
Ala-Asp
S5
D-Aspartate
T5
Methyl-
amine
S6
D-
Glutamate
S7
D-Lysine
S8
D-Serine
T6
N-Amyl-
amine
V4
Cytidine
W4
Alloxan
X4
Ala-Gly
U5
Formamide
V5
Cytosine
W5
Allantoin
X5
Ala-His
S9
D-Valine
U6
Glucuron-
amide
V6
Guanine
W6
Parabanate
X6
Ala-Leu
S10
L-Citrulline
S11
L-Homo-
serine
S12
L-Ornithine
T8
Ethylamine
T9
Ethanol-
amine
T10
Ethylen-
diamine
T11
Putrescine
T12
Agmatine
U8
D-Glucos-
amine
U9
D-Glucos-
amiate
U10
D-Mannos-
amine
U11
N-Acetyl-D-
glucosamine
U12
N-Acetyl-D-
galactos-
amine
V8
Thymine
V9
Thymidine
V10
Uracil
V11
Uridine
V12
Inosine
W8
4-Amino-
butanoate
W9
6-Amino-
hexanoate
W10
D,L-2-
Amino-
octanoate
W11
5-Amino-
pentanoate
W12
2-Amino-
pentanoate
X8
Gly-Asn
X9
Gly-Gln
X10
Gly-Glu
X11
Gly-Met
X12
Met-Ala
T7
N-Butyl-
amine
U7
D,L-
Lactamide
V7
Guanosine
W7
D,L-2-
Amino-
butanoate
X7
Ala-Thr
Modified carbohydrates
(Modified) alkanoates
PM3
44 3  RESULTS
Clear m/z shifts were observed for 61 metabolites, whereas low concentrated 
compounds could not be analysed due to limited spectra quality. Three compounds 
(benzoate, lactate and octanoate) showed minor m/z shifts and have to be regarded as 
partial contaminants. 20 compounds, amongst these solvents, like cyclohexane and 
pyridine, as well as carbon-free compounds, phosphate, hydroxylamine and borate, showed 
no isotope labelling. This was also true for some organic compounds, like hexadecanoate, 
octadecanoate and toluate.
This experiment also enabled detection of 20 new unknowns, showing clear m/z shift of 
mass fragments and were added to the internal mass spectral library. Due to labelling, 
structure-prediction of these compounds was partially possible (Table 10). A list of labelled 
and unlabelled compounds is provided in the supplementary material S1. 
Table 10: Unidentified compounds detected in P. inhibens DSM 17395, that showed clear m/z 
shifts when the bacterium was supplied with [U-13C] glucose. Compounds are sorted ascending 
by retention index; scenario numbers correspond to main experiments as defined in section 2.14.
Compound Detected in 
scenarios
Structure prediction
Unknown#1004.0-pin-mhe_001 4,5,6 small molecule, about 3 carbons
Unknown#1361.3-pin-mhe_010 1,2,5 4 carbons, probably pyrimidine derivative
Unknown#1366.9-pin-mhe_011 2,4,5 5 carbons
Unknown#1456.4-pin-mhe_014 2 4 or 5 carbons, probably (di-)carboxylate
Unknown#1589.9-pin-mhe_029 minimum 5 carbons, N-containing, only 1 TMS.
Unknown#1635.2-pin-mhe_031 1,2,4,5 2 or more TMS groups
Unknown#1651.8-pin-mhe_032 5,6 6 carbons, probably sugar
Unknown#1671.7-pin-mhe_019 6 carbons, minimum 2 TMS groups, might contain 
amine and carboxylate.
Unknown#1684.4-pin-mhe_034 6 carbons, minimum 2 TMS groups, might contain 
amine and carboxylate.
Unknown#1830.2-pin-mhe_038 1,2,5 sugar compound of more than 6 carbons
Unknown#1856.7-pin-mhe_040 5 probably sugar
Unknown#1937.2-pin-mhe_021 5 hexose-acid
Unknown#1946.5-pin-mhe_024 2,5 hexose, might contain a carboxy group
Unknown#1955.0-pin-mhe_027 5 hexose-acid
Unknown#2018.7-pin-mhe_028 2,4,5 phosphorylated, might be pentose-phosphate
Unknown#2078.9-pin-mhe_042 4 modified sugar
Unknown#2135.2-pin-mhe_044 similar to hexose-phosphate
Unknown#2334.1-pin-mhe_051 2,5 similar to hexose
Unknown#2363.8-pin-mhe_052 1 similar to hexose-phosphate
Unknown#2678.8-pin-mhe_069 similar to disaccharide
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3.3 Main experiments
3.3.1 Adaptation to growth with complex nutrients
3.3.1.1 Growth characteristics
P. inhibens DSM 17395 was cultivated in peptone and yeast-extract containing complex 
medium (MB medium) or in glucose-containing minimal medium (GM medium). This 
scenario simulates nutrient-rich conditions during collapse of phytoplanktonic bloom, 
respectively replenished nutrient conditions. Cells were cultivated in Erlenmeyer flasks 
and process-controlled bioreactors and were harvested for analysis at ½ ODmax. Samples 
from Erlenmeyer flasks, glucose medium served as reference condition. 
Due to medium adapted cells, no noticeable lag-phase was observed for either media. 
MB medium yielded considerably shorter lag-phase, higher growth rate and higher 
maximum optical density, compared to minimal medium (Figure 8). 
3.3.1.2 Extracellular metabolomic analysis
The actual composition of MB medium is unclear in regard to availability and 
concentration of individual organic molecules. GC-MS analysis of the medium allowed 
identification of 54 different compounds. Compared to t0, 49 compounds were less 
Figure 8: Growth of P. inhibens DSM 17395 in Marine Broth medium and glucose-containing 
minimal medium. Cultivation was conducted in process-controlled bioreactors. Abbreviations: 
MB medium, Marine Broth medium (complex medium); GM medium, glucose-containing minimal 
medium.
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abundant at ½ ODmax, two were more abundant, which were urea (≈ 90-fold higher 
concentrated), and 2-hydroxyphenylacetate (only detected at ½ ODmax). Three compounds 
showed no abundance changes: cyano-alanine, glucose, and borate. For most of the 
identified substrates, complete consumption or depletion rates of more than 50% of the 
initially provided amount were observed. Only three substrates were less than 20% 
depleted (phenylalanine, threonine and 4-hydroxybutanoate). In contrast to this, amino 
acids (especially glutamate, glycine, alanine and aspartate), organic acids, (citrate and 
succinate) and specific disaccharides showed high depletion rates. Also some nucleosides 
and nucleobases were significantly depleted. A complete list of identified substrates and 
their depletion rate at ½ ODmax is provided in the supplementary material S2.
3.3.1.3 Intracellular metabolomic analysis
Both proteomic and metabolomic analyses revealed considerable intracellular 
differences between the two tested media. Samples derived from MB medium revealed a 
rich repertoire of proteins, comprising a high number of different transporters and catabolic 
enzymes for several substrates (Zech et al., 2013a). The metabolomic dataset consists of 
155 detected compounds, 134 of which could be identified; 99 of these identified had a 
fold change > 1.5, or < 0.67. Correlation analysis combined with hierarchical clustering 
revealed that medium was the main responsible factor for metabolic abundance changes. 
Cultivation vessels, i.e. Erlenmeyer flask or bioreactor had minor impact on sample 
clustering, which might be due to the vessel or biological variances (Figure 9). 
Here, only samples derived from bioreactors were compared and statistically evaluated. 
Most metabolites were not normally distributed. Thus the significance of abundance 
changes was determined using the non-parametric Wilcoxon-Mann-Whitney test with false 
discovery rate control. Moderate significant p-values < 0.01 were observed for 56 of the 
identified metabolites, significant p-values < 0.001 were observed for 28 metabolites. For 
metabolites, absent in one of the tested groups, no p-value could be calculated 
(Supplementary material S3).
Abundance changes involve metabolites both more abundant and less abundant in cells 
derived from MB medium (Figure 10, Table 11, Supplementary material S3). Amongst the 
higher concentrated metabolites were imported substrates, especially amino acids, 
dipeptides and disaccharides (e.g. proline, tryptophan, tyrosine, glycyl-glycine, lactose, 
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Figure 10: Scatter plot of intracellular metabolomic data from cultivation in bioreactor with 
complex or minimal medium. Normalised peak areas of identified metabolites were plotted in 
double logarithmic scaling. Colouring of metabolites: green: significant increased; red: significant 
decreased; yellow: not significant changed abundance in cells grown in complex medium. 
Abbreviations: IMP, inosine-5'-monophosphate; KDG, 2-keto-3-deoxy-gluconate.
Figure 9: Correlation matrix of intracellular metabolomic data from the experiment 
“adaptation to growth with complex nutrients”. Spearman method was used for calculation of 
correlation; which is visualised as heatmap, red colour represents high correlation. Dendrogram is 
based on euclidean distance. Abbreviations: GM medium, glucose minimal medium; MB medium, 
Marine Broth medium; BR, samples derived from bioreactor; EM, derived from Erlenmeyer flasks.
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isomaltose and maltotriitol). Accordingly, also intermediates involved in degradation of 
amino acids were very abundant (e.g. 5-aminopentanoate, cadaverine and 4-hydroxy-
phenylacetate). In addition, some purines and pyrimidines were more abundant (e.g. 
uridine-5'-monophosphate, guanosine-5'-monophosphate, adenosine-5'-monophosphate, 
xanthine and hypoxanthine), whereas inosine-5'-monophosphate and adenine were 
significantly less abundant.
Further, elevated levels of C18:1, glycerol-3-phosphate and ethanolamine-phosphate were 
observed. These or similar membrane associated compounds were not detected 
extracellularly, in contrast to detected nucleosides and nucleobases that were significantly 
depleted at ½ ODmax (Supplementary material S2). Accordingly, some of such compounds 
were more abundant, especially xanthine and hypoxanthine, which are associated with 
purine degradation, respectively with purine salvage pathway. 
Several metabolites were less abundant compared to cells derived from minimal 
medium (e.g. 3-hydroxybutanoate and tartrate). Especially intermediates associated with 
Entner-Doudoroff pathway and Embden-Meyerhof-Parnas pathway, which are used for 
glucose degradation in P. inhibens DSM 17395 (Zech et al., 2009) were less abundant, 
(e.g. glucose-6-phosphate, glucono-1,5-lactone, 2-keto-3-deoxy-gluconate and pyruvate). 
Table 11: Fold changes of selected intracellular metabolites from the experiment  “adaptation 
to growth with complex nutrients”. Fold changes of abundance in cells grown in MB medium, as 
compared to cells grown in minimal medium. Significance of abundance changes was calculated 
with Wilcoxon-Mann-Whitney test and false discovery rate control: * p-value < 0.01; ** p-value 
< 0.001. See supplementary material S3 for complete list of metabolites.
Metabolites Fold change Metabolites Fold change
Adenine 0.3 ± 0.1 ** Inosine-5'-monophosphate 0.3 ± 0.1 * 
Adenosine-5'-monophosphate 4.3 ± 1.0 ** Isomaltose 25.2 ± 14.5 * 
5-Aminopentanoate ≈300 ± 147 **  2-Keto-3-deoxy-gluconate 0.4 ± 0.2    
Cadaverine 14.2 ± 7.7 **  Lactose 14.1 ± 3.7 *   
Citrate 1.7 ± 0.5     Malate 1.9 ± 0.7    
Ethanolaminephosphate 14 ± 3 **  Maltotriitol ≈100 ± 43        
Fumarate 0.1 ± 0.0 ** Octadecenoate (C18:1) 2.2 ± 0.6    
Glucono-1,5-lactone 0.2 ± 0.0     2-Oxoglutarate 0.2 ± 0.0 * 
Glucose-6-phosphate 0.2 ± 0.0 ** Proline 1.6 ± 0.2 * 
Glutamate 0.5 ± 0.0 ** Pyruvate <0.01 ± 0 *  __ 
Glutamine 4.5 ± 0.5 ** Succinate 12.4 ± 1.6 **
Glycerol-3-phosphate 2.5 ± 0.3 ** Tartrate 0.1 ± 0 ** 
Glycyl-glycine 4.8 ± 1.6 *  Tryptophan   3.2 ± 0.4 **
Guanosine-5'-monophosphate 4.1 ± 1.0 *  Tyrosine   7.9 ± 1.8 **
3-Hydroxybutanoate 0.3 ± 0.0 *  Uridine-5'-monophosphate    8.9 ± 11.4    
4-Hydroxyphenylacetate 7.1 ± 3.3     Xanthine 9.0 ± 6.2 *
Hypoxanthine 2.8 ± 0.7     
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The lower abundances of intermediates that are associated with carbohydrate catabolism is 
contradicted by the detected higher amounts of disaccharides.
Catabolic pathways feed into the TCA cycle, which was recently reconstructed for 
P. inhibens DSM 17395 (Zech et al., 2009). Interestingly enough, enzymes of this cycle 
were only slightly elevated (Zech et al., 2013a), whereupon abundances of metabolic 
intermediates were considerably and differentially changed. Citrate was slightly more 
abundant, 2-oxoglutarate and fumarate were significantly less abundant, whereas succinate 
and malate were more abundant. The low abundance of 2-oxoglutarate correlates with 
glutamate, but not with glutamine abundance. 
3.3.2 Dynamics of amino acid utilisation
3.3.2.1 Growth characteristics and amino acid depletion profile
P. inhibens DSM 17395 was cultivated in minimal medium supplied with 1% (w/v) 
casamino acids as carbon source. Growth is characterised by a maximum growth rate of 
0.17 h-1 and an ODmax of 4.8 after 35 h of incubation (Figure 11A). 
To study the dynamics of amino acid utilisation, supernatants and cells were sampled 
across the growth curve, i.e. in the lag-phase (t10), exponential growth phase (t15, t20) 
transition to stationary phase (t25) and stationary phase (t30, t35); subscript numbers represent 
cultivation time in hours. Supernatants were analysed via GC-MS to determine the 
depletion pattern of the 15 detectable amino acids. Due to preparation of casamino acids by 
acidic hydrolysation of casein, glutamine and asparagine are converted to glutamate, and 
aspartate respectively. Histidine concentration is below limit of detection. Cysteine and 
tryptophan are not present. The depletion profile is visualised in figure 11B. Most abundant 
amino acids are glutamate, proline, leucine and serine. Although most amino acids were 
essentially utilised in parallel, depletion of individual amino acids after 20 h incubation 
time is quite different. Amino acids were categorised according to their depletion at t20, (I): 
rapid, i.e. > 50% utilised (arginine, glycine, aspartate and glutamate), (II) moderate 
utilisation, i.e. about 28 – 48 % (lysine, alanine, leucine, methionine, tyrosine, proline); 
slow utilisation, i.e. less than 24% utilisation (serine, phenylalanine and threonine), and 
(IV) none, i.e. no significant utilisation observed (valine, isoleucine). Growth is neither C 
nor N limited, at the onset of stationary-phase, t25, since sufficient amino acids are still 
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available. Beyond t25, after complete consumption of glutamate, amino acids of categories 
II and III showed higher depletion rates, especially alanine, lysine, proline and serine. 
The supernatants were also screened for compounds exported by P. inhibens DSM 
17395. Besides some metabolites derived from amino acid metabolism (2-hydroxy-
phenylacetate and 2-isopropylmalate), a continuous massive accumulation of urea was 
observed across the time-course (Supplementary material S4).
3.3.2.2 Intracellular metabobolomic analysis
In addition to 1747 proteins as a result of the combination of the different proteomic 
approaches (Zech et al., 2013b), 111 metabolites were detected, 94 of which could be 
identified (Supplementary material S5). Of the identified metabolites, 86 showed changed 
abundances of > 1.5 or < 0.67 in at least one of the test states compared to the reference 
state t10. As the reference state comprised lowest intracellular metabolite abundances, 
abundance changes compared to reference were mostly also statistically significant. 
Accordingly, samples from t10 differed strongly from all other samples, as revealed by 
Figure 11: Growth curve of P. inhibens DSM 17395 in minimal medium with casamino acids 
and correspondent time-resolved depletion profiles of provided substrates. (A) Growth curve, 
as determined by measuring optical density, coloured dots mark sampling points. (B) Depletion 
profiles of 15 detected amino acids in cell-free culture supernatant. The relative abundance (Rel.a)  
is given in % of the theoretically pool of all amino acids available at t 0, as calculated on basis of 
peptide sequences of bovine casein. Categories I to IV according to their differing depletion grades 
at t20. 
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Pearson correlation (Figure 12A). Sampling points clustered according to growth phases, 
although only minor differences of metabolite compositions over the following sampling 
points were observed. These differences became more apparent through the calculation of 
Kendall's (τ) coefficient (Figure 12B), and were elucidated by testing consecutive sampling 
points against each other, either with t-test or with Wilcoxon-Mann-Whitney test, 
depending on data distribution.
For each of the investigated growth-phases specific metabolic characteristics could be 
determined; the most remarkable results will be described here. The complete list of 
metabolites and their abundances during the time-course is provided in the supplementary 
material S5.
The lag-phase is represented by sampling point t10, and is characterised by low 
metabolite abundances, i.e. most metabolites were more abundant in consecutive sampling 
points, except for homocysteine, pyroglutamate, putrescine and citrate, which were most 
abundant at t10. Only few metabolites showed constant abundances over the whole time-
course, e.g. adenine, guanine, malate and 2-oxoglutarate.
Figure 12: Correlation matrixes of intracellular metabolomic data from the experiment 
“dynamics of amino acid utilisation”. Correlation was calculated with Pearson coefficient (A) or 
with Kendall's (τ) coefficient (B), and was visualised as heatmap. Red colour represents high 
correlation between sampling points. Dendrograms are based on euclidean distance. Subscript 
numbers represent the sampling points in hours. Lag-phase is represented by t10, exponential 
growth-phase by t15 and t20, transition phase from exponential growth to stationary phase by t25, the 
stationary phase by t30 and t35.
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Accordingly, most metabolites increased significantly in abundance between lag-phase 
and exponential growth phase (t15, t20), including peptidoglycane associated compounds 
(alanyl-alanine and 2,6-diaminopimelate), some amino acids (e.g. proline) and 
intermediates of amino acid catabolism (e.g. cadaverine and pipecolate). Further, highest 
concentrations of 3-hydroxy- and 4-hydroxybutanoate were observed during exponential 
growth phase. Others, like the diamines spermidine and putrescine, decreased, as well as 
the membrane associated compounds glycerol-3-phosphate and glycerol-phospho-glycerol 
during this growth-phase. 
The transition phase between exponential growth and stationary phase is represented by 
t25. It coincides with the complete consumption of the preferred substrate glutamate. 
Accordingly, considerable intracellular metabolic abundance shifts could be observed in 
this growth phase (Figure 13A). Intracellularly, alternative substrates increased in 
abundance between t20 and t25, e.g. alanine, serine, threonine and lysine. For the last one, 
corresponding catabolic intermediates could be detected (2-aminoadipate, 5-amino-
pentanoate, cadaverine and pipecolate), all of which were significantly more abundant at t25 
compared to t20. Further, also increased abundances for compounds associated with 
gluconeogenesis or glucose degradation (e.g. dihydroxyacetone phosphate, 6-phospho-
gluconate and 2-keto-3-deoxy-gluconate) could be observed. Some nucleotides and 
derivatives (e.g. adenosine, uridine and uridine-5'-monophosphate), and some fatty acids 
(e.g. dodecanoate and octadecenoate) were slightly more abundant. 
Upon entry into stationary phase (Figure 13B), continued abundance-increase for most 
of these metabolites was observed (e.g. 6-phosphogluconate, serine and lysine), whereas 
only few decreased in abundance (e.g. N-acetyl-glutamate and glucose). Notably, some 
lysine degradation intermediates showed opposite abundance patterns: whereas abundance 
of 2-aminoadipate increased, abundance of 5-aminopentanoate decreased significantly. 
Between the two sampling points of stationary-phase, t30 and t35, only minor differences 
could be observed. These were rather decline of abundances (e.g. glucose, N-acetyl-
glutamate, threonine and proline) than rise of abundances (e.g. β-alanine, 2-aminoadipate 
and guanine). However, most metabolites did not show significant abundance changes 
between these two sampling-points.
In contrast to dynamic abundance-changes, which were observed for a broad range of 
different metabolites, intracellular concentration of the five detected TCA cycle 
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Figure 13: Intracellular metabolic changes in transition phase from exponential growth to 
stationary phase during cultivation on casamino acids. Normalised peak areas of all metabolites 
were plotted in double-logarithmic scale. Colouring: green: increased abundance, red: decreased 
abundance as compared to correspondent previous sampling point. (A) Metabolic shift from t20 
(exponential growth) to t25. (B) Metabolic shift from t25 to t30 (stationary phase). Abbreviations: 
DHAP, dihydroxyacetone phosphate; KDG, 2-keto-3-deoxy-gluconate; UMP, uridine-5'-
monophosphate.
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intermediates remained relatively constant over the whole time-course. Still, significant 
abundance changes could be observed for citrate and succinate, but these changes only 
concern the transition phase from lag-phase to exponential growth-phase. In contrast, 
fumarate abundances increased steadily during cultivation (Supplementary material S5). 
Notably, all 20 proteinogenic amino acids could be detected intracellularly. This 
includes extracellularly low abundant histidine plus the missing amino acids cysteine, 
tryptophan, asparagine and glutamine. The intracellular distribution patterns of the last two 
mentioned amino acids correlate with aspartate, respectively glutamate, i.e. show relatively 
constant abundances over the whole time-course. However, cysteine and tryptophan are 
temporarily low abundant at t20, with moderately rise of abundance after t20, whereas 
abundance of histidine increased clearly after t20 (Supplementary material S5).
3.3.3 Casamino acid consumption by plasmid-cured strains
3.3.3.1 Growth characteristics
Most members of the Roseobacter clade possess several plasmids, that encode essential 
genes for metabolic features and thus are probably one key-element for the global 
distribution of the Roseobacter clade (Petersen et al., 2013). P. inhibens DSM 17395 
possesses three extrachromosomal elements, the largest, 262 kbp, is the most relevant 
plasmid for growth, as it encodes genes for tropodithietic acid biosynthesis. The other two 
plasmids contain metabolic relevant genes, like hexose-isomerases on the 65 kbp plasmid 
or the glycine cleavage system on the 78 kbp plasmid. 
In this study, the impact of these extrachromosomal elements on growth and substrate 
utilisation were investigated. For this, the natural “M3” mutant strain, which lacks the 
262 kbp plasmid, the three plasmid-cured strains (Δ65kb, Δ262kb, Δ65kbΔ262kb), which 
lack the 65 kbp, the 262 kbp or both plasmids, as well as the wild-type strain, which served 
as reference, were cultivated in minimal medium supplied with 1% (w/v) casamino acids. 
In addition to measurements of optical density, culture supernatants were analysed to study 
probable different amino acid depletion of these strains. Some minor differences of growth 
characteristics as compared to time-dynamic amino acid utilisation experiment (see 
Figure 11A, section 3.3.2.1) could be observed. Here, wild-type reached higher ODmax 
(about 7.0 instead of 5.0). 
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Growth of Δ262kb, Δ65kbΔ262kb and “M3” mutant strain differed considerably from 
wild-type, as they reached significant higher ODmax, ranging from about 10 in case of 
Δ262kb up to 15 in case of Δ65kb262kb. While maximum growth rate of Δ262kb was 
similar to wild-type (both µm a x ≈ 0.18), “M3” mutant strain and Δ65kb262kb grew 
considerably faster (µm a x ≈ 0.23). In contrast to this Δ65kb showed similar growth 
characteristics as the wild-type (Figure 14).
3.3.3.2 Depletion profile of casamino acids
Samples for exometabolomic analyses were taken during cultivation: after 18 h 
(exponential growth), 24 h and 36 h incubation. The conducted analyses revealed that 
depletion profiles of provided amino acids differed considerably between studied strains 
(Figure 15). While only moderate consumption of amino acids was observed for wild-type 
(as observed previously, see Figure 11, Section 3.3.2.1), strains lacking the 262 kbp 
plasmid consumed all provided amino acids. This also includes isoleucine and valine, 
which were not utilised significantly by the wild-type. However, the depletion profile of 
amino acids observed for wild-type and ∆65kb were similar. 
According to depletion grades of amino acids in the exponential growth phase of the 
wild-type strain, amino acids were categorised into four groups (see Section 3.3.2.1), 
ranging from I (favoured amino acids) to IV (not significantly used) (Figure 15E). This 
Figure 14: Growth of P. inhibens DSM 17395 plasmid-cured strains in casamino acid 
medium. Beside wild-type, the plasmid-cured strains Δ262kb, Δ65kb, Δ65kb262kb, plus the 
natural mutant strain “M3”, which lacks the 262 kb plasmid, were cultivated in minimal medium, 
supplied with 1% (w/v) casamino acids. For better visualisation, dot-lines were included.
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Figure 15: Depletion profiles of casamino acids by wild-type and plasmid-cured strains of P. 
inhibens DSM 17395. The relative abundance (Rel.a) is given in (%) of the theoretically whole 
pool of amino acids available at t0. (A) wild-type, (B) “M3” mutant, (C) Δ65kb, (D) Δ262kb, (E) 
Δ65kbΔ262kb. Categories I to IV according to their differing depletion grades in the exponential 
growth phase by the wild-type strain as defined in section 3.3.2.1.
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preference pattern did not differ between wild-type and the other strains, despite 
considerable higher consumption rates. All strains preferred the amino acids of category I 
(arginine, glycine, aspartate and glutamate) as primary nutrient source. Of amino acids of 
category II, methionine, and proline were slightly more preferred than lysine and leucine 
by the three strains lacking the 262 kbp plasmid. However, no clear preference by Δ262kb, 
Δ65kbΔ262kb or “M3” mutant strain for any amino acid of category III (threonine, 
phenylalanine or serine) was observed; instead similar depletion rates were observed. In 
contrast to this, in case of the two amino acids of category IV, isoleucine was slightly 
preferred to valine.
Interestingly, although ∆262kb and “M3” mutant strain should be genetically quite 
similar, considerable differences in growth and depletion profiles between these two strains 
were observed. While in case of “M3” mutant strain, most amino acids were already 
consumed after 24 h, only moderate consumption after 24 h was observed for ∆262kb.  By 
comparison of Δ65kb with wild-type, loss of the smallest plasmid had only minor impact 
on growth and amino acid consumption. But, if comparing Δ65kb with Δ65kbΔ262kb 
considerably stronger effects could be observed, as Δ65kbΔ262kb grew significantly faster, 
reached higher ODmax and consumed amino acids faster than Δ262kb. 
3.3.4 Amino acid degradation
To study and to refine complex catabolic networks, which remained unclear in regard to 
the original genome annotation, P. inhibens DSM 17395 was grown in minimal medium 
supplied with one of nine selected L-amino acids (tryptophan, phenylalanine, methionine, 
leucine, isoleucine, valine, histidine, lysine and threonine), or succinate as reference 
condition. The sampling point for metabolomic analyses was ½ ODmax. In addition to GC-
MS-based metabolomic analysis, LC-MS analysis was applied to study coenzyme A 
dependent degradation of tryptophan (see Sections 2.8.3 and 2.10). 
3.3.4.1 Growth characteristics
The used substrate concentrations were C-equivalent, with exception of tryptophan and 
phenylalanine, where only half the amount of carbon was provided. Though, growth 
characteristics differed considerably dependent on the provided amino acid. According to 
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reached ODmax, substrates were grouped into low ODmax (≈ 1.0 to 1.3), moderate ODmax 
(≈ 1.6) (Figure 16A) and high ODmax (≈ 2.4 to 3.0) (Figure 16B). Lowest ODmax was 
observed for methionine, associated with slowest growth and longest lag-phase. Amongst 
the substrates of the first group, highest growth and shortest lag-phases were observed for 
phenylalanine and histidine, whereas lysine and tryptophan resulted in moderate growth 
(Figure 16A). Cultures provided with threonine and succinate grew fastest (≈ 2.0 h-1) and 
had shortest lag-phases. Although branched chain amino acids resulted in high ODmax, only 
a moderate growth rate was observed (1.0 h-1), plus considerably prolonged lag-phases 
were observed, especially in case of isoleucine (Figure 16B). 
Figure 16: Growth of P. inhibens DSM 17395 on selected amino acids. (A) Substrates resulting 
in low ODmax, (B) substrates resulting in high ODmax. For better visualisation dot-lines were 
included. Abbreviations of substrates: Trp, trytophan; Phe, phenylalanine; Met, methionine; His, 
histidine; Lys, lysine; Leu, leucine; Ile, isoleucine; Val, valine; Thr, threonine; Succ, succinate 
(reference condition). 
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3.3.4.2 Extracellular metabolomic analysis
The cell-free supernatant was screened for exported metabolites. Overall, 11 different 
metabolites could be identified extracellularly. Some were only detected under single 
cultivation conditions, e.g. 2-aminobenzoate and kynurenine in case of tryptophan, others 
were detected under several conditions, like 2-isopropylmalate and urea (Table 12). 
Table 12: Extracellularly detected metabolites during growth on selected amino acids. 
Metabolites detected in the corresponding culture supernatant at ½ ODm a x are marked with “x”. 
Abbreviations of substrates: Trp, tryptophan; Phe, phenylalanine; Met, methionine; Leu, leucine; 
Ile, isoleucine; Val, valine; His, histidine; Lys, lysine; Thr, threonine; Succ, succinate.
Metabolites Trp Phe Met Leu Ile Val His Lys Thr Succ
2-Aminobenzoate (anthranilate) x
Cadaverine x x
Fumarate x
2-Hydroxyphenylacetate x
2-Isopropylmalate x x x x x
Kynurenine x
2-Methylmalonate x
4-Methylthio-2-oxobutanoate x
Phenethylamine x
Phenylpyruvate x
Urea x x x x x x x x
3.3.4.3 Refinement of amino acid degradation pathways
The dataset of intracellular metabolomic analysis consists of 132 compounds, 110 of 
which could be identified. Of identified compounds, 80 were significantly altered in 
abundance by means of corrected p-value (< 10-6) obtained by one of the two conducted 
multivariate analyses (ANOVA and Kruskal-Wallis test).
In regard to predicted amino acid degradation pathways only a limited number of 
intermediates could be detected. Some of these were specifically formed under 
correspondent cultivation conditions or showed considerably higher abundance compared 
to the reference condition, cells grown with succinate (Table 13, Supplementary material 
S6 and S7) . Since GC-MS-based metabolomic analysis alone could not cover the whole 
amino acid degradation pathways, proteomic analyses were included to allow 
unambiguous refinement of these catabolic networks. The resulting networks are discussed 
in sections 4.3.4.3 to 4.3.4.9. 
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Table 13: Fold changes of selected intracellular metabolites involved in amino acid 
degradation from the experiment “amino acid degradation in P. inhibens DSM 17395”. 
Explanation of symbols: x, compound only detected in marked test-condition; *, p-value < 0.01; 
**, p-value < 0.001; ***, p-value < 0.0001. Abbreviations of substrates: Trp, tryptophan; Phe, 
phenylalanine; Met, methionine; Leu, leucine; Ile, isoleucine; Val, valine; His, histidine; Lys, 
lysine; Thr, threonine. Complete list of metabolites including their fold changes, errors and p-
values of significance is provided in the supplementary material S6 and S7.
Metabolites
Fold change in abundance as compared to cells grown with succinate
Trp Phe Met Leu Ile Val His Lys Thr
Tryptophan degradation
2-Aminobenzoate (anthranilate) 2.92 **
Alanine 0.20 *** 0.16 *** 0.28 *** 1.95 * 0.77 0.94 1.19 0.91 3.96 **
Phenylalanine degradation
Phenylalanine 0.33 *** 0.43 *** 0.25 *** 0.39 ** 0.51 * 0.48 *** 0.42 *** 0.46 ** 0.51 **
Phenylpyruvate 2.80 ** 0.15
Methionine degradation
Methionine 0.33 *** 0.74 5.28 ** 0.45 ** 0.51 ** 0.60 * 0.67 * 0.62 * 0.50 **
2-Oxobutanoate 7.11 **
Leucine degradation
Leucine 0.58 * 0.58 ** 0.36 ** 1.19 1.60 * 1.75 0.49 0.69 0.60
Isoleucine degradation
Isoleucine 0.64 0.40 *** 0.69 0.37 ** 24.9 0.93 0.56 * 0.58 * 0.83
3-Methyl-2-oxopentanoate x
Valine degradation
Valine 0.21 *** 0.09 *** 0.10 *** 0.27 ** 0.63 5.60 ** 0.25 *** 0.37 *** 0.43 **
2-Oxoisovalerate x
Histidine degradation
Urocanate 1.52
Glutamate 0.03 ** 0.06 ** 0.07 ** 0.64 1.00 0.58 * 1.26 0.25 ** 1.32
Lysine degradation
Lysine 0.05 ** 0.13 ** 0.36 * 0.24 ** 0.55 0.42 0.50 ** 3.18 1.12
2-Aminoadipate 0.35 ** 0.63 0.04
5-Aminopentanoate x x x x
Cadaverine 0.87 2.07 ** 14.9 ** 1.53 *** 4.39 ** 1.57 10.5 116 ** 1.12
Glutarate 0.14 0.16 2.22 1.53 6.22 ** 1.44 9.29 142 0.15 **
Threonine degradation
Threonine 0.60 ** 0.43 *** 0.62 0.43 ** 1.23 0.92 0.85 0.51 ** 4.62 **
Glycine 0.45 ** 0.32 *** 0.76 0.48 ** 0.70 0.94 0.53 * 0.47 *** 0.39 **
Serine 0.42 * 0.54 0.68 0.91 1.56 1.04 1.00 0.72 0.94
Pyruvate 1.72 ** 2.69 *** 1.44 2.00 ** 1.79 0.77 1.73 *** 1.54 * 1.73 *
Other compounds associated with amino acid metabolism
Homogentisate 3.72 **
Hydantoin-5-propionate x
4-Hydroxyphenylacetate 3.14 ** 0.45 0.06 1.03
Phenylacetate 1.72 **
Shikimate-3-phosphate 1.02 2.31 2.68 ** 2.66 ** 4.64 ** 3.48 ** 2.10 ** 2.38 2.44 **
TCA Cycle
2-Oxoglutarate 1.31 1.50 * 0.71 1.02 1.00 0.93 1.19 1.10 0.93
Citrate 1.16 1.11 0.57 1.10 0.97 1.04 2.24 * 2.70 *** 1.57
Fumarate 0.64 0.60 ** 0.62 1.20 0.86 1.25 0.95 0.66 * 1.00
Malate 0.50 ** 0.54 ** 0.40 ** 1.37 0.67 0.77 1.11 0.66 * 0.89
Succinate 0.55 * 0.45 *** 0.55 1.49 * 1.38 1.32 0.95 0.66 1.34 *
  Colour scale for fold changes: <0.1 <0.2 <0.4 <0.67 0.67–1.5 >1.5 >2.5 >5.0 >10.0
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3.3.4.4 Coenzyme A analysis
While the coenzyme A (CoA)-dependent degradation pathways of branched chain 
amino acids and phenylalanine could be covered completely by conducted proteomic and 
GC-MS-based metabolomic analysis, tryptophan degradation remained ambiguous. Thus, 
an additional LC-MS analysis was performed to refine this pathway in P. inhibens DSM 
17395. Cells grown on succinate served as reference.
Results of this analysis are shown in figure 17. Overall, 40 different CoA derivatives 
could be detected. Due to limited number of available standards, identification may be 
ambiguous in some cases. Data could not be normalised to the internal standard 
biochanin A, as this compound proved to be too different from target analytes, thus being 
inappropriate for sample preparation and chromatography conditions used. 
According to Spearman rank correlation, CoA derivatives clustered into two groups: (I) 
more abundant in cells grown with succinate; (II) more abundant in cells grown with 
tryptophan. Amongst the first group are CoA derivatives involved in primary metabolism, 
like succinyl-CoA and acetyl-CoA; decanoyl-CoA, representing fatty acid metabolism, as 
well as butanoyl-CoA and 3-hydroxybutanoyl-CoA, which are associated with butanoate 
metabolism. Amongst the second group are CoA derivatives that have a cyclohexane-
structure, are involved in benzoate degradation and may be derived from degradation of 
tryptophan (e.g. cyclohex-1,5-diene-1-carbanoyl-CoA or 2-hydroxy-5-oxo-cyclohex-1-
carbonyl-CoA). Notably, also CoA intermediates associated with the other studied amino 
acid degradation pathways could be detected in low concentrations in both test and 
reference conditions (e.g. phenylacetyl-CoA and isovaleryl-CoA). Additionally, almost all 
intermediates of the ethylmalonyl-CoA pathway (e.g. methylsuccinyl-CoA and 
methylmalonyl-CoA), were very abundant in cells derived from cultivation with succinate. 
3.3.4.5 General observations of metabolomic changes
Although only few detected metabolites are directly involved in the degradation of one 
of the nine studied amino acid degradation pathways, many additional significant changes 
in the metabolome could be observed, which were directly or indirectly associated with the 
correspondent catabolic processes. The most significant changes are shown in figure 18. 
Some amino acids provided under corresponding cultivation conditions are very 
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Figure 17: Detected coenzyme A derivatives in cells grown on tryptophan or succinate. 
Abundances of coenzyme A (CoA) derivatives are visualised as heatmap by blue-yellow colour  
scale (low to high abundance). For plotting, data were normalised internally in MultiExperiment 
Viewer. Dendrograms showing correlation of samples and analytes were calculated using Spearman 
method. Abbreviations: a, artefact, formed during sample-preparation; b, associated with benzoate 
degradation; c, associated with branched-chain amino acid degradation; d, intermediate of 
phenylalanine degradation; e, intermediate of ethlylmalonyl-CoA pathway; STD, identified by a 
chemical standard. 
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Figure 18: Heatmap of selected intracellular metabolites of the experiment “amino acid 
degradation”. Abundances of metabolites are visualised by blue-yellow colour scale (low to high 
abundance). Clustering of growth conditions (one of 9 different amino acids or succinate (Succ) as 
single carbon source) and metabolites was calculated using Spearman method. For plotting, data 
were internally normalised in MultiExperiment Viewer. Marked clusters indicate metabolites that 
showed similar distribution pattern.
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abundant intracellularly (methionine, isoleucine, valine, lysine and threonine). Otherwise, 
abundance of leucine is unchanged as compared to succinate-grown cells. Phenylalanine is 
even less abundant; tryptophan and histidine could not be detected. 
Notably, overall intracellular amino acid concentration in cells grown with single amino 
acids (except for cells grown with either threonine or histidine) were considerably low, as 
compared to succinate-grown cells, especially in case of cells grown with either 
tryptophan, phenylalanine, methionine or lysine. This also includes glutamate, which is 
typically one of the most abundant amino acids in P. inhibens DSM 17395. Besides low 
amino acid concentrations, also nicotinamide and nicotinate were significantly less 
abundant in cells grown with tryptophan, phenylalanine, methionine or lysine (see clusters 
III and IV in Figure 18).
Another interesting finding is the high abundance of the lysine degradation  
intermediates cadaverine, 5-aminopentanoate and glutarate not only in cells grown with 
lysine, but also in cells grown with methionine, histidine and isoleucine. Side products of 
corresponding substrate amino acid degradation could be detected in some sample groups 
(e.g. hydantoin-5-propionate in histidine-grown cells or phenylactetate in phenylalanine-
grown cells) (Table 13). Such compounds were also or alternatively detected in the 
medium (Table 12). Moreover, some methylated compounds were partially more abundant 
in cells grown with amino acids than compared to cells grown with succinate (e.g. 2-
methylmalate and 2-methylserine). Notably, benzoate was very abundant in valine-grown 
cells. (Supplementary material S6 and S7).
3.3.5 Carbohydrate degradation
3.3.5.1 Growth characteristics and extracellular metabolomic analysis
To study and to refine complex catabolic networks, which were unclear in regard to the 
original genome annotation, P. inhibens DSM 17395 was cultivated in minimal medium 
supplied with one out of five selected carbohydrates (N-acetyl-glucosamine, mannitol, 
sucrose, glucose, xylose) or succinate as reference condition. Sampling point for 
metabolomic analyses was ½ ODmax.  
Of used substrates, succinate was highest concentrated, therefore succinate resulted in 
highest ODmax (≈ 2.4), which was about twice as much as compared to the tested sugars. 
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Highest growth rate was observed for succinate and N-acetyl-glucosamine (about 0.2 h-1), 
whereas glucose and xylose induced only half of that growth rate. Mannitol and sucrose 
resulted in significantly lower growth rates (0.02 h-1 to 0.04 h-1) (Figure 19).
Depletion of the provided substrate at ½ ODmax correlates to the observed growth rate. In 
case of high growth rates (succinate and N-acetyl-glucosamine), more than 50% of the 
available substrate was consumed, whereas in case of slow growth rates (sucrose and 
mannitol), less than 25% of the substrate was consumed. Besides depletion of the substrate, 
extracellular metabolomic analysis revealed export of three compounds, all of which were 
detected in succinate medium. While fumarate was only detectable in succinate medium, 3-
hydroxybutanoate could also be found in sucrose medium; pyruvate was also detected in 
sucrose and mannitol medium (Table 14).
Figure 19: Growth of P. inhibens DSM 17395 on selected carbohydrates. For better 
visualisation, dot-lines were included. Abbreviations of substrates: NAG, N-acetyl-glucosamine; 
MTL, mannitol; SUCR, sucrose; GLC, glucose; XYL, xylose; Succ, succinate.
Table 14: Extracellularly detected metabolites during growth on selected carbohydrates. 
Abbreviations: x, compound detected in the corresponding culture supernatant at ½ ODmax. 
Metabolites
Fold change in substrate abundance as compared to t0
N-Acetyl-
glucosamine Mannitol Sucrose Gluose Xylose Succinate
N-Acetyl-glucosamine 0.46
Mannitol 0.77
Sucrose 0.81
Glucose 0.61
Xylose 0.57
Succinate 0.45
Fumarate x
3-Hydroxybutanoate x x
Pyruvate x x x
Colour scale for fold changes: <0.5 <0.75 <1.0
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3.3.5.2 Intracellular metabolomic analysis
The metabolomic dataset consists of 130 metabolites, 116 of which could be identified. 
Of all identified metabolites, 65 were significantly changed in abundance (corrected p-
value of t-test or Wilcoxon-Mann-Whitney test < 0.001) in at least one of the tested 
substrate conditions (cells grown with single carbohydrates), compared to the reference 
(cells grown with succinate). This was underlined by conducted correlation analysis on 
basis of Pearson coefficient, which revealed low correlation between reference and test-
conditions (ranging from 0.66 to 0.74). Cells grown with N-acetyl-glucosamine also 
differed strongly from the other studied growth conditions, but showed at least moderate 
correlation of about 0.82 to cells grown with mannitol or xylose. However, growth with 
mannitol, xylose, glucose or sucrose resulted in similar metabolomic composition, with 
correlation values ranging from 0.89 to 0.94.  (Figure 20).
The catabolism of selected carbohydrates consists of (1) a peripheral degradation 
pathway, mostly specific for the correspondent carbohydrates, (2) central metabolism, 
involving Entner-Doudoroff pathway, lower branch of Embden-Meyerhof-Parnas pathway 
and pentose phosphate pathway. These pathways of central metabolism are shared for the 
degradation of different carbohydrates. Despite structural similarities of target analytes, 
that resulted in ambivalent identification of some compounds, degradation of all studied 
carbohydrates could be almost completely covered by conducted metabolomic analysis. 
Blind spots, especially in regard to transporters, were covered by proteomic analyses and 
thus allowed refinement of this catabolic network, which is explained and discussed in 
section 4.3.5.1. Detected metabolic intermediates involved in degradation of studied 
carbohydrates are listed in table 15. Most of these intermediates were considerably more 
abundant in cells grown with carbohydrates compared to cells grown with succinate. 
Amongst, these are provided substrates, like N-acetyl-glucosamine, mannitol and sucrose, 
as well as intermediates of Entner-Doudoroff pathway. In regard to this pathway, highest 
fold changes were observed for glucono-1,5-lactone, gluconate, 6-phosphogluconate and 2-
keto-3-deoxy-gluconate. Some phosphorylated intermediates of Entner-Doudoroff pathway 
are unstable (Strohhäcker et al., 1993). This is why here and in the other main experiments, 
in some cases the phosphorylated intermediates are represented by their dephosphorylated 
analogues. Abundance changes of intermediates involved in the lower branch of Embden-
Meyerhof-Parnas pathway and pentose phosphate pathway were moderately more 
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abundant compared to cells grown with succinate. 
Carbohydrate degradation ends in acetyl-CoA, which feeds into the TCA cycle by 
formation of citrate. Accordingly, citrate was significantly more abundant in cells grown 
with N-acetyl-glucosamine, glucose or xylose. While abundance of 2-oxoglutarate did not 
differ between cells grown with succinate and cells grown with single carbohydrates, the 
remaining detected intermediates of the TCA cycle (succinate, fumarate and malate) were 
considerably lower concentrated in cells grown with single carbohydrates. Sole exception 
were cells grown with N-acetyl-glucosamine; here 2-oxoglutarate, fumarate and malate 
were significantly more abundant as compared to cells grown with succinate.
In addition to these metabolic changes directly associated with carbohydrate 
degradation, further considerable changes were observed. For example, in cells grown with 
N-acetyl-glucosamine elevated concentrations of N-acetyl-glutamate, O-acetyl-serine and 
iminodiacetate were observed. Another interesting finding are the formation of particular 
C4-carboxylates (erythronate, threonate and tartrate), which were high concentrated in cells 
grown on single carbohydrates (Table 15). Acidic sugars (e.g., glucosaminate and ribonate) 
were also formed under these conditions. Notably, there were also several metabolites that 
were less abundant in cells grown with carbohydrates, especially amino acids, butanoates 
and some lipid and phospholipid headgroup components (Supplementary material S8).
Figure 20: Correlation matrix of intracellular metabolomic data from the experiment 
“carbohydrate degradation”. Pearson coefficient was used for calculation of correlation, which 
is visualised as heatmap, red colour represent high correlation. Dendrogram is based on euclidean 
distance. Abbreviations for substrates: Succ, succinate (reference condition); NAG, N-acetyl-
glucosamine; GLC, glucose; MTL, mannitol; XYL, xylose; SUCR, sucrose.
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Table 15: Fold changes of selected intracellular metabolites involved in carbohydrate 
degradation from the experiment “carbohydrate degradation in P. inhibens DSM 17395”. 
Abbreviations: a, Fold change in metabolite abundance as compared to cells grown with succinate; 
x, compound only detected in test condition; n.d., not detected in test condition; XX, compound 
only detected in test condition, but intense peak observed here; *, compound probably 
dephosphorylated during extraction. Complete list of metabolites, including p-values for abundance 
changes, is provided in the supplementary material S8.
Metabolites
Mannitol Sucrose Glucose Xylose
Carbohydrate metabolism
12.0 ± 0.6 1.33 ± 0.16 1.69 ± 0.23 2.65 ± 0.29 1.36 ± 0.17
0.03 ± 0.01 0.12 ± 0.08 0.66 ± 0.31 47.3 ± 25.7 0.33 ± 0.18
Glucosamine 0.49 ± 0.07 0.12 ± 0.02 0.12 ± 0.02
Mannitol 0.76 ± 0.14 19.9 ± 2.5 1.02 ± 0.09 0.47 ± 0.06 0.43 ± 0.03
Fructose 0.73 ± 0.05 8.27 ± 0.66 17.3 ± 1.7 2.21 ± 0.20 1.05 ± 0.12
Sucrose x
Glucose 1.59 ± 0.07 2.00 ± 0.10 0.78 ± 0.04 1.04 ± 0.07 0.86 ± 0.05
Xylose x XX
Xylulose 0.81 ± 0.08 0.76 ± 0.07 0.52 ± 0.06 0.87 ± 0.10 0.87 ± 0.13
Central metabolism
Entner-Doudoroff pathway
Fructose-6-phosphate 0.07 ± 0.06 0.02 ± 0.01 4.28 ± 2.15 4.30 ± 2.44 0.44 ± 0.36
0.03 ± 0.01 0.04 ± 0.02 0.16 ± 0.06 0.30 ± 0.12 0.14 ± 0.06
Glucono-1,5-lactone * 4.70 ± 0.32 8.99 ± 0.57 9.83 ± 0.71 22.4 ± 2.3 4.99 ± 0.42
Galactonate / Gluconate * 11.4 ± 1.8 4.62 ± 0.74 8.06 ± 1.26 26.0 ± 3.7 6.58 ± 1.34
6-Phosphogluconate 0.24 ± 0.09 0.96 ± 0.37 5.05 ± 1.98 15.8 ± 6.0 0.17 ± 0.16
2-Keto-3-deoxy-gluconate (KDG) * 30.5 ± 4.3 4.66 ± 2.49 1.87 ± 0.10 3.18 ± 0.28 2.05 ± 0.13
Glyceraldehyde * 1.05 ± 0.13 0.75 ± 0.11 0.50 ± 0.07 0.64 ± 0.08 0.76 ± 0.09
Lower branch of Embden-Meyerhof-Parnas pathway
Dihydroxyacetone phosphate 1.68 ± 0.33 0.31 ± 0.15 0.39 ± 0.09 0.63 ± 0.17 0.60 ± 0.18
1,3-Dihydroxyacetone * 0.77 ± 0.04 0.95 ± 0.05 1.00 ± 0.06 1.12 ± 0.08 0.98 ± 0.05
3-Phosphoglycerate 3.77 ± 0.44 1.58 ± 0.16 1.66 ± 0.23 8.75 ± 1.04 2.60 ± 0.31
2-Phosphoglycerate 1.64 0.42 0.80 2.70
Phosphoenolpyruvate 1.95 ± 0.28 1.77 ± 0.24 1.27 ± 0.21 4.43 ± 0.66 1.84 ± 0.28
Pyruvate 7.71 ± 1.29 3.62 ± 0.60 3.11 ± 0.54 3.84 ± 0.57 5.35 ± 0.77
Pentose phosphate pathway
3.74 ± 2.99 2.75 ± 2.68 5.45 ± 5.20 0.48 ± 0.35 0.99 ± 0.93
Ribose 1.02 ± 0.05 2.30 ± 0.08 0.81 ± 0.07 0.89 ± 0.07 2.45 ± 0.11
0.09 ± 0.06 0.05 ± 0.05 0.17 ± 0.11 1.00 ± 1.00
TCA Cycle
Citrate 4.00 ± 0.58 1.28 ± 0.14 0.89 ± 0.15 5.06 ± 0.83 4.39 ± 0.72
2-Oxoglutarate 1.90 ± 0.12 0.73 ± 0.05 0.60 ± 0.04 1.10 ± 0.11 1.31 ± 0.10
Succinate 0.60 ± 0.06 0.30 ± 0.02 0.07 ± 0.01 0.13 ± 0.01 0.24 ± 0.02
Fumarate 2.11 ± 0.20 0.71 ± 0.06 0.35 ± 0.03 0.37 ± 0.05 0.52 ± 0.05
Malate 3.45 ± 0.35 0.48 ± 0.04 0.28 ± 0.03 0.34 ± 0.04 0.40 ± 0.04
Amino acid derivatives
6.77 ± 0.41 0.78 ± 0.06 0.87 ± 0.07 1.08 ± 0.12
18.6 ± 4.4 11.8 ± 3.9 0.91 ± 0.38 3.08 ± 0.67 11.5 ± 3.9
Ornithine 1.46 ± 0.74 0.41 ± 0.11 0.22 ± 0.06 0.38 ± 0.11 1.04 ± 0.32
Organic acids
Erythronate 8.23 ± 0.88 2.70 ± 0.28 1.61 ± 0.21 2.90 ± 0.35 1.91 ± 0.24
Iminodiacetate 31.1 ± 5.9 1.90 ± 0.36 0.77 ± 0.15 5.64 ± 1.17 2.13 ± 0.41
Tartrate 0.68 ± 0.15 1.59 ± 0.40 10.8 ± 2.2 169 ± 37 3.06 ± 0.68
Threonate 2.59 ± 0.72 4.20 ± 0.77 29.6 ± 5.5 13.1 ± 2.6 2.64 ± 0.54
Urea 0.98 ± 0.18 0.80 ± 0.34 0.26 ± 0.07 0.69 ± 0.18 0.27 ± 0.05
Fold change a
N-Acetyl-
glucosamine
N-Acetyl-glucosamine
Glucose/Glucosamine/Sorbitol-6-P
Glucose/Galactose/Mannose-6-P
Erythrose-4-P
Xylulose-/ Ribulose-5-P
N-Acetyl-glutamate
O-Acetyl-serine
<0.1n.d. <0.2 <0.4 <0.67 0.67 – 1.5 >1.5 >2.5 >5.0 >10.0Colour scale for fold changes:
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3.3.6 Metabolic responses to ammonium limited growth condition
Nitrogen is one of the key elements that limits bacterial growth in marine environments. 
Most of inorganic nitrogen in the ocean is available as nitrate (NO3-), whereas ammonium 
(NH4+) content is considerably lower. Of these, only ammonium can be utilised by 
P. inhibens DSM 17395 as nitrogen source (see Biolog phenotypic microarray analysis, 
Figure 7). To study the metabolic response of P. inhibens DSM 17395 to growth under 
nitrogen limited conditions, cells were cultivated in minimal medium providing only 1 mM 
ammonium (instead of 4.7 mM) and were harvested for metabolomic analysis along the 
time-course.
3.3.6.1 Growth characteristics and extracellular metabolomic analysis
Growth is characterised by a lag-phase of about 15 to 20 h and an ODmax (600 nm) of 
about 1.2, which was reached after 40 h. Afterwards, the optical density remained 
relatively constant (Figure 21). Further, ammonium concentration and cellular N/C ratio 
were determined along the time-course (performed by Sebastian Koßmehl, ICBM 
Oldenburg). These analyses revealed that the whole amount of provided ammonium was 
imported within the first 20 h. Accordingly, the highest cellular N/C ratio was observed at 
the beginning of cultivation, decreasing from t1 5 to t30 until this ratio remained constant. 
GC-MS analysis of the culture supernatant enabled detection of low amounts of 3-
hydroxybutanoate during stationary phase (Figure 21). This, besides the substrate glucose 
(which could not be quantified), was the only organic compound detected in the medium 
via GC-MS.
3.3.6.2 Intracellular metabolomic analysis
Samples for GC-MS-based metabolomic analysis were taken across the time-course 
from early growth stage (t15) to late stationary phase (t90); samples from ½ ODmax (t30) 
served as reference. Cultivation and harvesting were conducted by Sebastian Koßmehl 
(ICBM, Oldenburg). Overall, 114 metabolites could be detected, 91 of which could be 
identified. Most metabolites were significantly changed in abundance as compared to the 
reference condition. Therefore, also abundance changes between consecutive sampling 
points were elucidated. For this purpose, depending on data distribution, either t-test or 
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Wilcoxon-Mann-Whitney test were applied. In both cases, p-values were corrected. 
Overall, 29 compounds showed significant p-values (< 0.01) for consecutive sampling 
points. This number may be underestimated, since considerable fold changes were mostly 
observed between consecutive sampling points. However, these abundance shifts were 
mostly not significant, because the applied tests were inappropriate for the limited number 
of replicates (in average 5 or 6).
As revealed by Spearman correlation, samples clustered according to growth-phases, 
resulting in four different groups (Figure 22). The first group, comprising t15 and t20, was 
similar to the second group, comprising the consecutive samples from t25, t30 and t40. 
Metabolic composition at these five sampling-points differed considerably from metabolic 
composition of the other two groups in stationary phase (t50, t60) and (t75, t90). According to 
this hierarchical cluster analysis, considerable differences between early and late stationary 
phase were apparent.
Two characteristics are responsible for observed clustering: (1) number of detected 
metabolites at the corresponding sampling points, (2) the overall metabolite concentration. 
Figure 21: Growth of P. inhibens DSM 17395 under limited ammonium concentration. Growth 
was observed by measuring the optical density at 600 nm. Ammonium content in the medium was 
determined enzymatically, the cellular N/C ratio were determined with a Vario El cube (Elementar 
Analysensysteme, Hanau, Germany) as described previously by Ze c h et al. (2013a), each 
conducted by Sebastian Koßmehl (ICBM Oldenburg). The amount of 3-hydroxybutanoate in the 
medium was determined via GC-MS. For better visualisation, dot-lines were included. 
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Both were highest at early growth phases (around t15 to t25). Exponential growth phase (t30) 
marks the point, when both number of detected compounds and metabolite concentration 
considerably and continuously decreased, until only a few compounds remained. This 
striking metabolic shift of selected metabolites is visualised in a heatmap in figure 22. The 
complete list of metabolites is provided in the Supplementary material S9. Most 
Figure 22: Heatmap of selected intracellular metabolites of experiment “metabolic response 
to ammonium limited growth condition”. Abundances of metabolites across the time course are 
visualised by blue-yellow colour scale (low to high abundance). Subscript numbers on top of figure 
represent the sampling-time in hours. Correlation for clustering of sampling point and metabolites 
was calculated using spearman method. For plotting, metabolites were internally normalised in 
MultiExperiment Viewer. Marked clusters indicate metabolites that showed similar distribution 
pattern across the time course.   
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metabolites were more abundant at early sampling points (cluster II in figure 22). Only a 
few metabolites were more abundant in the stationary phase (clusters I and IV). Amongst 
the latter were some unidentified compounds, as well as 3-hydroxybutanoate, which was 
very abundant at t50 and t60. This coincides with detection of 3-hydroxybutanoate in the 
medium from t50 and following sampling points.
Interestingly enough, many metabolites were not or only detected in low concentrations 
during stationary phase. This also includes compounds that are usually very abundant in 
P. inhibens DSM 17395 or even increase in abundance during stationary phase, when 
grown on 4.7 mM ammonium, like glutamate, tartrate or glucuronate (Zech et al., 2009).  
Amongst the metabolites most abundant in the early growth phase were some 
intermediates of central metabolism, e.g. succinate, fumarate, malate and 2-keto-3-deoxy-
gluconate. Further, in accordance to higher cellular N/C ratio (Figure 21) at the beginning 
of cultivation, many nitrogen-containing compounds were most abundant at t15 and t20. This 
comprises amino acids, diamines, aminobutanoates and nucleobases. Further, it should be 
noted that the overall number of detected nitrogen-containing compounds was considerably 
lower compared to all other conducted experiments in this study.
The most significant metabolic shifts from the early growth phase to exponential growth 
phase, as well as from exponential growth phase to stationary phase are summarised in 
figure 23. Further results are provided in the Supplementary material S9.
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Figure 23: Intracellular metabolic changes during growth with limited ammonium 
concentration. Normalised peak areas of all metabolites were plotted in double-logarithmic scale. 
Colouring: green: increased abundance, red: decreased abundance as compared to the reference t30. 
(exponential growth phase). (A) Comparison between t20 and t30. (B) Comparison between stationary 
phase, t50 and t30. Abbreviations: KDG, 2-keto-3-deoxy-gluconate.
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4 Discussion
4.1 Biolog phenotypic microarray analysis
4.1.1 Carbon sources
The Biolog phenotypic microarray analysis was applied to define the substrate range of 
Phaeobacter inhibens DSM 17395 for carbon and nitrogen sources. Overall, 81 out of 190 
carbon sources were tested positive (Figure 6), revealing a broad range utilisable 
substrates. 
Since only respiratory activity was measured, positive responses did not necessarily 
prove usability for anabolic purposes. Some substrates tested positive, were negative tested 
on growth, which were citrate (Buddruhs et al., 2013), L- and D-arabinose and D-fucose 
(Wiegmann et al., 2014), as well as ethanolamine (determined by Felix Pritsch in the 
context of his bachelor of science thesis, 2012). However, all 20 proteinogenic amino acids 
and most monosaccharides can be used for growth (Drüppel et al., 2014; Wiegmann et al., 
2014). These substrates showed fast kinetics and strongest colour changes (Figure 6) and 
were also preferred utilised when grown in Marine Broth medium (Section 3.3.1.2). Thus 
P. inhibens DSM 17395 is well adapted to its natural habitat, as these compounds, along 
with dipeptides and simple carboxylates belong to the most abundant low molecular 
substrates available in marine environments, especially during seasonal bloom periods of 
phytoplankton (Ittekkot, 1982; Pettine et al., 1999). This could also be an explanation for 
observed high abundances and metabolic activity of members of the Roseobacter clade 
during seasonal bloom and collapse of phytoplankton populations (Alonso-Sáez et al., 
2007; Alonso-Sáez and Gasol, 2007). The broad substrate range revealed for P. inhibens 
DSM 17395 is also true for closely related strains P. inhibens DSM 16374 and P.  
gallaeciensis CIP 105210, as shown recently by Buddruhs et al. (2013). However, such a 
broad substrate range is not a general characteristic for the Roseobacter clade, as for 
example Dinoroseobacter shibae DFL 12T can only utilises 19 of 190 tested carbon sources 
(Rex et al., 2013). Interestingly, bromosuccinate can be used by P. inhibens DSM 17395 
and D. shibae DFL 12T. Halogenic compounds can be formed by ozon (Narukawa et al., 
2003), or be produced by algae as protectant against bacteria and fungi (Cabrita et al., 
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2010). This could be a specific adaptation to life with algae and an explanation for 
observed association of the Roseobacter clade with algae (Brinkhoff et al., 2008). 
Substrates that were tested negative, were mostly uncommon compounds, e.g. synthetic 
L-glucose, lactulose, D-amino acids or the polysorbates Tween 20, 40 and 80. Otherwise, 
oligo- and polysaccharides, which were tested negative, are available in marine 
environments (e.g. Sakugawa et al., 1990). This negative test results, however, were in 
accordance to previous findings, that P. inhibens DSM 17395 is tweenase, gelatinase and 
amylase negative (Ruiz-Ponte et al., 1998; Martens et al., 2006; Buddruhs et al., 2013). 
Amongst negative tested substrates were also tartrate, 5-aminopentanaote, gluconate and 
glucuronate, which were very abundant in P. inhibens DSM 17395 in particular conducted 
experiments of this study. Since catabolic enzymes for these substrates are encoded on the 
genome, missing transporters are probably reason for this negative result, whereby for 5-
aminopentanoate, definitely a transporter must be available, as it was used as nitrogen 
source. However, probably this transporter is only expressed under nitrogen limited 
conditions. Such regulation upon nitrogen limited condition was for example shown for 4-
aminobutanoate import in Escherichia coli (Brechtel and King, 1998).
Interestingly L-valine gave a stronger response as nitrogen source than as carbon source, 
indicating its better usability as amino donor than as carbon source. After import of valine, 
only one transamination reaction is required to obtain the nitrogen for anabolic purposes, 
whereas further energy-demanding degradation reactions are required until usable as 
carbon source (the correspondent pathway is discussed in section 4.3.4.7, figure 27).
4.1.2 Nitrogen sources
72 of 95 tested nitrogen sources were positive, revealing a broad range of transporters. 
Most of tested substrates have an easy accessible nitrogen (e.g. an amino-group), that 
require few enzymatic reactions (like transamination or deamination) to provide the 
nitrogen for anabolic purposes. Also nucleobases, whose concentration in seawater can 
reach about 9 µg/l and are usually rapidly degraded by bacteria (Montani et al., 1988), 
were utilised by P. inhibens DSM 17395 as nitrogen source. As shown by Felix Pritsch in 
the context of his bachelor of science thesis (2012), P. inhibens DSM 17395 can use single 
nucleobases, such as adenine or uracil (i.e. without bound ribose), merely as nitrogen 
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source. Not all nitrogen atoms of nucleobases are usable, as revealed by export of urea, 
which is in accordance with nucleobase degradation in bacteria (Vogels and Van der Drift, 
1976) and observed formation of urea by marine bacteria when supplied with nucleobases 
(Berg and Jørgensen, 2006). All L-amino acids and dipeptides tested positive as carbon 
source, were also tested positive as nitrogen source, as correspondent nitrogen atoms are 
easy accessible and require not necessarily specific transaminases. 
Amongst negative tested nitrogen sources were short-chain amines (i.e. compounds 
without a carboxylate group), as well as amides. Urea was negative, due to missing urease 
in P. inhibens DSM 17395. Accordingly, urea is rather used to dispose of excess nitrogen 
and thus was detected in culture supernatant of P. inhibens DSM 17395 when provided 
with nitrogen-rich substrates, like casamino acids (Section 3.3.2.1). Amongst inorganic 
nitrogen sources, only ammonia was tested positive, although nitrate and nitrite comprise 
much higher concentrations in marine environments. This non-utilisability of nitrate is 
compensated by the broad range of utilisable organic nitrogen sources. 
4.1.3 General observations
Overall, for most tested substrates (C and N sources), respiratory activity was observed 
within the first 12 h of incubation, indicating the relative fast adaptation of P. inhibens 
DSM 17395 to changing nutrient conditions. This, along with the broad substrate range 
enables to utilise almost any available substrate, which is beneficial in marine 
environments, as provided substrates are extremely versatile and low concentrated. The 
broad substrate range of P. inhibens DSM 17395 is accomplished by transporters that have 
broader substrate range, e.g. branched-chain amino acid transporter (discussed in section 
4.3.2.1), as well as catabolic pathways that are shared by several substrates, e.g. Entner-
Douodroff pathway for carbohydrates (Section 4.3.5) or enzymes with broader substrate 
specificity, e.g. in case of branched-chain amino acid degradation (Section 4.3.4.7).
4.2 Isotope labelling
Isotope labelling was applied to distinguish between metabolites of biological origin 
and potential contaminants. Biological origin could be confirmed for 61 metabolites, which 
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comprised all common detectable metabolites of primary metabolism, like TCA cycle 
intermediates and typical compounds, such as amino acids and carbohydrates. 
Notably, several saturated fatty acids were unlabelled. Most probably these compounds 
derived from plastic consumables; whereas significant abundance increases, e.g. as 
determined during growth on casamino acids (Section 3.3.2.2) cannot be explained by 
contaminants alone, but must be of biological origin. Also benzoate was mostly unlabelled, 
but is usually detected in P. inhibens DSM 17395 and was even significantly more 
abundant when grown on valine (Section 3.3.4.5). It probably derived from degradation of 
4-aminobenzoate or maybe other aromatic compounds, like tryptophan. In contrast to this, 
toluate was completely unlabelled. Accordingly no significant abundance change was 
observed for this compound in any of conducted experiments, except for the final 
experiment “metabolic response to growth under limited ammonium” (Section 3.3.6.2), 
where it decreased along with most other metabolites over the course of time. The origin of 
this aromatic contamination currently remains unclear.
4.3 Main experiments
In this section, results from metabolomic analysis of conducted cooperation experiments 
were discussed by including correspondent proteomic data of joint publications. Detailed 
information about methods and results of proteomic analyses are provided in the 
correspondent publications (Table 16). A list of discussed enzymes, together with EC 
numbers and gene-loci tags are provided in the supplementary material S10.
Table 16: Source of discussed proteomic data. 
Name of experiment Reference
(1) Adaptation to growth with complex nutrients (Zech et al., 2013a)
(2) Dynamics of amino acid utilisation (Zech et al., 2013b)
(3) Casamino acid consumption by plasmid-cured strains No proteomic analyses 
performed.
(4) Amino acid degradation (Drüppel et al., 2014)
(5) Carbohydrate degradation (Wiegmann et al., 2014)
(6) Metabolic responses to ammonium limited growth condition Proteomic analyses still in 
progress, thus not included.
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4.3.1 Adaptation to growth with complex nutrients
4.3.1.1 Growth characteristics
Cultivation of P. inhibens DSM 17395 in complex medium (MB medium) and glucose 
minimal medium (GM medium) was applied to simulate nutrient-rich conditions during 
collapse of phytoplanktonic bloom, respectively replenished nutrient conditions. Observed 
shorter lag-phase, higher µmax and ODmax upon growth with MB medium compared to GM 
medium, resulted from different amount of provided carbon: 229 mM in case of MB 
medium, 66 mM in case of GM medium. According to this, also considerable higher O2 
consumption rate and CO2 production rate were observed in MB medium (Table 17). 
Interestingly enough, whereas provided carbon in GM medium was almost completely 
consumed, cells grown in MB medium entered stationary phase although more than 50% 
of initially provided carbon was still available. Thus, growth seems not to be C limited, 
which was also observed during cultivation on casamino acids (Section 3.3.3.1). However, 
whereas in case of casamino acids, remaining carbon sources were definitely utilisable by 
P. inhibens DSM 17395, remaining substrates in MB medium may not be utilisable. 
Probably, remaining carbon sources were polymers, like proteins or polysaccharides, 
which cannot be utilised by P. inhibens DSM 17395 as revealed by Biolog phenotypic 
microarray analysis (Section 3.1.1). Additionally, formation of tropodithietic acid and acyl-
Table 17: Physiological properties of P. inhibens DSM 17395 during growth in complex 
medium and minimal medium in process-controlled bioreactors. Abbreviations: MB medium, 
Marine Broth medium; GM medium, glucose-containing minimal medium. Shown data were taken 
from table 1 in (Zech et al., 2013a).
Physiological properties during growth MB medium GM medium
Exponential growth phase
Maximum specific growth rate, µmax (h-1)   0.36 ± 0.0   0.10 ± 0.0
Biomass formation rate (mg l-1 h-1)   81.8 ± 2.6   26.4 ± 2.0
O2 consumption rate (mmol l-1 h-1)   4.27 ± 1.1   0.60 ± 0.0
CO2 production rate (mmol l-1 h-1)   3.44 ± 0.5   0.66 ± 0.0
Entry into stationary phase
Optical density (measured at 600 nm)   4.23 ± 0.3   1.97 ± 0.1
Cellular dry weight (mg/l) 1186.5 ± 79.9 646.0 ± 5.0
Total carbon consumed (mmol/l) 96.60 ± 4.8 60.30 ± 1.6
Total O2 consumption (mmol/l)   59.37 ± 12.3 22.61 ± 0.1
Total CO2 production (mmol/l) 47.96 ± 4.3 24.90 ± 1.3
Cellular N/C ratio    0.208    0.085
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homoserine-lactones as determined by Berger et al. (2012) upon growth on MB medium 
could contribute to limit further growth of P. inhibens DSM 17395. Other factors, such as 
insufficient O2 supply or inappropriate pH are unlikely, as these parameters were controlled 
and kept constant in a process controlled bioreactor.
Due to the high amount of peptone and yeast extract, MB medium is nitrogen-rich. 
Accordingly, a considerable higher cellular N/C ratio was determined in cells derived from 
MB medium (Table 17). This is reflected by intracellular metabolomic analysis. Here, 
considerable higher abundances of several nitrogen-containing compounds, like amino 
acids, nucleosides and nucleobases, were observed. Further, the high intracellular amounts 
of glycyl-glycine, 5-aminopentanoate, cadaverine and spermidine could also be interpreted 
as temporary nitrogen-storage. 
4.3.1.2 Extracellular metabolomic analysis
Substrate depletion. Analysis of MB medium revealed high depletion of several 
provided substrates. Amongst most depleted substrates were amino acids and particular 
carbohydrates that showed also strong responses as carbon sources in the Biolog 
phenotypic microarray analysis (Section 3.1.1). Interestingly, some substrates that showed 
strong response in phenotypic microarray analysis, were only moderately consumed in MB 
medium (e.g. arginine, threonine, lysine, serine). This indicates preferences of P. inhibens 
DSM 17395 for particular substrates, when providing complex substrate mixture. Several 
factors, such as efficiency or inhibition of uptake or catabolism can be responsible for this 
observation, which was also observed for many other bacteria before (e.g. Strobel, 1993; 
Görke and Stülke, 2008; Jojima et al., 2010; Rabus et al., 2014). 
Exported compounds. The export of 2-hydroxyphenylacetate, which was also detected 
in medium with phenylalanine as single carbon source (Table 12) resulted probably from 
degradation of phenylalanine or similar compounds. This side product cannot be utilised, 
which is also true for the structural similar compounds 3- and 4-hydroxyphenylacetate 
(both negative in Biolog phenotypic microarray analysis, Figure 6). Export of urea is the 
main flow to dispose of excess nitrogen, which is obtained by degradation of N-rich 
compounds, like amino acids. All enzymes involved in the urea cycle were detected, except 
for argininosuccinate lyase (Figure 24). Urea also originated from purine catabolism, as 
each degraded purine molecule yields one molecule urea plus additional ammonium. 
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4.3.1.3 Intracellular metabolomic analysis
Statistical data analysis. To exclude any potential impact of the cultivation vessel on 
metabolic abundance changes (see Figure 9), metabolomic data were elucidated different 
to the published approach (Zech et al., 2013a). Only data from bioreactors were used, 
because of following reasons: First, cultivation in bioreactors was process-controlled; thus 
impact of pH or oxygen supply on metabolism was minimised. Second, larger replicate 
numbers allowed an even more robust statistical analysis. Main cause for non-normally 
distributed metabolomic data were extreme concentration differences of intracellular 
metabolites between the two cultivation conditions. For interpretation of data, cells derived 
from minimal medium served as reference condition.
Substrate import. High abundance of several metabolites observed in cells derived 
from MB medium can partially result from insufficient applied washing procedure. 
However, as many of these compounds could not be detected extracellularly, uptake is in 
most cases more probable. Several transport systems could be detected by proteomic 
analyses. For substrate uptake, many substrate-specific ABC transporter were identified by 
proteomic analyses. Further, 13 different outer-membrane embedded porins were detected 
that allow the unspecific passage of solutes into the periplasm for molecules < 200 Da, 
which is the case for most provided substrates in the medium, except for long-chain fatty 
acids, derived from extracellular lipid degradation (Zech et al., 2013a). 
Membrane components. Import of extracellular fatty acids and associated compounds 
(e.g. C18:1, C12:0 and glycerol-3-phosphate) might be accomplished by flip-flop mechanisms 
across the outer membrane as described e.g. by Gurtovenko and Vattulainen (2007) and 
Schaffer (2002). Further, a putative glycerol-3-P-diester uptake system is encoded on the 
genome (not identified by proteomic analyses), which could be used for import of 
ethanolamine-based lipids (Zech et al., 2013a). Since corresponding enzymes for 
degradation of ethanolamine-phosphate are not encoded on the genome, ethanolamine-
phosphate accumulated intracellularly. In contrast to this, degradation of glycerol-3-
phosphate and fatty acids could be covered by proteomic analysis. Correspondent enzymes 
were not changed in abundance, except for acyl-CoA dehydrogenase, which was more 
abundant in cells derived from MB medium (Figure 24). Thus, fatty acid degradation 
seems to be less relevant under these cultivation, despite the fact of exported enzymes for 
lipid degradation (Zech et al., 2013a). Instead, the higher abundances of membrane 
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associated compounds could be a result of higher growth rate. However, intracellular 
concentration of alanyl-alanine and 2,6-diaminopimelate, both involved in peptidoglycan 
biosynthesis, did not change between the two tested growth conditions (Supplementary 
material S3).
Nucleotide metabolism. High growth-rate did not affect abundances of enzymes for 
nucleotide metabolism, with exception of adenylate kinase, CTP synthase and carbamoyl-
phosphate synthase, that were slightly more abundant in cells grown in MB medium (Zech 
et al., 2013a). However, nucleotide biosynthesis is regulated by allosteric feedback 
inhibition, which explains these unchanged enzyme concentrations. Biosynthesis of 
inosine-5'-monophosphate (IMP) is inhibited by guanosine-5'-monophosphate (GMP), and 
adenosine-5'-monophosphate (AMP) and thus IMP does not accumulate in cells (Ledesma-
Amaro et al., 2013). Since both AMP and GMP were more abundant in cells derived from 
MB medium, IMP was less abundant. Further, higher abundance of catabolic intermediates 
xanthine and hypoxanthine was observed. Therefore, in accordance with depletion of some 
representative nucleotides and nucleobases in the medium (Supplementary material S2) 
and slightly more abundant unspecific ABC nucleoside transporter (Zech et al., 2013a), 
uptake of these compounds for catabolic purposes is very likely.
Diamine formation. High abundance of cadaverine in cells grown in MB medium, 
resulted most probably from degradation of imported lysine (see section 4.3.4.4 for 
discussion of lysine degradation), as cadaverine was not detectable in the medium. In 
contrast to this, spermidine could be imported from the medium, which might be 
accomplished by a spermidine/putrescine specific ABC transporter. 2 out of 4 subunits of 
this transporter could be identified by proteomic analysis. Besides uptake, degradation of 
arginine and ornithine could also contribute to high abundance of spermidine (Figure 24). 
These diamines can have several functions, e.g. as signalling molecules or as protection 
against oxygen toxicity (Kusano et al., 2008). However, maybe these compounds just 
accumulated, as known polyamine antiporters (Kusano et al., 2008; Tomitori et al., 2012) 
are not encoded. Therefore, excess nitrogen had to be exported via urea.
Amino acid degradation. Several amino acids were available in MB medium and were 
utilised by P. inhibens DSM 17395. Alanine and glycine, both strongly depleted, might be 
imported by an alanine/glycine cation symporter (gene loci: PGA1_c07110 and 
PGA1_78p00280), which were identified by proteomic analyses. Both amino acids are 
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Figure 24: Overview of selected pathways that are active when grown in MB medium or 
glucose minimal medium. Metabolites were analysed by GC-MS, proteins by several proteomic 
approaches as described in joint publication (Zech et al., 2013a). Further information to detected 
metabolites and enzymes are provided in the supplementary material S3 and S10.
Acetoacetyl-
CoAAcetyl-CoA
Ornithine
Arginine
 3-Hydroxy-
butanoylCoA
Polyhydroxy-
butanoate
 PHB-
granules
Pyruvate
 Phospho-
enolpyruvate
3-P-hydroxy-
pyruvate Serine
Glycine
Cysteine
Shikimate
Chorismate
Phenylalanine
Tyrosine
Glucose
Glucono-1,5-lactone-P *
2-Keto-3-deoxy-gluconate-6-P *
Dihydroxyacetone- P
Fructose-1,6-bis-P
Putrescine Spermidine
(EC 4.1.1.17) (EC 2.5.1.16)
Glycerol-3-P
Ribose-5-P
TktA
Histidine
Histidinal
Histidinol
Nucleotide biosynthesis
CitrateOxaloacetate
2-Oxo-
glutarate
Succinyl-CoA
Malate
Fumarate
Succinate
Proteins identified
Metabolites detected intracellularly
Proteins predicted only
Legend
more abundant in MB grown cells
less abundant in MB grown cells
UreaOrnithine
Citrulline
Arginosuccinate
Arginine
Glutamate
Glutamine
Carbamoyl-
phosphate
3-Oxo-acyl-
CoA
L-3-Hydroxy-
acyl-CoA
Trans-2,3-
enoyl-CoA
Acyl-CoA
AcdA1
FadA1FadJ
FadJ, FadB1
Isoleucine Valine
Leucine
 Homo-
gentisate
4-Hydroxyphenyl-
pyruvate
Tyrosine
TyrB
Hpd
Glyceraldehyde-3-P
GlpD
TpiA
GapB Gap
Glk
Zwf2
Pgl
3-P-Glycerate
1,3-Bis-P-glycerate
Eda
Glyceraldehyde-3-P
Pgk
PykA
GluD
ArcA
ArcB
GlnA
GltA
Mdh
FumC
PhaA PhaB PhaC
PhaZ
GltBD
ArcAArgF
ArgG
ArgH
CarAB
HisD1
HisD1
GlyA
FdA
Leucine
degradation
Isoleucine/
Valine
degradation
Amino acid biosynthesis
TCA cycle
Urea cycle
Fatty acid and lipids
degradation
Arginine degradation
Polyhydroxybutanoate (PHB) metabolism
G
lu
co
ne
og
en
es
is
G
lu
co
se
 d
eg
ra
da
tio
n
Tyrosine
degradation
multiple enzyme reactions
SerB
PGA1_c11650 SpeE
SerC
(EC 2.7.1.2)
(EC 1.1.1.49)
(EC 3.1.1.31)
(EC 1.1.1.23)
(EC 1.1.1.23)
Edd(EC 4.2.1.12)
(EC 2.2.1.1)
(EC 1.1.5.3)
(EC 4.2.1.14)
(EC 4.1.3.16)
(EC 4.1.2.13)
(EC 5.3.1.1)
(EC 1.2.1.59) (EC 1.2.1.12)
(EC 2.7.2.3)
(EC 2.7.1.40)
Pyruvate dehydrogenase
 
(EC 2.6.1.52) (EC 3.1.3.3)
(EC 3.5.3.1)
(EC 3.5.3.1)
(EC 4.3.1.12)
(EC 1.4.1.3)
(EC 6.3.1.2) (EC 1.4.1.13)
(EC 6.3.5.5)
(EC 2.1.3.3)
(EC 6.3.4.5)
(EC 4.3.2.1)
(EC 2.1.2.1)
(EC 2.6.1.57)
(EC 1.13.11.27)
(EC 2.3.3.1)
(EC 1.1.1.37)
(EC 4.2.1.2)
(EC 3.1.1.75)
(EC 2.3.1.-)(EC 1.1.1.36)(EC 2.3.1.9)
(EC 1.3.99.-)
(EC 2.3.1.16)(EC 1.1.1.35)
(EC 5.1.2.3)
(EC 4.2.1.17)
(EC 4.2.1.17)
(EC 5.1.2.3)
(EC 1.1.1.35)
Proline
(EC 1.5.5.2)
PutA
*
PhaR
PhaP  (phasin)
dephosphorylated during sample treatment
(E
C
 4
.1
.1
.4
9)
P
ck
A
(E
C
 6
.4
.1
.1
)
P
yc
4  DISCUSSION 83
degraded via pyruvate to acetyl-CoA. In case of alanine, degradation is accomplished by 
alanine dehydrogenase. Glycine degradation involves two catalytic steps: First, glycine is 
methylated via glycine hydroxymethyl-transferase; then resulting serine is deaminated via 
serine deaminase to obtain pyruvate. All required enzymes were detected by proteomic 
analysis. Shortness of these pathways might be a reason for preferred utilisation. High 
depletion rate was also observed for proline and glutamate. Degradation of these two 
amino acids feed into the TCA cycle via 2-oxoglutarate. Accordingly, complete 
consumption at ½ ODmax is probably main responsible for significant lower abundance of 
glutamate and 2-oxoglutarate (Figure 24) in cells grown in MB medium as compared to 
cells grown in minimal medium. Alternatively, considering the putative role of glutamate 
as compatible solute, its concentration might be reduced, due to the enormous import of 
substrates. 
Polyhydroxybutanoate (PHB) metabolism. 3-hydroxybutanoate, which was abundant 
in cells grown on glucose and could be detected in all other conducted main experiments, 
is associated with PHB metabolism. Biosynthesis of this polymer requires plenty acetyl-
CoA and reducing equivalents, in this case NADPH (Senior and Dawes, 1971; Madison 
and Huisman, 1999). Since acetyl-CoA is end-product of glucose degradation, biosynthesis 
of PHB might be directly induced under this condition (Figure 24). This could also be a 
specific adaptation to nutrient limiting conditions, since PHB can function as temporary 
energy and carbon storage that can easily be hydrolysed, yielding 3-hydroxybutanoate 
monomers. Thus, PHB guarantees efficient growth, as shown by De Eugenio et al. (2010) 
f o r Pseudomonas putida. Furthermore, synthesis of PHB might be used to replenish 
NADP+, as suggested recently for D. shibae DFL12T (Laass et al., 2014). Since NADP+ is 
important for some oxidation reactions, such as conversion of glucose-6-phosphate by 
glucose-6-phosphate-dehydrogenase, P. inhibens DSM 17395 could tune its metabolism to 
sole carbon source (i.e. glucose) utilisation.
TCA cycle. Degradation of branched-chain amino acids that were moderately 
consumed, resulted in formation of succinyl-CoA and thus to elevated concentration of 
succinate. Moreover, imported succinate from the medium may contribute to this high 
intracellular succinate amount. Increased abundance of malate might be explained by 
degradation of aspartate to oxaloacetate. Latter compound can be converted to malate by 
reversible malate dehydrogenase reaction (e.g. Ohshima and Sakuraba, 1986). Lower 
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abundance of fumarate reflects minor relevance of tyrosine degradation, which yields 
fumarate as end-product. Interestingly, concentration of citrate was not significantly 
changed. This indicates similar actively condensation of oxaloacetate and acetyl-CoA to 
citrate, under both growth conditions, although in case of cells grown in MB medium, 
more pathways yielded acetyl-CoA, compared to cells grown in minimal medium, where 
only one catabolic pathway was active (Figure 24). Thus it appears that on the one hand, 
simultaneous utilisation of complex nutrients is inefficient, and that on the other hand, 
P. inhibens DSM 17395 is capable to tune its metabolism to efficient utilisation of only one 
single substrate, maybe by polyhydroxybutanoate metabolism, as discussed above. 
Carbohydrate degradation. Although several carbohydrates, especially disaccharides, 
were available in MB medium and were imported, degradation of these substrates was not 
very active; in contrast to gluconeogenesis. Key-enzymes of the Entner-Doudoroff 
pathway (6-phosphogluconate dehydratase and 2-dehydro-3-deoxy-6-phosphogluconate 
aldolase) and catabolic intermediates were considerably less abundant in cells grown in 
MB medium (Figure 24) as compared to cells grown in glucose-containing minimal 
medium. Due to instability of particular phosphorylated intermediates of Entner-
Doudoroff-pathway, such as 2-keto-3-deoxy-6-phosphogluconate (Strohhäcker et al., 
1993), only correspondent dephosphorylated compounds were detected and will refer in 
this and all other experiments to the correspondent phosphorylated intermediates. The 
observed down-regulation of Entner-Doudoroff pathway in cells grown in MB medium is 
contradicted by high intracellular abundances of disaccharides. Either, these disaccharides 
were stored temporarily or appropriate catabolic enzymes were missing. In case of lactose 
and maltotriose, missing enzymes are very probable, as Biolog phenotypic microarray 
analysis was negative (Section 3.1.1). Moreover, the pyruvate dehydrogenase multienzyme 
complex was less abundant in cells grown in MB medium. This indicates minor relevance 
of this enzyme complex under this condition compared to growth in minimal medium. 
Since many catabolic pathways that are active during growth in MB medium directly yield 
acetyl-CoA, this enzyme complex can easily by be circumvented. 
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4.3.2 Dynamics of amino acid utilization
4.3.2.1 Growth characteristics and extracellular metabolomic analysis
Growth. Cultivation of P. inhibens DSM 17395 with casamino acids in a time-dynamic 
experiment was applied to study time-resolved amino acid utilisation. The provided amino 
acids, each at different concentrations, reflect naturally occurring amino acid mixtures, 
similar to hydrolysates of microalgae (Brown, 1991). Remarkably, cells entered stationary 
phase, although sufficient amino acids were still available and amino acids were still 
imported. Stop of growth was also observed during growth in MB medium, and was in 
both cases, probably a result of quorum-sensing, due to formation of acyl-homoserine-
lactones under these conditions as shown by Berger et al. (2012).
Amino acid depletion. Amino acids were utilised simultaneously, but with different 
depletion rates. Rapid utilisation of glutamate, aspartate, arginine and glycine was 
independent of provided concentrations or complexity of catabolic pathways. One may 
speculate whether glutamate preference results from time-delayed release of amino acids: 
glutamate in the early stage of phytoplanktonic bloom, compared to high abundances of 
aspartate, glycine, alanine and lysine after collapse of phytoplankton populations (Ittekkot, 
1982). Overall, observed preference pattern for amino acids are similar to that in MB 
medium. In contrast to growth in MB medium, where no significant uptake differentiation 
of the three branched-chain amino acids was observed, clear preference for leucine was 
observed during growth on casamino acids. This preference can be caused by different 
factors, such as specificity of the shared transport system, e.g. shown for Campylobacter 
jejuni (Ribardo and Hendrixson, 2011), or inhibition of transportation by other amino 
acids, including branched-chain amino acids, as observed in Corynebacterium glutamicum 
(Ebbighausen et al., 1989). Transport of branched-chain amino acids can also be affected 
by pH (Driessen et al., 1987). Further, as shown by Yu et al. (2014) the branched-chain 
amino acid transaminase can have clear specificity for either leucine, isoleucine or valine 
derived 2-oxoacids.. 
Exported metabolites. To dispose of excess nitrogen from degradation of amino acids, 
urea was exported, as observed before during growth in MB medium (Section 3.3.1.2). 
Two intermediates of urea cycle were detected intracellularly (ornithine and arginine), 
whose concentration remained relatively constant, whereas urea itself was only detected 
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extracellularly and increased considerably with cultivation time. Partially, urea could also 
originate from carbodiimide (Khorana, 1953). Carbodiimide may be formed from arginine 
at high temperatures (e.g. autoclavation) (Lewis and Wolfenden, 2014). The extracellular 
increase of 2-isopropylmalate is surprising. It indicates overflow metabolism under 
nutrient excess. Adverse effects from imbalanced cellular metabolism is then compensated 
by export of overflow metabolites (Carneiro et al., 2011). However, formation of 2-
isopropylmalate as intermediate of leucine biosynthesis is directly inhibited by leucine. 
Due to high intracellular abundance of leucine, accumulation of 2-isopropylmalate should 
not occur, unless this feedback inhibition is defective in P. inhibens DSM 17395.
4.3.2.2 Intracellular metabolomic analysis
In this section, time-dynamic intracellular metabolic changes will be discussed in the 
context of their correspondent pathways. An overview about these pathways is provided in 
figure 25.
Amino acid degradation. Degradation of imported amino acids could be confirmed by 
proteomic analysis identifying all relevant key enzymes (e.g. glutamate dehydrogenase, 
aspartate aminotransferase and the glycine cleavage system). Glutamate was the preferred 
substrate, therefore complete consumption of glutamate at t25, resulted in significantly 
metabolic changes. Substrate utilisation was shifted, e.g. to alanine. Accordingly, 
abundance and activity of alanine dehydrogenase increased after t2 5 (Zech et al., 2013b). 
Other strongly depleted amino acids in this phase were proline, serine and lysine. As 
proline degradation proceeded via glutamate to 2-oxoglutarate, glutamate concentration 
was kept constant. In case of lysine degradation, several catabolic intermediates could be 
detected. 5-aminopentanoate and 2-aminoadipate represent two different branches of lysine 
degradation that are both used in P. inhibens DSM 17395. Different time-dependent 
distribution of these two compounds is remarkable and indicates different purposes of 
these two branches (see section 4.3.4.4 for discussion). Import and degradation of other 
amino acids is reflected by extracellular amino acid depletion, by intracellular  
accumulation of correspondent amino acids and high abundances of several catabolic 
enzymes. 
Amino acid biosynthesis. Glutamine and asparagine could be easily synthesised by 
amination of imported glutamate and aspartate. Since cysteine was not provided in the 
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Figure 25: Overview of time-dynamic metabolic changes during growth on casamino acids. 
Relative abundances are shown as fold changes to reference state (t10), orange squares mark amino 
acids. Abbreviations: *, compound dephosphorylated during sample treatment; AMP, adenosine-5'-
monophosphate; ATP, adenosine-5'-triphosphate; GMP, guanosine-5'-monophosphate; IMP, 
inosine-5'-monophosphate; KDG, 2-keto-3-deoxy-gluconate; PEP, phosphoenolpyruvate.
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medium, it had to be synthesised. Intracellular cysteine concentration increased 
significantly between t20 and t30, coinciding with high abundance of correspondent 
biosynthetic enzymes until t30 (Zech et al., 2013b). Further, also tryptophan had to be 
synthesised, as casamino acids did not contain any tryptophan. Biosynthesis was indicated 
by slightly increased abundance of tryptophan upon entry into the stationary phase. 
However, enzymes of tryptophan biosynthesis were not identified in this experiment. 
Whether increased abundance of histidine in the stationary phase resulted from 
biosynthesis or uptake from the medium is unclear, since neither specific enzymes of 
histidine biosynthesis, nor of histidine degradation could be detected in this experiment. 
Fatty acids and acyl homoserine lactone formation. Increase of fatty acids during 
exponential growth phase, can be explained by higher needs of these precursors for cell 
membranes (Schujman and Mendoza, 2005). Concentration of dodecanoate and 
octadecenoate even slightly raised during transition to stationary phase, although 
abundance of fatty acid biosynthetic enzymes (enoyl-[acyl-carrier-protein] reductase 
(NADH) and 3-Oxoacyl-[acyl-carrier-protein] reductase) decreased in stationary phase. 
Though, formation of fatty acids continued in stationary phase, maybe as result of 
generated acetyl-CoA from degradation of some amino acids (e.g. serine, glycine and 
leucine).
Another explanation for increase of fatty acids over time, could be related to 3-hydroxy-
C10-homoserine lactone, the characteristic quorum sensing molecule of P. inhibens DSM 
17395. Its formation under growth with casamino acids was confirmed by Berger et al. 
(2012). The precursor 3-hydroxydecanoate can either reactivated to generate longer alkyl-
chains, or be condensed with S-adenosyl-methionine to mentioned quorum sensing 
molecule. Formation of acylhomoserine lactones yields 5-methylthioadenosine (Dickschat, 
2010), which explains elevated amounts of latter compound. Notably, as Seyedsayamdost 
et al. (2011) have shown, P. gallaeciensis BS107 reacts to p-coumarate, probably by 
formation of p-coumaryl-homoserine lactone. This might explain increased abundance of 
structural similar compound 2-hydroxycoumarate, which is derived from phenylalanine 
metabolism.
Peptidoglycan and phospholipid headgroup components. The growth curve is 
reflected by similar abundance curves of alanyl-alanine and 2,6-diaminopimelate, probably 
because of their role in peptidoglycan formation and remodelling (Typas et al., 2012). This 
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was contradicted by the time-dependent abundance distribution of phospholipid headgroup 
components, which were highest concentrated at t15.
Nucleotide associated compounds. Efficient growth requires high amounts of 
nucleotides for gene replication. Accordingly, most compounds involved in purine and 
pyrimidine metabolism were considerably high abundant from t15 until stationary phase. As 
regulation is feedback inhibited (Ledesma-Amaro et al., 2013; Reaves et al., 2013), 
abundance changes for correspondent enzymes were not observed. Further, constant 
abundance levels for most of these compounds, especially for nucleobases also indicates 
active role of purine and pyrimidine salvage pathway.
Gluconeogenesis and Entner-Doudoroff pathway. In contrast to growth with complex 
nutrients, carbohydrates were absent in casamino acid medium. Therefore, higher 
gluconeogenic activity was required to maintain relevant metabolic functions (e.g. cell wall 
formation or pentose phosphate pathway). Accordingly, abundances of fructose-1,6-
bisphosphate, fructose-6-phosphate, glucose and glucose-6-phosphate significantly 
increased in the early stage of growth, reaching highest amounts around t20. Interestingly, 
disaccharides were not detected, indicating their minor role as storage compound or 
compatible solute in P. inhibens DSM 17395. Upon formation of glucose, also 
intermediates involved in glucose degradation via Entner-Doudoroff pathway were 
detected. An explanation could be the postulated constitutive expression of the glucokinase 
(Wiegmann et al., 2014). Abundances of these intermediates increased significantly during 
transition phase to stationary phase and reached along with the key enzyme 6-phospho-
gluconolactonase highest concentration in stationary phase. Carbohydrate degradation in 
P. inhibens DSM 17395 is discussed in more detail in section 4.3.5.1.
TCA cycle. While concentration of citrate, 2-oxoglutarate, succinate and malate 
remained relative constant after t15, concentration of fumarate steadily increased, especially 
from t15 to t25. The increase of fumarate could result from degradation of tyrosine, despite 
the minor role of tyrosine as substrate. Furthermore, the overall constant concentration of 
TCA cycle intermediates indicate rapidly reuse of these compounds for anabolism. Or 
amino acid degradation was slower than expected, as indicated by high abundances of 
intracellular amino acids and thus resulted only into low feed into the TCA cycle. Enzymes 
of TCA cycle displayed constant abundances, except for isocitrate dehydrogenase, which 
slightly increased in stationary phase.
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4.3.3 Casamino acid consumption by plasmid-cured strains
P. inhibens DSM 17395 strains, lacking one or two plasmids, were cultivated on 
casamino acids to study the impact of plasmids on growth and substrate utilisation. Since 
strains lacking the 262 kbp plasmid reached considerable higher ODmax compared to the 
wild-type, essential genes that inhibit growth have to be located on this plasmid. Usually, 
quorum sensing is applied to trigger entry into the stationary phase. For this, members of 
the Roseobacter clade possess luxI, which encodes homoserine lactone synthase and a luxR 
gene, which is a response regulator (Schaefer et al., 2008). As shown for D. shibae 
DFL12T,  ΔluxI resulted in considerable higher growth rate, higher cell density and reduced 
diversity of cell morphology (Patzelt et al., 2013). In contrast to this, ΔluxI mutants of 
P. inhibens DSM 17395 showed delayed biosynthesis of tropodithietic acids, as 
biosynthesis of this antibiotic is apparently upregulated by homoserine lactones (Berger et  
al., 2012). However, in P. inhibens DSM 17395 luxI and luxR are located on the 
chromosome, as well as genes for peripheral synthesis pathways for the quorum sensing 
signalling molecules. Maybe a histidine kinase located on the 262 kbp plasmid 
(PGA1_262p02120) is involved in quorum sensing as described for Vibrio harveyi (Waters 
and Bassler, 2005). Another explanation for higher ODmax could be the loss of essential 
genes for tropodithietic acid, which are encoded on the 262 kbp plasmid. Tropodithietic 
acid can also function as signal molecule, as it induces its own biosynthesis, thus it was 
suggested that it is used as quorum-sensing molecule (Geng and Belas, 2010b; Zan et al., 
2014). Therefore, the considerable higher ODmax reached by strains lacking the 262 kbp 
strongly implicates the dominant role of tropodithietic acid for growth regulation in 
P. inhibens DSM 17395.
Based on the genome sequence data, utilisation of amino acids is not affected directly 
by genes located the 65 kbp and/or 262 kbp plasmid. Most genes involved in amino acid 
degradation are located on the chromosome, with exception of 3-oxo-5,6-dehydrosuberyl-
CoA semialdehyde dehydrogenase, involved in phenylalanine degradation (Supplementary 
material S10). Therefore, apart from higher consumption rate, amino acid utilisation 
preferences did not differ between tested strains. However, higher impact on amino acid 
utilisation could be expected by loss of the 78 kbp plasmid, as the relevant glycine 
cleavage system is encoded on this plasmid (Supplementary material S10).
4  DISCUSSION 91
4.3.4 Amino acid degradation
Cultivation of P. inhibens DSM 17395 on one of nine amino acids (phenylalanine, 
lysine, histidine, methionine, leucine, isoleucine, valine, threonine and tryptophan) as 
single carbon source was applied to study and to refine these catabolic networks. Cells 
grown on succinate served as reference condition. Based on the original annotated genome 
(Thole et al., 2012), degradation of these nine amino acids remained unclear, e.g. due to 
missing enzymes or alternative pathways were possible. By combination of metabolomic, 
proteomic, enzymatic and bioinformatic approaches, unclear pathways could be resolved. 
In addition to published data of this cooperation experiment (Drüppel et al., 2014), LC-MS 
data from coenzyme A analysis of cells grown on succinate were included here. The 
refined pathways are discussed in the subsections 4.3.4.3 t o 4.3.4.9. Further, some 
additional metabolic features were observed in P. inhibens DSM 17395 during growth on 
individual amino acids, which is discussed in subsection 4.3.4.10.
4.3.4.1 Growth characteristics
Only half of carbon was provided in case of tryptophan and phenylalanine as compared 
to the other substrates, therefore growth on these two amino acids only resulted in 
moderate ODmax. In case of lysine and histidine relative low ODmax indicate inefficient 
substrate utilisation, whereas in case of methionine production of toxic sulfur-containing 
compounds and acids, like methanethiol, are probably main responsible for slow growth 
and low ODmax. As response to toxic compounds, scanning electron microscopy revealed 
that growth on methionine resulted in formation of prolonged cells (Drüppel et al., 2014). 
Of the three branched-chain amino acids, shortest lag-phase was observed for leucine, 
indicating more effective utilisation as compared to isoleucine and valine, which was also 
noticed when P. inhibens DSM 17395 was provided with casamino acid mixture (Section 
3.3.2). Specificity of branched chain amino acid uptake and degradation for one of these 
three amino acids was also observed in other bacteria (Ebbighausen et al, 1989; Ribardo 
and Hendrixson, 2011; Yu et al., 2014).
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4.3.4.2 Exometabolomic analysis
Extracellularly detected compounds were either intermediates involved in catabolism of 
correspondent substrates or side products of studied catabolic pathways. Export might 
compensate overflow metabolism, as observed e.g. for E. coli (Carneiro et al., 2011). Such 
overflow metabolites were 2-aminobenzoate and kynurenine,  intermediates of tryptophan 
degradation (see Section 4.3.4.9), as well as cadaverine, an intermediate of lysine 
degradation, which was detected in the supernatant of lysine and phenylalanine medium. 
Alternatively, exported compounds could be dead-end products from side reactions of 
catabolism, such as phenethylamine, which derived from phenylalanine by aromatic-L-
amino-acid decarboxylase, or 2-hydroxyphenylanine, which derived from phenylpyruvate 
by 4-hydroxyphenyl pyruvate dioxygenase (Figure 26). 
Another example for a dead-end product is 2-methylmalonate, which was found in 
medium supplied with isoleucine. It was most probably produced by an aldehyde 
dehydrogenase (NAD+ or NADP+) from methylmalonate semialdehyde, which is an 
intermediate of valine and isoleucine degradation. 2-methylmalonate could not be 
degraded further, as orthologues of (S)-methylmalonyl-CoA hydrolase (EC 3.1.2.17) are 
not encoded on the genome, which explains export of this intermediate. 
Export of urea under all substrate conditions, except for tryptophan and succinate, again 
confirms the dominant role of urea cycle to dispose of excess nitrogen.
4.3.4.3 Refinement of phenylalanine degradation
Most bacteria, including P. inhibens DSM 17395, do not possess orthologues of 
phenylalanine 4-monoxygenase (EC 1.14.16.1) (Fitzpatrick, 2003). Accordingly, 
degradation of phenylalanine via initial hydroxylation to tyrosine and subsequent tyrosine 
degradation is rather uncommon for bacteria. Despite elevated concentrations of 
homogentisate, one representative of tyrosine degradation, major role of this pathway for 
phenylalanine degradation could be excluded. The only possibility to direct phenylalanine 
to homogentisate has to be accomplished via 4-hydroxyphenylacetate, which was 
significant more abundant in cells grown on phenylalanine. However,  formation of 4-
hydroxyphenylactate, as well as consecutive hydroxylation has to proceed via side 
reactions, since specific enzymes, which could catalyse correspondent reactions were not 
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identified by proteomic analyses, and orthologues were not found on the genome. 
Therefore, degradation of phenylalanine proceeds via phenylacetate pathway as 
described by Teufel et al. (2010), which is visualised in figure 26. To direct phenylalanine 
to phenylacetyl-CoA several routes were found in databases, like KEGG (Kanehisa et al., 
2014), or MetaCyc (Caspi et al., 2014). In P. inhibens DSM 17395, transamination of 
phenylalanine by aromatic amino acid aminotransferase produces phenylpyuvate, which is 
then directly converted to phenylacetyl-CoA by indolepyruvate ferredoxin oxidoreductase. 
Both enzymes were identified by proteomic analysis. Alternative routes to produce 
phenylacetyl-CoA are incomplete, but may be active through unspecific side reactions of 
identified enzymes, as indicated by detection of intermediates, such as phenylacetate. 
Followed degradation of phenylacetyl-CoA to succinyl-CoA could be completely covered 
by proteomic analysis. These findings could be underlined by detection of three out of six 
coenzyme A derivatives in succinate grown cells, in which amino acid degradation was 
partially active. 
4.3.4.4 Refinement of lysine degradation
Of the 20 proteinogenic amino acids, highest number of possible degradation pathways 
have been described for lysine, listing 10 different in MetaCyc (Caspi et al., 2014).  The 
genome annotation of P. inhibens DSM 17395 suggested enzyme candidates for several 
lysine degradation pathways. Based on conducted analyses, two main branches were found 
to be active (Figure 26). 
The first branch is accomplished by initial decarboxylation of lysine by lysine/ornithine 
decarboxylase (identified by proteomic analyses) to cadaverine. Then, one of two class III 
aminotransferases, which were identified by proteomic analyses, produces 1-piperideine or 
5-aminopentanal. No enzyme candidate for conversion of 1-piperideine to 5-aminopentanal 
could be predicted by genome analysis. In case of 5-aminopentanal, an aldehyde 
dehydrogenase could be identified by proteomic analyses. The resulting 5-
aminopentanoate is transaminated to glutarate semialdehyde. This reaction is catalysed by 
one of the two mentioned aminotransferases. Oxidation by mentioned aldehyde 
dehydrogenase yields glutarate. The final activation of glutarate to glutaryl-CoA is 
accomplished by a succinyl-CoA/formyl-CoA transferase or a putative glutaryl-CoA ligase 
(PGA1_c27870), which were identified by proteomic analyses.
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Figure 26: Refined degradation pathways for phenylalanine, lysine and histidine in 
P. inhibens DSM 17395. CoA derivatives were detected via LC-MS in cells grown on succinate. 
Other data from GC-MS and proteomic analyses as described in the joint publication (Drüppel et  
al., 2014).
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Proteomic data suggests, that the second branch via 2-aminoadipate is accomplished by 
the same enzymes as for the first branch, with exception of the final step from 2-
oxoadipate to glutaryl-CoA, which is catalysed by a specific 2-oxoisovalerate  
dehydrogenase, which was identified by proteomic analyses. Initial transamination of 
lysine yields (S)-2-amino-6-oxohexanoate, which is converted spontaneously to (S)-
2,3,4,5-tetrahydropiperidine-2-carboxylate or maybe to structure isomer pipecolate, which 
could be detected during growth on casaminoacids. Then, an aldehyde dehydrogenase 
produces 2-aminoadipate, which is transaminated to 2-oxoglutarate and finally activated to 
glutaryl-CoA.
The two branches merge at glutaryl-CoA, whose degradation is accomplished by 
conversion to crotonyl-CoA and followed decarboxylation to crotonyl-CoA. Both steps are 
catalysed by glutaryl-CoA dehydrogenase, as described for Pseudomonas sp. (Härtel et al., 
1993). The consecutive conversion to acetoacetyl-CoA may either proceed via R- or S-
enantiomer of 3-hydroxybutanoyl-CoA. Coenzyme A analysis allowed identification of 3-
hydroxybutanoyl-CoA, but without a discrimination between its enantiomers. According to 
proteomic data, probably both options are active. Acetoacetyl-CoA could not be detected, 
as it is instable at pH > 6 (King and Reiss, 1985) and thus not compatible with pH 
conditions used for sample preparation and LC-MS analysis. The final cleavage of 
acetoacetyl-CoA to two molecules acetyl-CoA is accomplished by acetyl-CoA 
acetyltransferase. All enzymes involved in degradation of glutaryl-CoA pathway were 
identified by proteomic analyses. 
Currently it is unclear, whether both branches of lysine degradation to glutaryl-CoA are 
used in equal measure. The low abundance of 2-aminoadipate, indicates a minor role 
compared to degradation via cadaverine, or effective and fast catalytic processes. Further, 
diverse intracellular abundances of correspondent key-metabolites, when grown on 
complex medium, with casamino acid, or lysine alone, suggests different purposes of these 
two degradation branches. Since 5-aminopentanoate was only positive as nitrogen source 
in the Biolog phenotypic microarray analysis (Section 3.1.3), the branch via 5-
aminopentanoate might serve primarily as nitrogen salvage.
Notably, although all enzymes for the widespread saccharopine pathway for lysine 
degradation are encoded on the genome, none of them were lysine-specifically produced 
(Drüppel et al., 2014).
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4.3.4.5 Refinement of histidine degradation
Two intermediates of histidine degradation were identified via GC-MS, which were 
urocanate and glutamate. Both were not significantly changed in abundance as compared 
to succinate-grown cells. However, all enzymes involved in histidine degradation could be 
identified by proteomic analysis. Correspondent genes are organised in one single gene 
cluster (Drüppel et al., 2014). This agrees with findings, that histidine degradation is highly 
conserved and widespread in bacteria (Bender, 2012). According to metabolomic and 
proteomic data, histidine is degraded via 5-steps to glutamate, as described for 
Pseudomonas species (Bender, 2012) (Figure 26). The detected intermediate hydantoin-5-
propionate belongs to alternative degradation pathway, which is not active due to missing 
orthologues of required enzymes. 
4.3.4.6 Refinement of methionine degradation
According to genomic data, methionine degradation via 2-oxobutanoate could be 
conducted either by a 5-step conversion via 5-methyl-thioadenosine and homocysteine, or 
directly by methionine-γ-lyase (Kreis and Hession, 1973). The first option was only 
theoretical, since for bacteria it is only described for anabolic purposes (Cooper, 1983). 
Accordingly, methionine degradation in P. inhibens DSM 17395 proceeds via the direct 
step, which was revealed by conducted metabolomic and proteomic analyses. Methionine-γ-
lyase and corresponding enzyme activity were detected. Further, the resulting product 2-
oxobutanoate was more abundant in cells grown on methionine as compared to cells grown 
on succinate. Interestingly enough,  protein c16590, which is encoded next to methionine-
γ-lyase was detected by proteomic analyses. This protein shares functional domains of the 
E1 complex of the pyruvate dehydrogenase complex. Since c16590 was very abundant in 
methionine grown cells, it could enable to catalyse conversion of 2-oxobutanoate to 
propanoyl-CoA by modification of the pyruvate dehydrogenase (Drüppel et al., 2014). The 
subsequent degradation of propanoyl-CoA to succinyl-CoA could completely be covered 
by proteomic analyses. Further, involved CoA intermediates were detected in cells grown 
on succinate. The refined methionine degradation is visualised in figure 27.
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Figure 27: Refined degradation pathways for methionine, leucine, isoleucine and valine in 
P. inhibens DSM 17395. CoA derivatives were detected via LC-MS in cells grown on succinate. 
Other data from GC-MS and proteomic analyses as described in the joint publication (Drüppel et  
al., 2014).
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4.3.4.7 Refinement of branched-chain amino acid degradation
Degradation of branched chain amino acids is well described and is accomplished by 
initially deamination, followed by the conversion to a coenzyme A thioester. Consecutive 
degradation proceeds via several coenzyme A intermediates (Massey et al., 1976). Since 
these compounds were not compatible with GC-MS, these pathways could not be covered 
by GC-MS-based metabolomic analysis. Some of involved coenzyme A derivatives could 
be detected in cells grown on succinate by LC-MS analysis. Remaining blind spots could 
be completely covered by proteomic analysis, which allowed complete reconstruction of 
leucine, isoleucine and valine degradation, which is visualised in figure 27. Notably, the 
first three reactions are identical for these three branched chain amino acids and were 
conducted by the same set of enzymes (Figure 27). For initial deamination of the amino 
acid, two enzymes were detected by proteomic analyses: branched-chain amino acid 
transferase and leucine dehydrogenase. Notably, leucine degradation finally yields acetyl-
CoA, whereas both isoleucine and valine are directed via propanoyl-CoA to succinyl-CoA 
as described for methionine degradation. 
4.3.4.8 Refinement of threonine degradation
Based on genome data, three different enzymes were possible for initial threonine 
degradation (threonine ammonia lyase, threonine aldolase and threonine-3-dehydro-
genase). Since only presence and corresponding activity of the latter enzyme was detected, 
only one pathway is active, which is visualised in figure 28. Threonine degradation is 
initialised by oxidation to 2-amino-3-oxobutanoate. After cleavage to acetyl-CoA and 
glycine, resulting glycine is degraded via identified glycine cleavage system to ammonia, 
CO2 and a methylene group with tetrahydrofolate as acceptor molecule. Alternatively, 
glycine is converted to serine by methylene-tetrahydrofolate-dependent serine hydroxy-
methyltransferase, which was identified by proteomic analyses. Interestingly, glycine is 
significant lower abundant in cells grown on threonine, indicating high consumption rate 
of glycine by these two enzymes. Deamination of serine to pyruvate might be 
accomplished by serine dehydratase, which could not be detected here by proteomic 
analyses, but was detected during growth in MB medium (Zech et al., 2013a). The elevated 
concentration of the product pyruvate indicates that this reaction is active either through 
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that specific enzyme or through a similar unspecific enzyme. The final step, conversion of 
pyruvate to acetyl-CoA is accomplished by pyruvate dehydrogenase, all subunits could be 
detected by proteomic analysis.
4.3.4.9 Refinement of tryptophan degradation
According to conducted analyses, tryptophan degradation is initialised by conversion to 
N-formyl-L-kynurenine. The corresponding enzyme could be detected by proteomic 
analysis. For the consecutive conversion to L-kynurenine, no enzyme homologue of 
arylformidase could be predicted from the genome. Although, this enzyme could not be 
detected by proteomic analysis, corresponding enzyme activity was observed. Furthermore, 
the product kynurenine was detected in the culture supernatant via GC-MS. Protein-Blast 
of arylformidase of Rhodobacter capsulatus SB 1003 against the genome of P. inhibens 
DSM 17395 predicted a gene candidate for arylformidase, which could be confirmed by 
transcript analysis. Cleavage of kynurenine by kynureninase (identified by proteomic 
Figure 28: Refined threonine degradation in P. inhibens DSM 17395. Metabolites were analysed 
via GC-MS, proteins as described in the joint publication (Drüppel et al., 2014).
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analyses) yields 2-aminobenzoate and alanine. The latter compound is degraded via 
pyruvate to acetyl-CoA (Figure 29). Degradation of 2-aminobenzoate remained unclear. 
Based on proteomic data it was suggested, that identified 2-aminobenzoate-CoA ligase 
activates 2-aminobenzoate, which is then reduced to 2-amino-5-oxocyclohex-1-ene-
carboxyl-CoA as described for Azoarcus evansii (Schühle et al., 2001), (Figure 29). 
But consecutive β-oxidation to acetyl-CoA has not been described so far (Fuchs, 2008) 
and neither could be based on proteomic data. Coenzyme A analysis allowed identification 
of hexanoyl-CoA and pentanoyl-CoA, both are more abundant in cells grown on 
tryptophan compared to cells grown on succinate (Figure 17). These two compounds might 
be derived from β-oxidation. Though, correspondent precursors, including 2-amino-
benzoyl-CoA could not be identified. Instead, elevated concentrations of benzoyl-CoA and 
other CoA intermediates with a cyclohexane-ring structure were observed. This indicates 
some kind of benzoyl-CoA degradation as described for bacteria under anaerobic 
conditions (e.g. Heider et al., 1998; Fuchs et al., 2011), respectively some kind of aerobic 
hybrid pathway (Díaz et al., 2013). Benzoyl-CoA could be produced through deamination 
of 2-aminobenzoyl-CoA. As Altenschmidt et al. (1991) have shown, the identified 
aminobenzoyl-CoA ligase can also activate benzoate. Thus, alternative to proposed 
published tryptophan degradation in P. inhibens DSM 17395 (Drüppel et al., 2014), 2-
aminobenzoate might be deaminated first, and then activated to benzoyl-CoA (Figure 29). 
Benzoyl-CoA degradation is most likely conducted by an alternative degradation, operable 
under aerobic condition, which has so far not yet been described before. The proposed 
sequential degradation of benzyol-CoA, based on detected coenzyme A intermediates is 
visualised in figure 29. The final degradation steps from 3-hydroxypimelyl-CoA to 
malonyl-CoA, plus further degradation of malonyl-CoA can be accomplished by different 
enzymes encoded on the genome.
4.3.4.10 General observations
The substrate amino acids were under correspondent cultivation conditions 
intracellularly significant more abundant as compared to cells grown on succinate, 
especially in case of cells grown on methionine, isoleucine, valine, lysine or threonine. 
This was either caused by insufficient washing efficiency, or resulted from faster uptake 
than followed degradation process. In contrast to this, decreased abundance of 
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Figure 29: Refined tryptophan degradation in P. inhibens DSM 17395. CoA derivatives were 
specifically formed when grown on tryptophan and were detected via LC-MS. Other data included 
in this figure, such as GC-MS and proteomic data were obtained as described in joint publication 
(Drüppel et al., 2014).
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phenylalanine and constant concentration of leucine under correspondent cultivation 
conditions, indicate higher efficiency of initial substrate degradation (Table 13). 
Another striking result was the overall low abundances of intracellular amino acids in 
most of the cells grown on single amino acids, especially in case of cells grown on 
tryptophan, phenylalanine, methionine or lysine (see figure18, supplementary material S6 
and S7) as compared to cells grown on succinate. This is even more surprising, since 
additional nitrogen was provided (amino-group of the amino acid) compared to cells grown 
on succinate. The overall amino acid content correlates to the glutamate content, as 
glutamate is the most important nitrogen donor for amino acid biosynthesis (Merrick and 
Edwards, 1995). Accordingly, amino acid content of cells grown on histidine was similar to 
cells grown on succinate, because glutamate was obtained as the end product of histidine 
degradation and two out of three nitrogen atoms of histidine are released as utilisable 
ammonium (see figure 26). The amino acid content is further indirectly influenced by the 
TCA cycle. Any anabolic process drains intermediates of the TCA cycle, which have to be 
replenished.
The glyoxylate-shunt, described e.g. for E. coli as short-cut of the TCA cycle (Cortay et  
al., 1989), is not operable in P. inhibens DSM 17395, as the key enzyme isocitrate lyase or 
orthologues genes are not encoded on the genome. Instead, anaplerotic reactions have to be 
used. However, of described enzymatic reactions, pyruvate carboxylase phosphoenol-
pyruvate carboxykinase and malic enzyme were less abundant in cells grown on single 
amino acids compared to cells grown on succinate. Sole exception were cells grown on 
methionine; here malic enzyme was considerably more abundant compared to cells grown 
on succinate (Drüppel et al., 2014). Thus, the ethylmalonyl-CoA pathway (Figure 30), 
which could be almost completely reconstructed for P. inhibens DSM 17395 based on 
proteomic data and LC-MS-based coenzyme A analysis, is used for replenishment of the 
TCA cycle. 
The ethylmalonyl-CoA pathway was first described by Alber et al. (2006). But two 
reactions are still uncharacterised: (1) (S)-ethylmalonyl-CoA to methylsuccinyl-CoA, (2) 
methylsuccinyl-CoA to mesaconyl-CoA. The correspondent products of these two 
reactions could be detected in P. inhibens DSM 17395. However, it remains unclear, which 
enzymes catalyse these two reactions, as correspondent enzymes were not identified by 
proteomic analyses. A mutase has to catalyse the first reaction, the second reaction could 
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Figure 30: Ethylmalonyl-CoA pathway in P. inhibens DSM 17395. CoA derivatives were 
detected via LC-MS in cells grown on succinate. Included protomic data was taken from published  
joint experiment (Drüppel et al., 2014).
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be catalysed by a putative 2-methylfumaryl-CoA-dehydrogenase as described for 
Rhodobaccter sphaeroides (Erb et al., 2009). An orthologue of second enzyme was found 
on the genome of P. inhibens DSM 17395 (PGA1_c01110). 
Interestingly, key-enzymes of the ethylmalonyl-CoA pathway (crotonyl-CoA 
carboxylase and crotonyl-CoA reductase) were most abundant in cells grown on leucine 
and lysine (Drüppel et al., 2014). In case of leucine this could be explained by formation of 
acetoacetyl-CoA and acetyl-CoA upon degradation of leucine that could directly injected 
into the ethylmalonyl-CoA pathway. In case of lysine, crotonyl-CoA is formed upon 
degradation of lysine. Overall, enzymes of ethylmalonyl-CoA pathway were more 
abundant in cells grown on single amino acids, except for cells grown on histidine, where 
replenishment of the TCA cycle might be less relevant, due to higher glutamate content.
Higher amounts of cadaverine, detected in cells grown on lysine, methionine, isoleucine 
or histidine, indicate purpose of cadaverine as nitrogen salvage. Polyamine formation 
could be a response of P. inhibens DSM 17395 to growth with amino acid rich medium, 
since polyamines were also detected in higher abundances during growth with complex 
nutrients and casamino acids (Sections 3.3.1 and 3.3.2). Presence of cadaverine resulted 
also in higher abundances of degradation products, such as 5-aminopentanoate and 
glutarate.
4.3.5 Carbohydrate degradation
P. inhibens DSM 17395 was cultivated on one out of five selected carbohydrates or 
succinate to study their utilisation and degradation. The studied carbohydrates represent the 
most relevant carbohydrate classes available in marine environments, such as N-acetyl-
glucosamine, which is component of chitin, the second most abundant polymer in the 
environment. Chitin is component of fungal cell wall, exosceletons of worms, molluscs, 
insects and part of peptidoglykane of gram negative bacteria (Rinaudo, 2006). Sucrose is 
the most abundant disaccharide, which is formed by higher plants during photosynthesis 
(Reid and Abratt, 2005). Mannitol represents sugar alcohols, it is used as compatible solute 
by algae (Iwamoto and Shiraiwa, 2005). Glucose represents the most abundant neutral 
hexose, xylose represents a neutral pentose. As Poretsky et al. (2010) have shown, 
members of the Roseobacter clade have the highest number of transporter associated genes 
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amongst heterotrophic marine bacteria. This also explains observation that the Roseobacter 
clade dominates glucose uptake in marine environments (Alonso and Pernthaler, 2006). 
Thus, studying carbohydrate degradation is of major relevance to understand ecological 
success of the Roseobacter clade.
4.3.5.1 Refinement of carbohydrate degradation
The major route for glucose degradation was recently reconstructed for P. inhibens 
DSM 17395 by metabolomic, fluxomic and proteomic analyses (Zech et al., 2009; Fürch 
et al., 2009; Zech et al., 2013a). Based on genome data, the peripheral degradation 
pathways for alternative sugars remained unclear. By combining metabolomic, proteomic, 
enzymatic and bioinformatic analysis the complete pathways could be refined, which is 
visualised in figure 31 and was published recently (Wiegmann et al., 2014). 
Transport. Carbohydrates can pass the outer membrane via porins. The transport across 
the cytoplasmic membrane is accomplished by ABC transporters as revealed by proteomic 
analyses. Such ABC transporter have a high specificity and high efficiency for low 
substrate concentrations up 10-6-fold concentration differences, but are less energy efficient 
than phosphotransferase systems (Davidson and Maloney, 2007). Though, due to the 
generally low substrate concentrations in marine environments, employing ABC trans-
porters represents an adaptation strategy of P. inhibens DSM 17395 to its environment. 
Notably, under each cultivation condition different transporter complexes were produced, 
indicating specificity for the correspondent carbohydrate class. However, the transporter 
produced during growth on glucose, is also capable importing sucrose and xylose and thus 
indicates low specificity of glucose import (Figure 31). Succinate import is accomplished 
via a TRAP transporter (Mulligan et al., 2011; Walmsley et al., 1992). Since this 
transportation is ATP-independent, uptake of succinate is less energy demanding than other 
substrates that are imported by ABC transporters, like carbohydrates and amino acids.
N-acetyl-glucosamine degradation. The initial phosphorylation of N-acetyl-
glucosamine was unclear, but could be resolved to be catalysed by identified N-acetyl-
glucosamine kinase. The resulting product was then cleaved to acetate and glucosamine-6-
phosphate. Activation of acetate by identified acetate-CoA ligase allows a short-cut of N-
acetyl-glucosamine degradation, which is a beneficial feature allowing faster utilisation of 
the substrate for anabolic purposes, explaining the higher growth rates (Figure 19). 
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Figure 31: Refined carbohydrate degradation pathways in P. inhibens DSM 17395. 
Metabolites were analysed via GC-MS, proteins were analysed as described in joint publication 
(Wiegmann et al., 2014).
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(EC 2.7.2.3)
(EC 5.4.2.12)
(EC 4.2.1.11)
(EC 2.7.1.40)
(EC 1.2.4.1 / 2.3.1.12 / 1.8.1.4)
(EC 5.3.1.1)
(EC 1.2.1.59)
(EC 4.1.2.13)
(EC 3.1.3.11)
Outer membrane
Periplasm
Cytoplasmic 
membrane
Cytoplasm
(EC 2.6.1.16)
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Isomerisation of glucosamine-6-phosphate to fructose-6-phosphate is catalysed by 
specifically produced NagB in cells grown with N-acetyl-glucosamine. This protein 
functions most probably as glutamine-fructose-6-phosphate transaminase or alternatively 
as glucosamine-6-phosphate deaminase. In contrast to this, GlmS, another glutamine-
fructose-6-phosphate transaminase was less abundant in cells grown on N-acetyl-
glucosamine and more abundant under the other substrate conditions. Thus, NagB is used 
for catabolism, GlmS for anabolism. Finally, a conversion to glucose-6-phosphate allows 
degradation by the Entner-Doudoroff pathway (Figure 31).
Peripheral degradation of the other carbohydrates. Mannitol degradation proceeds 
probably by mannitol 2-dehydrogenase, which was produced specifically upon growth on 
mannitol or sucrose. Phosphorylation by fructokinase, which was identified by proteomic 
analyses, then yields fructose-6-phosphate, which is degraded analogue to N-acetyl-
glucosamine. Sucrose degradation proceeds by initially cleavage into glucose and fructose. 
The responsible enzyme α-glucosidase was not detected by proteomic analysis, but was 
detected by transcript analysis. Fructose is degraded as described for mannitol degradation. 
Glucose degradation is initialised by phosphorylation of the substrate. Since P. inhibens 
DSM 17395 does not possess a phosphotransferase uptake system, which phosphorylates 
glucose upon import, phosphorylation is conducted by phosphoglukokinase. The resulting 
glucose-6-phoshphate is then degraded by the Entner-Doudoroff pathway. Data indicated 
that glucokinase is expressed constitutive, as it is solitary localised on the genome 
(Wiegmann et al., 2014). Xylose degradation proceeds by initial isomerisation to xylulose, 
followed by phosphorylation to xylulose-5-phosphate. Further degradation is linked with 
pentose phosphate pathway. Besides glyceraldehyde-3-phosphate, which is directly 
inserted into the Embden-Meyerhof-Parnas pathway, pentose phosphate pathway also 
yields fructose-6-phosphate, which is degraded via Entner-Doudoroff pathway.
Entner-Doudoroff pathway, Embden-Meyerhof-Parnas pathway and TCA cycle. 
Since all carbohydrates, including xylose are degraded via the Entner-Doudoroff pathway 
followed by degradation via the Embden-Meyerhof-Parnas pathway, most intermediates 
were considerably more abundant in cells grown on single carbohydrates compared to cells 
grown on succinate. This was underlined by high abundance of correspondent enzymes. In 
contrast to this, enzymes specifically involved in gluconeogenesis, such as pyruvate 
carboxylase and glyceraldehyde-3-phosphate dehydrogenase were more abundant in cells 
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grown on succinate. This also explains presence and higher abundance of some 
intermediates of Embden-Meyerhof-Parnas pathway in cells grown on succinate. Notably, 
proteomic analysis revealed that proteins involved in pentose phosphate pathway, pyruvate 
dehydrogenase complex and the TCA cycle showed mainly no abundance changes between 
the six studied substrate conditions. This was contradicted by lower abundances of all 
intermediates of the TCA cycle, except for citrate, in cells grown on single carbohydrates 
compared to cells grown on succinate. Sole exceptions were cells grown on N-acetyl-
glucosamine, where citrate, 2-oxoglutarate, fumarate and malate were considerably more 
abundant as compared to cells grown on succinate. The reason for abundance changes of 
TCA cycle intermediates are different entry points into the TCA cycle (i.e. citrate in case of 
carbohydrate degradation or simply import of succinate in case of reference condition) and 
draining of intermediates for anabolic purposes.
4.3.5.2 General observations
Formation of acetylated compounds. In cells grown on N-acetyl-glucosamine, 
considerable higher amounts of acetylated metabolites were detected. Biosynthesis of 
detected O-acetyl-serine involves acetyltransferase and cysteine synthase, both enzymes 
were detected, but showed no abundance changes. This was also true for arginine 
biosynthesis bifunctional protein (Wiegmann et al., 2014), which catalyses formation of N-
acetyl-glutamate, which was abundant under this condition. Thus, higher biosynthesis rates 
in these cases were accomplished by higher abundance of the precursor acetyl-CoA.
Formation of C4-carboxylates. The biosynthesis and purpose of the very abundant C4-
carboxylates (tartrate, erythronate and threonate) in cells grown on single carbohydrates is 
not clear. Database survey, e.g. BRENDA (Schomburg et al., 2012) revealed only few 
known enzyme reactions, producing or consuming these compounds. As Flint (1994)  has 
shown, fumarase in E. coli uses tartrate as substrate and can perform reverse reaction. 
Thus, some C4-intermediates of the TCA cycle could be used as precursor, e.g. by 
hydratisation of succinate as shown for meso-tartrate dehydrogenase (Kohn and Jakoby, 
1966), but it seems not to be encoded on the genome of P. inhibens DSM 17395. 
The abundance of C4-carboxylates correlates with growth on individual carbohydrates. 
Therefore, involvement of intermediates and enzymes of Entner-Doudoroff pathway and 
Embden-Meyerhof-Parnas pathway are very likely. Maybe, tartrate was produced from 
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glycerate, glyceraldehyde or glycerate-3-phosphate by reverse reaction of tartrate 
decarboxylase. Another explanation may be the oxidation of erythrose-4-phosphate, an 
intermediate of the pentose phosphate pathway, to erythronate-4-phosphate. In E. coli K-12 
this reaction is catalysed by an erythrose-4-phosphate dehydrogenase like enzyme (Zhao et  
al., 1995). Notably, glyceraldehyde-3-phosphate dehydrogenase from P. inhibens DSM 
17395 shows high similarity to this enzyme. Due to high abundant glyceraldehyde-3-
phosphate dehydrogenase in cells grown on single carbohydrates (Wiegmann et al., 2014), 
side-reaction could produce erythronate and the isomer threonate. Oxidation of threonate 
or erythronate would yield tartrate, as observed in plants (Helsper and Loewus, 1982).
So far, about the biological functions of C4-carboxylates in P. inhibens DSM 17395 can 
only be speculated. Tartrate is known to inhibit enzymes, such as malate dehydrogenase 
(Voegele et al., 1999) or fumarase (Genda et al., 2006) and to chelate metal-ions (Violante 
et al., 2010). C4-carboxylates might be used as compatible solute or temporary carbon 
storage. As Mustakhimov et al. (2010) have shown for halophilic bacteria, concentration of 
tartrate and other C4-dicarboxylates concentration increased as response to osmotic stress. 
This indicates a potential role of tartrate as compatible solute in P. inhibens DSM 17395.
4.3.6 Metabolic responses to ammonium limited growth condition
Cultivation under ammonium limited medium conditions (1 mM NH4Cl) was applied to 
study the metabolic responses of P. inhibens DSM 17395 to such starvation conditions, in a 
time-course experiment. 
Growth characteristics. Growth characteristics were similar to those with 4.7 mM 
NH4Cl in the “carbohydrate degradation” experiment (see section 3.3.5.1). The determined 
cellular N/C ratio at the beginning of cultivation (≈0.24) was similar to cells grown in MB 
medium upon entry into the stationary phase (≈0.21) (Table 17) and to cellular N/C ratio in 
natural planctonic bacteria in lakes (≈0.2) (Nagata, 1986). Apparently, due to nitrogen 
starvation, the cellular N/C ratio decreased considerably over the following cultivation 
time, finally being lower than during growth with sufficient ammonium (Table 17). This 
was reflected by decline of nitrogen-containing metabolites (e.g. amino acids) over time 
(Figure 22), which could also be observed in a similar study with the fission yeast 
Schizosaccharomyces pombe (Sajiki et al., 2013).  
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Ammonium assimilation and nitrogen control. In almost all cells, glutamate and 
glutamine are the key nitrogen donors for anabolic processes. Therefore, incorporation of 
nitrogen is facilitated by assimilation of ammonium with 2-oxoglutarate, which yields 
glutamate (Merrick and Edwards, 1995). In P. inhibens DSM 17395 this is accomplished 
by glutamate synthase or glutamate dehydrogenase and consecutive glutamate-ammonia 
ligase, which produces glutamine. Accordingly, complete consumption of ammonium at t20 
resulted in time-delayed intracellular increase of 2-oxoglutarate, as also observed for 
S. pombe (Sajiki et al., 2013) and simultaneous decrease of glutamate at t25. Upon this 
nitrogen starvation, most probably gene expression of glutamate synthase and transporters 
for ammonium and organic nitrogen sources is upregulated as shown for P. putida under 
nitrogen limiting conditions (Poblete-Castro et al., 2012). Since nitrogen assimilation 
reactions are energy-demanding, it is, along with biosynthesis of nitrogen-containing 
compounds, strongly regulated in bacteria (Merrick and Edwards, 1995; Leigh and 
Dodsworth, 2007). This may be the explanation for the apparent biosynthesis stop of 
nitrogen-containing compounds, respectively for the slow decline over time, such as 
nucleobases and aminobutanoates. 
Metabolic changes upon nitrogen starvation. Due to the early nitrogen starvation, 
around t20 to t25, abundance of metabolites already decreased between t25 and t30, i.e. before 
½ ODmax was reached. This decrease also included nitrogen-free compounds, such as 
carbohydrates and intermediates of the TCA cycle. Upon entry into stationary phase, some 
amino acids became temporarily more abundant. Since biosynthesis of nitrogen-containing 
compounds is assumed to be slowed down, these compounds have to derive from 
degradation of proteins. Elevated levels of 5-aminopentanoate at t40, an intermediate of 
lysine degradation,  underlines this hypothesis. 
In contrast to this, elevated concentrations of nicotinate and nicotinamide in the 
stationary phase, might either be result of degradation of NAD, or might be involved in 
nitrogen control, as it was shown for the NAD synthetase in Rhodobacter sp. (Merrick and 
Edwards, 1995). 
The increase of intracellular and extracellular 3-hydroxybutanoate upon entry into the 
stationary phase indicated formation of polyhydroxybutanoate, which was also shown 
recently for P. putida under nitrogen-limiting conditions (Poblete-Castro et al., 2012). This 
formation could be a direct response to starvation conditions and could also contribute to 
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the low cellular N/C ratio. 
Although most metabolites decreased in abundance during stationary phase, some 
unknown compounds increased markedly in that phase. Some of those unknown 
compounds were specific for this experiment. In stationary phase, bacteria show general 
stress responses, as investigated and reviewed several times (e.g. Kolter et al., 1993; Tani 
et al., 2002; Nyström, 2004). Thus one may speculate, whether these unknown compounds 
were formed as stress response.
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5 Conclusion
Heterotrophic marine bacteria are mainly challenged by nutrient conditions, which 
comprise a high complexity, diversity and seasonal fluctuation. To unravel how marine 
bacteria can overcome such conditions, the metabolism of P. inhibens DSM 17395 was 
studied in detail by combining metabolomic and proteomic approaches. 
In this thesis, several key characteristics were determined explaining the special 
adaptation of this bacterium to its native environment. The broad substrate range for 
carbon and nitrogen sources, as revealed by Biolog phenotypic microarray analysis, 
facilitate the bacterium to utilise any available substrate. High number of different 
transporters, encoded on the genome, as well as multiple functionality of particular 
catabolic enzymes contribute to this skill. P. inhibens DSM 17395 uses mostly ABC 
transporters that are very efficient at typical low substrate concentrations in seawater. 
MB medium represents complex nutrient conditions that are typical (seasonal) in the 
natural environments of P. inhibens DSM 17395. In most bacteria metabolite repression is 
active, resulting in utilisation of only one or few different compounds (Görke and Stülke, 
2008). In contrast to this, P. inhibens DSM 17395 is capable to tune its metabolism to 
simultaneous utilisation of several substrates. In accordance with observed high 
intracellular concentrations of imported substrates, first priority is to import substrates to 
safe them against potential competitors. Alternatively, metabolism was efficiently adapted 
to one specific substrate, if only one was provided. Formation of disaccharides is rather 
exclusively induced upon active utilisation of carbohydrates. As alternative for energy and 
carbon storage, P. inhibens DSM 17395 builds poly-3-(R)-hydroxybutanoate. Biosynthesis 
of this polymer could also be used to replenish NADP+, allowing to tune particular 
catabolic pathways.
Cultivation on casamino acids in a time-dynamic experiment showed that P. inhibens 
DSM 17395 used most of supplied substrates simultaneously. Upon complete consumption 
of preferred substrates, the metabolism switched quickly to utilisation of alternative 
substrates. Cells entered stationary phase although sufficient utilisable amino acids were 
still available. The most probable reason for this was acyl-homoserine-lactone induced 
quorum sensing. However, the antibiotic tropodithietic acid, which is produced by 
P. inhibens DSM 17395, seems to have a higher impact on growth stop, as revealed by 
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cultivation of plasmid-cured strains. These strains lost the ability to produce this antibiotic 
and reached considerable higher cell densities.
Growth on individual substrates revealed some constraints of metabolism. Side 
reactions produced some unexpected dead-end products. These were exported, along with 
overflow intermediates and the waste product urea. Such exported compounds may have 
an impact on the carbon and nitrogen cycle in the marine habitat. Replenishment of TCA 
cycle for anabolic processes is inefficient, since the complex ethylmalonyl-CoA pathway is 
used in P. inhibens DSM 17395. The requirement of this pathway is diminished, if several 
substrates are utilised simultaneously that feed the TCA cycle at different entry-points. 
Furthermore particular catabolic pathways, such as lysine degradation generate precursors 
of the ethylmalonyl-CoA pathway. Therefore, P. inhibens DSM 17395 is rather adapted to 
growth on substrate mixtures.
Degradation of structural similar carbohydrates in P. inhibens DSM 17395 is performed 
efficiently. Only few enzymes are required for peripheral degradation, until all 
carbohydrates are degraded by the Entner-Doudoroff pathway. This pathway compensates 
absent phosphofruktokinase and non operable oxidative pentose phosphate pathway. The 
Entner-Doudoroff pathway generates per mol substrate 1 mol ATP and NADH less than 
glycolysis, but one mol NADPH more. The latter is important for anabolic purposes, e.g. 
amino acids and fatty acid biosynthesis. 
Homologous enzymes of central metabolism and studied degradation pathways are 
widespread distributed across the Roseobacter clade (Drüppel et al., 2014; Wiegmann et  
al., 2014). Therefore, many of the observed metabolic features of P. inhibens DSM 17395 
may be assigned to other members of the Roseobacter clade. The formation of structural 
unknown compounds and uncommon metabolites, e.g. tartrate, have so far not yet been 
assigned to perform biological functions. These detected uncommon compounds could be a 
specific adaptation to the marine environment, or even be a general characteristic of the 
Roseobacter clade. 
114   REFERENCES
References
Alber, B.E., Spanheimer, R., Ebenau-Jehle, C., Fuchs, G., 2006. Study of an alternate glyoxylate cycle for  
acetate assimilation by Rhodobacter sphaeroides. Mol. Microbiol. 61, 297–309.
Alonso, C., Pernthaler, J., 2006. Roseobacter and SAR11 dominate microbial glucose uptake in coastal North 
Sea waters. Environ. Microbiol. 8, 2022–2030.
Alonso-Sáez, L., Balagué, V., Sà, E.L., Sánchez, O., González, J.M., Pinhassi, J., Massana, R., Pernthaler, J.,  
Pedrós-Alió, C., Gasol, J.M., 2007. Seasonality in bacterial diversity in north-west Mediterranean 
coastal waters: assessment through clone libraries, fingerprinting and FISH. FEMS Microbiol. Ecol. 
60, 98–112.
Alonso-Sáez, L., Gasol, J.M., 2007. Seasonal Variations in the Contributions of Different Bacterial Groups to 
the Uptake of Low-Molecular-Weight Compounds in Northwestern Mediterranean Coastal Waters. 
Appl. Environ. Microbiol. 73, 3528–3535.
Altenschmidt, U., Oswald, B., Fuchs, G., 1991. Purification and characterization of benzoate-coenzyme A 
ligase and 2-aminobenzoate-coenzyme A ligases from a denitrifying Pseudomonas sp. J. Bacteriol. 
173, 5494–5501.
Appeltans, W., Ahyong, S.T., Anderson, G., Angel, M.V., Artois, T., Bailly, N., Bamber, R., Barber, A.,  
Bartsch, I., Berta, A., Błażewicz-Paszkowycz, M., Bock, P., Boxshall, G., Boyko, C.B., Brandão, 
S.N., Bray, R.A., Bruce, N.L., Cairns, S.D., Chan, T.-Y., Cheng, L., Collins, A.G., Cribb, T., Curini-
Galletti, M., Dahdouh-Guebas, F., Davie, P.J.F., Dawson, M.N., De Clerck, O., Decock, W., De 
Grave, S., de Voogd, N.J., Domning, D.P., Emig, C.C., Erséus, C., Eschmeyer, W., Fauchald, K.,  
Fautin, D.G., Feist, S.W., Fransen, C.H.J.M., Furuya, H., Garcia-Alvarez, O., Gerken, S., Gibson, 
D., Gittenberger, A., Gofas, S., Gómez-Daglio, L., Gordon, D.P., Guiry, M.D., Hernandez, F., 
Hoeksema, B.W., Hopcroft, R.R., Jaume, D., Kirk, P., Koedam, N., Koenemann, S., Kolb, J.B., 
Kristensen, R.M., Kroh, A., Lambert, G., Lazarus, D.B., Lemaitre, R., Longshaw, M., Lowry, J.,  
Macpherson, E., Madin, L.P., Mah, C., Mapstone, G., McLaughlin, P.A., Mees, J., Meland, K., 
Messing, C.G., Mills, C.E., Molodtsova, T.N., Mooi, R., Neuhaus, B., Ng, P.K.L., Nielsen, C., 
Norenburg, J., Opresko, D.M., Osawa, M., Paulay, G., Perrin, W., Pilger, J.F., Poore, G.C.B., Pugh, 
P., Read, G.B., Reimer, J.D., Rius, M., Rocha, R.M., Saiz-Salinas, J.I., Scarabino, V., Schierwater, 
B., Schmidt-Rhaesa, A., Schnabel, K.E., Schotte, M., Schuchert, P., Schwabe, E., Segers, H., Self-
Sullivan, C., Shenkar, N., Siegel, V., Sterrer, W., Stöhr, S., Swalla, B., Tasker, M.L., Thuesen, E.V.,  
Timm, T., Todaro, M.A., Turon, X., Tyler, S., Uetz, P., van der Land, J., Vanhoorne, B., van 
Ofwegen, L.P., van Soest, R.W.M., Vanaverbeke, J., Walker-Smith, G., Walter, T.C., Warren, A., 
Williams, G.C., Wilson, S.P., Costello, M.J., 2012. The Magnitude of Global Marine Species 
Diversity. Curr. Biol. 22, 2189–2202.
Apple, J.K., Del Giorgio, P.A., Kemp, W.M., 2006. Temperature regulation of bacterial production, 
respiration, and growth efficiency in a temperate salt-marsh estuary. Aquat. Microb. Ecol. 43, 243–
254.
Bantscheff, M., Lemeer, S., Savitski, M.M., Kuster, B., 2012. Quantitative mass spectrometry in proteomics: 
critical review update from 2007 to the present. Anal. Bioanal. Chem. 404, 939–965.
Bender, R.A., 2012. Regulation of the Histidine Utilization (Hut) System in Bacteria. Microbiol. Mol. Biol.  
Rev. 76, 565–584.
Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a practical and powerful approach to 
multiple testing. J. R. Stat. Soc. Ser. B Methodol. 289–300.
Benton, H.P., Want, E.J., Ebbels, T.M.D., 2010. Correction of mass calibration gaps in liquid 
chromatography–mass spectrometry metabolomics data. Bioinformatics 26, 2488–2489.
Berger, M., Neumann, A., Schulz, S., Simon, M., Brinkhoff, T., 2011. Tropodithietic Acid Production in 
  REFERENCES 115
Phaeobacter gallaeciensis Is Regulated by N-Acyl Homoserine Lactone-Mediated Quorum Sensing. 
J. Bacteriol. 193, 6576–6585.
Berger, M., Brock, N.L., Liesegang, H., Dogs, M., Preuth, I., Simon, M., Dickschat, J.S., Brinkhoff, T., 2012. 
Genetic Analysis of the Upper Phenylacetate Catabolic Pathway in the Production of Tropodithietic 
Acid by Phaeobacter gallaeciensis. Appl. Environ. Microbiol. 78, 3539–3551.
Berg, G.M., Jørgensen, N.O.G., 2006. Purine and pyrimidine metabolism by estuarine bacteria. Aquat.  
Microb. Ecol. 42, 215–226.
Bertini, I., Hu, X., Luchinat, C., 2013. Global metabolomics characterization of bacteria: pre-analytical 
treatments and profiling. Metabolomics. 1–9.
Biebl, H., Allgaier, M., Tindall, B.J., Koblizek, M., Lünsdorf, H., Pukall, R., Wagner-Döbler, I., 2005. 
Dinoroseobacter shibae gen. nov., sp. nov., a new aerobic phototrophic bacterium isolated from 
dinoflagellates. Int. J. Syst. Evol. Microbiol. 55, 1089–1096.
Bochner, B.R., 2009. Global phenotypic characterization of bacteria. FEMS Microbiol. Rev. 33, 191–205.
Bolten, C.J., Kiefer, P., Letisse, F., Portais, J.-C., Wittmann, C., 2007. Sampling for Metabolome Analysis of 
Microorganisms. Anal. Chem. 79, 3843–3849.
Börner, J., Buchinger, S., Schomburg, D., 2007. A high-throughput method for microbial metabolome 
analysis using gas chromatography/mass spectrometry. Anal. Biochem. 367, 143–151.
Brechtel, C.E., King, S.C., 1998. 4-Aminobutyrate (GABA) transporters from the amine-polyamine-choline 
superfamily: substrate specificity and ligand recognition profile of the 4-aminobutyrate permease 
from Bacillus subtilis. Biochem J 333, 565–571.
Breider, S., Scheuner, C., Schumann, P., Fiebig, A., Petersen, J., Pradella, S., Klenk, H.-P., Brinkhoff, T., 
Göker, M., 2014. Genome-scale data suggest reclassifications in the Leisingera-Phaeobacter cluster 
including proposals for Sedimentitalea gen. nov. and Pseudophaeobacter gen. nov. Front.  
Microbiol. 5.
Brinkhoff, T., Bach, G., Heidorn, T., Liang, L., Schlingloff, A., Simon, M., 2004. Antibiotic Production by a 
Roseobacter Clade-Affiliated Species from the German Wadden Sea and Its Antagonistic Effects on 
Indigenous Isolates. Appl. Environ. Microbiol. 70, 2560–2565.
Brinkhoff, T., Giebel, H.-A., Simon, M., 2008. Diversity, ecology, and genomics of the Roseobacter clade: a 
short overview. Arch. Microbiol. 189, 531–539.
Broadhurst, D.I., Kell, D.B., 2006. Statistical strategies for avoiding false discoveries in metabolomics and  
related experiments. Metabolomics 2, 171–196.
Brown, M.R., 1991. The amino-acid and sugar composition of 16 species of microalgae used in mariculture. 
J. Exp. Mar. Biol. Ecol. 145, 79–99.
Buddruhs, N., Pradella, S., Göker, M., Päuker, O., Pukall, R., Spröer, C., Schumann, P., Petersen, J., 
Brinkhoff, T., 2013. Molecular and phenotypic analyses reveal the non-identity of the Phaeobacter 
gallaeciensis type strain deposits CIP 105210T and DSM 17395. Int. J. Syst. Evol. Microbiol. 63, 
4340–4349.
Cabrita, M.T., Vale, C., Rauter, A.P., 2010. Halogenated Compounds from Marine Algae. Mar. Drugs 8, 
2301–2317.
Carneiro, S., Villas-Bôas, S.G., Ferreira, E.C., Rocha, I., 2011. Metabolic footprint analysis of recombinant 
Escherichia coli strains during fed-batch fermentations. Mol. BioSyst. 7, 899-910
Caspi, R., Altman, T., Billington, R., Dreher, K., Foerster, H., Fulcher, C.A., Holland, T.A., Keseler, I.M.,  
Kothari, A., Kubo, A., Krummenacker, M., Latendresse, M., Mueller, L.A., Ong, Q., Paley, S., 
Subhraveti, P., Weaver, D.S., Weerasinghe, D., Zhang, P., Karp, P.D., 2014. The MetaCyc database 
of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. 
116   REFERENCES
Nucleic Acids Res. 42, D459–D471.
Cooper, A.J.L., 1983. Biochemistry of Sulfur-Containing Amino Acids. Annu. Rev. Biochem. 52, 187–222.
Cortay, J.C., Bleicher, F., Duclos, B., Cenatiempo, Y., Gautier, C., Prato, J.L., Cozzone, A.J., 1989. 
Utilization of acetate in Escherichia coli: structural organization and differential expression of the 
ace operon. Biochimie 71, 1043–1049.
Costa, M.S. da, Santos, H., Galinski, E.A., 1998. An overview of the role and diversity of compatible solutes 
in Bacteria and Archaea, in: Antranikian, G. (Ed.), Biotechnology of Extremophiles, Advances in 
Biochemical Engineering/Biotechnology. Springer Berlin Heidelberg, pp. 117–153.
Cox, J., Mann, M., 2011. Quantitative, High-Resolution Proteomics for Data-Driven Systems Biology. Annu.  
Rev. Biochem. 80, 273–299.
D’Alvise, P.W., Lillebø, S., Prol-Garcia, M.J., Wergeland, H.I., Nielsen, K.F., Bergh, Ø., Gram, L., 2012. 
Phaeobacter gallaeciensis Reduces Vibrio anguillarum in Cultures of Microalgae and Rotifers, and 
Prevents Vibriosis in Cod Larvae. PLoS ONE 7, e43996.
D’Alvise, P.W., Lillebø, S., Wergeland, H.I., Gram, L., Bergh, Ø., 2013. Protection of cod larvae from 
vibriosis by Phaeobacter spp.: A comparison of strains and introduction times. Aquaculture 384–
387, 82–86.
Dang, H., Li, T., Chen, M., Huang, G., 2007. Cross-Ocean Distribution of Rhodobacterales Bacteria as 
Primary Surface Colonizers in Temperate Coastal Marine Waters. Appl. Environ. Microbiol. 74, 52–
60.
Dash, H.R., Mangwani, N., Chakraborty, J., Kumari, S., Das, S., 2013. Marine bacteria: potential candidates 
for enhanced bioremediation. Appl. Microbiol. Biotechnol. 97, 561–571.
Davidson, A.L., Maloney, P.C., 2007. ABC transporters: how small machines do a big job. Trends Microbiol. 
15, 448–455.
De Eugenio, L.I., Escapa, I.F., Morales, V., Dinjaski, N., Galán, B., García, J.L., Prieto, M.A., 2010. The 
turnover of medium-chain-length polyhydroxyalkanoates in Pseudomonas putida KT2442 and the 
fundamental role of PhaZ depolymerase for the metabolic balance. Environ. Microbiol. 12, 207–221.
Dettmer, K., Aronov, P.A., Hammock, B.D., 2007. Mass spectrometry-based metabolomics. Mass Spectrom.  
Rev. 26, 51–78.
Dewapriya, P., Kim, S., 2014. Marine microorganisms: An emerging avenue in modern nutraceuticals and 
functional foods. Food Res. Int. 56, 115–125.
Díaz, E., Jiménez, J.I., Nogales, J., 2013. Aerobic degradation of aromatic compounds. Curr. Opin.  
Biotechnol. 24, 431–442.
Dickschat, J.S., 2010. Quorum sensing and bacterial biofilms. Nat. Prod. Rep. 27, 343.
Dittmar, T., Paeng, J., 2009. A heat-induced molecular signature in marine dissolved organic matter. Nat.  
Geosci. 2, 175–179.
Driessen, A.J., Jong, S. de, Konings, W.N., 1987. Transport of branched-chain amino acids in membrane 
vesicles of Streptococcus cremoris. J. Bacteriol. 169, 5193–5200.
Drüppel, K., Hensler, M., Trautwein, K., Koßmehl, S., Wöhlbrand, L., Schmidt-Hohagen, K., Ulbrich, M., 
Bergen, N., Meier-Kolthoff, J.P., Göker, M., Klenk, H.-P., Schomburg, D., Rabus, R., 2014. 
Pathways and substrate-specific regulation of amino acid degradation in Phaeobacter inhibens DSM 
17395 (archetype of the marine Roseobacter clade). Environ. Microbiol. 16, 218–238.
Duarte, C.M., Hendriks, I.E., Moore, T.S., Olsen, Y.S., Steckbauer, A., Ramajo, L., Carstensen, J., Trotter, 
J.A., McCulloch, M., 2013. Is Ocean Acidification an Open-Ocean Syndrome? Understanding 
Anthropogenic Impacts on Seawater pH. Estuaries Coasts 36, 221–236.
  REFERENCES 117
Ebbighausen, H., Weil, B., Krämer, R., 1989. Transport of branched-chain amino acids in Corynebacterium 
glutamicum. Arch. Microbiol. 151, 238–244.
Eom, S.-H., Kim, Y.-M., Kim, S.-K., 2013. Marine bacteria: potential sources for compounds to overcome 
antibiotic resistance. Appl. Microbiol. Biotechnol. 97, 4763–4773.
Erb, T.J., Fuchs, G., Alber, B.E., 2009. (2S)-Methylsuccinyl-CoA dehydrogenase closes the ethylmalonyl-
CoA pathway for acetyl-CoA assimilation. Mol. Microbiol. 73, 992–1008.
Fiehn, O., 2002. Metabolomics - the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155–171.
Fitzpatrick, P.F., 2003. Mechanism of Aromatic Amino Acid Hydroxylation. Biochemistry (Mosc.) 42, 
14083–14091.
Flint, D.H., 1994. Initial Kinetic and Mechanistic Characterization of Escherichia coli Fumarase A. Arch.  
Biochem. Biophys. 311, 509 – 516.
Fuchs, G., 2008. Anaerobic Metabolism of Aromatic Compounds. Ann. N. Y. Acad. Sci. 1125, 82–99.
Fuchs, G., Boll, M., Heider, J., 2011. Microbial degradation of aromatic compounds — from one strategy to 
four. Nat. Rev. Microbiol. 9, 803–816.
Fürch, T., Preusse, M., Tomasch, J., Zech, H., Wagner-Döbler, I., Rabus, R., Wittmann, C., 2009. Metabolic 
fluxes in the central carbon metabolism of Dinoroseobacter shibae and Phaeobacter gallaeciensis, 
two members of the marine Roseobacter clade. BMC Microbiol. 9, 209.
Gaboyer, F., Tindall, B.J., Ciobanu, M.-C., Duthoit, F., Le Romancer, M., Alain, K., 2013. Phaeobacter  
leonis sp. nov., an alphaproteobacterium from Mediterranean Sea sediments. Int. J. Syst. Evol.  
Microbiol. 63, 3301–3306.
Genda, T., Watabe, S., Ozaki, H., 2006. Purification and characterization of fumarase from Corynebacterium 
glutamicum. Biosci. Biotechnol. Biochem. 70, 1102–1109.
Geng, H., Belas, R., 2010a. Molecular mechanisms underlying roseobacter–phytoplankton symbioses. Curr.  
Opin. Biotechnol. 21, 332–338.
Geng, H., Belas, R., 2010b. Expression of Tropodithietic Acid Biosynthesis Is Controlled by a Novel 
Autoinducer. J. Bacteriol. 192, 4377–4387.
Giovannoni, S.J., Stingl, U., 2005. Molecular diversity and ecology of microbial plankton. Nature 437, 343–
348.
Górecki, T., Panić, O., Oldridge, N., 2006. Recent Advances in Comprehensive Two‐Dimensional Gas 
Chromatography (GC×GC). J. Liq. Chromatogr. Amp Relat. Technol. 29, 1077–1104.
Görke, B., Stülke, J., 2008. Carbon catabolite repression in bacteria: many ways to make the most out of  
nutrients. Nat. Rev. Microbiol. 6, 613–624.
Gruber, N., Galloway, J.N., 2008. An Earth-system perspective of the global nitrogen cycle. Nature 451, 293–
296.
Gurtovenko, A.A., Vattulainen, I., 2007. Molecular Mechanism for Lipid Flip-Flops. J. Phys. Chem. B 111, 
13554–13559.
Halket, J.M., Waterman, D., Przyborowska, A.M., Patel, R.K.P., Fraser, P.D., Bramley, P.M., 2005. Chemical 
derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. J. Exp.  
Bot. 56, 219–243.
Hall, R.D., 2006. Plant metabolomics: from holistic hope, to hype, to hot topic. New Phytol. 169, 453–468.
Hansell, D., Carlson, C., Repeta, D., Schlitzer, R., 2009. Dissolved Organic Matter in the Ocean: A  
Controversy Stimulates New Insights. Oceanography 22, 202–211.
118   REFERENCES
Härtel, U., Eckel, E., Koch, J., Fuchs, G., Linder, D., Buckel, W., 1993. Purification of glutaryl-CoA 
dehydrogenase from Pseudomonas sp., an enzyme involved in the anaerobic degradation of 
benzoate. Arch. Microbiol. 159, 174–181.
Heider, J., Boll, M., Breese, K., Breinig, S., Ebenau-Jehle, C., Feil, U., Gad’on, N., Laempe, D., Leuthner, B., 
Mohamed, M.E.-S., Schneider, S., Burchhardt, G., Fuchs, G., 1998. Differential induction of 
enzymes involved in anaerobic metabolism of aromatic compounds in the denitrifying bacterium 
Thauera aromatica. Arch. Microbiol. 170, 120–131.
Helsper, J.P., Loewus, F.A., 1982. Metabolism of l-Threonic Acid in Rumex x acutus L. and Pelargonium 
crispum (L.) L’Hér. Plant Physiol. 69, 1365–1368.
Hiller, K., Hangebrauk, J., Jäger, C., Spura, J., Schreiber, K., Schomburg, D., 2009. MetaboliteDetector: 
Comprehensive Analysis Tool for Targeted and Nontargeted GC/MS Based Metabolome Analysis. 
Anal. Chem. 81, 3429–3439. 
Holm, S., 1979. A simple sequentially rejective multiple test procedure. Scand J Stat 6, 65–70.
Horai, H., Arita, M., Kanaya, S., Nihei, Y., Ikeda, T., Suwa, K., Ojima, Y., Tanaka, K., Tanaka, S., Aoshima,  
K., Oda, Y., Kakazu, Y., Kusano, M., Tohge, T., Matsuda, F., Sawada, Y., Hirai, M.Y., Nakanishi, H., 
Ikeda, K., Akimoto, N., Maoka, T., Takahashi, H., Ara, T., Sakurai, N., Suzuki, H., Shibata, D., 
Neumann, S., Iida, T., Tanaka, K., Funatsu, K., Matsuura, F., Soga, T., Taguchi, R., Saito, K., 
Nishioka, T., 2010. MassBank: a public repository for sharing mass spectral data for life sciences. J.  
Mass Spectrom. JMS 45, 703–714.
Imhoff, J.F., Labes, A., Wiese, J., 2011. Bio-mining the microbial treasures of the ocean: New natural  
products. Biotechnol. Adv., Marine Biotechnology in Europe European Science Foundation-COST 
Conference: “Marine Biotechnology: Future Challenges” 29, 468–482.
Ittekkot, V., 1982. Variations of dissolved organic matter during a plankton bloom: qualitative aspects, based 
on sugar and amino acid analyses. Mar. Chem. 11, 143–158.
Iwamoto, K., Shiraiwa, Y., 2005. Salt-Regulated Mannitol Metabolism in Algae. Mar. Biotechnol. 7, 407–
415.
Jojima, T., Omumasaba, C.A., Inui, M., Yukawa, H., 2010. Sugar transporters in efficient utilization of mixed 
sugar substrates: current knowledge and outlook. Appl. Microbiol. Biotechnol. 85, 471–480.
Kanani, H.H., Klapa, M.I., 2007. Data correction strategy for metabolomics analysis using gas 
chromatography–mass spectrometry. Metab. Eng. 9, 39–51.
Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M., 2014. Data, information, 
knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42, D199–D205.
Karl, D., Letelier, R., Tupas, L., Dore, J., Christian, J., Hebel, D., 1997. The role of nitrogen fixation in  
biogeochemical cycling in the subtropical North Pacific Ocean. Nature 388, 533–538.
Kell, D.B., 2004. Metabolomics and systems biology: making sense of the soup. Curr. Opin. Microbiol. 7, 
296–307.
Kell, D.B., 2006. Systems biology, metabolic modelling and metabolomics in drug discovery and 
development. Drug Discov. Today 11, 1085–1092.
Khorana, H.G., 1953. The Chemistry of Carbodiimides. Chem. Rev. 53, 145–166.
King, M.T., Reiss, P.D., 1985. Separation and measurement of short-chain coenzyme-A compounds in rat  
liver by reversed-phase high-performance liquid chromatography. Anal. Biochem. 146, 173–179.
Kirchman, D.L., Morán, X.A.G., Ducklow, H., 2009. Microbial growth in the polar oceans — role of  
temperature and potential impact of climate change. Nat. Rev. Microbiol. 7, 451–459.
Koch, B.P., Witt, M., Engbrodt, R., Dittmar, T., Kattner, G., 2005. Molecular formulae of marine and 
  REFERENCES 119
terrigenous dissolved organic matter detected by electrospray ionization Fourier transform ion 
cyclotron resonance mass spectrometry. Geochim. Cosmochim. Acta 69, 3299–3308.
Kohn, L.D., Jakoby, W.B., 1966. [48] l- and mesotartaric acid dehydrogenase (crystalline), in: Willis A. Wood 
(Ed.), Methods in Enzymology, Carbohydrate Metabolism. Academic Press, pp. 236–240.
Kolter, R., Siegele, D.A., Tormo, A., 1993. The Stationary Phase of The Bacterial Life Cycle. Annu. Rev.  
Microbiol. 47, 855–874.
Kreis, W., Hession, C., 1973. Isolation and purification of L-methionine-alpha-deamino-gamma-
mercaptomethane-lyase (L-methioninase) from Clostridium sporogenes. Cancer Res. 33, 1862–
1865.
Kruskal, W.H., Wallis, W.A., 1952. Use of Ranks in One-Criterion Variance Analysis. J. Am. Stat. Assoc. 47, 
583.
Kusano, T., Berberich, T., Tateda, C., Takahashi, Y., 2008. Polyamines: essential factors for growth and 
survival. Planta 228, 367–381.
Laass, S., Kleist, S., Bill, N., Drüppel, K., Kossmehl, S., Wöhlbrand, L., Rabus, R., Klein, J., Rohde, M.,  
Bartsch, A., Wittmann, C., Schmidt-Hohagen, K., Tielen, P., Jahn, D., Schomburg, D., 2014. Gene 
Regulatory and Metabolic Adaptation Processes of Dinoroseobacter shibae DFL12T during Oxygen 
Depletion. J. Biol. Chem. 289, 13219–13231.
Ladau, J., Sharpton, T.J., Finucane, M.M., Jospin, G., Kembel, S.W., O’Dwyer, J., Koeppel, A.F., Green, J.L.,  
Pollard, K.S., 2013. Global marine bacterial diversity peaks at high latitudes in winter. ISME J. 7, 
1669–1677.
Ledesma-Amaro, R., Jiménez, A., Santos, M.A., Revuelta, J.L., 2013. Biotechnological production of feed 
nucleotides by microbial strain improvement. Process Biochem. 48, 1263–1270.
Leigh, J.A., Dodsworth, J.A., 2007. Nitrogen Regulation in Bacteria and Archaea. Annu. Rev. Microbiol. 61, 
349–377.
Lewis, C.A., Wolfenden, R., 2014. The Nonenzymatic Decomposition of Guanidines and Amidines. J. Am.  
Chem. Soc. 136, 130–136.
Liu, M., Xiao, T., Sun, J., Wei, H., Wu, Y., Zhao, Y., Zhang, W., 2013. Bacterial community structures  
associated with a natural spring phytoplankton bloom in the Yellow Sea, China. Deep Sea Res. Part  
II Top. Stud. Oceanogr. 97, 85–92.
Madison, L.L., Huisman, G.W., 1999. Metabolic Engineering of Poly(3-Hydroxyalkanoates): From DNA to 
Plastic. Microbiol. Mol. Biol. Rev. 63, 21–53.
Maes, C., O’Kane, T.J., 2014. Seasonal variations of the upper ocean salinity stratification in the Tropics. J.  
Geophys. Res. Oceans 119, 1706–1722.
Mann, H.B., Whitney, D.R., 1947. On a Test of Whether one of Two Random Variables is Stochastically 
Larger than the Other. Ann. Math. Stat. 18, 50–60.
Martens, T., Heidorn, T., Pukall, R., Simon, M., Tindall, B.J., Brinkhoff, T., 2006. Reclassification of 
Roseobacter gallaeciensis Ruiz-Ponte et al. 1998 as Phaeobacter gallaeciensis gen. nov., comb. 
nov., description of Phaeobacter inhibens sp. nov., reclassification of Ruegeria algicola (Lafay et  
al. 1995) Uchino et al. 1999 as Marinovum algicola gen. nov., comb. nov., and emended 
descriptions of the genera Roseobacter, Ruegeria and Leisingera. Int. J. Syst. Evol. Microbiol. 56, 
1293–1304.
Massey, L.K., Sokatch, J.R., Conrad, R.S., 1976. Branched-chain amino acid catabolism in bacteria. 
Bacteriol. Rev. 40, 42–54.
Merrick, M.J., Edwards, R.A., 1995. Nitrogen control in bacteria. Microbiol. Rev. 59, 604–622.
120   REFERENCES
Mills, M.M., Ridame, C., Davey, M., La Roche, J., Geider, R.J., 2004. Iron and phosphorus co-limit nitrogen  
fixation in the eastern tropical North Atlantic. Nature 429, 292–294.
Montani, S., Tada, K., Okaichi, T., 1988. Purine and pyrimidine bases in marine particles in the Seto Inland 
Sea, Japan. Mar. Chem. 25, 359–371.
Mulligan, C., Fischer, M., Thomas, G.H., 2011. Tripartite ATP-independent periplasmic (TRAP) transporters 
in bacteria and archaea. FEMS Microbiol. Rev. 35, 68–86.
Mustakhimov, I.I., Reshetnikov, A.S., Khmelenina, V.N., Trotsenko, Y.A., 2010. Regulatory aspects of 
ectoine biosynthesis in halophilic bacteria. Microbiology 79, 583–592.
Nagata, T., 1986. Carbon and Nitrogen Content of Natural Planktonic Bacteria. Appl. Environ. Microbiol. 52, 
28–32.
Narukawa, M., Kawamura, K., Hatsushika, H., Yamazaki, K., Li, S.-M., Bottenheim, J.W., Anlauf, K.G., 
2003. Measurement of Halogenated Dicarboxylic Acids in the Arctic Aerosols at Polar Sunrise. J.  
Atmospheric Chem. 44, 323–335.
Nebbioso, A., Piccolo, A., 2013. Molecular characterization of dissolved organic matter (DOM): a critical 
review. Anal. Bioanal. Chem. 405, 109–124.
Nedwell, D.., 1999. Effect of low temperature on microbial growth: lowered affinity for substrates limits 
growth at low temperature. FEMS Microbiol. Ecol. 30, 101–111.
Neumann, A., Patzelt, D., Wagner-Döbler, I., Schulz, S., 2013. Identification of New N-Acylhomoserine 
Lactone Signalling Compounds of Dinoroseobacter shibae DFL-12T by Overexpression of luxI  
Genes. ChemBioChem 14, 2355–2361.
Nyström, T., 2004. Stationary-Phase Physiology. Annu. Rev. Microbiol. 58, 161–181.
Ohshima, T., Sakuraba, H., 1986. Purification and characterization of malate dehydrogenase from the 
phototrophic bacterium, Rhodopseudomonas capsulata. Biochim. Biophys. Acta BBA - Protein  
Struct. Mol. Enzymol. 869, 171–177.
Patzelt, D., Wang, H., Buchholz, I., Rohde, M., Gröbe, L., Pradella, S., Neumann, A., Schulz, S., Heyber, S.,  
Münch, K., Münch, R., Jahn, D., Wagner-Döbler, I., Tomasch, J., 2013. You are what you talk:  
quorum sensing induces individual morphologies and cell division modes in Dinoroseobacter 
shibae. ISME J 7, 2274–2286.
Petersen, J., Brinkmann, H., Berger, M., Brinkhoff, T., Päuker, O., Pradella, S., 2011. Origin and Evolution of 
a Novel DnaA-Like Plasmid Replication Type in Rhodobacterales. Mol. Biol. Evol. 28, 1229–1240.
Petersen, J., Frank, O., Göker, M., Pradella, S., 2013. Extrachromosomal, extraordinary and essential—the 
plasmids of the Roseobacter clade.  Appl. Microbiol. Biotechnol. 97, 2805–2815.
Pettine, M., Patrolecco, L., Manganelli, M., Capri, S., Farrace, M.G., 1999. Seasonal variations of dissolved 
organic matter in the northern Adriatic Sea. Mar. Chem. 64, 153–169.
Pettine, M., Capri, S., Manganelli, M., Patrolecco, L., Puddu, A., Zoppini, A., 2001. The Dynamics of DOM 
in the Northern Adriatic Sea. Estuar. Coast. Shelf Sci. 52, 471–489.
Peyraud, R., Kiefer, P., Christen, P., Massou, S., Portais, J.-C., Vorholt, J.A., 2009. Demonstration of the 
ethylmalonyl-CoA pathway by using 13C metabolomics. Proc. Natl. Acad. Sci. 106, 4846–4851.
Poblete-Castro, I., Escapa, I.F., Jäger, C., Puchalka, J., Lam, C.M.C., Schomburg, D., Prieto, M.A., Santos, 
V.A.M. dos, 2012. The metabolic response of P. putida KT2442 producing high levels of 
polyhydroxyalkanoate under single- and multiple-nutrient-limited growth: Highlights from a multi-
level omics approach. Microb. Cell Factories 11, 34.
Poretsky, R.S., Sun, S., Mou, X., Moran, M.A., 2010. Transporter genes expressed by coastal  
bacterioplankton in response to dissolved organic carbon. Environ. Microbiol. 12, 616–627.
  REFERENCES 121
Porsby, C.H., Webber, M.A., Nielsen, K.F., Piddock, L.J.V., Gram, L., 2011. Resistance and Tolerance to 
Tropodithietic Acid, an Antimicrobial in Aquaculture, Is Hard To Select. Antimicrob. Agents  
Chemother. 55, 1332–1337.
Pradella, S., Päuker, O., Petersen, J., 2010. Genome organisation of the marine Roseobacter clade member 
Marinovum algicola. Arch. Microbiol. 192, 115–126.
Pritsch, F., 2012. Metabolomanalyse von Phaeobacter inhibens DSM 17395 unter Verwendung von 
heterogenen Kohlenstoffquellen (Bachelor of science thesis). TU Braunschweig, Braunschweig.
Quester, S., Schomburg, D., 2011. EnzymeDetector: an integrated enzyme function prediction tool and 
database. BMC Bioinformatics 12, 376.
Rabus, R., Trautwein, K., Wöhlbrand, L., 2014. Towards habitat-oriented systems biology of “Aromatoleum 
aromaticum” EbN1. Appl. Microbiol. Biotechnol. 98, 3371–3388.
Rao, D., Webb, J.S., Holmström, C., Case, R., Low, A., Steinberg, P., Kjelleberg, S., 2007. Low Densities of 
Epiphytic Bacteria from the Marine Alga Ulva australis Inhibit Settlement of Fouling Organisms. 
Appl. Environ. Microbiol. 73, 7844–7852.
Reaves, M.L., Young, B.D., Hosios, A.M., Xu, Y.-F., Rabinowitz, J.D., 2013. Pyrimidine homeostasis is 
accomplished by directed overflow metabolism. Nature 500, 237–241.
Reay, D.S., Nedwell, D.B., Priddle, J., Ellis-Evans, J.C., 1999. Temperature Dependence of Inorganic 
Nitrogen Uptake: Reduced Affinity for Nitrate at Suboptimal Temperatures in Both Algae and 
Bacteria. Appl. Environ. Microbiol. 65, 2577–2584.
Reid, S.J., Abratt, V.R., 2005. Sucrose utilisation in bacteria: genetic organisation and regulation. Appl.  
Microbiol. Biotechnol. 67, 312–321.
Reul, N., Fournier, S., Boutin, J., Hernandez, O., Maes, C., Chapron, B., Alory, G., Quilfen, Y., Tenerelli, J.,  
Morisset, S., Kerr, Y., Mecklenburg, S., Delwart, S., 2014. Sea Surface Salinity Observations from 
Space with the SMOS Satellite: A New Means to Monitor the Marine Branch of the Water Cycle.  
Surv. Geophys. 35, 681–722.
Rex, R., Bill, N., Schmidt-Hohagen, K., Schomburg, D., 2013. Swimming in Light: A Large-Scale 
Computational Analysis of the Metabolism of Dinoroseobacter shibae. PLoS Comput Biol 9, 
e1003224.
Ribardo, D.A., Hendrixson, D.R., 2011. Analysis of the LIV System of Campylobacter jejuni Reveals 
Alternative Roles for LivJ and LivK in Commensalism beyond Branched-Chain Amino Acid 
Transport. J. Bacteriol. 193, 6233–6243.
Righetti, P., Campostrini, N., Pascali, J., Hamdan, M., Astner, H., 2004. Quantitative proteomics: a review of 
different methodologies. Eur. J. Mass Spectrom. 10, 335.
Rinaudo, M., 2006. Chitin and chitosan: Properties and applications. Prog. Polym. Sci. 31, 603–632.
Ruiz-Ponte, C., Cilia, V., Lambert, C., Nicolas, J.L., 1998. Roseobacter gallaeciensis sp. nov., a new marine  
bacterium isolated from rearings and collectors of the scallop Pecten maximus. Int. J. Syst.  
Bacteriol. 48 Pt 2, 537–542.
Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T.,  
Thiagarajan, M., Sturn, A., Snuffin, M., Rezantsev, A., Popov, D., Ryltsov, A., Kostukovich, E., 
Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V., Quackenbush, J., 2003. TM4: a free, open-source 
system for microarray data management and analysis. BioTechniques 34, 374–378.
Sajiki, K., Pluskal, T., Shimanuki, M., Yanagida, M., 2013. Metabolomic Analysis of Fission Yeast at the 
Onset of Nitrogen Starvation. Metabolites 3, 1118–1129.
Sakugawa, H., Handa, N., Yagi, K., 1990. Distribution of glycosylglycerols and oligosaccharides in the 
marine environment and their ecological significance in the deep sea. Mar. Biol. 106, 309–313.
122   REFERENCES
Sarmento, H., Romera-Castillo, C., Lindh, M., Pinhassi, J., Sala, M.M., Gasol, J.M., Marrasé, C., Taylor,  
G.T., 2013. Phytoplankton species-specific release of dissolved free amino acids and their selective 
consumption by bacteria. Limnol. Oceanogr. 58, 1123–1135.
Scalbert, A., Brennan, L., Fiehn, O., Hankemeier, T., Kristal, B.S., van Ommen, B., Pujos-Guillot, E., 
Verheij, E., Wishart, D., Wopereis, S., 2009. Mass-spectrometry-based metabolomics: limitations 
and recommendations for future progress with particular focus on nutrition research. Metabolomics 
5, 435–458.
Schaefer, A.L., Greenberg, E.P., Oliver, C.M., Oda, Y., Huang, J.J., Bittan-Banin, G., Peres, C.M., Schmidt, 
S., Juhaszova, K., Sufrin, J.R., Harwood, C.S., 2008. A new class of homoserine lactone quorum-
sensing signals. Nature 454, 595–599.
Schaffer, J.E., 2002. Fatty acid transport: the roads taken. Am. J. Physiol. - Endocrinol. Metab. 282, E239–
E246.
Schomburg, I., Chang, A., Placzek, S., Söhngen, C., Rother, M., Lang, M., Munaretto, C., Ulas, S., Stelzer,  
M., Grote, A., Scheer, M., Schomburg, D., 2012. BRENDA in 2013: integrated reactions, kinetic  
data, enzyme function data, improved disease classification: new options and contents in BRENDA. 
Nucleic Acids Res. 41, D764–D772.
Schühle, K., Jahn, M., Ghisla, S., Fuchs, G., 2001. Two Similar Gene Clusters Coding for Enzymes of a New 
Type of Aerobic 2-Aminobenzoate (Anthranilate) Metabolism in the Bacterium Azoarcus evansii. J.  
Bacteriol. 183, 5268–5278.
Schujman, G.E., Mendoza, D. de, 2005. Transcriptional control of membrane lipid synthesis in bacteria. 
Curr. Opin. Microbiol. 8, 149–153.
Senior, P.J., Dawes, E.A., 1971. Poly-β-hydroxybutyrate biosynthesis and the regulation of glucose 
metabolism in Azotobacter beijerinckii. Biochem J 125, 55–66.
Seyedsayamdost, M.R., Case, R.J., Kolter, R., Clardy, J., 2011. The Jekyll-and-Hyde chemistry of 
Phaeobacter gallaeciensis. Nat. Chem. 3, 331–335.
Shapiro, S.S., Wilk, M.B., 1965. An Analysis of Variance Test for Normality (Complete Samples). 
Biometrika 52, 591.
Shiba, T., 1991. Roseobacter litoralis gen. nov., sp. nov., and Roseobacter denitrificans sp. nov., Aerobic 
Pink-Pigmented Bacteria which Contain Bacteriochlorophyll a. Syst. Appl. Microbiol. 14, 140–145.
Sintes, E., Witte, H., Stodderegger, K., Steiner, P., Herndl, G.J., 2013. Temporal dynamics in the free-living 
bacterial community composition in the coastal North Sea. FEMS Microbiol. Ecol. 83, 413–424.
Smith, C.A., Want, E.J., O’Maille, G., Abagyan, R., Siuzdak, G., 2006. XCMS: Processing Mass 
Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and 
Identification. Anal. Chem. 78, 779–787. 
Sogin, M.L., Morrison, H.G., Huber, J.A., Welch, D.M., Huse, S.M., Neal, P.R., Arrieta, J.M., Herndl, G.J., 
2006. Microbial diversity in the deep sea and the underexplored “rare biosphere.” Proc. Natl. Acad.  
Sci. 103, 12115–12120.
Sorek, R., Cossart, P., 2010. Prokaryotic transcriptomics: a new view on regulation, physiology and 
pathogenicity. Nat. Rev. Genet. 11, 9–16.
Strehmel, N., Kopka, J., Scheel, D., Böttcher, C., 2013. Annotating unknown components from GC/EI-MS-
based metabolite profiling experiments using GC/APCI(+)-QTOFMS. Metabolomics 1–13.
Strobel, H.J., 1993. Evidence for catabolite inhibition in regulation of pentose utilization and transport in the  
ruminal bacterium Selenomonas ruminantium. Appl. Environ. Microbiol. 59, 40–46.
Strohhäcker, J., Graaf, A.A. de, Schoberth, S.M., Wittig, R.M., Sahm, H., 1993. 31P Nuclear magnetic 
resonance studies of ethanol inhibition in Zymomonas mobilis. Arch. Microbiol. 159, 484–490.
  REFERENCES 123
Subrahmanyam, B., Grunseich, G., Nyadjro, E.S., 2013. Preliminary SMOS Salinity Measurements and 
Validation in the Indian Ocean. IEEE Trans. Geosci. Remote Sens. 51, 19–27.
Sunda, W.G., Huntsman, S.A., 1997. Interrelated influence of iron, light and cell size on marine 
phytoplankton growth. Nature 390, 389–392.
Tani, T.H., Khodursky, A., Blumenthal, R.M., Brown, P.O., Matthews, R.G., 2002. Adaptation to famine: A 
family of stationary-phase genes revealed by microarray analysis. Proc. Natl. Acad. Sci. 99, 13471–
13476.
Tautenhahn, R., Böttcher, C., Neumann, S., 2008. Highly sensitive feature detection for high resolution 
LC/MS. BMC Bioinformatics 9, 504.
Teufel, R., Mascaraque, V., Ismail, W., Voss, M., Perera, J., Eisenreich, W., Haehnel, W., Fuchs, G., 2010. 
Bacterial phenylalanine and phenylacetate catabolic pathway revealed. Proc. Natl. Acad. Sci. 107, 
14390–14395.
Thole, S., Kalhoefer, D., Voget, S., Berger, M., Engelhardt, T., Liesegang, H., Wollherr, A., Kjelleberg, S., 
Daniel, R., Simon, M., Thomas, T., Brinkhoff, T., 2012. Phaeobacter gallaeciensis genomes from 
globally opposite locations reveal high similarity of adaptation to surface life. ISME J. 6, 2229–
2244.
Tomitori, H., Kashiwagi, K., Igarashi, K., 2012. Structure and function of polyamine-amino acid antiporters  
CadB and PotE in Escherichia coli. Amino Acids 42, 733–740.
Typas, A., Banzhaf, M., Gross, C.A., Vollmer, W., 2012. From the regulation of peptidoglycan synthesis to  
bacterial growth and morphology. Nat. Rev. Microbiol. 10, 123–136.
Tyrrell, T., 1999. The relative influences of nitrogen and phosphorus on oceanic primary production. Nature  
400, 525–531.
Vandecandelaere, I., Segaert, E., Mollica, A., Faimali, M., Vandamme, P., 2008. Leisingera aquimarina sp. 
nov., isolated from a marine electroactive biofilm, and emended descriptions of Leisingera  
methylohalidivorans Schaefer et al. 2002, Phaeobacter daeponensis Yoon et al. 2007 and 
Phaeobacter inhibens Martens et al. 2006. Int. J. Syst. Evol. Microbiol. 58, 2788–2793.
Vandecandelaere, I., Segaert, E., Mollica, A., Faimali, M., Vandamme, P., 2009. Phaeobacter caeruleus sp. 
nov., a blue-coloured, colony-forming bacterium isolated from a marine electroactive biofilm. Int. J.  
Syst. Evol. Microbiol. 59, 1209–1214.
Vauclare, Madern, D., Girard, E., Gabel, F., Zaccai, G., Franzetti, B., 2014. New insights into microbial  
adaptation to extreme saline environments. BIO Web Conf. 2, 10.
Violante, A., Cozzolino, V., Perelomov, L., Caporale, A.G., Pigna, M., 2010. Mobility and bioavailability of 
heavy metals and metalloids in soil environments. J. Soil Sci. Plant Nutr. 10, 268–292.
Voegele, R.T., Mitsch, M.J., Finan, T.M., 1999. Characterization of two members of a novel malic enzyme 
class. Biochim. Biophys. Acta 1432, 275–285.
Vogels, G.D., Van der Drift, C., 1976. Degradation of purines and pyrimidines by microorganisms. Bacteriol.  
Rev. 40, 403–468.
Wagner-Döbler, I., Biebl, H., 2006. Environmental biology of the marine Roseobacter lineage. Annu. Rev.  
Microbiol. 60, 255–280.
Wagner-Döbler, I., Rheims, H., Felske, A., El-Ghezal, A., Flade-Schröder, D., Laatsch, H., Lang, S., Pukall, 
R., Tindall, B.J., 2004. Oceanibulbus indolifex gen. nov., sp. nov., a North Sea alphaproteobacterium 
that produces bioactive metabolites. Int. J. Syst. Evol. Microbiol. 54, 1177–1184.
Walmsley, A.R., Shaw, J.G., Kelly, D.J., 1992. The mechanism of ligand binding to the periplasmic C4-
dicarboxylate binding protein (DctP) from Rhodobacter capsulatus. J. Biol. Chem. 267, 8064–8072.
124   REFERENCES
Waters, C.M., Bassler, B.L., 2005. QUORUM SENSING: Cell-to-Cell Communication in Bacteria. Annu.  
Rev. Cell Dev. Biol. 21, 319–346.
Weckwerth, W., 2003. Metabolomics in Systems Biology. Annu. Rev. Plant Biol. 54, 669–689.
Whitman, W.B., Coleman, D.C., Wiebe, W.J., 1998. Prokaryotes: The unseen majority. Proc. Natl. Acad. Sci. 
95, 6578–6583.
Wiegmann, K., Hensler, M., Wöhlbrand, L., Ulbrich, M., Schomburg, D., Rabus, R., 2014. Carbohydrate 
Catabolism in Phaeobacter inhibens DSM 17395, a Member of the Marine Roseobacter Clade. 
Appl. Environ. Microbiol. 80, 4725–4737.
Wilcoxon, F., 1945. Individual Comparisons by Ranking Methods. Biom. Bull. 1, 80.
Yoon, J.-H., Kang, S.-J., Lee, S.-Y., Oh, T.-K., 2007. Phaeobacter daeponensis sp. nov., isolated from a tidal 
flat of the Yellow Sea in Korea. Int. J. Syst. Evol. Microbiol. 57, 856–861.
Yu, X., Wang, X., Engel, P.C., 2014. The specificity and kinetic mechanism of branched-chain amino acid 
aminotransferase from Escherichia coli studied with a new improved coupled assay procedure and 
the enzyme’s potential for biocatalysis. FEBS J. 281, 391–400.
Zan, J., Liu, Y., Fuqua, C., Hill, R.T., 2014. Acyl-Homoserine Lactone Quorum Sensing in the Roseobacter  
Clade. Int. J. Mol. Sci. 15, 654–669.
Zech, H., Thole, S., Schreiber, K., Kalhöfer, D., Voget, S., Brinkhoff, T., Simon, M., Schomburg, D., Rabus, 
R., 2009. Growth phase-dependent global protein and metabolite profiles of Phaeobacter 
gallaeciensis strain DSM 17395, a member of the marine Roseobacter-clade. PROTEOMICS 9, 
3677–3697.
Zech, H., Hensler, M., Koßmehl, S., Drüppel, K., Wöhlbrand, L., Trautwein, K., Hulsch, R., Maschmann, U., 
Colby, T., Schmidt, J., Reinhardt, R., Schmidt-Hohagen, K., Schomburg, D., Rabus, R., 2013a. 
Adaptation of Phaeobacter inhibens DSM 17395 to growth with complex nutrients. PROTEOMICS 
13, 2851–2868.
Zech, H., Hensler, M., Koßmehl, S., Drüppel, K., Wöhlbrand, L., Trautwein, K., Colby, T., Schmidt, J.,  
Reinhardt, R., Schmidt-Hohagen, K., Schomburg, D., Rabus, R., 2013b. Dynamics of amino acid 
utilization in Phaeobacter inhibens DSM 17395. PROTEOMICS 13, 2869–2885.
Zhang, D.-C., Li, H.-R., Xin, Y.-H., Liu, H.-C., Chi, Z.-M., Zhou, P.-J., Yu, Y., 2008. Phaeobacter arcticus 
sp. nov., a psychrophilic bacterium isolated from the Arctic. Int. J. Syst. Evol. Microbiol. 58, 1384–
1387.
Zhao, G., Pease, A.J., Bharani, N., Winkler, M.E., 1995. Biochemical characterization of gapB-encoded 
erythrose 4-phosphate dehydrogenase of Escherichia coli K-12 and its possible role in pyridoxal 5’-
phosphate biosynthesis. J. Bacteriol. 177, 2804–2812.
 Supplementary material i
Supplementary material
S1: Complete list of 13C labelled and unlabelled compounds in P. inhibens DSM 17395 after 
growth on [U-13C] glucose. 
Samples were prepared as described in section2.8.2 and analysed via GC-MS (sections 2.12.1 and 
2.12.2).
Metabolites with clear isotope shift
1,6-Anhydro-glucose Ethanolaminephosphate 2-Keto-3-deoxy-gluconate Putrescine
3-Hydroxybutanoate Fructose Leucine Pyroglutamate
3-Hydroxyecanoate Fructose-6-phosphate Lysine Pyruvate
2-Methylmalate Fumarate Malate Ribose
2-Oxoglutarate Glucoheptonate-1,4-lactone Maleate Serine
2-Phosphoglycerate Gluconate Melibiose Succinate
3-Phosphoglyerate Gluconate-1,5-lactone Tartrate
Alanine Glucose Threonate
Aspartate Glucose-6-phosphate Threonine
Glucuronate Nicotinamide Thymine
Carbodiimide Glutamate Tyrosine
Citrate Glycerate Uracil
Di-saccharides (RI 2740, 2754, Glycerol-3-phosphate Ornithine Urea
2762, 2812, e.g. Trehalose, Maltose) Glycerophosphoglycerol Pentose-5-phosphate Valine
Diethanolamine Glycine Phenylalanine
Dihydroxyacetone phosphate Isoleucine Phosphoenolpyruvate
Metabolites with weak isotope shift
Benzoate Lactate
Unidentified compounds with clear isotope shift
Unknown#1004.0-pin-mhe_001 Unknown#1651.8-pin-mhe_032 Unknown#1946.5-pin-mhe_024
Unknown#1361.3-pin-mhe_010 Unknown#1671.7-pin-mhe_019 Unknown#1955.0-pin-mhe_027 Unknown#2334.1-pin-mhe_051
Unknown#1366.9-pin-mhe_011 Unknown#1684.4-pin-mhe_034 Unknown#2018.7-pin-mhe_028 Unknown#2363.8-pin-mhe_052
Unknown#1456.4-pin-mhe_014 Unknown#1830.2-pin-mhe_038 Unknown#2078.9-pin-mhe_042 Unknown#2678.8-pin-mhe_069
Unknown#1589.9-pin-mhe_029 Unknown#1856.7-pin-mhe_040 Unknown#2090.48-ypy-mse_021
Unknown#1635.2-pin-mhe_031 Unknown#1937.2-pin-mhe_021 Unknown#2135.2-pin-mhe_044
Detected compounds, without isotope-shift
Borate Hydroxylamine Unknown#1169.8-pae-bth_013 NA109003_(classified_
Cyclohexane Lumichrome Unknown#1201.75-ppu-cja_004 unknown)_1104.97
Diphosphate Unknown#1248.7-cgl-sst_008 NA114002_(classified_
Dodecanol Phosphate Unknown#1277.1-ppu-cja_005 unknown)_1144.3
Glycerol Pyridine Unknown#1385.3-pae-bth_024
Toluate NA344 (RI 2070)
N-Acetyl-glutamate
N-Acetyl-glucosamine
N,N-dimethyl-glycine/ or Glyoxylate
β-Alanine
O-Acetylserine
Octadecenoate (C
18:1
)
Octanoate (C
8:0
)
Unknown#2269.25-ypy-mse_027
Octadecanoate (C
18:0
)
Hexadecanoate (C
16:0
)
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S2: Identified extracellular metabolites in Marine Broth medium.
Abbreviations: a, Fold change in abundance at ½ ODmax, as compared to sterile medium prior to 
inoculation; x, compound was not detected in reference condition; n.d. compound was not detected 
at ½ ODmax, indicating complete consumption of that substrate. 
Metabolites Metabolites
Amino acids, dipeptides and derivatives Carboxylates
Alanine 0.05 ± 0.02 4-Aminobutanoate n.d.
Arginine 0.65 ± 0.13 Citrate 0.07 ± 0.02
Asparagine 0.47 ± 0.09 Erythronate 0.17 ± 0.13
Aspartate 0.29 ± 0.06 Glycerate 0.41 ± 0.09
0.48 ± 0.12 Glycolate 0.26 ± 0.07
3-Cyano-alanine 1.03 ± 0.25 4-Hydroxybutanoate 0.89 ± 0.07
Glutamate <0.01 ± 0 2-Hydroxyphenylacetate x
Glycine 0.09 ± 0.03 Lactate 0.02 ± 0.02
Glycyl-glycine 0.05 ± 0.01 Maleamate 0.43 ± 0.03
Isoleucine 0.64 ± 0.06 Succinate n.d.
Leucine 0.57 ± 0.11 Threonate 0.63 ± 0.10
Lysine 0.74 ± 0.09
Methionine 0.25 ± 0.07 Saccharides and derivatives
n.d.
Ornithine 0.4 ± 0.05 Arabinonate 0.42 ± 0.10
Phenylalanine 0.83 ± 0.04 Arabinose 0.11 ± 0.08
Proline 0.08 ± 0.01 Cellobiose / Maltose n.d.
Pyroglutamate 0.91 ± 0.06 Glucose 1.17 ± 0.19
Serine 0.62 ± 0.09 Glycerol 0.17 ± 0.04
Threonine 0.94 ± 0.09 Lactose <0.01 ± 0
Tryptophan 0.56 ± 0.07 Melibiose n.d.
Tyrosine 0.64 ± 0.05 0.23 ± 0.10
Valine 0.6 ± 0.07 Sucrose <0.01 ± 0
Trehalose n.d.
Others
Purines and Pyrimidines and derivatives
Borate (inorganic) 0.98 ± 0.08
Glycerol-3-phosphate n.d. Adenine 0.36 ± 0.09
Nicotinate 0.36 ± 0.08 Adenosine 0.01 ± 0.01
Phosphate (inorganic) 1.6 ± 0.75 Cytosine 0.33 ± 0.04
Spermidine n.d. Uracil 0.01 ± 0.01
Urea 94.2 ± 91.3
Fold change a Fold change a
β-Alanine
N,N-Dimethylglycine
Myo-inositol
Colour scale for fold changes: <0.1 <0.25 <0.5 <0.75 0.75 – 1.25 >1.25 >10
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S3: Fold changes of all intracellularly detected metabolites in the experiment “adaptation to 
growth with complex nutrients.” 
Significance of fold-changes were calculated with Wilcoxon-Mann-Whitney test and false 
discovery rate control. Abbreviations: GM, glucose minimal; MB, Marine Broth, BR, bioreactor; x, 
metabolite not detected in reference conditions but in test condition; n.d. metabolite not detected in 
respective cultivation condition.
Metabolites
Fold change in abundance as compared to GM EM
Erlenmeyer flask Bioreactor
MB medium MB medium GM medium Fold change p-Value
Amino acids, dipeptides and derivatives
Alanine 0.49 ± 0.07 0.94 ± 0.10 0.80 ± 0.12 1.18 ± 0.13 0.17801
Alanyl-alanine 0.61 ± 0.15 1.11 ± 0.26 0.67 ± 0.21 1.65 ± 0.49 0.07038
Arginine 1.09 ± 0.05 0.31 ± 0.05 1.35 ± 0.21 0.23 ± 0.05 0.00190
Asparagine 1.86 ± 0.22 1.47 ± 0.18 1.50 ± 0.22 0.98 ± 0.13 0.88028
Aspartate 0.18 ± 0.05 0.38 ± 0.04 1.08 ± 0.12 0.36 ± 0.03 0.00028
0.95 ± 0.42 2.10 ± 1.01 1.73 ± 0.85 1.21 ± 0.44 0.32434
x x x 1.05 ± 0.37 0.88028
Cysteine 0.37 ± 0.07 0.35 ± 0.06 0.40 ± 0.06 0.88 ± 0.17 0.41224
Cystine 0.08 ± 0.01 0.05 ± 0.01 0.29 ± 0.06 0.17 ± 0.05 0.00052
x n.d. n.d.
Glutamate 0.20 ± 0.04 0.35 ± 0.06 0.76 ± 0.13 0.47 ± 0.04 0.00076
Glutamine 6.22 ± 0.56 4.13 ± 0.39 0.91 ± 0.08 4.51 ± 0.47 0.00028
Glycine 0.41 ± 0.02 0.62 ± 0.03 1.06 ± 0.04 0.58 ± 0.03 0.00028
Glycyl-phenylalanine 1.29 ± 0.07 0.30 ± 0.07 0.35 ± 0.05 0.86 ± 0.24 0.50571
Glycyl-glycine 18.8 ± 6.1 6.81 ± 2.14 1.41 ± 0.54 4.84 ± 1.64 0.00264
5-Hydroxy-lysine x x n.d. x
Histidine 0.90 ± 0.17 0.27 ± 0.05 2.40 ± 0.47 0.11 ± 0.02 0.00028
Homocysteine 2.80 ± 1.43 1.03 ± 0.51 1.09 ± 0.59 0.94 ± 0.25 0.25089
Isoleucine 1.22 ± 0.17 1.85 ± 0.26 1.63 ± 0.26 1.14 ± 0.13 0.41224
Leucine 0.49 ± 0.10 1.28 ± 0.06 1.74 ± 0.12 0.73 ± 0.05 0.00125
Lysine 0.70 ± 0.06 1.08 ± 0.10 1.29 ± 0.16 0.84 ± 0.09 0.25089
Methionine 0.16 ± 0.06 0.37 ± 0.12 0.95 ± 0.33 0.39 ± 0.09 0.00255
0.32 ± 0.09 0.46 ± 0.15 0.18 ± 0.09 1.59 ± 0.45 0.16188
Ornithine 1.92 ± 0.24 2.65 ± 0.34 1.29 ± 0.24 2.05 ± 0.30 0.00076
Phenylalanine 1.11 ± 0.18 1.76 ± 0.19 1.42 ± 0.21 1.24 ± 0.15 0.17801
Proline 1.55 ± 0.27 2.00 ± 0.36 1.27 ± 0.21 1.58 ± 0.18 0.00510
Serine 1.13 ± 0.15 1.22 ± 0.15 0.91 ± 0.13 1.33 ± 0.22 0.11054
Threonine 0.94 ± 0.17 1.88 ± 0.27 1.17 ± 0.22 1.61 ± 0.21 0.00190
Tryptophan 8.25 ± 2.57 11.8 ± 3.7 3.65 ± 1.15 3.25 ± 0.36 0.00028
Tyrosine 5.92 ± 1.86 6.37 ± 2.32 0.81 ± 0.27 7.85 ± 1.78 0.00028
Valine 0.55 ± 0.13 1.19 ± 0.16 1.32 ± 0.20 0.90 ± 0.09 0.64214
TCA cycle intermediates
Citrate 4.85 ± 1.24 5.47 ± 1.35 3.16 ± 1.05 1.73 ± 0.468 0.07038
2-Oxoglutarate 0.03 ± 0.01 0.03 ± 0 0.17 ± 0.05 0.15 ± 0.04 0.00359
Succinate 12.5 ± 2.5 14.5 ± 1.8 1.17 ± 0.09 12.4 ± 1.6 0.00028
Fumarate 0.08 ± 0.03 0.05 ± 0.01 0.56 ± 0.10 0.09 ± 0.02 0.00028
Malate 1.79 ± 0.83 4.14 ± 1.45 2.21 ± 0.98 1.87 ± 0.66 0.09916
Organic acids
2-Aminobutanoate 1.02 ± 0.26 1.29 ± 0.19 0.48 ± 0.09 2.69 ± 0.52 0.00105
5-Aminopentanoate 1300 ± 1300 3600 ± 3600 11.7 ± 13.05 309 ± 157 0.00028
Benzoate 0.83 ± 0.68 4.29 ± 3.52 3.76 ± 3.87 0.95 ± 0.31 0.44515
2-Coumarate 1.21 0.84 1.02 0.83 ± 0.09 0.06991
2,4-Diaminobutanoate 0.58 ± 0.10 0.39 ± 0.07 0.60 ± 0.17 0.65 ± 0.17 0.27525
2,6-Diaminopimelate 0.57 ± 0.04 0.59 ± 0.06 0.46 ± 0.08 1.27 ± 0.22 0.29720
Glutarate x x n.d. x
Glycerate 1.33 ± 0.54 1.08 ± 0.22 4.96 ± 1.01 0.22 ± 0.05 0.00170
Glycolate 0.15 ± 0.04 0.26 ± 0.07 0.95 ± 0.20 0.27 ± 0.06 0.00033
3-Hydroxybutanoate 0.16 ± 0.02 0.29 ± 0.03 0.93 ± 0.10 0.31 ± 0.02 0.00970
4-Hydroxybutanoate 5.92 ± 1.49 8.49 ± 2.18 1.06 ± 0.27 8.02 ± 0.86 0.00028
4-Hydroxyphenylacetate 23.7 ± 6.3 8.45 ± 1.91 0.60 ± 0.25 7.07 ± 3.31 0.01187
2-Hydroxyglutarate 1.74 ± 0.73 1.35 ± 0.58 2.06 ± 0.99 0.65 ± 0.18 0.91309
Comparison between bioreactors 
MB BR vs GM BR
β-Alanine
β-Alanyl-lysine
γ-Glutamyl-leucine
N-Acetyl-glutamate
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S3: Fold changes of all intracellularly detected metabolites in the experiment “adaptation to 
growth with complex nutrients.” (Continued)
Metabolites
Fold change in abundance as compared to GM EM
Erlenmeyer flask Bioreactor
MB medium MB medium GM medium Fold change p-Value
Indole-3-acetate 0.25 ± 0.03 0.45 ± 0.05 0.85 ± 0.08 0.53 ± 0.06 0.00125
Lactate 0.11 ± 0.03 0.19 ± 0.03 0.56 ± 0.09 0.34 ± 0.06 0.00190
2-Methyl-citrate 7.10 ± 5.84 0.58 ± 0.13 0.90 ± 0.17 0.64 ± 0.20 0.11281
3-Oxalomalate 0.41 ± 0.14 0.27 ± 0.04 0.43 ± 0.08 0.62 ± 0.08 0.00970
Pantothenate 1.13 ± 0.11 1.00 ± 0.11 0.45 ± 0.11 2.23 ± 0.54 0.00608
3-Phosphoglycerate 18.3 ± 9.6 11.6 ± 6.6 6.29 ± 3.59 1.84 ± 0.71 0.29720
Pyruvate <0.01 ± 0 <0.01 ± 0 0.29 ± 0.10 <0.01 ± 0 0.00925
Shikimate 4.08 ± 1.34 5.72 ± 1.60 2.46 ± 0.86 2.33 ± 0.66 0.01310
Tartrate <0.01 ± 0 <0.01 ± 0 0.85 ± 0.14 <0.01 ± 0 0.00028
Toluate 0.83 ± 0.20 1.42 ± 0.29 1.56 ± 0.35 0.91 ± 0.16 0.60349
Saccharides and derivatives
Arabinose 0.43 ± 0.05 0.19 ± 0.03 0.30 ± 0.07 0.42 ± 0.12 0.00356
Arabitol x x x 1.21 ± 1.20 0.25086
6-Deoxy-Mannose 0.69 ± 0.25 1.00 ± 0.17 1.13 ± 0.20 0.88 ± 0.11 0.20962
Fructose 0.26 ± 0.07 0.16 ± 0.06 1.11 ± 0.34 0.15 ± 0.05 0.00088
Fructose-1,6-bisphosphate x x n.d. x
Fructose-1-phosphate 2.43 ± 1.11 1.92 ± 0.44 1.27 ± 0.18 1.51 ± 0.71 0.59558
Fructose-6-phosphate 0.32 ± 0.20 0.24 ± 0.15 0.34 ± 0.21 0.71 ± 0.09 0.02473
Glucoheptonate-1,4-lactone 0.32 ± 0.10 0.64 ± 0.13 2.11 ± 0.40 0.30 ± 0.06 0.00222
Gluconate-1,4-lactone 0.03 ± 0.02 0.02 ± 0.01 0.02 ± 0.02 0.94 ± 0.23 0.88028
Gluconate 0.06 ± 0.01 0.04 ± 0.01 0.19 ± 0.05 0.21 ± 0.06 0.01477
Glucono-1,5-lactone 0.06 ± 0.01 0.03 ± 0.01 0.18 ± 0.05 0.20 ± 0.06 0.01896
Glucuronate n.d. n.d. n.d. x
Glucosamine-6-phosphate <0.01 ± 0 0.02 ± 0 0.39 ± 0.07 0.03 ± 0.01 0.00163
Glucose 0.34 ± 0.03 0.39 ± 0.05 0.89 ± 0.10 0.44 ± 0.06 0.00035
Glucose-6-phosphate 0.09 ± 0.01 0.05 ± 0.01 0.27 ± 0.04 0.19 ± 0.04 0.00028
Glycerol 0.14 ± 0.09 0.14 ± 0.09 0.78 ± 0.40 0.18 ± 0.08 0.01310
Isomaltose (or similar) 46.2 ± 11.1 24.6 ± 6.0 0.98 ± 0.36 25.2 ± 14.5 0.00239
2-Keto-3-deoxy-gluconate (KDG) 0.24 ± 0.10 0.15 ± 0.05 0.44 ± 0.16 0.42 ± 0.15 0.16604
Lactose (or similar) 24.2 ± 3.50 28.6 ± 4.5 2.03 ± 0.42 14.1 ± 3.7 0.00105
Maltose 2.87 2.35 n.d. x
Maltotriitol (or similar) x x x 129 ± 42.8 0.04752
Maltotriose (or similar) x x n.d. x
Mannitol 1.50 ± 0.19 1.67 ± 0.22 1.38 ± 0.23 1.21 ± 0.15 0.20962
Melibiose 0.15 ± 0.02 0.10 ± 0.02 n.d. x
Myo-inositol x x n.d. x
0.22 ± 0.09 0.18 ± 0.07 0.05 ± 0.02 3.65 ± 1.24 0.00222
Sorbose x x n.d. x
Sucrose 2.09 1.23 2.74 0.45 0.16048
Trehalose 0.47 ± 0.11 0.41 ± 0.11 0.78 ± 0.09 0.52 ± 0.14 0.00028
Trehalose-6-phosphate x x x 0.69 ± 0.78 0.19498
Ribose 2.00 ± 0.37 0.72 ± 0.25 0.44 ± 0.10 1.65 ± 0.55 0.72600
Xylose 0.66 ± 0.08 0.42 ± 0.07 0.76 ± 0.11 0.55 ± 0.11 0.01714
Xylulose 0.04 ± 0.02 0.02 ± 0.01 0.08 ± 0.02 0.22 ± 0.13 0.02473
Xylulose-5-phosphate 0.67 ± 0.23 0.41 ± 0.14 1.35 ± 0.41 0.33 ± 0.04 0.00088
Diamines
Cadaverine 10.4 ± 6.1 16.6 ± 9.7 1.16 ± 0.92 14.2 ± 7.7 0.00028
Propane-1,3-diamine 0.33 ± 0.10 0.94 ± 0.22 2.20 ± 0.55 0.43 ± 0.09 0.01148
Putrescine 0.18 ± 0.03 0.14 ± 0.01 1.25 ± 0.14 0.11 ± 0.01 0.00028
Spermidine 10.1 ± 2.6 10.8 ± 2.5 1.39 ± 0.31 7.77 ± 1.11 0.00028
Membrane components
Ethanolaminephosphate 110 ± 110 105 ± 105 7.63 ± 7.76 13.7 ± 3.0 0.00035
Glycerol-3-phosphate 0.91 ± 0.28 1.49 ± 0.16 0.60 ± 0.09 2.49 ± 0.34 0.00035
Glycerophosphoglycerol 0.35 ± 0.08 0.29 ± 0.07 0.44 ± 0.11 0.66 ± 0.18 0.44238
Tetradecanol x x n.d. x
0.74 ± 0.13 1.11 ± 0.23 2.31 ± 0.50 0.48 ± 0.09 0.01477
2.16 ± 0.33 0.89 ± 0.14 1.15 ± 0.20 0.78 ± 0.21 0.51965
0.14 ± 0.08 0.21 ± 0.12 0.32 ± 0.19 0.64 ± 0.20 0.02982
0.24 ± 0.06 0.42 ± 0.10 0.70 ± 0.17 0.59 ± 0.09 0.00171
Comparison between bioreactors 
MB BR vs GM BR
N-Acetyl-glucosamine
3-Hydroxydecanoate (C
10:0, 3-OH
)
Dodecanoate (C
12:0
)
Tetradecanoate (C
14:0
)
Hexadecanoate (C
16:0
)
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S3: Fold changes of all intracellularly detected metabolites in the experiment “adaptation to 
growth with complex nutrients.” (Continued)
Metabolites
Fold change in abundance as compared to GM EM
Erlenmeyer flask Bioreactor
MB medium MB medium GM medium Fold change p-Value
0.26 ± 0.02 0.43 ± 0.06 0.86 ± 0.10 0.54 ± 0.08 0.00171
4.76 ± 1.32 3.75 ± 0.94 1.71 ± 0.44 2.19 ± 0.58 0.02473
Purines, pyrimidines and derivatives
Adenine 0.16 ± 0.02 0.19 ± 0.03 0.62 ± 0.07 0.30 ± 0.05 0.00064
Adenosine 1.02 ± 0.10 0.82 ± 0.09 1.01 ± 0.13 0.81 ± 0.12 0.20962
Adenosine-5'-monophosphate (AMP) 5.66 ± 0.54 3.36 ± 0.30 0.78 ± 0.18 4.32 ± 1.02 0.00028
Cytosine <0.01 ± 0 0.29 ± 0.06 0.32 ± 0.08 0.92 ± 0.24 0.80836
4,5-Dihydroorotate 1.15 ± 0.19 1.60 ± 0.27 1.30 ± 0.23 1.24 ± 0.16 0.13807
Guanine 0.29 ± 0.08 0.39 ± 0.10 0.59 ± 0.16 0.66 ± 0.13 0.07926
Guanosine-5'-monophosphate (GMP) 3.63 4.03 1.29 4.14 ± 1.02 0.00163
Hypoxanthine 2.83 ± 0.35 3.56 ± 0.86 1.29 ± 0.27 2.76 ± 0.74 0.01477
Inosine-5'-monophosphate (IMP) 0.23 ± 0.03 0.14 ± 0.02 0.49 ± 0.09 0.28 ± 0.06 0.00432
Thymine 0.78 ± 0.14 1.11 ± 0.17 1.30 ± 0.24 0.86 ± 0.16 0.60349
Uracil 0.35 ± 0.07 0.95 ± 0.13 1.33 ± 0.21 0.71 ± 0.08 0.01896
Urate 0.50 ± 0.11 1.39 ± 0.22 1.25 ± 0.20 1.11 ± 0.08 0.16412
Uridine 1.81 ± 0.54 1.14 ± 0.28 0.93 ± 0.26 1.23 ± 0.22 0.13807
Uridine 5'-monophosphate (UMP) 14.6 8.86 1.00 8.86 ± 11.4 0.04752
Xanthine 4.54 ± 3.72 5.45 ± 4.06 0.60 ± 0.47 9.03 ± 6.19 0.00317
Others
3-Amino-propane-1,2-diol x x x 20.5 ± 20.5 0.00925
1,3-Dihydroxyacetone 0.02 ± 0.01 <0.01 5.12 ± 2.09 <0.01 0.16188
Dihydroxyacetone phosphate 0.35 ± 0.16 0.51 ± 0.27 0.67 ± 0.27 0.76 ± 0.14 0.00170
Diphosphate x x n.d. x
Nicotinate 1.48 ± 0.20 2.54 ± 0.38 1.50 ± 0.19 1.70 ± 0.27 0.03697
Nicotinamide 0.66 ± 0.07 0.66 ± 0.04 0.65 ± 0.06 1.01 ± 0.10 0.85006
Phosphate 0.19 ± 0.02 0.49 ± 0.04 1.07 ± 0.09 0.45 ± 0.04 0.00035
Phosphate monomethyl ester 0.76 ± 0.20 1.39 ± 0.40 0.72 ± 0.24 1.93 ± 0.34 0.04369
Saccharopine 4.19 ± 2.59 1.04 ± 0.62 1.23 ± 0.73 0.85 ± 0.22 0.14452
Tryptamine x x n.d. x
Urea 1.07 ± 0.19 4.80 ± 0.89 3.00 ± 0.66 1.60 ± 0.26 0.00853
Urocanate 1.83 ± 0.68 1.26 ± 0.48 4.06 ± 2.12 0.31 ± 0.12 0.16412
Unidentified compounds
NA374 (RI_2172.3) 6.02 ± 1.57 3.27 ± 1.27 2.44 ± 0.97 4.01 ± 1.95 1.00000
NA411 (RI_2231.6) x x n.d. x
NA438 (RI_2324.9) 61.1 71.8 4.93 29.2 ± 9.7 0.00239
Unknown#1475.5-pin-mhe_016 36.3 ± 17.3 102 ± 35.3 10.5 ± 4.3 23.2 ± 6.5 0.00608
Unknown#1570.6-pin-mhe_018 1.37 ± 0.68 1.23 ± 0.23 0.85 ± 0.10 1.44 ± 0.27 0.47064
Unknown#1586.9-pae-bth_039 0.84 ± 0.23 1.09 ± 0.18 1.49 ± 0.29 0.73 ± 0.11 0.09916
Unknown#1679.6-pin-mhe_020 0.64 ± 0.07 0.93 ± 0.07 1.24 ± 0.17 0.75 ± 0.10 0.16412
Unknown#1830.2-pin-mhe_038 0.77 ± 0.06 0.72 ± 0.05 0.94 ± 0.10 0.76 ± 0.09 0.08903
Unknown#2018.7-pin-mhe_028 1.22 ± 0.22 1.35 ± 0.19 0.61 ± 0.08 2.21 ± 0.33 0.00222
Unknown#2139.8-pin-mhe_046 1.55 ± 0.18 0.41 ± 0.08 0.08 ± 0.02 9.82 ± 2.23 0.00933
Unknown#2148.0-pin-mhe_047 0.12 ± 0.02 0.14 ± 0.02 0.14 ± 0.02 1.01 ± 0.13 0.80836
Unknown#2197.0-pin-mhe_048 8.01 ± 1.65 3.22 ± 0.80 2.29 ± 0.27 1.40 ± 0.36 0.91309
Unknown#2236.82-ypy-mse_026 1.23 ± 0.24 0.78 ± 0.12 0.34 ± 0.08 2.50 ± 0.68 0.02299
Unknown#2263.9-pin-mhe_049 2.32 ± 0.66 0.87 ± 0.31 0.53 ± 0.28 1.79 ± 0.90 0.07876
Unknown#2269.25-ypy-mse_027 0.96 ± 0.11 0.96 ± 0.11 0.33 ± 0.04 2.87 ± 0.36 0.00028
Unknown#2334.1-pin-mhe_051 2.51 ± 0.20 1.70 ± 0.12 1.73 ± 0.16 0.98 ± 0.38 0.88028
Unknown#2414.8-pin-mhe_057 x x x 125 ± 14.3 0.04752
Unknown#2423.9-pin-mhe_058 0.25 ± 0.02 0.46 ± 0.04 0.83 ± 0.07 0.56 ± 0.04 0.00033
Unknown#2548.1-pin-mhe_066 2.10 ± 0.49 1.99 ± 0.38 1.02 ± 0.25 2.34 ± 0.50 0.02392
Unknown#3363.5-pin-mhe_074 1.03 ± 0.43 0.68 ± 0.28 0.49 ± 0.22 2.76 ± 0.62 0.17801
Unknown#3423.2-pin-mhe_075 3.98 ± 1.19 0.40 ± 0.12 0.84 ± 0.28 0.60 ± 0.10 0.02657
Comparison between bioreactors 
MB BR vs GM BR
Octadecanoate (C
18:0
)
9-Octadecenoate (C
18:1
)
   Colour scale for fold changes: <0.1 <0.2 <0.67 0.67-1.5<0.4 >1.5 >2.5 >5.0 >10.0
<0.001 <0.01 <0.05   p-value (Wilcoxon-Mann-Whitney Test, with false discovery rate control)
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S4: Fold changes of identified extracellular amino acids and metabolites in the experiment 
“dynamics of amino acid utilisation”.
*, Compound not detected at t0, therefore later sample point was taken as reference condition, 
marked by value “1.00”.
Metabolites
Amino acids
Alanine 0.88 ± 0.06 0.76 ± 0.03 0.72 ± 0.03 0.69 ± 0.04 0.49 ± 0.03 0.35 ± 0.02
Arginine 0.82 ± 0.08 0.62 ± 0.09 0.44 ± 0.06 0.38 ± 0.04 0.14 ± 0.03 0.16 ± 0.03
Aspartate 0.95 ± 0.10 0.70 ± 0.04 0.46 ± 0.05 0.18 ± 0.03 <0.01 ± 0 <0.01 ± 0
Glutamate 0.85 ± 0.07 0.52 ± 0.03 0.14 ± 0.01 <0.01 ± 0 <0.01 ± 0 <0.01 ± 0
Glycine 0.82 ± 0.07 0.67 ± 0.03 0.44 ± 0.02 0.14 ± 0.02 <0.01 ± 0 <0.01 ± 0.01
Isoleucine 0.92 ± 0.05 0.83 ± 0.06 0.88 ± 0.04 1.03 ± 0.04 0.97 ± 0.05 1.06 ± 0.06
Leucine 0.91 ± 0.06 0.80 ± 0.04 0.73 ± 0.04 0.78 ± 0.05 0.67 ± 0.04 0.65 ± 0.04
Lysine 0.93 ± 0.06 0.83 ± 0.04 0.71 ± 0.03 0.67 ± 0.05 0.44 ± 0.02 0.38 ± 0.02
Methionine 0.88 ± 0.10 0.62 ± 0.06 0.51 ± 0.05 0.4 ± 0.06 0.29 ± 0.04 0.2 ± 0.03
Phenylalanine 0.94 ± 0.05 0.84 ± 0.03 0.81 ± 0.02 0.73 ± 0.04 0.62 ± 0.02 0.64 ± 0.03
Proline 0.93 ± 0.07 0.76 ± 0.05 0.59 ± 0.04 0.49 ± 0.04 0.23 ± 0.02 0.08 ± 0.01
Serine 0.93 ± 0.07 0.86 ± 0.05 0.81 ± 0.06 0.75 ± 0.06 0.59 ± 0.03 0.49 ± 0.05
Threonine 0.94 ± 0.07 0.86 ± 0.05 0.84 ± 0.05 0.87 ± 0.06 0.77 ± 0.04 0.73 ± 0.04
Tyrosine 0.86 ± 0.09 0.67 ± 0.06 0.59 ± 0.04 0.61 ± 0.05 0.50 ± 0.04 0.54 ± 0.04
Valine 0.99 ± 0.07 0.91 ± 0.05 0.96 ± 0.06 1.10 ± 0.07 1.00 ± 0.06 1.05 ± 0.06
Others
2-Aminobutanoate 0.91 ± 0.08 0.78 ± 0.05 0.74 ± 0.04 0.76 ± 0.05 0.57 ± 0.04 0.5 ± 0.04
Glycerol 0.24 ± 0.02 0.2 ± 0.02 0.19 ± 0.01 0.17 ± 0.02 0.18 ± 0.01 0.18 ± 0.02
3-Hydroxybutanoate 1.89 ± 0.39 2.65 ± 0.57 2.75 ± 0.71 4.16 ± 0.90 5.25 ± 1.58 2.22 ± 0.48
2-Hydroxyphenylacetate 1.20 ± 0.45 1.51 ± 0.62 2.51 ± 1.00 4.07 ± 1.59 4.19 ± 1.64 4.72 ± 1.85
2-Isopropylmalate * 1.00 ± 0.51 6.39 ± 3.06 8.96 ± 4.28 12.6 ± 6.0 13.7 ± 6.5 15.9 ± 7.6
1.00 ± 0.35 0.85 ± 0.22 0.43 ± 0.18
Pyroglutamate 0.97 ± 0.08 0.79 ± 0.06 0.68 ± 0.06 0.64 ± 0.06 0.60 ± 0.04 0.60 ± 0.05
Urea 25.0 ± 18.4 94.0 ± 69.0 189.7 ± 139 354.9 ± 261 428.9 ± 315 488.8 ± 359
Colour scale for fold changes: <0.1 <0.25 <0.5 <0.67 0.67 – 1.5 >1.5 >2.5 >5 >10
Fold change in abundance as compared to t
0
t10 t15 t20 t25 t30 t35
N-Acetyl-serine *
S5: Fold changes of all intracellularly detected metabolites in the experiment “dynamics of 
amino acid utilisation”. 
Symbols between sampling points represent significance of abundance changes, legend is provided 
at the bottom of this table. *, Compound not detected in reference condition (t10), therefore a later 
sampling point was used as reference condition, marked by value “1.00”.
Metabolites
Amino acids and derivatives
Alanine 2.23 ± 0.11 2.37 ± 0.16 3.23 ± 0.21 3.65 ± 0.23 3.55 ± 0.19
Arginine 1.70 ± 0.16 1.95 ± 0.16 1.89 ± 0.17 2.66 ± 0.23 2.23 ± 0.19
Asparagine 4.09 ± 0.37 3.23 ± 0.32 5.27 ± 0.50 5.89 ± 0.59 6.45 ± 0.63
Aspartate 1.25 ± 0.20 1.47 ± 0.22 2.41 ± 0.35 2.69 ± 0.41 2.43 ± 0.37
1.68 ± 0.16 2.34 ± 0.26 2.46 ± 0.28 4.06 ± 0.41 5.35 ± 0.56
Cysteine 2.75 ± 0.16 1.34 ± 0.07 1.82 ± 0.10 3.93 ± 0.23 3.42 ± 0.28
Glutamate 2.33 ± 0.17 2.10 ± 0.16 2.47 ± 0.19 2.61 ± 0.19 2.23 ± 0.17
Glutamine 2.71 ± 0.24 2.33 ± 0.16 2.65 ± 0.16 3.26 ± 0.27 2.85 ± 0.23
Glycine 1.58 ± 0.08 1.66 ± 0.10 1.80 ± 0.10 2.33 ± 0.11 2.21 ± 0.11
Histidine 3.52 ± 0.32 3.64 ± 0.40 8.22 ± 0.84 18.6 ± 1.9 19.2 ± 1.9
Homocysteine 0.37 ± 0.06 0.38 ± 0.06 0.56 ± 0.09 0.73 ± 0.11 0.48 ± 0.08
Homoserine 1.43 ± 0.22 1.57 ± 0.23 1.25 ± 0.18 1.36 ± 0.20 1.48 ± 0.21
Isoleucine 1.45 ± 0.09 1.49 ± 0.08 2.90 ± 0.18 3.20 ± 0.19 2.94 ± 0.20
Leucine 1.92 ± 0.39 2.85 ± 0.51 2.75 ± 0.47 2.88 ± 0.41 2.55 ± 0.37
Lysine 1.99 ± 0.11 1.93 ± 0.11 3.43 ± 0.23 5.78 ± 0.42 6.19 ± 0.45
Methionine 0.81 ± 0.15 0.85 ± 0.15 0.86 ± 0.15 0.90 ± 0.16 0.82 ± 0.15
0.76 ± 0.16 2.68 ± 0.39 9.59 ± 1.05 4.68 ± 0.60 2.63 ± 0.32
Ornithine 1.40 ± 0.18 1.18 ± 0.15 1.38 ± 0.19 1.65 ± 0.22 1.91 ± 0.26
Fold change in abundance as compared to reference condition (t
10
)
t15 t20 t25 t30 t35
β-Alanine
N-Acetyl-glutamate
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S5: Fold changes of all intracellularly detected metabolites in the experiment “dynamics of 
amino acid utilisation”. (Continued)
Metabolites
Phenylalanine 2.35 ± 0.18 2.00 ± 0.19 2.06 ± 0.22 2.98 ± 0.27 2.93 ± 0.26
Proline 2.71 ± 0.16 4.60 ± 0.28 5.75 ± 0.35 6.10 ± 0.33 4.76 ± 0.30
Pyroglutamate 0.51 ± 0.08 0.53 ± 0.13 0.30 ± 0.09 0.46 ± 0.09 0.13 ± 0.03
Serine 1.65 ± 0.16 1.48 ± 0.13 2.66 ± 0.28 5.45 ± 0.52 5.37 ± 0.49
Threonine 1.84 ± 0.18 1.97 ± 0.16 6.84 ± 0.67 6.53 ± 0.58 4.52 ± 0.40
Tryptophan 2.23 ± 0.12 1.70 ± 0.11 1.88 ± 0.12 3.00 ± 0.26 3.09 ± 0.24
Tyrosine 1.91 ± 0.19 1.74 ± 0.18 3.06 ± 0.29 3.60 ± 0.41 2.99 ± 0.34
Valine 1.36 ± 0.14 1.88 ± 0.16 4.63 ± 0.43 5.23 ± 0.42 4.19 ± 0.36
Amino acid metabolism
2-Aminoadipate 46.3 ± 31.2 69.3 ± 46.2 206 ± 138 480 ± 319 718 ± 478
5-Aminopentanoate 1.74 ± 0.60 0.87 ± 0.29 4.08 ± 1.35 0.92 ± 0.31 0.62 ± 0.21
2-Coumarate 4.45 ± 0.37 4.97 ± 0.46 7.69 ± 0.55 11.7 ± 0.82 11.3 ± 1.0
2,4-Diaminobutanoate 1.68 ± 0.09 3.21 ± 0.23 4.15 ± 0.25 3.64 ± 0.29 1.75 ± 0.18
2-Isopropylmalate 0.76 ± 0.07 9.22 ± 1.26 21.9 ± 2.9 8.30 ± 0.86 11.3 ± 0.9
Pipecolate 2.41 ± 0.17 4.46 ± 0.32 7.76 ± 0.61 16.9 ± 1.1 22.2 ± 1.5
Diamines
Cadaverine 3.13 ± 0.33 6.37 ± 0.68 8.67 ± 0.93 8.55 ± 0.87 5.65 ± 0.56
Putrescine 1.03 ± 0.15 0.45 ± 0.05 0.12 ± 0.01 0.05 ± 0.01 0.03 ± 0
Spermidine 3.06 ± 0.42 1.06 ± 0.16 0.92 ± 0.19 2.81 ± 0.41 2.58 ± 0.36
Purines, pyrimidines and derivatives
Adenine 1.05 ± 0.12 1.17 ± 0.14 0.94 ± 0.11 1.08 ± 0.12 0.97 ± 0.11
Adenosine 4.83 ± 0.67 11.5 ± 1.2 18.0 ± 1.8 15.4 ± 1.8 13.9 ± 1.9
Adenosine-5'-monophosphate (AMP) 4.27 ± 0.57 4.95 ± 0.68 4.77 ± 0.63 4.87 ± 0.69 4.30 ± 0.59
Cytosine 1.38 ± 0.08 1.09 ± 0.09 0.80 ± 0.06 0.78 ± 0.05 0.57 ± 0.06
4,5-Dihydroorotate 1.81 ± 0.15 2.56 ± 0.21 1.95 ± 0.16 1.93 ± 0.19 1.28 ± 0.11
Guanine 1.25 ± 0.08 1.10 ± 0.11 1.03 ± 0.10 0.97 ± 0.07 0.78 ± 0.06
Guanosine 1.14 ± 0.18 1.22 ± 0.27 2.77 ± 0.43 4.26 ± 0.88 6.40 ± 1.09
Guanosine-5'-monophosphate (GMP) 8.12 ± 1.47 5.09 ± 0.91 4.21 ± 0.75 5.32 ± 0.97 2.95 ± 0.53
Hypoxanthine 1.83 ± 0.14 1.82 ± 0.12 1.65 ± 0.10 1.58 ± 0.11 0.95 ± 0.08
Inosine-5'-monophosphate (IMP) 2.58 ± 0.39 1.94 ± 0.29 1.93 ± 0.27 1.96 ± 0.28 1.57 ± 0.23
Thymine 1.36 ± 0.10 2.32 ± 0.15 2.62 ± 0.15 2.15 ± 0.14 1.75 ± 0.11
Uracil 1.23 ± 0.09 1.14 ± 0.09 0.89 ± 0.07 1.06 ± 0.08 1.10 ± 0.08
Uridine 2.12 ± 0.16 2.86 ± 0.25 5.53 ± 0.43 5.27 ± 0.49 4.08 ± 0.35
Uridine 5'-monophosphate (UMP) 10.7 ± 5.4 19.3 ± 9.5 36.3 ± 17.6 26.5 ± 12.9 17.3 ± 8.5
Urate 1.28 ± 0.07 1.22 ± 0.08 1.51 ± 0.10 2.17 ± 0.15 2.50 ± 0.17
Xanthine 1.85 ± 0.14 1.92 ± 0.10 1.55 ± 0.08 1.40 ± 0.09 0.96 ± 0.06
Butanoates
2-Aminobutanoate 3.01 ± 0.35 4.70 ± 0.52 4.70 ± 0.46 6.61 ± 0.58 8.28 ± 0.70
3-Hydroxybutanoate 10.6 ± 2.0 8.50 ± 1.66 3.60 ± 0.66 3.83 ± 0.67 2.12 ± 0.38
4-Hydroxybutanoate 24.3 ± 8.2 12.4 ± 4.1 3.91 ± 1.31 4.41 ± 1.46 2.49 ± 0.82
Fatty acids
0.52 ± 0.09 0.72 ± 0.14 0.95 ± 0.17 1.47 ± 0.58 0.85 ± 0.17
1.22 ± 0.10 1.80 ± 0.16 2.58 ± 0.22 3.60 ± 0.36 2.97 ± 0.28
1.00 ± 0.14 1.19 ± 0.17 1.51 ± 0.20 2.04 ± 0.42 1.35 ± 0.17
0.94 ± 0.14 1.17 ± 0.20 1.69 ± 0.23 1.87 ± 0.31 1.70 ± 0.25
1.82 ± 0.32 2.13 ± 0.39 3.48 ± 0.66 4.38 ± 0.91 4.63 ± 1.11
Peptidoglycan components
Alanyl-alanine 5.48 ± 1.56 11.3 ± 3.3 24.9 ± 7.1 38.0 ± 10.9 45.3 ± 13.1
2,6-Diaminopimelate 3.59 ± 0.23 16.9 ± 0.9 24.7 ± 1.0 22.7 ± 1.3 17.6 ± 1.0
Phospholipid headgroup components
1,3-Dihydroxyacetone 1.96 ± 0.30 2.98 ± 0.39 2.57 ± 0.30 3.16 ± 0.33 2.68 ± 0.35
Glycerophosphoglycerol 11.5 ± 4.2 0.24 ± 0.09 0.40 ± 0.11 0.41 ± 0.12 0.34 ± 0.13
Ethanolamine 7.64 ± 0.83 3.03 ± 0.35 1.85 ± 0.23 4.69 ± 0.50 2.79 ± 0.28
Glycerol 3.75 ± 1.33 1.59 ± 0.54 0.80 ± 0.30 1.42 ± 0.50 0.86 ± 0.29
Glycerol-3-phosphate 2.25 ± 0.15 1.20 ± 0.09 0.85 ± 0.06 1.16 ± 0.10 0.38 ± 0.04
Fold change in abundance as compared to reference condition (t
10
)
t15 t20 t25 t30 t35
3-Hydroxydecanoate (C
10:0, 3-OH
)
Dodecanoate (C
12:0
)
Hexadecanoate (C
16:0
)
Octadecanoate (C
18:0
)
6-Octadecenoate (C
18:1
)
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S5: Fold changes of all intracellularly detected metabolites in the experiment “dynamics of 
amino acid utilisation”. (Continued)
Metabolites
TCA Cycle
Citrate 0.64 ± 0.14 0.51 ± 0.11 0.47 ± 0.10 0.67 ± 0.14 0.78 ± 0.17
Fumarate 1.20 ± 0.12 1.86 ± 0.19 2.96 ± 0.30 3.56 ± 0.37 3.75 ± 0.39
Malate 1.07 ± 0.05 0.97 ± 0.06 0.87 ± 0.04 1.02 ± 0.06 0.99 ± 0.05
2-Oxoglutarate 1.18 ± 0.17 1.06 ± 0.16 1.00 ± 0.14 0.87 ± 0.12 0.70 ± 0.10
Succinate 2.17 ± 0.15 2.07 ± 0.14 1.69 ± 0.11 1.91 ± 0.13 1.67 ± 0.11
Pentose-Phosphate-Pathway
Ribose-5-phosphate * 1.00 ± 1.41 18.1 ± 18.5 22.5 ± 22.5 36.3 ± 36.5 38.7 ± 38.8
Xylose 1.82 ± 0.21 1.27 ± 0.14 1.06 ± 0.16 1.70 ± 0.23 1.56 ± 0.17
Xylulose-5-phosphate 2.56 ± 1.39 5.97 ± 3.21 7.24 ± 3.88 6.51 ± 3.50 6.26 ± 3.37
Gluconeogenesis and Entner-Doudoroff pathway
Phosphoenolpyruvate 0.77 ± 0.26 0.93 ± 0.31 2.58 ± 0.87 2.54 ± 0.86 1.69 ± 0.57
Dihydroxyacetone phosphate * 1.00 ± 1.41 20.7 ± 20.7 1.81 ± 2.22 1.85 ± 2.62
Fructose-1,6-bisphosphate * 1.00 ± 0.46 3.31 ± 1.11 1.83 ± 0.71 0.23 ± 0.17 0.78 ± 0.34
Fructose-6-phosphate 0.96 ± 0.13 1.87 ± 0.35 1.57 ± 0.29 1.04 ± 0.20 1.15 ± 0.23
Glucose 1.25 ± 0.08 2.45 ± 0.21 3.34 ± 0.28 1.62 ± 0.14 0.46 ± 0.07
Glucose-6-phosphate 1.61 ± 0.22 3.42 ± 0.44 2.98 ± 0.37 1.89 ± 0.23 1.10 ± 0.15
2-Keto-3-deoxy-gluconate (KDG) 0.70 ± 0.09 0.52 ± 0.08 2.50 ± 0.45 3.22 ± 0.39 2.10 ± 0.27
6-Phosphogluconate 0.80 ± 0.17 4.49 ± 0.97 35.5 ± 7.4 55.7 ± 11.3 57.0 ± 11.8
3-Phosphoglycerate 1.45 ± 0.17 1.11 ± 0.13 1.42 ± 0.16 2.14 ± 0.27 2.51 ± 0.30
Pyruvate 1.37 ± 0.15 2.01 ± 0.19 1.65 ± 0.14 1.48 ± 0.15 1.22 ± 0.11
Sugars
1,6-Anhydro-glucose 0.84 ± 0.12 1.80 ± 0.25 2.81 ± 0.32 1.48 ± 0.20 0.55 ± 0.11
Gluconate / galactonate 1.17 ± 0.10 1.78 ± 0.20 4.85 ± 0.56 4.82 ± 0.45 3.35 ± 0.32
2-Amino-2-deoxy-gluconate 0.50 ± 0.04 0.41 ± 0.04 0.31 ± 0.02 0.59 ± 0.05 1.35 ± 0.10
2.77 ± 0.23 2.96 ± 0.27 1.73 ± 0.17 2.53 ± 0.26 2.40 ± 0.25
Others
Glycerate 2.01 ± 0.17 1.67 ± 0.12 1.06 ± 0.07 1.96 ± 0.13 1.93 ± 0.13
5-Methylthio-adenosine 2.16 ± 0.15 5.54 ± 0.46 9.58 ± 0.74 8.92 ± 0.58 9.54 ± 0.71
Nicotinamide 1.31 ± 0.14 1.98 ± 0.20 2.21 ± 0.16 2.34 ± 0.18 1.93 ± 0.18
Nicotinate 2.29 ± 0.32 3.73 ± 0.54 4.82 ± 0.86 3.03 ± 0.41 2.96 ± 0.34
Phosphate 1.14 ± 0.07 1.32 ± 0.08 1.12 ± 0.06 1.18 ± 0.07 1.14 ± 0.07
Toluate 0.98 ± 0.06 1.15 ± 0.08 1.03 ± 0.06 1.14 ± 0.09 1.14 ± 0.07
Unidentified compounds
Unknown#1195.3-pin-mhe_003 2.33 ± 0.55 3.29 ± 0.71 4.58 ± 0.99 4.51 ± 0.87 4.75 ± 0.97
Unknown#1345.9-pin-mhe_008 1.11 ± 0.14 2.02 ± 0.27 1.74 ± 0.25 1.72 ± 0.24 1.71 ± 0.22
Unknown#1361.3-pin-mhe_010 1.73 ± 0.14 2.01 ± 0.16 1.86 ± 0.17 2.89 ± 0.25 2.56 ± 0.22
Unknown#1440.7-pin-mhe_013 0.79 ± 0.03 0.80 ± 0.04 0.59 ± 0.02 0.67 ± 0.04 0.72 ± 0.03
Unknown#1679.6-pin-mhe_020 1.79 ± 0.32 1.97 ± 0.36 1.78 ± 0.36 2.31 ± 0.46 2.37 ± 0.42
Unknown#1771.2-pin-mhe_036 1.44 ± 0.34 2.09 ± 0.43 2.02 ± 0.46 1.36 ± 0.34 1.28 ± 0.32
Unknown#1953.9-pin-mhe_025 1.49 ± 0.09 1.69 ± 0.12 1.99 ± 0.13 1.78 ± 0.14 1.43 ± 0.13
Unknown#2088.0-pin-mhe_043 0.57 ± 0.10 0.77 ± 0.15 0.91 ± 0.27 1.52 ± 0.29 0.93 ± 0.44
Unknown#2334.1-pin-mhe_051 1.64 ± 0.14 3.21 ± 0.30 3.59 ± 0.29 3.58 ± 0.37 2.64 ± 0.26
Unknown#2370.5-pin-mhe_053 1.62 ± 0.23 3.76 ± 0.36 7.85 ± 0.70 8.07 ± 0.67 10.1 ± 1.1
Unknown#2394.5-pin-mhe_056 0.82 ± 0.07 1.49 ± 0.07 3.17 ± 0.09 7.41 ± 0.23 10.3 ± 0.4
Unknown#2442.5-pin-mhe_059 * 1.00 ± 0.16 2.51 ± 0.30 4.32 ± 0.50 4.17 ± 0.51
Unknown#2498.6-pin-mhe_062 * 1.00 ± 0.14 5.19 ± 0.58 7.02 ± 0.82
Unknown#2510.0-pin-mhe_063 1.01 ± 0.04 0.99 ± 0.05 0.82 ± 0.03 1.06 ± 0.05 1.03 ± 0.05
Unknown#2557.6-pin-mhe_067 * 1.00 ± 0.08 1.64 ± 0.14
Unknown#2602.0-pin-mhe_068 * 1.00 ± 0.34 1.55 ± 0.47 2.50 ± 0.57 2.53 ± 0.51
Unknown#3158.4-pin-mhe_073 2.30 ± 0.34 3.41 ± 0.52 4.62 ± 0.64 5.34 ± 0.75 4.39 ± 0.66
<0.0001 <0.001 <0.01 <0.05
Fold change in abundance as compared to reference condition (t
10
)
t15 t20 t25 t30 t35
N-Acetyl-glucosamine
Significance of abundance changes between sampling points; corrected 
  p-Values from t-test (    ) or Wilcoxon-Mann-Whitney test (     )
> 10.0> 5.0> 2.5> 1.50.67 – 1.5< 0.4< 0.1 < 0.2 < 0.67Colour scale for fold changes:
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S6: Fold changes of all intracellular metabolites of P. inhibens DSM 17395 detected in the experiment “amino acid degradation”.
Abbreviation: x, compound not detected in reference condition, but in respective test condition. Substrates: Trp, tryptophan; Phe, phenylalanine; Met,  
methionine; Leu, leucine; Ile, isoleucine; Val, valine; His, histidine; Lys, lysine; Thr, threonine.
Metabolites
Fold change in abundance as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
Amino acids and derivatives
Alanine 0.20 ± 0.03 0.16 ± 0.02 0.28 ± 0.05 1.95 ± 0.26 0.77 ± 0.12 0.94 ± 0.12 1.19 ± 0.28 0.91 ± 0.12 3.96 ± 0.56
Asparagine 22.7 ± 3.4 1.27 ± 0.17 0.70 ± 0.07 1.05 ± 0.09 1.18 ± 0.12 0.78 ± 0.09 1.42 ± 0.18 0.44 ± 0.19 1.66 ± 0.16
Aspartate 0.18 ± 0.03 0.84 ± 0.18 0.70 ± 0.10 0.84 ± 0.11 1.00 ± 0.11 0.40 ± 0.04 3.35 ± 0.49 0.73 ± 0.15 3.63 ± 0.41
0.67 ± 0.15 0.55 ± 0.10 0.52 ± 0.10 0.45 ± 0.08 0.57 ± 0.11 0.77 ± 0.14 0.82 ± 0.15 0.53 ± 0.10 0.73 ± 0.15
Cysteine   6.01 ± 0.55      0.50 ± 0.51
Glutamate 0.03 ± 0.02 0.06 ± 0.04 0.07 ± 0.02 0.64 ± 0.09 1.00 ± 0.11 0.58 ± 0.07 1.26 ± 0.18 0.25 ± 0.10 1.32 ± 0.12
Glycine 0.45 ± 0.06 0.32 ± 0.03 0.76 ± 0.15 0.48 ± 0.05 0.70 ± 0.09 0.94 ± 0.12 0.53 ± 0.07 0.47 ± 0.05 0.39 ± 0.04
Homocysteine 0.78 ± 0.08 0.96 ± 0.10 0.85 ± 0.15 0.60 ± 0.05 0.97 ± 0.11 1.00 ± 0.09 1.83 ± 0.24 0.41 ± 0.14 0.88 ± 0.07
Homoserine 0.72 ± 0.09 0.65 ± 0.06 1.17 ± 0.15 0.56 ± 0.07 0.90 ± 0.14 0.98 ± 0.11 0.80 ± 0.10 0.45 ± 0.07 1.02 ± 0.13
Isoleucine 0.64 ± 0.08 0.40 ± 0.04 0.69 ± 0.10 0.37 ± 0.05 24.9 ± 6.6 0.93 ± 0.14 0.56 ± 0.19 0.58 ± 0.07 0.83 ± 0.08
Leucine 0.58 ± 0.07 0.58 ± 0.07 0.36 ± 0.05 1.19 ± 0.15 1.60 ± 0.18 1.75 ± 0.30 0.49 ± 0.05 0.69 ± 0.09 0.60 ± 0.12
Lysine 0.05 ± 0.02 0.13 ± 0.05 0.36 ± 0.08 0.24 ± 0.05 0.55 ± 0.09 0.42 ± 0.08 0.50 ± 0.08 3.18 ± 1.05 1.12 ± 0.17
Methionine 0.33 ± 0.04 0.74 ± 0.32 5.28 ± 0.99 0.45 ± 0.04 0.51 ± 0.06 0.60 ± 0.08 0.67 ± 0.08 0.62 ± 0.18 0.50 ± 0.06
0.99 ± 0.10 0.71 ± 0.09 0.59 ± 0.05 0.96 ± 0.08 0.88 ± 0.09 1.04 ± 0.11 1.30 ± 0.18 0.76 ± 0.08 1.82 ± 0.21
Ornithine 1.27 ± 0.40 0.12 ± 0.03 0.26 ± 0.04 0.65 ± 0.09 0.24 ± 0.04 0.42 ± 0.05 0.87 ± 0.11 0.54 ± 0.10 0.79 ± 0.09
Phenylalanine 0.33 ± 0.04 0.43 ± 0.05 0.25 ± 0.02 0.39 ± 0.04 0.51 ± 0.08 0.48 ± 0.04 0.42 ± 0.05 0.46 ± 0.05 0.51 ± 0.06
Proline 0.44 ± 0.06 0.25 ± 0.03 0.16 ± 0.02 0.54 ± 0.06 0.43 ± 0.07 0.66 ± 0.07 0.40 ± 0.05 0.37 ± 0.05 0.49 ± 0.06
Pyroglutamate 0.70 ± 0.14 1.26 ± 0.26 0.77 ± 0.07 0.92 ± 0.09 0.88 ± 0.09 0.78 ± 0.06 1.45 ± 0.15 1.10 ± 0.20 1.30 ± 0.13
Serine 0.42 ± 0.11 0.54 ± 0.08 0.68 ± 0.16 0.91 ± 0.14 1.56 ± 0.23 1.04 ± 0.10 1.00 ± 0.16 0.72 ± 0.13 0.94 ± 0.13
Threonine 0.60 ± 0.06 0.43 ± 0.04 0.62 ± 0.08 0.43 ± 0.04 1.23 ± 0.19 0.92 ± 0.13 0.85 ± 0.11 0.51 ± 0.06 4.62 ± 0.37
Tyrosine 0.24 ± 0.06 0.13 ± 0.04 0.22 ± 0.05 0.47 ± 0.07 0.90 ± 0.16 0.79 ± 0.12 0.72 ± 0.10 0.54 ± 0.09 0.98 ± 0.12
Valine 0.21 ± 0.03 0.09 ± 0.01 0.10 ± 0.01 0.27 ± 0.03 0.63 ± 0.14 5.60 ± 1.07 0.25 ± 0.03 0.37 ± 0.05 0.43 ± 0.05
Tryptophan degradation
2-Aminobenzoate (anthranilate) 2.92 ± 0.25    
Phenylalanine degradation
Phenylpyruvate 2.80 ± 0.48  0.15 ± 0.11
Methionine degradation
2-Oxobutanoate 7.11 ± 0.04
Isoleucine degradation
3-Methyl-2-Oxopentanoate x
β-Alanine
N-Acetyl-glutamate
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S6: Fold changes of all intracellular metabolites of P. inhibens DSM 17395 detected in the experiment “amino acid degradation”. (Continued)
Metabolites
Fold change in abundance as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
Valine degradation
2-Oxoisovalerate x
Histidine degradation
Urocanate 1.52 ± 0.55
Lysine degradation
2-Aminoadipate 0.35 ± 0.06 0.63 ± 0.14 0.04 ± 0.04
5-Aminopentanoate x x  x  x   
Cadaverine 0.87 ± 0.09 2.07 ± 0.30 14.9 ± 8.1 1.53 ± 0.09 4.39 ± 0.48 1.57 ± 0.11 10.5 ± 9.5 116 ± 16 1.12 ± 0.09
Glutarate 0.14 ± 0.10 0.16 ± 0.11 2.22 ± 0.46 1.53 ± 0.32 6.22 ± 1.29 1.44 ± 0.26 9.29 ± 8.35 142 ± 38 0.15 ± 0.05
Other compounds associated with amino acid metabolism
Homogentisate  3.72 ± 0.41        
Hydantoin-5-propionate       x    
4-Hydroxyphenylacetate  3.14 ± 0.38 0.45 ± 0.17  0.06 ± 0.06 1.03 ± 0.12    
Phenylacetate  1.72 ± 0.19        
Shikimate-3-phosphate 1.02 ± 0.09 2.31 ± 0.20 2.68 ± 0.54 2.66 ± 0.55 4.64 ± 0.98 3.48 ± 0.74 2.10 ± 0.44 2.38 ± 0.61 2.44 ± 0.50
TCA Cycle
2-Oxoglutarate 1.31 ± 0.12 1.50 ± 0.13 0.71 ± 0.06 1.02 ± 0.09 1.00 ± 0.12 0.93 ± 0.09 1.19 ± 0.14 1.10 ± 0.10 0.93 ± 0.09
Citrate 1.16 ± 0.20 1.11 ± 0.24 0.57 ± 0.07 1.10 ± 0.15 0.97 ± 0.18 1.04 ± 0.14 2.24 ± 0.44 2.70 ± 0.35 1.57 ± 0.24
Fumarate 0.64 ± 0.08 0.60 ± 0.05 0.62 ± 0.08 1.20 ± 0.14 0.86 ± 0.11 1.25 ± 0.13 0.95 ± 0.12 0.66 ± 0.06 1.00 ± 0.08
Malate 0.50 ± 0.07 0.54 ± 0.07 0.40 ± 0.07 1.37 ± 0.18 0.67 ± 0.11 0.77 ± 0.10 1.11 ± 0.17 0.66 ± 0.08 0.89 ± 0.11
Succinate 0.55 ± 0.07 0.45 ± 0.04 0.55 ± 0.10 1.49 ± 0.11 1.38 ± 0.14 1.32 ± 0.10 0.95 ± 0.09 0.66 ± 0.07 1.34 ± 0.10
Gluconeogenesis
Dihydroxyacetone phosphate 1.83 ± 0.15 2.57 ± 0.33 1.33 ± 0.12 1.28 ± 0.33 1.04 ± 0.11 1.00 ± 0.10 0.96 ± 0.08 1.09 ± 0.09 1.66 ± 0.15
Fructose 1.70 ± 0.18 2.19 ± 0.25 1.20 ± 0.13 1.46 ± 0.56 0.96 ± 0.10 0.86 ± 0.10 0.64 ± 0.13 1.22 ± 0.19 0.96 ± 0.11
Fructose-1-phosphate 0.28 ± 0.15 0.11 ± 0.11 0.68 ± 0.11 0.65 ± 0.10 0.59 ± 0.10 0.64 ± 0.09 0.72 ± 0.12 1.05 ± 0.18 0.65 ± 0.11
Fructose-6-phosphate  0.59 ± 0.31 3.05 ± 1.72 1.15 ± 0.11 1.41 ± 0.15 2.06 ± 0.87 0.88 ± 0.15 1.54 ± 0.22 1.29 ± 0.11
Glucose 0.87 ± 0.11 1.23 ± 0.15 2.10 ± 0.74 1.22 ± 0.14 1.38 ± 0.25 1.20 ± 0.13 0.88 ± 0.12 1.09 ± 0.13 0.87 ± 0.14
Glucose-6-phosphate 0.10 ± 0.05 0.12 ± 0.06 0.39 ± 0.07 0.66 ± 0.14 0.44 ± 0.09 0.72 ± 0.14 0.55 ± 0.12 0.46 ± 0.09 0.64 ± 0.12
3-Phosphoglycerate 1.18 ± 0.14 1.14 ± 0.16 1.13 ± 0.15 0.98 ± 0.11 0.98 ± 0.13 1.11 ± 0.14 1.07 ± 0.13 1.05 ± 0.13 0.93 ± 0.10
Phosphoenolpyruvate 1.51 ± 0.17 1.78 ± 0.24 1.37 ± 0.12 1.03 ± 0.10 1.04 ± 0.13 1.05 ± 0.10 1.07 ± 0.10 1.13 ± 0.10 0.97 ± 0.09
Pyruvate 1.72 ± 0.14 2.69 ± 0.23 1.44 ± 0.17 2.00 ± 0.18 1.79 ± 0.36 0.77 ± 0.07 1.73 ± 0.13 1.54 ± 0.12 1.73 ± 0.17
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S6: Fold changes of all intracellular metabolites of P. inhibens DSM 17395 detected in the experiment “amino acid degradation”. (Continued)
Metabolites
Fold change in abundance as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
Entner-Doudoroff pathway
Gluconate / galactonate 0.83 ± 0.08 0.97 ± 0.10 1.14 ± 0.13 1.07 ± 0.07 0.90 ± 0.09 0.44 ± 0.02 0.81 ± 0.06 1.13 ± 0.10 0.62 ± 0.05
Gluconate-1,4-lactone 1.69 ± 0.13 1.02 ± 0.16 0.49 ± 0.03 0.54 ± 0.06 0.48 ± 0.04 1.33 ± 0.07 0.17 ± 0.07 0.50 ± 0.05 0.58 ± 0.05
Glucono-1,5-lactone 1.96 ± 0.20 1.66 ± 0.26 1.42 ± 0.17 0.81 ± 0.09 0.79 ± 0.11 1.16 ± 0.14 0.81 ± 0.10 1.12 ± 0.13 0.69 ± 0.07
Glyceraldehyde 1.07 ± 0.20 1.04 ± 0.20 1.06 ± 0.28 0.57 ± 0.21 1.44 ± 0.47 1.38 ± 0.23 1.70 ± 0.33 1.53 ± 0.30 0.86 ± 0.28
2-Keto-3-deoxy-gluconate (KDG) 1.90 ± 0.16 1.95 ± 0.24 1.43 ± 0.12 1.31 ± 0.13 1.10 ± 0.14 0.76 ± 0.07 1.06 ± 0.12 1.28 ± 0.12 0.97 ± 0.10
6-Phospho-gluconate 1.39 ± 0.43 0.12 ± 0.12 1.55 ± 0.31 1.80 ± 0.29 1.26 ± 0.19 1.11 ± 0.19 0.27 ± 0.15 1.00 ± 0.14 0.65 ± 0.21
Pentose phosphate pathway
2-Deoxyribose  10.4 ± 4.8 6.23 ± 2.82 4.39 ± 2.03 4.58 ± 2.12  4.24 ± 1.96 4.79 ± 2.18 4.13 ± 1.89
Ribose-5-phosphate 0.97 ± 0.23 1.68 ± 0.28 1.18 ± 0.20 1.22 ± 0.20 0.82 ± 0.13 0.78 ± 0.10 0.91 ± 0.13 1.08 ± 0.17 1.02 ± 0.15
Xylose-1-phosphate 0.29 ± 0.21 0.75 ± 0.29 1.00 ± 0.15 1.00 ± 0.06 1.57 ± 0.26 0.64 ± 0.11 1.03 ± 0.09 1.28 ± 0.12 0.90 ± 0.08
Xylulose-5-phosphate 1.25 ± 0.13 2.01 ± 0.26 1.24 ± 0.09 0.85 ± 0.06 0.95 ± 0.09 0.93 ± 0.06 1.10 ± 0.08 1.01 ± 0.10 0.84 ± 0.07
Other sugars and derivatives
1,6-Anhydro-glucose 3.68 ± 0.28 5.81 ± 0.43 5.53 ± 0.33 3.55 ± 0.24 11.0 ± 0.8 4.20 ± 0.20 3.08 ± 0.32 5.68 ± 0.44 2.10 ± 0.16
1.57 ± 0.18 0.63 ± 0.07 0.63 ± 0.08 0.88 ± 0.11 1.61 ± 0.24 0.89 ± 0.11 0.16 ± 0.07 0.42 ± 0.04 0.36 ± 0.06
Hexose 0.82 ± 0.04 0.80 ± 0.06 0.85 ± 0.04 0.65 ± 0.03 0.73 ± 0.06 0.88 ± 0.03 0.61 ± 0.04 0.59 ± 0.03 0.59 ± 0.04
Arabinose 1.75 ± 0.17 2.63 ± 0.28 1.29 ± 0.12 1.07 ± 0.12 1.15 ± 0.13 1.30 ± 0.11 1.03 ± 0.13 1.20 ± 0.12 1.03 ± 0.10
Galactose 1.36 ± 0.20 0.64 ± 0.09 0.52 ± 0.08 0.44 ± 0.07 0.55 ± 0.07 0.89 ± 0.14 0.12 ± 0.07 0.45 ± 0.09 0.48 ± 0.08
Lipid and phospholipid headgroup components
Ethanolamine 1.18 ± 0.19 1.82 ± 0.38 1.44 ± 0.27 1.23 ± 0.21 1.91 ± 0.28 1.18 ± 0.18 1.37 ± 0.20 1.57 ± 0.32 1.74 ± 0.23
Ethanolaminephosphate 0.57 ± 0.06 0.64 ± 0.07 1.01 ± 0.10 0.89 ± 0.08 1.36 ± 0.17 0.80 ± 0.08 1.01 ± 0.13 0.86 ± 0.09 1.06 ± 0.11
Glycerol-3-phosphate 1.00 ± 0.12 0.92 ± 0.11 1.83 ± 0.28 1.61 ± 0.18 2.30 ± 0.28 0.70 ± 0.08 1.98 ± 0.19 1.48 ± 0.18 2.94 ± 0.26
Glycerophosphoglycerol 0.37 ± 0.12 0.43 ± 0.13 3.46 ± 0.96 1.69 ± 0.50 2.59 ± 0.69 0.58 ± 0.16 2.21 ± 0.53 1.31 ± 0.44 5.10 ± 1.23
1.07 ± 0.16 0.79 ± 0.10 0.63 ± 0.12 0.86 ± 0.13 0.80 ± 0.11 0.91 ± 0.13 0.63 ± 0.07 0.74 ± 0.11 0.95 ± 0.13
2.27 ± 0.26 1.67 ± 0.21 1.15 ± 0.20 0.97 ± 0.13 0.62 ± 0.08 0.70 ± 0.08 0.73 ± 0.08 1.08 ± 0.13 0.98 ± 0.11
2.53 ± 0.27 3.14 ± 0.41 1.69 ± 0.22 1.51 ± 0.21 1.20 ± 0.17 1.28 ± 0.16 1.16 ± 0.14 1.52 ± 0.18 1.29 ± 0.15
0.87 ± 0.19 0.85 ± 0.19 1.54 ± 0.32 1.35 ± 0.23 1.78 ± 0.34 1.20 ± 0.22 1.23 ± 0.21 1.49 ± 0.27 0.79 ± 0.14
1-Hexadecanol 0.47 ± 0.11 0.42 ± 0.09 0.72 ± 0.18 0.95 ± 0.27 0.81 ± 0.19 1.34 ± 0.30 0.59 ± 0.14 0.66 ± 0.17 0.61 ± 0.14
1.07 ± 0.23 1.25 ± 0.29 1.73 ± 0.32 1.43 ± 0.24 1.82 ± 0.34 1.22 ± 0.23 1.45 ± 0.30 1.50 ± 0.31 0.85 ± 0.16
1.43 ± 0.12 1.77 ± 0.18 3.93 ± 0.31 2.11 ± 0.19 2.56 ± 0.24 1.40 ± 0.12 1.86 ± 0.18 1.53 ± 0.20 1.40 ± 0.15
Peptidoglycan components
Alanyl-alanine 0.20 ± 0.12 0.29 ± 0.15 0.42 ± 0.18 1.94 ± 0.78 2.21 ± 0.77 2.91 ± 0.95 1.29 ± 0.56 0.41 ± 0.19 3.51 ± 1.34
Glucosamine-6-phosphate  0.48 ± 0.27 0.06 ± 0.06 0.90 ± 0.09 0.69 ± 0.06 0.85 ± 0.07 0.90 ± 0.11 0.30 ± 0.13 0.91 ± 0.06
1-O-Methyl-β-galactopyranoside
Octanoate (C
8:0
)
3-Hydroxydecanoate (C
10:0, 3-OH
)
Dodecanoate (C
12:0
)
Hexadecanoate (
C16:0
)
Octadecanoate (C
18:0
)
9-Octadecenoate (C
18:1
)
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S6: Fold changes of all intracellular metabolites of P. inhibens DSM 17395 detected in the experiment “amino acid degradation”. (Continued)
Metabolites
Fold change in abundance as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
1.62 ± 0.13 2.41 ± 0.35 1.73 ± 0.16 1.11 ± 0.14 1.54 ± 0.20 1.23 ± 0.12 1.38 ± 0.14 1.10 ± 0.15 1.14 ± 0.13
Butanoates
2-Aminobutanoate 0.44 ± 0.12 0.49 ± 0.14 0.89 ± 0.27 0.59 ± 0.09 0.83 ± 0.15 0.87 ± 0.16 1.64 ± 0.26 0.91 ± 0.16 0.77 ± 0.19
4-Aminobutanoate 1.17 ± 0.07 1.24 ± 0.12 0.17 ± 0.07 0.71 ± 0.05 0.65 ± 0.08 0.95 ± 0.07 1.36 ± 0.61 0.29 ± 0.06 0.91 ± 0.04
3-Aminoisobutanoate 0.81 ± 0.23 0.71 ± 0.17 1.09 ± 0.22 0.97 ± 0.18 1.17 ± 0.20 1.03 ± 0.20 1.45 ± 0.27 1.16 ± 0.25 1.31 ± 0.28
2,4-Diaminobutanoate 0.80 ± 0.09 1.34 ± 0.14 1.58 ± 0.15 1.44 ± 0.19 1.44 ± 0.21 1.22 ± 0.14 1.97 ± 0.22 1.36 ± 0.16 1.77 ± 0.18
2-Hydroxybutanoate 1.86 ± 0.63 1.79 ± 0.42 0.84 ± 0.17 1.17 ± 0.25 1.22 ± 0.27 0.94 ± 0.23 1.11 ± 0.29 1.50 ± 0.33 1.63 ± 0.38
3-Hydroxybutanoate 1.07 ± 0.21 11.6 ± 2.5 0.62 ± 0.12 0.97 ± 0.19 1.55 ± 0.31 0.93 ± 0.18 5.98 ± 1.30 1.70 ± 0.32 5.56 ± 1.24
4-Hydroxybutanoate 0.40 ± 0.12 0.21 ± 0.05 0.85 ± 0.25 0.61 ± 0.15 1.09 ± 0.21 1.21 ± 0.25 0.81 ± 0.20 0.69 ± 0.16 0.80 ± 0.24
Nicotinamide metabolism
Nicotinamide 0.31 ± 0.05 0.50 ± 0.09 0.47 ± 0.07 0.80 ± 0.07 1.03 ± 0.12 1.10 ± 0.10 1.13 ± 0.14 0.51 ± 0.11 0.73 ± 0.11
Nicotinate 0.38 ± 0.08 0.46 ± 0.10 0.55 ± 0.13 0.98 ± 0.25 0.66 ± 0.15 1.00 ± 0.31 0.61 ± 0.16 0.49 ± 0.11 0.95 ± 0.44
Purines, pyrimidines and derivatives
Adenine    0.59 ± 0.57 1.77 ± 1.53  8.80 ± 6.45 0.72 ± 0.70 4.36 ± 3.09
Adenosine 0.56 ± 0.26 0.16 ± 0.16 0.24 ± 0.13 1.24 ± 0.22 1.00 ± 0.17 1.56 ± 0.26 0.79 ± 0.22 0.09 ± 0.09 0.95 ± 0.20
Cytosine 0.18 ± 0.07 0.17 ± 0.07 0.23 ± 0.04 0.70 ± 0.10 0.64 ± 0.09 0.71 ± 0.08 0.69 ± 0.10 0.26 ± 0.04 0.90 ± 0.10
4,5-Dihydroorotate 6.58 ± 3.92 33.4 ± 19.9 20.8 ± 12.4 28.4 ± 25.2 14.6 ± 8.7 2.81 ± 1.68 11.4 ± 6.8 13.8 ± 8.22 7.38 ± 4.40
Orotate 0.32 ± 0.17  2.65 ± 0.27 0.20 ± 0.11 0.51 ± 0.21 0.69 ± 0.06 2.09 ± 0.29 0.20 ± 0.14 18.4 ± 1.9
Thymine 0.22 ± 0.05 0.61 ± 0.11 1.29 ± 0.19 1.52 ± 0.17 2.12 ± 0.31 0.54 ± 0.05 1.76 ± 0.20 0.89 ± 0.12 1.61 ± 0.16
Uracil 0.32 ± 0.14 0.37 ± 0.12 0.78 ± 0.16 0.80 ± 0.15 1.01 ± 0.21 1.53 ± 0.23 0.75 ± 0.15 0.56 ± 0.09 0.69 ± 0.14
Uridine 0.71 ± 0.16 0.30 ± 0.17 0.76 ± 0.08 0.92 ± 0.09 0.95 ± 0.10 1.52 ± 0.12 0.81 ± 0.10 0.19 ± 0.10 2.69 ± 1.40
Others
Benzoate 1.28 ± 0.22 1.05 ± 0.21 1.51 ± 0.21 0.98 ± 0.20 1.41 ± 0.25 10.8 ± 1.5 1.26 ± 0.23 1.93 ± 0.33 1.20 ± 0.19
Carbodiimide 0.96 ± 0.11 0.82 ± 0.09 1.12 ± 0.13 0.96 ± 0.11 1.14 ± 0.12 1.28 ± 0.15 1.03 ± 0.12 0.85 ± 0.09 0.93 ± 0.11
Diphosphate 0.16 ± 0.05 0.15 ± 0.03 0.32 ± 0.09 0.50 ± 0.12 0.55 ± 0.11 0.80 ± 0.14 0.40 ± 0.09 0.33 ± 0.10 0.45 ± 0.13
Glucoheptonate-1,4-lactone 1.09 ± 0.19 1.50 ± 0.27 1.18 ± 0.20 1.33 ± 0.18 1.00 ± 0.12 1.11 ± 0.15 0.93 ± 0.11 1.03 ± 0.18 1.12 ± 0.14
Glycerate 2.43 ± 0.23 4.16 ± 0.42 2.08 ± 0.19 1.41 ± 0.13 1.53 ± 0.20 1.16 ± 0.12 1.51 ± 0.17 1.52 ± 0.14 1.44 ± 0.14
2-Hydroxyglutarate 1.34 ± 0.24 1.47 ± 0.29 0.93 ± 0.15 1.29 ± 0.25 0.98 ± 0.17 0.95 ± 0.18 0.83 ± 0.20 1.11 ± 0.19 1.12 ± 0.18
2-Methylmalate 0.20 ± 0.08 0.23 ± 0.09 0.72 ± 0.19 2.53 ± 0.44 1.55 ± 0.27 2.48 ± 0.46 1.23 ± 0.27 1.00 ± 0.21 2.97 ± 0.54
2-Methylmalonate 0.35 ± 0.09 0.24 ± 0.06 1.37 ± 0.33 0.98 ± 0.18 1.38 ± 0.22 1.38 ± 0.42 0.77 ± 0.15 1.08 ± 0.20 0.88 ± 0.15
2-Methylserine 2.07 ± 0.21 2.25 ± 0.27 4.51 ± 0.61 6.49 ± 2.68 1.89 ± 0.22 1.41 ± 0.13 3.19 ± 1.05 2.30 ± 0.77 2.50 ± 0.26
Phosphate 0.99 ± 0.07 0.97 ± 0.08 0.87 ± 0.07 0.87 ± 0.07 0.99 ± 0.12 0.90 ± 0.08 0.89 ± 0.07 0.82 ± 0.06 0.96 ± 0.07
N-Acetyl-glucosamine
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S6: Fold changes of all intracellular metabolites of P. inhibens DSM 17395 detected in the experiment “amino acid degradation”. (Continued)
Metabolites
Fold change in abundance as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
Phosphate monomethyl ester 2.27 ± 0.38 2.32 ± 0.31 1.42 ± 0.18 1.13 ± 0.17 1.55 ± 0.61 1.00 ± 0.13 1.07 ± 0.16 1.19 ± 0.16 1.06 ± 0.16
Putrescine 1.01 ± 0.11 3.13 ± 0.35 0.55 ± 0.04 1.72 ± 0.17 1.36 ± 0.14 1.19 ± 0.10 0.73 ± 0.08 0.51 ± 0.08 1.40 ± 0.12
Toluate 1.21 ± 0.21 0.84 ± 0.09 1.30 ± 0.12 0.89 ± 0.10 1.08 ± 0.10 1.25 ± 0.11 1.01 ± 0.12 1.07 ± 0.11 1.08 ± 0.09
Unidentified compounds
NA66 (RI_1325) 1.24 ± 0.77 2.05 ± 0.56 1.77 ± 0.48 40.2 ± 40.2 11.3 ± 11.3 1.32 ± 1.73 2.26 ± 4.54 15.7 ± 15.7 2.93 ± 2.93
Unknown#1171.6-pin-mhe_002 0.55 ± 1.44 0.40 ± 1.06 1.03 ± 2.68 1.20 ± 3.15 1.10 ± 2.82 1.12 ± 2.85 1.62 ± 4.21 0.93 ± 2.46 1.09 ± 3.01
Unknown#1226.1-pin-mhe_004   0.74 ± 0.24 1.58 ± 0.24 2.92 ± 0.44 1.12 ± 0.20 1.71 ± 0.30 1.05 ± 0.25 1.70 ± 0.33
Unknown#1234.8-pin-mhe_005    x  x      
Unknown#1325.8-pin-mhe_007 0.95 ± 0.14 1.31 ± 0.22 1.67 ± 0.24 0.98 ± 0.22 0.85 ± 0.16 1.10 ± 0.13 0.86 ± 0.16 0.63 ± 0.13 0.86 ± 0.11
Unknown#1348.0-pin-mhe_009 5.30 ± 3.62 2.15 ± 1.35 0.55 ± 0.27 0.49 ± 0.25 0.44 ± 0.22 0.65 ± 0.32 0.55 ± 0.29 0.76 ± 0.53 0.41 ± 0.20
Unknown#1361.3-pin-mhe_010 0.45 ± 0.06 0.87 ± 0.10 1.10 ± 0.11 0.98 ± 0.11 0.67 ± 0.08 0.86 ± 0.11 1.12 ± 0.13 0.65 ± 0.09 1.12 ± 0.12
Unknown#1366.9-pin-mhe_011 1.13 ± 0.24 2.33 ± 0.46 1.22 ± 0.18 0.99 ± 0.16 0.63 ± 0.11 0.83 ± 0.12 1.08 ± 0.18 0.93 ± 0.21 1.10 ± 0.17
Unknown#1461.8-pin-mhe_015  x   x  x  x  x  x  x  
Unknown#1586.9-pae-bth_039 0.29 ± 0.06 0.48 ± 0.07 0.34 ± 0.03 0.53 ± 0.07 0.89 ± 0.12 0.57 ± 0.06 1.06 ± 0.11 0.64 ± 0.10 0.85 ± 0.10
Unknown#1635.2-pin-mhe_031 2.45 ± 0.41 2.71 ± 0.41 1.31 ± 0.27 1.58 ± 0.35 1.08 ± 0.19 0.58 ± 0.11 1.04 ± 0.23 2.43 ± 0.39 1.50 ± 0.25
Unknown#1647.7-pae-bth_045  x  x  x  x  x  x  x  x  
Unknown#1669.1-pin-mhe_033 0.27 ± 0.08 0.80 ± 0.14 1.00 ± 0.19 1.12 ± 0.18 0.68 ± 0.16 0.89 ± 0.18 1.14 ± 0.23 0.68 ± 0.13 1.26 ± 0.20
Unknown#1746.5-cgl-sst_058 1.97 ± 1.25 0.98 ± 0.43 1.30 ± 0.60 0.87 ± 0.40 1.09 ± 0.51 1.59 ± 0.81 1.13 ± 0.50 0.92 ± 0.40 1.42 ± 0.64
Unknown#1881.9-pin-mhe_041 1.67 ± 0.20 2.42 ± 0.28 1.39 ± 0.16 0.94 ± 0.13 0.91 ± 0.16 1.41 ± 0.14 1.02 ± 0.15 1.06 ± 0.13 0.85 ± 0.12
Unknown#1953.9-pin-mhe_025 2.12 ± 0.59 2.32 ± 0.60 3.02 ± 0.95 2.00 ± 0.60 1.54 ± 0.47 1.72 ± 0.51 1.47 ± 0.39 1.77 ± 0.47 1.43 ± 0.39
Unknown#2018.7-pin-mhe_028 0.49 ± 0.08 0.54 ± 0.09 0.66 ± 0.06 0.84 ± 0.08 0.79 ± 0.09 1.08 ± 0.09 0.84 ± 0.09 0.64 ± 0.08 0.63 ± 0.07
Unknown#2078.9-pin-mhe_042 1.21 ± 0.19 0.86 ± 0.23 0.85 ± 0.18 1.10 ± 0.21 0.56 ± 0.12 0.90 ± 0.17 0.93 ± 0.27 0.81 ± 0.13 0.77 ± 0.12
Unknown#2090.48-ypy-mse_021 1.38 ± 0.18 1.54 ± 0.20 1.41 ± 0.13 1.23 ± 0.12 1.45 ± 0.17 1.46 ± 0.15 1.18 ± 0.08 1.35 ± 0.12 0.85 ± 0.08
Unknown#2274.6-dsh-nbi_004 0.72 ± 0.15 0.93 ± 0.15 1.21 ± 0.17 1.45 ± 0.14 1.26 ± 0.20 1.13 ± 0.15 1.14 ± 0.10 1.14 ± 0.15 1.22 ± 0.15
Unknown#2329.3-pin-mhe_050 1.00 ± 0.12 1.34 ± 0.17 0.97 ± 0.12 0.74 ± 0.13 1.72 ± 0.24 1.44 ± 0.16 0.32 ± 0.11 0.64 ± 0.10 0.45 ± 0.08
Unknown#2334.1-pin-mhe_051 0.54 ± 0.29 0.74 ± 0.40 1.01 ± 0.53 1.49 ± 0.79 1.34 ± 0.70 0.71 ± 0.38 1.49 ± 0.78 0.75 ± 0.41 1.00 ± 0.52
  Colour scale for fold changes: <0.1 <0.2 <0.4 <0.67 0.67 – 1.5 >1.5 >2.5 >5.0 >10.0
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S7: Significance of abundance changes of intracellular metabolites detected in the experiment “amino acid degradation”.  
Substrates: Trp, tryptophan; Phe, phenylalanine; Met, methionine; Leu, leucine; Ile, isoleucine; Val, valine; His, histidine; Lys, lysine; Thr, threonine. 
Metabolites
p-values for abundance changes as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
Amino acids and derivatives
Alanine 4E-006 1E-006 5E-005 0.0019 1.0000 1.0000 0.9675 1.0000 0.0003
Asparagine 8E-005 0.4077 0.1446 0.6125 1.0000 1.0000 0.5899 1.0000 0.0009
Aspartate 0.0003 0.2966 0.0281 0.2488 1.0000 9E-005 0.0018 0.0394 1E-006
0.0653 0.0084 0.005 0.2243 0.0237 0.3306 0.5599 0.0083 0.1259
Cysteine 0.0002 0.1721
Glutamate 0.0003 0.0002 0.0002 0.0103 1.0000 0.0042 1.0000 0.0008 1.0000
Glycine 0.0002 8E-007 0.036 0.0007 1.0000 0.4241 0.003 7E-005 0.0004
Homocysteine 0.0301 1.0000 0.0245 0.0012 1.0000 1.0000 0.012 0.0052 1.0000
Homoserine 0.0301 0.0055 0.6586 0.0215 0.524 0.8944 0.1468 0.001 0.8358
Isoleucine 0.1011 3E-005 1.0000 0.0005 0.1367 0.508 0.0052 0.0021 1.0000
Leucine 0.0019 0.0009 0.0002 1.0000 0.0056 0.0298 0.0009 0.0394 0.0476
Lysine 0.0094 0.0003 0.0056 0.0005 0.2405 0.0144 0.0041 0.9607 1.0000
Methionine 1E-006 0.0106 0.0002 0.0005 0.0006 0.0064 0.0073 0.0053 0.0006
0.8551 0.0084 0.0007 1.0000 0.2022 0.8871 0.4431 0.0202 0.0007
Ornithine 0.7488 0.0002 1E-005 0.022 9E-006 0.0008 0.4276 0.2181 1.0000
Phenylalanine 3E-008 1E-006 1E-010 0.0005 0.0038 2E-006 1E-006 0.0005 0.0001
Proline 0.0002 0.0002 2E-008 0.0019 0.0007 0.0091 0.0012 0.0008 0.0008
Pyroglutamate 0.0394 0.6778 0.0146 1.0000 0.2022 0.0259 0.0191 0.7665 0.0414
Serine 0.0019 0.0166 0.0732 1.0000 0.0341 1.0000 1.0000 1.0000 1.0000
Threonine 0.0009 4E-006 0.0496 0.0007 1.0000 1.0000 1.0000 0.0008 0.0003
Tyrosine 0.0003 0.0002 3E-007 0.0012 1.0000 0.0542 1.0000 0.0366 1.0000
Valine 9E-008 3E-009 4E-009 0.0005 1.0000 0.0005 3E-007 3E-005 0.0006
Tryptophan degradation
2-Aminobenzoate (anthranilate) 0.0003
Phenylalanine degradation
Phenylpyruvate 0.0002 0.7905
Methionine degradation
2-Oxobutanoate 0.0002
Isoleucine degradation
3-Methyl-2-Oxopentanoate
β-Alanine
N-Acetyl-glutamate
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S7: Significance of abundance changes of intracellular metabolites detected in the experiment “amino acid degradation”. (Continued)
Metabolites
p-values for abundance changes as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
2-Oxoisovalerate
Histidine degradation
Urocanate 0.9003
Lysine degradation
2-Aminoadipate 0.0005 1.0000 0.1826
5-Aminopentanoate
Cadaverine 0.3901 0.0003 0.0002 7E-005 0.0004 0.0032 0.8501 0.0005 0.1931
Glutarate 0.8127 1.0000 0.1801 0.1512 0.0006 1.0000 0.7849 0.0179 0.0009
Other compounds associated with amino acid metabolism
Homogentisate 0.0002
Hydantoin-5-propionate
4-Hydroxyphenylacetate 0.0002 1.0000 0.4187 0.5411
Phenylacetate 0.0004
Shikimate-3-phosphate 0.8273 0.1332 0.0002 0.0009 0.0004 0.0005 0.0062 0.0107 0.0009
TCA Cycle
2-Oxoglutarate 0.024 0.0033 0.1254 0.894 1.0000 1.0000 0.4861 1.0000 1.0000
Citrate 0.8273 0.8012 0.1112 0.8349 1.0000 1.0000 0.0035 3E-005 1.0000
Fumarate 0.0061 0.0002 0.0032 1.0000 0.1565 0.1372 0.4593 0.0014 0.8647
Malate 0.0004 0.0004 0.0005 1.0000 0.0341 0.1881 0.6181 0.0083 0.5511
Succinate 0.0023 2E-007 0.0389 0.0015 0.9395 0.2557 1.0000 0.0291 0.0021
Gluconeogenesis
Dihydroxyacetone phosphate 0.0003 0.0036 0.0036 1.0000 0.7209 1.0000 0.9003 1.0000 0.003
Fructose 0.0009 0.0004 0.0828 1.0000 1.0000 0.4241 0.074 0.0743 0.8995
Fructose-1-phosphate 0.5765 0.6334 0.0316 1.0000 0.0213 0.0483 0.1468 0.7311 0.0916
Fructose-6-phosphate 0.2299 0.0036 1.0000 0.0885 0.1281 0.5835 0.0039 0.0509
Glucose 0.5227 0.2299 0.0513 1.0000 0.2442 0.34 0.6949 0.6662 0.6186
Glucose-6-phosphate 0.0128 1.0000 0.244 0.2195 0.6426 1.0000 0.1701 0.0453 1.0000
3-Phosphoglycerate 0.2256 0.5742 1.0000 0.7885 1.0000 1.0000 0.7849 1.0000 1.0000
Phosphoenolpyruvate 0.0083 0.0097 0.0059 1.0000 0.9415 0.8871 0.5599 0.4575 0.8647
Pyruvate 0.0003 3E-007 1.0000 0.0005 1.0000 0.9817 7E-005 0.0024 0.0063
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S7: Significance of abundance changes of intracellular metabolites detected in the experiment “amino acid degradation”. (Continued)
Metabolites
p-values for abundance changes as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
Entner-Doudoroff pathway
Gluconate / galactonate 0.1361 0.8687 0.4831 1.0000 0.2238 0.0005 0.0587 0.3357 0.0007
Gluconate-1,4-lactone 0.0019 0.2299 2E-008 0.0008 1E-007 0.0014 0.0083 0.0005 0.0003
Glucono-1,5-lactone 2E-005 0.9087 0.7316 0.0877 1.0000 0.5982 1.0000 1.0000 0.6604
Glyceraldehyde 0.8273 1.0000 0.761 1.0000 0.9144 1.0000 1.0000 0.0677 0.643
2-Keto-3-deoxy-gluconate (KDG) 0.0009 0.0055 0.0032 1.0000 0.9144 0.0298 0.5599 0.0268 0.9403
6-Phospho-gluconate 0.4536 0.2299 0.2559 0.7372 0.3804 0.9212 1.0000 1.0000 0.0408
Pentose phosphate pathway
2-Deoxyribose 0.0082 0.2339 0.2488 1.0000 1.0000 1.0000 1.0000
Ribose-5-phosphate 0.7135 0.6899 1.0000 1.0000 0.2022 1.0000 1.0000 1.0000 1.0000
Xylose-1-phosphate 0.0428 0.0089 0.8271 1.0000 0.027 0.0585 0.8855 0.0346 0.1931
Xylulose-5-phosphate 1.0000 0.0616 0.0513 0.1259 1.0000 1.0000 1.0000 1.0000 0.1135
Other sugars and derivatives
1,6-Anhydro-glucose 0.0003 2E-009 5E-012 0.0005 2E-010 4E-014 0.0008 9E-009 4E-005
0.0027 0.0005 0.0032 1.0000 0.0137 0.4809 0.0083 0.0005 0.0003
Hexose 0.099 0.0167 0.4586 0.0005 0.0476 0.0483 5E-007 1E-008 5E-007
Arabinose 0.0023 2E-005 0.8982 1.0000 0.524 0.0277 1.0000 1.0000 1.0000
Galactose 0.0027 0.0048 0.0007 0.0513 0.001 0.2817 0.044 0.0009 0.0008
Lipid and phospholipid headgroup components
Ethanolamine 0.6725 0.0263 0.1954 1.0000 0.005 0.5982 0.1468 0.1385 0.0731
Ethanolaminephosphate 0.0016 0.0055 0.5916 1.0000 0.0518 0.0111 0.808 0.0748 1.0000
Glycerol-3-phosphate 1.0000 1.0000 0.4531 0.0092 0.0028 0.6152 0.0004 0.8018 8E-008
Glycerophosphoglycerol 0.0209 0.179 0.0013 1.0000 0.0075 0.4241 0.0093 0.7311 0.0003
0.6725 0.1645 0.0211 1.0000 0.1891 0.6216 0.0073 0.1297 1.0000
0.0008 0.1805 0.954 1.0000 0.0098 0.5388 0.0352 1.0000 1.0000
5E-008 4E-005 0.0024 1.0000 0.5065 1.0000 1.0000 0.1319 0.0846
0.6725 0.4725 0.104 1.0000 0.0237 0.34 0.1701 0.0748 0.4453
1-Hexadecanol 0.0209 0.0075 0.306 1.0000 0.7995 0.1281 0.1592 0.3357 0.1501
1.0000 1.0000 0.8438 0.0716 0.6688 0.3668 1.0000 1.0000 1.0000
0.0805 0.0161 3E-009 7E-005 0.0004 0.1603 0.0012 0.9881 0.9558
Peptidoglycan components
Alanyl-alanine 0.0023 0.0106 0.0573 1.0000 0.03 0.0111 0.6949 0.0512 0.0373
Glucosamine-6-phosphate 0.0893 0.1511 0.4465 0.0083 1.0000 0.0945 1.0000 1.0000
1-O-Methyl-β-galactopyranoside
Octanoate (C
8:0
)
3-Hydroxydecanoate (C
10:0, 3-OH
)
Dodecanoate (C
12:0
)
Hexadecanoate (
C16:0
)
Octadecanoate (C
18:0
)
9-Octadecenoate (C
18:1
)
 Supplementary material xvii
S7: Significance of abundance changes of intracellular metabolites detected in the experiment “amino acid degradation”. (Continued)
Metabolites
p-values for abundance changes as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
0.0005 0.0003 0.0009 1.0000 0.0451 1.0000 0.7658 0.8019 1.0000
Butanoates
2-Aminobutanoate 0.0051 0.0106 0.2559 0.7141 0.4744 1.0000 0.7624 1.0000 0.0916
4-Aminobutanoate 1.0000 1.0000 2E-005 0.0017 0.0746 0.34 0.0276 0.0005 1.0000
3-Aminoisobutanoate 0.3005 0.059 0.761 1.0000 0.4047 0.954 0.074 0.7311 0.4807
2,4-Diaminobutanoate 1.0000 1.0000 0.018 1.0000 0.0642 1.0000 0.0048 1.0000 0.0006
2-Hydroxybutanoate 0.5227 1.0000 0.7268 0.5434 1.0000 0.8796 0.8501 1.0000 1.0000
3-Hydroxybutanoate 0.961 0.0002 0.1319 1.0000 0.0451 0.5694 0.0045 0.0239 0.0054
4-Hydroxybutanoate 0.0043 0.0072 0.2559 0.1391 1.0000 1.0000 0.4593 1.0000 0.1799
Nicotinamide metabolism
Nicotinamide 1E-006 0.0019 0.0007 0.064 1.0000 1.0000 1.0000 0.2062 1.0000
Nicotinate 0.0009 0.0097 0.0211 1.0000 0.3232 0.8944 0.1592 0.0222 0.1655
Purines, pyrimidines and derivatives
Adenine 1.0000 0.5806 0.9003 0.5807 0.484
Adenosine 0.0267 0.2299 0.8915 1.0000 0.8425 0.0165 0.2476 0.5649 0.5319
Cytosine 0.0005 0.0004 6E-007 0.064 0.446 0.6429 1.0000 0.0005 1.0000
4,5-Dihydroorotate 0.1516 0.0249 0.005 1.0000 0.027 0.5343 0.1315 0.1259 1.0000
Orotate 1.0000 5E-007 0.5434 1.0000 0.2534 0.0398 0.594 2E-011
Thymine 0.0003 0.3631 1.0000 0.0158 0.1121 0.001 0.0357 1.0000 0.0352
Uracil 0.0083 0.1348 1.0000 0.3292 1.0000 0.6164 1.0000 0.6463 1.0000
Uridine 0.0638 1.0000 1.0000 0.7211 1.0000 0.0077 1.0000 1.0000 0.5511
Others
Benzoate 1.0000 1.0000 0.4873 1.0000 0.1284 6E-011 1.0000 0.0034 1.0000
Carbodiimide 0.9216 0.179 0.2797 1.0000 0.0709 0.0483 0.9675 0.5835 0.7647
Diphosphate 0.0004 0.0005 0.0036 1.0000 0.0709 0.34 0.1225 0.0061 0.0166
Glucoheptonate-1,4-lactone 0.9216 0.179 0.514 1.0000 0.9415 0.6984 0.5835 0.7675 0.5038
Glycerate 2E-006 1E-008 3E-006 0.0066 1.0000 1.0000 0.2241 0.0014 0.1065
2-Hydroxyglutarate 1.0000 0.0968 1.0000 0.2309 1.0000 1.0000 1.0000 1.0000 0.5038
2-Methylmalate 0.0267 0.0435 0.0462 0.0001 0.0187 0.0028 0.3595 0.8309 0.0006
2-Methylmalonate 0.0036 0.0006 0.6586 1.0000 0.2985 0.8796 0.3595 0.9607 0.5511
2-Methylserine 0.0002 0.0017 0.0002 1.0000 0.0009 0.2172 0.0021 0.0025 0.0003
Phosphate 1.0000 1.0000 0.0934 0.1997 1.0000 0.4809 1.0000 1.0000 1.0000
N-Acetyl-glucosamine
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S7: Significance of abundance changes of intracellular metabolites detected in the experiment “amino acid degradation”. (Continued)
Metabolites
p-values for abundance changes as compared to succinate grown cells
Trp Phe Met Leu Ile Val His Lys Thr
Phosphate monomethyl ester 0.0014 0.0004 0.0109 1.0000 0.8865 0.6216 0.5418 0.1385 0.5845
Putrescine 1.0000 0.0002 0.0002 0.0144 0.0111 1.0000 0.7656 0.0021 0.0839
Toluate 0.8127 1.0000 0.8996 0.5434 1.0000 1.0000 1.0000 1.0000 1.0000
Unidentified compounds
NA66 (RI_1325) 1.0000 0.2073 0.2045 0.0128 0.1319 1.0000 0.4861 0.2382 0.0135
Unknown#1171.6-pin-mhe_002 0.5765 0.3639 0.715 1.0000 0.9314 0.7876 0.5418 0.6662 0.8358
Unknown#1226.1-pin-mhe_004 0.1954 0.0328 0.0006 1.0000 0.0251 0.5263 0.0509
Unknown#1234.8-pin-mhe_005 
Unknown#1325.8-pin-mhe_007 1.0000 1.0000 0.0036 0.8793 1.0000 1.0000 1.0000 0.1014 1.0000
Unknown#1348.0-pin-mhe_009 0.2046 0.0399 0.6586 1.0000 0.1565 0.1689 0.4276 0.0145 0.0509
Unknown#1361.3-pin-mhe_010 0.0005 0.2716 0.453 1.0000 0.0075 0.5694 0.4431 0.0129 0.3698
Unknown#1366.9-pin-mhe_011 0.8886 0.0019 0.0573 1.0000 0.0137 0.4809 0.7806 0.4315 0.4453
Unknown#1461.8-pin-mhe_015
Unknown#1586.9-pae-bth_039 0.0003 0.0022 5E-007 0.0017 1.0000 0.0035 0.7849 0.5283 1.0000
Unknown#1635.2-pin-mhe_031 0.0007 0.0002 0.4238 1.0000 0.8648 0.0277 1.0000 0.0039 1.0000
Unknown#1647.7-pae-bth_045
Unknown#1669.1-pin-mhe_033 0.0031 0.134 1.0000 0.7885 1.0000 1.0000 1.0000 1.0000 1.0000
Unknown#1746.5-cgl-sst_058 0.8273 0.0399 0.0281 1.0000 0.0805 0.0298 0.0587 0.1014 0.0274
Unknown#1881.9-pin-mhe_041 0.0031 0.0003 0.0192 1.0000 0.524 0.0146 0.941 0.6127 0.3941
Unknown#1954.3-pin-mhe_026 0.0071 0.004 0.0032 1.0000 0.0137 0.0146 0.0169 0.0129 0.0257
Unknown#2018.7-pin-mhe_028 0.0006 0.0013 0.0009 1.0000 0.0642 0.34 0.1701 0.0061 0.0025
Unknown#2078.9-pin-mhe_042 0.4912 0.2716 0.1954 1.0000 0.0098 0.34 0.2105 0.2142 0.0509
Unknown#2090.48-ypy-mse_021 1.0000 0.8915 0.0032 0.0786 1.0000 0.0064 0.0523 0.5467 1.0000
Unknown#2274.6-dsh-nbi_004 0.0505 1.0000 0.7894 0.2102 0.353 1.0000 1.0000 1.0000 0.3427
Unknown#2329.3-pin-mhe_050 1.0000 0.7468 0.4831 1.0000 0.0039 0.0542 0.0056 0.803 0.2932
Unknown#2334.1-pin-mhe_051 0.7908 0.134 0.0169 1.0000 0.013 0.2061 0.0083 0.402 0.0274
p-Values: <0.0001 <0.001 <0.01 <0.05
underlined: t-test, Holm-Bonferroni correction
alternatively: Wilcoxon-Mann-Whitney Test, False Discovery Rate Control
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S8: Intracellularly detected metabolites of P. inhibens DSM 17395 in the experiment “carbohydrate degradation”.
Abbreviations: NAG, N-acetyl-glucosamine; MTL, mannitol; SUCR, sucrose; GLC, glucose; XYL, xylose; *, compound probably dephosphorylated during  
sample treatment; x, compound not detected in reference condition; XX, compound not detected in reference condition, but intense peak observed in test  
condition.
Metabolites
Fold change in metabolite abundance as compared to succinate grown cells p-Values for abundance changes 
NAG MTL SUCR GLC XYL NAG MTL SUCR GLC XYL
Sugars and derivatives
Hexoses
1,6-Anhydro-glucose 1.46 ± 0.09 1.71 ± 0.09 0.84 ± 0.06 1.07 ± 0.08 1.23 ± 0.11 0.00015 0.00011 0.11588 0.31577 0.05948
6-Deoxy-mannose 13.0 ± 2.5 15.6 ± 2.1 4.07 ± 0.55 4.64 ± 0.63 15.0 ± 2.0 0.00025 0.00011 0.00112 0.00073 0.00018
Fructose 0.73 ± 0.05 8.27 ± 0.66 17.3 ± 1.7 2.21 ± 0.20 1.05 ± 0.12 0.00870 0.00016 0.00131 0.00039 0.91107
Fructose-6-phosphate 0.07 ± 0.06 0.02 ± 0.01 4.28 ± 2.15 4.30 ± 2.44 0.44 ± 0.36 0.1310754 0.1308055 0.0351274 0.1459156 0.4791699
Glucose 1.59 ± 0.07 2.00 ± 0.10 0.78 ± 0.04 1.04 ± 0.07 0.86 ± 0.05 3.5E-08 1.1E-09 0.01389 0.34174 0.03513
0.03 ± 0.01 0.04 ± 0.02 0.16 ± 0.06 0.30 ± 0.12 0.14 ± 0.06 0.015791 0.0728393 0.428487 0.3770686 0.5050026
0.03 ± 0.01 0.12 ± 0.08 0.66 ± 0.31 47.3 ± 25.7 0.33 ± 0.18 0.6641592 0.580338 0.0850328 0.0191952 0.6709364
Gluconate-1,4-lactone 0.91 ± 0.11 1.97 ± 0.22 1.44 ± 0.33 0.81 ± 0.09 1.13 ± 0.13 0.00015 0.00011 0.00112 0.00012 0.00018
Glucoheptonate-1,4-lactone (Heptose) 1.53 ± 0.12 0.70 ± 0.07 0.69 ± 0.06 0.56 ± 0.08 2.18 ± 0.38 0.00028 0.00645 0.02669 0.00066 0.02620
Glucosamine 0.49 ± 0.07 0.12 ± 0.02 0.12 ± 0.02 0.00105 0.01296 0.00080
Glucosaminate XX x x x x
12.0 ± 0.6 1.33 ± 0.16 1.69 ± 0.23 2.65 ± 0.29 1.36 ± 0.17 1.0E-10 0.04265 0.23790 0.00592 1.0000
x x x
Glucuronate 3.35 ± 0.44 87.0 ± 17.6 0.01454 0.00015
Mannitol 0.76 ± 0.14 19.9 ± 2.5 1.02 ± 0.09 0.47 ± 0.06 0.43 ± 0.03 0.03080 0.00011 0.47815 0.00256 0.00018
Pentoses / Pentose-Phosphate Pathway
Arabinonate 9.34 ± 2.73 11.2 ± 2.0 4.25 ± 0.83 21.6 ± 12.3 110 ± 19.2 0.0645205 0.080547 0.0402735 0.3021725 0.0526444
Erythrose-4-phosphate 3.74 ± 2.99 2.75 ± 2.68 5.45 ± 5.20 0.48 ± 0.35 0.99 ± 0.93 0.0645205 0.8059139 0.5844601 0.679489 0.6709364
Ribonate 5.71 ± 2.13 13.6 ± 1.5 5.49 ± 0.95 8.90 ± 1.11 69.5 ± 9.3 0.0215946 0.0728393 0.0181589 0.0191952 0.0237982
Ribose 1.02 ± 0.05 2.30 ± 0.08 0.81 ± 0.07 0.89 ± 0.07 2.45 ± 0.11 1.0000 1.3E-13 1.0000 0.26492 1.6E-11
Xylose x XX
Xylulose 0.81 ± 0.08 0.76 ± 0.07 0.52 ± 0.06 0.87 ± 0.10 0.87 ± 0.13 0.09208 0.01358 0.05173 1.0000 0.44062
Xylulose-/ Ribulose-5-phosphate 0.09 ± 0.06 0.05 ± 0.05 0.17 ± 0.11 1.00 ± 1.00 0.05960 0.78382 0.86521
Di-Saccharides
Melibiose x x x x x
Sucrose x
x
XX x
Glucose/Galactose/Mannose-6-P
Glucose/Glucosamine/Sorbitol-6-P
N-Acetyl-glucosamine
N-Acetyl-mannosamine
α-D-Glucopyranosyl-(1,6)-mannitol
α-D-Mannopyranosyl-(1,2)-D-mannopyranose  
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S8: Intracellularly detected metabolites of P. inhibens DSM 17395 in the experiment “carbohydrate degradation”. (Continued)
Metabolites
Fold change in metabolite abundance as compared to succinate grown cells p-Values for abundance changes 
NAG MTL SUCR GLC XYL NAG MTL SUCR GLC XYL
Entner-Doudoroff pathway
Glucono-1,5-lactone * 4.70 ± 0.32 8.99 ± 0.57 9.83 ± 0.71 22.4 ± 2.3 4.99 ± 0.42 0.00015 0.00011 0.00112 0.00012 0.00018
Galactonate / Gluconate * 11.4 ± 1.8 4.62 ± 0.74 8.06 ± 1.26 26.0 ± 3.7 6.58 ± 1.34 2.0E-05 0.00030 4.0E-05 2.3E-07 0.01746
6-Phosphogluconate 0.24 ± 0.09 0.96 ± 0.37 5.05 ± 1.98 15.8 ± 6.0 0.17 ± 0.16 0.015791 0.51537 0.015791 0.0191952 0.0526444
2-Keto-3-deoxy-gluconate (KDG) * 30.5 ± 4.3 4.66 ± 2.49 1.87 ± 0.10 3.18 ± 0.28 2.05 ± 0.13 0.00020 0.00016 1.0E-07 0.00015 7.9E-07
Glyceraldehyde * 1.05 ± 0.13 0.75 ± 0.11 0.50 ± 0.07 0.64 ± 0.08 0.76 ± 0.09 0.74436 0.09832 0.00474 0.04120 0.34395
Dihydroxyacetone phosphate 1.68 ± 0.33 0.31 ± 0.15 0.39 ± 0.09 0.63 ± 0.17 0.60 ± 0.18 0.2040539 0.0761095 0.0181589 0.1700449 0.2691744
1,3-Dihydroxyacetone * 0.77 ± 0.04 0.95 ± 0.05 1.00 ± 0.06 1.12 ± 0.08 0.98 ± 0.05 0.00819 0.37593 1.0000 1.0000 1.0000
3-Phosphoglycerate 3.77 ± 0.44 1.58 ± 0.16 1.66 ± 0.23 8.75 ± 1.04 2.60 ± 0.31 0.00037 0.00226 0.14412 0.00029 0.00090
2-Phosphoglycerate 1.64 0.42 0.80 2.70 0.3634587 0.2186292 0.3089399 0.191776
Phosphoenolpyruvate 1.95 ± 0.28 1.77 ± 0.24 1.27 ± 0.21 4.43 ± 0.66 1.84 ± 0.28 0.00245 0.00786 0.21103 0.00019 0.00912
Pyruvate 7.71 ± 1.29 3.62 ± 0.60 3.11 ± 0.54 3.84 ± 0.57 5.35 ± 0.77 0.00018 0.00011 0.00112 1.9E-06 2.8E-08
TCA Cycle
Citrate 4.00 ± 0.58 1.28 ± 0.14 0.89 ± 0.15 5.06 ± 0.83 4.39 ± 0.72 0.00015 0.02385 0.61250 0.00012 0.00044
2-Oxoglutarate 1.90 ± 0.12 0.73 ± 0.05 0.60 ± 0.04 1.10 ± 0.11 1.31 ± 0.10 0.00015 0.00226 0.00135 0.26492 0.00443
Succinate 0.60 ± 0.06 0.30 ± 0.02 0.07 ± 0.01 0.13 ± 0.01 0.24 ± 0.02 0.00142 9.5E-10 9.8E-13 6.8E-12 1.1E-10
Fumarate 2.11 ± 0.20 0.71 ± 0.06 0.35 ± 0.03 0.37 ± 0.05 0.52 ± 0.05 0.00024 0.01203 0.00112 0.00012 0.00033
Malate 3.45 ± 0.35 0.48 ± 0.04 0.28 ± 0.03 0.34 ± 0.04 0.40 ± 0.04 2.2E-08 0.00043 0.00112 1.5E-05 9.0E-05
Amino acids and derivatives
Alanine 4.21 ± 1.05 0.47 ± 0.12 0.05 ± 0.01 0.16 ± 0.04 0.27 ± 0.06 0.00039 1.0000 0.00112 0.00255 0.01326
Aspartate 0.13 ± 0.02 0.08 ± 0.01 0.05 ± 0.01 0.06 ± 0.01 0.03 ± 0 0.00015 0.00011 0.00112 0.00012 0.00018
0.55 ± 0.03 0.44 ± 0.03 0.24 ± 0.01 0.28 ± 0.03 0.42 ± 0.02 0.00015 0.00011 0.00112 0.00012 0.00018
Glutamate 0.89 ± 0.09 0.75 ± 0.09 0.43 ± 0.05 0.70 ± 0.07 0.66 ± 0.07 0.6641592 0.2186292 0.015791 0.1093279 0.0489275
Glutamine 1.12 ± 0.17 1.48 ± 0.23 1.41 ± 0.14 1.33 ± 0.11 1.09 ± 0.09 0.42638 0.00316 0.49292 0.25900 1.0000
Glycine 0.76 ± 0.09 0.36 ± 0.03 0.20 ± 0.02 0.18 ± 0.02 0.23 ± 0.02 0.05008 3.8E-06 7.0E-08 0.00012 1.7E-07
Homoserine 1.16 ± 0.13 1.39 ± 0.20 1.23 ± 0.16 1.21 ± 0.33 3.02 ± 1.58 1.0000 1.0000 1.0000 1.0000 0.01959
Isoleucine 1.20 ± 0.27 1.27 ± 0.16 0.16 ± 0.02 0.77 ± 0.11 0.58 ± 0.08 0.59820 0.08867 0.00592 0.03256 0.02620
Leucine 1.05 ± 0.18 1.43 ± 0.14 0.24 ± 0.03 0.74 ± 0.09 0.56 ± 0.06 0.52612 0.00081 0.00112 0.02867 0.01326
Lysine 0.19 ± 0.06 0.42 ± 0.09 0.08 ± 0.02 0.21 ± 0.04 0.17 ± 0.05 0.015791 0.0728393 0.015791 0.0191952 0.0237982
Methionine 2.53 ± 0.35 0.31 ± 0.03 0.12 ± 0.01 0.26 ± 0.03 0.47 ± 0.05 0.00632 2.4E-07 0.00112 0.00012 6.7E-05
1.02 ± 0.12 0.73 ± 0.08 1.38 ± 0.17 2.23 ± 0.28 1.29 ± 0.15 0.33716 0.01810 0.03253 0.00019 0.01326
6.77 ± 0.41 0.78 ± 0.06 0.87 ± 0.07 1.08 ± 0.12 6.3E-14 0.29151 1.0000 0.91107
18.6 ± 4.4 11.8 ± 3.9 0.91 ± 0.38 3.08 ± 0.67 11.5 ± 3.9 0.00015 0.00751 0.5844601 0.1700449 0.01326
β-Alanine
N,N-Dimethylglycine
N-Acetyl-glutamate
O-Acetyl-serine
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S8: Intracellularly detected metabolites of P. inhibens DSM 17395 in the experiment “carbohydrate degradation”. (Continued)
Metabolites
Fold change in metabolite abundance as compared to succinate grown cells p-Values for abundance changes 
NAG MTL SUCR GLC XYL NAG MTL SUCR GLC XYL
Phenylalanine 0.91 ± 0.08 0.35 ± 0.03 0.13 ± 0.01 0.24 ± 0.03 0.37 ± 0.03 0.26021 0.00011 0.00112 0.00012 0.00018
Proline 0.57 ± 0.06 0.39 ± 0.04 0.06 ± 0.01 0.13 ± 0.02 0.27 ± 0.03 0.00125 0.00105 0.00112 0.00026 0.00119
Pyroglutamate 0.64 ± 0.11 0.91 ± 0.12 0.55 ± 0.07 0.70 ± 0.10 0.70 ± 0.12 1.0000 1.0000 0.02669 0.15101 1.0000
Serine 1.15 ± 0.15 0.41 ± 0.05 0.25 ± 0.03 0.33 ± 0.04 0.42 ± 0.05 0.84682 0.00027 0.00112 0.00012 0.00033
Threonine 1.17 ± 0.18 1.01 ± 0.10 0.31 ± 0.03 0.42 ± 0.06 0.74 ± 0.08 0.36543 0.90807 0.00112 0.00014 0.09520
Tyrosine 0.93 ± 0.07 0.72 ± 0.10 0.17 ± 0.03 0.43 ± 0.05 0.48 ± 0.10 0.5237063 0.0761095 0.015791 0.0191952 0.0213179
Valine 1.99 ± 0.30 1.64 ± 0.20 0.54 ± 0.07 0.62 ± 0.08 0.66 ± 0.08 0.01358 0.00011 0.09908 0.03256 0.05237
Organic acids
2-Aminoadipate 0.36 ± 0.11 1.36 ± 0.36 0.08 ± 0.06 0.29 ± 0.11 0.71 ± 0.23 0.1275492 0.2965681 0.0181589 0.0951313 0.6709364
Benzoate 1.35 ± 0.22 1.74 ± 0.22 1.45 ± 0.19 1.76 ± 0.27 1.91 ± 0.26 0.14508 0.00093 0.01181 0.00513 0.00119
Erythronate 8.23 ± 0.88 2.70 ± 0.28 1.61 ± 0.21 2.90 ± 0.35 1.91 ± 0.24 0.00015 0.00011 0.03253 0.00014 0.00096
Glycerate 0.99 ± 0.07 1.98 ± 0.12 1.86 ± 0.11 2.21 ± 0.18 1.34 ± 0.07 0.84682 6.9E-08 4.1E-07 0.00097 0.00024
Glyoxylate 1.72 ± 0.05 1.31 ± 0.17 2.20 ± 0.30 5.33 ± 0.57 3.03 ± 0.31 0.0280729 0.2965681 0.0210547 0.0191952 0.0304541
2-Hydroxyglutarate 2.03 ± 0.26 0.44 ± 0.06 0.29 ± 0.04 0.19 ± 0.03 0.63 ± 0.08 0.00015 0.01175 0.00046 0.00190 0.43082
Iminodiacetate 31.1 ± 5.9 1.90 ± 0.36 0.77 ± 0.15 5.64 ± 1.17 2.13 ± 0.41 0.00015 0.00128 0.47815 0.00012 0.00044
Lactate 1.30 ± 0.32 0.33 ± 0.07 0.51 ± 0.13 0.42 ± 0.13 0.30 ± 0.07 0.96233 0.00030 0.09908 0.00793 0.00052
Maleate 2.53 ± 0.23 0.64 ± 0.22 0.42 ± 0.08 0.69 ± 0.25 0.52 ± 0.10 0.015791 0.3826504 0.015791 0.1700449 0.0213179
Malonate x x x x x
2-Methyl-malate 4.02 ± 0.26 2.59 ± 0.16 2.29 ± 0.15 4.20 ± 0.40 2.88 ± 0.20 7.4E-13 0.00011 4.3E-09 0.00014 0.00018
2-Methyl-serine 1.83 ± 0.13 2.81 ± 0.13 3.29 ± 0.17 1.27 ± 0.09 0.91 ± 0.06 2.7E-05 3.2E-14 1.5E-12 0.00145 1.0000
Nicotinamide 0.91 ± 0.53 1.03 ± 0.58 0.72 ± 0.38 0.86 ± 0.49 0.85 ± 0.45 0.8689045 1.0000 0.647778 1.00000 0.7382145
Nicotinate 0.39 ± 0.05 0.71 ± 0.10 0.58 ± 0.07 0.66 ± 0.06 0.42 ± 0.06 0.00033 0.03256 0.01384 0.00816 0.00063
Phenylacetate 0.39 ± 0.03 0.79 ± 0.08 0.88 ± 0.09 0.81 ± 0.08 0.59 ± 0.05 2.1E-06 1.0000 1.0000 1.0000 0.00052
Succinate-methylester 0.96 ± 0.11 1.34 ± 0.10 1.04 ± 0.09 1.29 ± 0.12 1.05 ± 0.09 1.0000 0.02100 1.0000 0.49383 1.0000
Tartrate 0.68 ± 0.15 1.59 ± 0.40 10.8 ± 2.2 169 ± 37 3.06 ± 0.68 0.42638 0.01058 0.00112 0.00012 0.00044
Threonate 2.59 ± 0.72 4.20 ± 0.77 29.6 ± 5.5 13.1 ± 2.6 2.64 ± 0.54 0.00151 0.00011 0.00112 0.00012 0.00104
Urea 0.98 ± 0.18 0.80 ± 0.34 0.26 ± 0.07 0.69 ± 0.18 0.27 ± 0.05 0.71081 0.48175 0.08503 0.26832 0.05264
Lipid and phospholipid headgroup components
Ethanolamine 0.41 ± 0.05 0.23 ± 0.02 0.12 ± 0.02 0.19 ± 0.03 0.18 ± 0.02 0.00020 0.00011 0.00112 0.00012 0.00018
Ethanolaminephosphate 1.01 ± 0.17 0.09 ± 0.09 0.23 ± 0.04 0.36 ± 0.06 0.36 ± 0.05 0.9168149 0.2616974 0.0210547 0.0191952 0.0526444
Diethanolamine 6.30 ± 1.16 8.24 ± 1.30 2.19 ± 0.51 5.14 ± 0.82 7.85 ± 1.28 0.00015 0.00011 0.01717 0.00012 0.00018
Glycerol-3-phosphate 0.18 ± 0.02 0.11 ± 0.01 0.05 ± 0 0.12 ± 0.02 0.07 ± 0.01 0.00015 0.00011 0.00170 0.00012 0.00018
Glycerophosphoglycerol 0.05 ± 0.04 0.03 ± 0.02 0.09 ± 0.06 0.89 ± 0.52 0.07 ± 0.04 0.6104239 0.580338 0.824878 0.7760652 0.7963619
0.67 ± 0.07 0.29 ± 0.03 0.27 ± 0.03 0.31 ± 0.03 0.25 ± 0.03 0.00361 0.00011 0.00112 0.00012 0.00018
0.57 ± 0.04 0.60 ± 0.06 0.67 ± 0.08 0.63 ± 0.05 0.52 ± 0.06 0.00013 0.00105 0.10814 0.00019 0.00044
Octanoate (C
8:0
)
3-Hydroxydecanoate (C
10:0, 3-OH
)
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S8: Intracellularly detected metabolites of P. inhibens DSM 17395 in the experiment “carbohydrate degradation”. (Continued)
Metabolites
Fold change in metabolite abundance as compared to succinate grown cells p-Values for abundance changes 
NAG MTL SUCR GLC XYL NAG MTL SUCR GLC XYL
0.59 ± 0.05 1.13 ± 0.09 1.52 ± 0.16 1.52 ± 0.13 0.95 ± 0.09 0.00240 1.0000 0.06992 0.00217 0.59502
Dodecanol 0.44 ± 0.10 13.6 ± 3.7 11.5 ± 3.3 5.63 ± 2.31 4.75 ± 2.13 0.07662 0.00276 0.00842 0.07126 0.37877
0.36 ± 0.06 0.44 ± 0.08 0.25 ± 0.04 0.28 ± 0.05 0.41 ± 0.08 0.04895 0.01203 0.00828 0.00066 0.00615
Tetradecanol 0.79 ± 0.03 1.84 ± 0.12 1.69 ± 0.10 1.61 ± 0.12 1.28 ± 0.13 0.00039 0.00011 0.00112 0.00056 0.04024
0.71 ± 0.05 1.02 ± 0.08 0.83 ± 0.08 0.96 ± 0.10 1.12 ± 0.32 0.02643 1.0000 1.0000 1.0000 0.34395
0.51 ± 0.08 1.11 ± 0.11 1.11 ± 0.13 0.80 ± 0.17 0.93 ± 0.16 0.00059 0.25355 0.41893 0.78527 0.46466
0.29 ± 0.13 0.22 ± 0.08 0.80 ± 0.26 0.47 ± 0.15 0.20 ± 0.10 0.1563382 0.2186292 0.5844601 0.3770686 0.0720765
Butanoates
2-Aminobutanoate 0.42 ± 0.06 0.16 ± 0.02 0.12 ± 0.02 0.19 ± 0.04 0.19 ± 0.05 0.00024 0.00011 0.00112 0.00012 0.00024
4-Aminobutanoate 0.81 ± 0.05 0.55 ± 0.04 0.21 ± 0.01 0.19 ± 0.01 0.46 ± 0.03 0.13779 2.3E-06 6.2E-13 0.00012 6.6E-09
3-Aminoisobutanoate 3.03 ± 0.16 0.29 ± 0.02 0.09 ± 0.01 0.20 ± 0.02 0.50 ± 0.04 0.00015 0.00011 0.00328 0.00012 0.00030
2-Hydroxybutanoate 0.82 ± 0.06 1.25 ± 0.10 1.16 ± 0.10 1.29 ± 0.11 1.06 ± 0.09 1.0000 0.75550 1.0000 0.52215 1.0000
3-Hydroxybutanoate 0.19 ± 0.03 0.29 ± 0.03 0.34 ± 0.04 0.29 ± 0.03 0.18 ± 0.02 4.4E-07 3.0E-06 1.2E-05 3.7E-06 2.1E-07
4-Oxobutanoate 0.80 ± 0.11 0.51 ± 0.05 0.36 ± 0.04 0.48 ± 0.05 0.59 ± 0.07 0.11677 0.00118 1.4E-05 0.00047 0.02187
Diamines and dipeptides
Cadaverine 0.93 ± 0.15 1.17 ± 0.18 0.73 ± 0.12 1.36 ± 0.33 1.06 ± 0.18 0.6641592 0.51537 0.428487 0.2683235 0.9063486
Glycyl-glycine 0.92 ± 0.08 0.46 ± 0.07 0.06 ± 0.02 0.18 ± 0.03 0.71 ± 0.11 0.04389 0.00081 0.00170 0.00039 0.01010
Putrescine 0.99 ± 0.12 0.52 ± 0.07 0.12 ± 0.04 0.13 ± 0.02 0.53 ± 0.08 1.0000 0.01169 0.13538 2.1E-06 0.02843
Nucleosides and nucleobases
Cytosine 0.35 ± 0.05 0.30 ± 0.07 0.06 ± 0.01 0.05 ± 0.01 0.33 ± 0.07 0.00105 0.00055 0.00016 0.00045 0.00595
Thymine 1.20 ± 0.06 0.94 ± 0.10 0.16 ± 0.03 0.22 ± 0.07 0.99 ± 0.09 0.14012 0.82479 5.2E-06 8.5E-06 1.0000
Uracil 0.66 ± 0.10 0.74 ± 0.12 0.66 ± 0.07 0.31 ± 0.06 0.55 ± 0.09 0.015791 0.2616974 0.0850328 0.0191952 0.0213179
Uridine 0.28 ± 0.26 2.11 ± 2.11 1.03 ± 1.03 0.27 ± 0.25 18.3 ± 16.8 0.3349823 0.2186292 0.8681263 0.3021725 0.0213179
Others
Borate 0.67 ± 0.09 0.54 ± 0.11 2.18 ± 0.19 7.71 ± 0.90 1.75 ± 0.13 0.00497 0.00188 0.00112 0.00012 1.0E-06
Carbodiimide 0.69 ± 0.06 1.20 ± 0.06 0.85 ± 0.07 0.84 ± 0.10 0.90 ± 0.07 0.00361 0.00081 0.11588 0.11228 0.24743
Hydrogen sulfide 0.78 ± 0.06 0.82 ± 0.04 0.80 ± 0.05 0.51 ± 0.04 0.84 ± 0.05 0.01585 0.00105 0.01384 0.00012 0.01982
Phosphate 0.79 ± 0.11 0.88 ± 0.10 0.67 ± 0.09 0.69 ± 0.09 0.81 ± 0.10 0.05626 0.09832 0.13538 0.04120 0.08474
Phosphate monomethyl ester 0.88 ± 0.09 1.29 ± 0.12 1.36 ± 0.13 1.34 ± 0.11 1.11 ± 0.11 1.00000 0.01369 0.37782 0.10349 1.0000
Toluate 0.94 ± 0.12 1.41 ± 0.15 1.30 ± 0.15 1.41 ± 0.19 1.42 ± 0.15 0.74436 0.01576 0.03955 0.02152 0.01186
Dodecanoate (C
12:0
)
Tetradecanoate (C
14:0
)
Hexadecanoate (C
16:0
)
Octadecanoate (C
18:0
)
Octadecenoate (C
18:1
)
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S8: Intracellularly detected metabolites of P. inhibens DSM 17395 in the experiment “carbohydrate degradation”. (Continued)
Metabolites
Fold change in metabolite abundance as compared to succinate grown cells p-Values for abundance changes 
NAG MTL SUCR GLC XYL NAG MTL SUCR GLC XYL
Unidentified compounds
Unknown#1252.3-pin-mhe_006 1.16 ± 0.107 0.70 ± 0.053 0.36 ± 0.031 0.58 ± 0.049 0.71 ± 0.056 1.0000 0.00268 4.9E-07 0.00068 0.04914
Unknown#1361.3-pin-mhe_010 1.81 ± 0.208 0.94 ± 0.071 0.58 ± 0.043 0.51 ± 0.043 1.59 ± 0.13 0.00256 1.0000 0.00020 3.2E-05 0.00168
Unknown#1366.9-pin-mhe_011 1.31 ± 0.10 1.05 ± 0.061 0.89 ± 0.059 0.84 ± 0.065 1.56 ± 0.109 0.00711 0.18596 0.30950 0.04120 0.00040
Unknown#1651.8-pin-mhe_032 0.77 ± 0.782 2.67 ± 3.12 1.15 ± 1.183 7.47 ± 7.487 89.0 ± 89.1 0.26021 0.24252 1.00000 0.12714 0.13631
Unknown#1830.2-pin-mhe_038 0.59 ± 0.026 0.78 ± 0.035 0.34 ± 0.017 0.47 ± 0.029 0.58 ± 0.028 2.8E-08 0.00193 5.3E-13 1.0E-09 2.9E-08
Unknown#1856.7-pin-mhe_040 5.79 ± 5.789 3.49 ± 3.491 2.04 ± 2.055 9.85 ± 9.898 1.68 ± 1.68 0.14721 0.12714 0.16064 0.12714 0.15691
Unknown#1942.0-pin-mhe_022 x x x
Unknown#1946.5-pin-mhe_024 x x x XX x
Unknown#1955.0-pin-mhe_027 x x x x x
Unknown#2135.2-pin-mhe_044 x x x
Unknown#2139.6-pin-mhe_045 x x x
Unknown#2477.7-pin-mhe_061 x
Unknown#2545.5-pin-mhe_065 x
Unknown#2836.5-pin-mhe_072 x
from Wilcoxon-Mann-Whitney test with false discovery rate control
underlined, p-value from t-test with Bonferoni Holms correction, otherwise
n.det. <0.1 <0.2 <0.4 <0.67 0.67 – 1.5 >2.5>1.5 >5.0 >10.0 <0.0001<0.001<0.01<0.05n.signif.p-Value:Colour scale for fold changes:
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S9: Intracellularly detected metabolites in P. inhibens DSM 17395 during growth under ammonium limited conditions.
Symbols between sampling point represent significance of abundance changes; a legend is provided at the bottom of this table. Abbreviations: x, compound 
detected, but absent in reference condition, t30; *, compound probably dephosphorylated during extraction; 1, Ornithine was improper detected and quantified; 
slightly higher abundant at beginning of cultivation, i.e. t15 and t20.
Metabolites
Amino acids and derivatives
Alanine 3.34 ± 0.54 2.44 ± 0.44 1.10 ± 0.21 1 1.11 ± 0.23 0.92 ± 0.19 0.47 ± 0.17 0.02 ± 0.01 0.02 ± 0
Aspartate 5.78 ± 0.91 5.78 ± 0.79 0.55 ± 0.06 1 1.15 ± 0.14 1.65 ± 0.29 0.50 ± 0.15   
3.35 ± 0.53 3.00 ± 0.34 1.57 ± 0.19 1 0.97 ± 0.10 0.44 ± 0.07 0.15 ± 0.05   
Glutamate 1.89 ± 0.20 1.84 ± 0.13 0.85 ± 0.09 1 1.21 ± 0.05 0.95 ± 0.08 0.33 ± 0.08 0.01 ± 0 0.00 ± 0
Glycine 1.63 ± 0.09 1.05 ± 0.06 1.32 ± 0.11 1 1.07 ± 0.07 0.37 ± 0.06 0.09 ± 0.03 0.00 ± 0 0.00 ± 0
Homoserine 1.70 ± 0.22 1.33 ± 0.14 0.91 ± 0.07 1 0.84 ± 0.06 0.94 ± 0.14 0.95 ± 0.09 1.25 ± 0.10 1.61 ± 0.15
Isoleucine 6.79 ± 1.35 9.81 ± 2.22 1.75 ± 0.42 1 1.39 ± 0.31 0.61 ± 0.11 0.02 ± 0.01 0.02 ± 0.01 0.06 ± 0.02
Leucine 14.8 ± 4.8 19.7 ± 7.2 3.50 ± 1.74 1 2.00 ± 1.09 0.74 ± 0.25 0.26 ± 0.10 0.91 ± 0.74 0.47 ± 0.15
Methionine 6.71 ± 0.77 3.96 ± 0.41 1.85 ± 0.20 1 1.46 ± 0.16 0.63 ± 0.10 0.52 ± 0.15   
1.48 ± 0.47 1.63 ± 0.44 1.06 ± 0.21 1 1.43 ± 0.25 0.77 ± 0.18 0.38 ± 0.09   
0.40 ± 0.06 0.44 ± 0.06 0.76 ± 0.11 1 1.38 ± 0.20 2.00 ± 0.28 0.63 ± 0.17 0.14 ± 0.04  
14.3 ± 2.6 30.9 ± 3.2 1.67 ± 0.27 1 1.04 ± 0.09     
x  x  x  x  x  x    
Phenylalanine 2.62 ± 0.48 2.05 ± 0.17 1.33 ± 0.12 1 4.36 ± 0.35 0.48 ± 0.04 0.07 ± 0.02   
Proline 3.28 ± 0.63 3.34 ± 0.76 1.26 ± 0.20 1 1.00 ± 0.25 0.53 ± 0.09 0.31 ± 0.07 0.02 ± 0 0.04 ± 0.01
Pyroglutamate 2.40 ± 0.29 2.14 ± 0.26 1.41 ± 0.15 1 1.08 ± 0.12 0.61 ± 0.10 0.25 ± 0.05 0.01 ± 0 0.01 ± 0
Serine 2.44 ± 0.53 2.35 ± 0.32 1.06 ± 0.19 1 1.47 ± 0.28 1.21 ± 0.17 0.39 ± 0.07 0.24 ± 0.14  
Threonine 3.76 ± 0.26 2.92 ± 0.19 1.27 ± 0.09 1 1.28 ± 0.09 0.61 ± 0.06 0.33 ± 0.07   
Valine 7.33 ± 0.76 4.37 ± 0.67 1.46 ± 0.12 1 0.86 ± 0.05 0.32 ± 0.02 0.13 ± 0.04 0.03 ± 0 0.06 ± 0
Diamines and dipeptides
Glycyl-glycine 18.7 ± 2.3 10.8 ± 2.0 0.84 ± 0.17 1 3.17 ± 0.27 1.15 ± 0.24 0.20 ± 0.06   
Putrescine 11.4 ± 1.7 13.4 ± 1.0 1.61 ± 0.19 1 1.84 ± 0.11 0.58 ± 0.10 0.75 ± 0.18   
Sugars
1,6-Anhydro-glucose 2.25 ± 0.24 1.98 ± 0.23 2.22 ± 0.31 1 1.06 ± 0.12 0.19 ± 0.03   0.61 ± 0.13
6-Deoxy-mannose 7.38 ± 0.38 11.4 ± 1.0 1.31 ± 0.08 1 1.51 ± 0.13 0.71 ± 0.05 0.68 ± 0.10 0.47 ± 0.03 0.74 ± 0.09
Arabinonate 0.63 ± 0.04 0.75 ± 0.04 1.60 ± 0.09 1 0.78 ± 0.04 0.33 ± 0.02 0.20 ± 0.01   
Erythrose/Threose 0.60 ± 0.12 0.70 ± 0.16 0.92 ± 0.21 1 0.88 ± 0.17 0.59 ± 0.12 0.53 ± 0.08 0.53 ± 0.10 0.66 ± 0.12
Galactarate 1.05 ± 0.26 2.19 ± 0.53 1.81 ± 0.27 1 0.96 ± 0.08 0.55 ± 0.09    
Gluconate * 0.41 ± 0.09 0.47 ± 0.11 1.53 ± 0.18 1 0.48 ± 0.03 0.20 ± 0.07 0.10 ± 0.04 0.01 ± 0  
Glucoheptonate-1,4-lactone 0.89 ± 0.06 0.91 ± 0.15 1.22 ± 0.09 1 0.98 ± 0.08 0.49 ± 0.08    
Fold change in abundance as compared to reference condition (t
30
)
t15 t20 t25 t30 t40 t50 t60 t75 t90
β-Alanine
N-Acetyl-glutamate
N,N-Dimethylglycine
O-Acetyl-serine
Ornithine 1
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Metabolites
Gluconate-1,4-lactone 1.19 ± 0.40 0.64 ± 0.24 2.90 ± 0.90 1 0.50 ± 0.17 0.55 ± 0.17 1.40 ± 0.52 0.45 ± 0.17 0.24 ± 0.07
Glucuronate-3,6-lactone 1.68 ± 0.33 6.12 ± 1.56 2.03 ± 0.18 1 1.01 ± 0.08 0.08 ± 0.02 0.08    
1.74 ± 0.17 1.63 ± 0.19 2.65 ± 0.62 1 1.07 ± 0.08 0.75 ± 0.05    
Ribose/Xylose 1.02 ± 0.09 0.93 ± 0.08 1.00 ± 0.08 1 0.87 ± 0.06 0.80 ± 0.06 0.68 ± 0.05 0.54 ± 0.07 0.36 ± 0.06
Ribose/Xylose-5-phosphate 1.10 ± 0.26 0.64 ± 0.14 0.94 ± 0.17 1 0.94 ± 0.15 0.63 ± 0.29 0.45    
Entner-Doudoroff and Embden-Meyerhof-Parnas pathway
Glucose 0.99 ± 0.06 0.88 ± 0.06 1.48 ± 0.12 1 0.56 ± 0.03 0.30 ± 0.02 0.20 ± 0.02 0.06 ± 0.01 0.04 ± 0
Hexose-6-phosphate  0.11 ± 0.04 0.74 ± 0.26 1 0.54 ± 0.18     
Glucono-1,5-lactone * 0.40 ± 0.08 0.37 ± 0.04 2.06 ± 0.30 1 0.26 ± 0.03 0.19 ± 0.02 0.18 ± 0.02 0.02 ± 0  
2-Keto-3-deoxy-gluconate (KDG) * 0.93 ± 0.10 0.52 ± 0.06 2.05 ± 0.17 1 1.44 ± 0.14 0.30 ± 0.05 0.16 ± 0.03   
Dihydroxyacetone phosphate 0.85 ± 0.15  1.08 ± 0.05 1 0.69 ± 0.04 0.41 ± 0.09    
1,3-Dihydroxyacetone * 1.02 ± 0.14 0.93 ± 0.15 1.52 ± 0.21 1 0.84 ± 0.11 0.65 ± 0.10 0.54 ± 0.07   
Fructose 0.88 ± 0.14 1.40 ± 0.15 1.49 ± 0.10 1 0.64 ± 0.14 0.35 ± 0.02 0.32 ± 0.03 0.12 ± 0.01  
Fructose-1-phosphate *  0.16 ± 0.06 0.76 ± 0.27 1 0.50 ± 0.16     
Fructose-6-phosphate  0.86  0.95 ± 0.12 1 0.55 ± 0.07     
3-Phosphoglycerate 0.29 ± 0.03 0.20 ± 0.03 0.71 ± 0.13 1 0.34 ± 0.03 0.53 ± 0.14 0.19 ± 0.09   
2-Phosphoglycerate 1.19 ± 0.13 0.99 ± 0.07 1.11 ± 0.09 1 0.82 ± 0.05 0.81 ± 0.09    
Phosphoenolpyruvate 1.50 ± 0.13 1.26 ± 0.09 1.32 ± 0.12 1 0.84 ± 0.05 0.62 ± 0.07    
Pyruvate 0.81 ± 0.15 0.39 ± 0.04 0.89 ± 0.13 1 0.94 ± 0.09 0.39 ± 0.07 0.14 ± 0.02 0.12 ± 0.02 0.18 ± 0.02
TCA cycle
Citrate 0.90 ± 0.29 0.31 ± 0.10 0.93 ± 0.16 1 0.31 ± 0.05 0.43 ± 0.11 0.52 ± 0.18 0.41 ± 0.14  
2-Oxoglutarate 0.99 ± 0.13 0.68 ± 0.04 1.53 ± 0.10 1 1.35 ± 0.10 0.48 ± 0.05 0.31 ± 0.03   
Succinate 2.08 ± 0.27 2.41 ± 0.42 2.30 ± 0.39 1 1.43 ± 0.23 0.77 ± 0.14 0.29 ± 0.06 0.02 ± 0.01 0.09 ± 0.02
Fumarate 2.38 ± 0.35 2.36 ± 0.43 1.63 ± 0.22 1 1.43 ± 0.25 0.88 ± 0.14 0.30 ± 0.05 0.12 ± 0.02 0.14 ± 0.02
Malate 2.19 ± 0.28 1.28 ± 0.14 2.13 ± 0.20 1 1.75 ± 0.21 0.47 ± 0.06 0.12 ± 0.02   
Butanoates
3-Aminoisobutanoate 4.20 ± 0.53 4.73 ± 0.46 1.49 ± 0.16 1 0.83 ± 0.09 0.54 ± 0.06 0.43 ± 0.08   
4-Aminobutanoate 9.28 ± 1.82 7.23 ± 0.99 1.37 ± 0.20 1 1.23 ± 0.17     
2-Hydroxybutanoate 1.39 ± 0.12 1.17 ± 0.07 1.09 ± 0.11 1 0.95 ± 0.07 0.82 ± 0.10 0.70 ± 0.07 0.80 ± 0.10 1.03 ± 0.10
3-Hydroxybutanoate 0.16 ± 0.02 0.18 ± 0.03 0.89 ± 0.08 1 1.08 ± 0.10 3.06 ± 0.31 3.77 ± 0.41 0.12 ± 0.02 0.07 ± 0.01
4-Oxobutanoate 1.43 ± 0.20 1.29 ± 0.17 1.18 ± 0.16 1 0.99 ± 0.14 0.68 ± 0.09 0.51 ± 0.08   
Lipid and phosphoplipid headgroup components
Diethanolamine 5.50 ± 1.40 6.77 ± 1.14 1.70 ± 0.29 1 1.12 ± 0.16 0.99 ± 0.16 0.61 ± 0.15   
Fold change in abundance as compared to reference condition (t
30
)
t15 t20 t25 t30 t40 t50 t60 t75 t90
N-Acetyl-glucosamine
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Metabolites
Ethanolamine 1.31 ± 0.15 0.76 ± 0.09 0.81 ± 0.22 1 0.74 ± 0.09 0.70 ± 0.11 0.39 ± 0.08 0.05 ± 0.01 0.07 ± 0.02
Glycerol-3-phosphate 0.65 ± 0.08 0.21 ± 0.02 0.81 ± 0.07 1 0.69 ± 0.06 0.38 ± 0.04 0.11 ± 0.02   
Glycerophosphoglycerol 0.35 ± 0.16 0.16 ± 0.04 0.39 ± 0.09 1 1.30 ± 0.28 0.82 ± 0.43    
1.04 ± 0.34 0.53 ± 0.19 0.69 ± 0.24 1 0.58 ± 0.20 0.71 ± 0.23 0.74 ± 0.25 0.70 ± 0.24 0.83 ± 0.30
1.22 ± 0.15 0.86 ± 0.12 0.93 ± 0.14 1 0.82 ± 0.11 0.84 ± 0.15 0.65 ± 0.12 0.46 ± 0.07 0.56 ± 0.09
1.33 ± 0.17 1.08 ± 0.16 1.01 ± 0.14 1 1.10 ± 0.28 0.97 ± 0.13 1.00 ± 0.14 1.07 ± 0.14 1.45 ± 0.18
1.34 ± 0.12 1.39 ± 0.12 1.29 ± 0.16 1 1.07 ± 0.20 0.71 ± 0.10 0.71 ± 0.08 0.63 ± 0.08 1.02 ± 0.07
1.30 ± 0.27 1.62 ± 0.33 1.48 ± 0.37 1 1.04 ± 0.22 0.54 ± 0.21 0.66 ± 0.24 0.74 ± 0.14 1.31 ± 0.26
0.87 ± 0.20 1.00 ± 0.20 1.30 ± 0.31 1 1.03 ± 0.16 0.50 ± 0.28 0.39 ± 0.16 0.53 ± 0.11 1.13 ± 0.30
1.27 ± 0.21 0.95 ± 0.20 1.00 ± 0.20 1 0.72 ± 0.12 0.75 ± 0.16 0.71 ± 0.18   
Nucleosides and nucleobases
Cytosine 17.2 ± 5.8 12.8 ± 6.0 0.92 ± 0.18 1 1.29 ± 0.25 13.3 ± 5.9    
Thymine 3.57 ± 0.90 4.45 ± 1.15 1.33 ± 0.33 1 1.17 ± 0.33 0.73 ± 0.23 0.24 ± 0.06   
Uracil 3.67 ± 1.22 3.23 ± 1.15 1.09 ± 0.38 1 1.02 ± 0.39 0.55 ± 0.25 0.28 ± 0.11 0.37   
Organic acids
5-Aminopentanoate 1.61 ± 0.20 1.54 ± 0.20 0.76 ± 0.09 1 3.38 ± 0.42 1.31 ± 0.21 0.98 ± 0.35   
Benzoate 1.24 ± 0.25 1.03 ± 0.21 1.22 ± 0.26 1 0.85 ± 0.16 0.97 ± 0.17 0.61 ± 0.11 0.75 ± 0.12 0.94 ± 0.14
Erythronate 1.02 ± 0.10 1.35 ± 0.15 1.40 ± 0.12 1 0.62 ± 0.05 0.38 ± 0.04 0.13 ± 0.01   
Glycerate 0.66 ± 0.10 0.61 ± 0.10 0.70 ± 0.11 1 0.52 ± 0.07 2.01 ± 0.38 2.51 ± 0.54 0.34 ± 0.04 0.48 ± 0.07
2-Hydroxyglutarate 0.66 ± 0.08 0.45 ± 0.04 1.50 ± 0.17 1 1.41 ± 0.14 0.38 ± 0.05 0.33 ± 0.08   
Iminodiacetate 4.30 ± 0.73 2.03 ± 1.12 2.67 ± 0.30 1 0.40 ± 0.04 0.21 ± 0.03 0.06    
Lactate 0.89 ± 0.22 0.63 ± 0.15 1.00 ± 0.31 1 1.15 ± 0.35 0.41 ± 0.13 0.50 ± 0.21 0.33 ± 0.10 0.47 ± 0.10
Malonate 1.07 ± 0.18 1.32 ± 0.20 1.24 ± 0.20 1 1.12 ± 0.19 0.73 ± 0.11 0.60 ± 0.09 0.76 ± 0.10 0.96 ± 0.13
2-Methyl-malate 0.89 ± 0.11 0.88 ± 0.12 0.75 ± 0.09 1 0.81 ± 0.10 0.57 ± 0.07 0.30 ± 0.03 0.21 ± 0.03  
2-Methyl-serine 1.09 ± 0.11 1.02 ± 0.11 1.20 ± 0.13 1 0.97 ± 0.14 1.19 ± 0.15 1.19 ± 0.21   
Nicotinamide 2.52 ± 0.86 2.59 ± 0.90 0.77 ± 0.10 1 0.63 ± 0.09 2.18 ± 0.70 1.36 ± 0.42   
Nicotinate 1.39 ± 0.13 1.39 ± 0.18 1.13 ± 0.15 1 5.60 ± 0.81 2.84 ± 0.33 0.77 ± 0.11   
Succinate-methylester 2.07 ± 0.23 2.19 ± 0.34 1.27 ± 0.19 1 1.04 ± 0.17 1.07 ± 0.13 1.03 ± 0.13 1.31 ± 0.13 1.69 ± 0.17
Tartrate 4.05 ± 0.49 13.7 ± 1.3 4.61 ± 0.53 1 1.27 ± 0.10 0.17 ± 0.02 0.05 ± 0   
Threonate 2.76 ± 0.42 5.08 ± 0.55 1.82 ± 0.16 1 0.97 ± 0.08 0.30 ± 0.02    
Others
Borate 0.73 ± 0.22 3.68 ± 0.56 1.30 ± 0.23 1 2.60 ± 0.41 0.66 ± 0.34 0.05 ± 0.03 0.16 ± 0.04 0.38 ± 0.09
Diphosphate 1.40 ± 0.64 1.27 ± 0.54 1.49 ± 0.51 1 1.25 ± 0.52 0.44 ± 0.18 0.19 ± 0.06 0.22 ± 0.06 0.34 ± 0.10
Phosphate 1.22 ± 0.26 0.91 ± 0.17 1.09 ± 0.29 1 0.93 ± 0.17 0.69 ± 0.21 0.41 ± 0.09 0.16 ± 0.04 0.24 ± 0.05
Fold change in abundance as compared to reference condition (t
30
)
t15 t20 t25 t30 t40 t50 t60 t75 t90
Octanoate (C
8:0
)
3-Hydroxydecanoate (C
10:0, 3-OH
)
Dodecanoate (C
12:0
)
Tetradecanoate (C
14:0
)
Hexadecanoate (C
16:0
)
Octadecanoate (C
18:0
)
Octadecenoate (C
18:1
)
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Metabolites
Phosphate monomethyl ester 1.35 ± 0.25 1.14 ± 0.24 1.02 ± 0.19 1 0.81 ± 0.14 0.78 ± 0.14 0.85 ± 0.19   
Propane-1,2-diol 1.95 ± 0.39 1.74 ± 0.24 1.11 ± 0.18 1 1.08 ± 0.20 0.98 ± 0.17 0.86 ± 0.14 1.00 ± 0.14 1.78 ± 0.28
Toluate 1.62 ± 0.13 1.63 ± 0.17 1.20 ± 0.12 1 0.93 ± 0.09 0.83 ± 0.08 0.48 ± 0.06 0.35 ± 0.06 0.57 ± 0.06
Unidentified compounds
Unknown#1004.0-pin-mhe_001 2.26 ± 0.33 1.40 ± 0.10 0.86 ± 0.10 1 1.09 ± 0.11 1.18 ± 0.14 0.61 ± 0.15 0.11 ± 0.01 0.15 ± 0.02
Unknown#1018.14-ppu-cja_002 1.48 ± 0.13 1.49 ± 0.09 1.08 ± 0.09 1 0.94 ± 0.07 0.91 ± 0.08 0.77 ± 0.05 0.70 ± 0.09 1.25 ± 0.12
Unknown#1093.67-ypy-mse_001 1.53 ± 0.18 1.70 ± 0.24 0.95 ± 0.17 1 1.32 ± 0.29 0.71 ± 0.24 0.29 ± 0.08 0.17 ± 0.03 0.33 ± 0.04
Unknown#1226.1-pin-mhe_004 1.02 ± 0.22 1.36 ± 0.29 1.04 ± 0.24 1 0.81 ± 0.18 1.02 ± 0.20 0.69 ± 0.13 0.24 ± 0.05 0.17 ± 0.03
Unknown#1361.3-pin-mhe_010 0.81 ± 0.08 0.86 ± 0.08 0.69 ± 0.07 1 0.94 ± 0.10 0.57 ± 0.05 0.24 ± 0.03 0.08 ± 0.01 0.09 ± 0.01
Unknown#1366.9-pin-mhe_011 1.42 ± 0.23 1.32 ± 0.22 1.00 ± 0.15 1 1.05 ± 0.19 0.89 ± 0.12 0.70 ± 0.11 0.73 ± 0.10 0.88 ± 0.12
Unknown#1392.1-pin-mhe_012 0.81 ± 0.37 1.73 ± 1.19 1.45 ± 0.70 1 4.72 ± 2.53 4.83 ± 2.18 11.4 ± 6.1 11.9 ± 5.8 18.0 ± 8.7
Unknown#1394.5-dsh-skl_001 1.39 ± 0.12 1.30 ± 0.09 1.16 ± 0.10 1 0.98 ± 0.08 0.89 ± 0.08 0.96 ± 0.07 1.03 ± 0.19 1.39 ± 0.12
Unknown#1586.9-pae-bth_039 2.04 ± 0.48 2.15 ± 0.45 1.23 ± 0.25 1 2.84 ± 0.55 1.45 ± 0.26 0.51 ± 0.13 0.58 ± 0.11 1.86 ± 0.37
Unknown#1594.3-pin-mhe_030 1.66 ± 0.17 1.10 ± 0.09 0.99 ± 0.08 1 1.42 ± 0.11 8.57 ± 0.69 12.9 ± 1.3 1.54 ± 0.24 1.68 ± 0.15
Unknown#1635.2-pin-mhe_031 1.34 ± 0.27 0.66 ± 0.17 1.41 ± 0.61 1 0.79 ± 0.19 0.74 ± 0.16 0.66 ± 0.16 0.59 ± 0.12 0.69 ± 0.18
Unknown#1651.8-pin-mhe_032 0.74 ± 0.08 3.84 ± 0.41 1.32 ± 0.13 1 1.78 ± 0.15 0.45 ± 0.03 0.27 ± 0.03   
Unknown#1811.9-pin-mhe_037 1.00 ± 0.67 0.86 ± 0.46 0.76 ± 0.36 1 1.59 ± 0.82 1.50 ± 0.75 2.90 ± 1.83 1.50 ± 0.77 2.36 ± 1.14
Unknown#1830.2-pin-mhe_038 1.62 ± 0.11 1.52 ± 0.09 1.26 ± 0.06 1 0.73 ± 0.03 0.56 ± 0.03 0.32 ± 0.02 0.25 ± 0.02 0.29 ± 0.06
Unknown#1836.1-pin-mhe_039 1.01 ± 0.31 2.79 ± 1.51 1.68 ± 0.71 1 6.23 ± 2.47 5.96 ± 2.10 12.0 ± 6.7 2.24 ± 1.43 6.12 ± 3.02
Unknown#1856.7-pin-mhe_040 0.91 ± 0.09 1.98 ± 0.15 1.52 ± 0.15 1 0.96 ± 0.06 0.37 ± 0.04 0.37 ± 0.03   
Unknown#1937.2-pin-mhe_021 1.74 ± 0.34 6.35 ± 1.77 1.99 ± 0.15 1 1.09 ± 0.08 0.19 ± 0.03    
Unknown#1944.9-pin-mhe_023 0.41 ± 0.08 0.64 ± 0.12 2.34 ± 0.54 1 0.31 ± 0.04 0.26 ± 0.04 0.18 ± 0.04   
Unknown#1954.3-pin-mhe_026 0.37 ± 0.08 0.42 ± 0.09 2.17 ± 0.42 1 0.27 ± 0.03 0.18 ± 0.03 0.14 ± 0.03   
Unknown#2018.7-pin-mhe_028 2.17 ± 1.38 2.62 ± 1.16 1.88 ± 0.83 1 1.05 ± 0.45 0.47 ± 0.29    
Unknown#2090.48-ypy-mse_021 1.09 ± 0.25 1.82 ± 0.31 1.22 ± 0.25 1 1.60 ± 0.27 0.98 ± 0.36 0.57    
Unknown#2139.6-pin-mhe_045 1.20 ± 0.35 1.14 ± 0.35 1.13 ± 0.34 1 1.17 ± 0.30 1.55 ± 0.41 2.48 ± 0.62 3.05 ± 0.78 4.23 ± 1.07
1.27 ± 0.64 1.00 ± 0.24 1.48 ± 0.26 1 1.22 ± 0.19 0.50 ± 0.10    
Colour scale for fold changes:
<0.0001 <0.001 <0.01 <0.05
Fold change in abundance as compared to reference condition (t
30
)
t15 t20 t25 t30 t40 t50 t60 t75 t90
Unknown#2269.25-ypy-mse_027
Significance of abundance changes between sampling points; 
corrected p-Values from t-test (    ) or Wilcoxon-Mann-Whitney test (     )
< 0.1 < 0.2 < 0.4 < 0.67 0.67 – 1.5 > 1.5 > 2.5 > 5.0 > 10.0
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S10: Selected enzymes and proteins of P. inhibens DSM 17395. 
If not indicated otherwise, E-values were obtained from EnzymeDetector, based on Swiss-Prot 
sequences. Abbreviations: Acc.-No., protein accession number; M, presumably multifunctional 
enzyme; S, Swiss-Prot sequence used for protein blast; T, TrEMBL sequence used for protein blast.
Locus Tag Enzyme/protein function E-value
Glycerol-phospho-lipids degradation
PGA1_c02710 ugpB
PGA1_c02730 ugpE
PGA1_c02740 ugpC2 3.6.3.20 glycerol-3- phosphate- transporting ATPase 6.00E-171
PGA1_c05210 ugpC1 3.6.3.20 glycerol-3- phosphate- transporting ATPase 9.00E-071
PGA1_c05220 ugpC putative sn-glycerol-3-phosphate import ATP-binding protein
PGA1_c08240 glpD 1.1.5.3 glycerol-3-phosphate dehydrogenase 7.00E-143
Fatty acids degradation / Beta oxidation
PGA1_c12020 fadJ 1.1.1.35 3-hydroxyacyl-CoA dehydrogenase 3.00E-123 M
PGA1_c12020 fadJ 4.2.1.17 enoyl-CoA hydratase 3.00E-123 M
PGA1_c12020 fadJ 5.1.2.3 3-hydroxybutyryl-CoA epimerase 3.00E-123 M
PGA1_c12030 fadA1 2.3.1.16 acetyl-CoA C-acyltransferase 1.00E-080 M
PGA1_c12030 fadA1 2.3.1.9 acetyl-CoA C-acetyltransferase 3.00E-076 M
PGA1_c16990 fadB1 4.2.1.17 putative enoyl-CoA hydratase 6.00E-097
PGA1_c17340 acdA1 1.3.8.1 short-chain acyl-CoA dehydrogenase 4.00E-080 M
PGA1_c17340 acdA1 1.3.99.12 2-methyacyl-CoA dehydrogenase M
PGA1_c22180 fadD1 6.2.1.30 long-chain-fatty- acid-CoA ligase 2.00E-069
PGA1_c29100 fadH 1.3.1.34 2,4-dienoyl-CoA reductase (NADPH) 0
Fatty acids biosynthesis
PGA1_c04640 fabI 1.3.1.9 enoyl-[acyl-carrier-protein] reductase 5.00E-105
PGA1_c04650 fabB 2.3.1.41 3-oxoacyl-[acyl-carrier-protein] synthase 0
PGA1_c04660 fabA 5.3.3.14 trans-2-decenoyl- [acyl- carrier protein] isomerase 9.00E-075 M
PGA1_c04660 fabA 4.2.1.59 3-hydroxyacyl-[acyl- carrier- protein] dehydratase 9.00E-075 M
PGA1_c11240 fabH 2.3.1.41 3-oxoacyl-[acyl-carrier-protein] synthase 0
PGA1_c12600 accC 6.3.4.14 biotin carboxylase 0
PGA1_c12600 accC 6.4.1.2 biotin carboxylase (Acetyl-CoA carboxylase subunit A)
PGA1_c12610 accB biotin carboxyl carrier protein of acetyl-CoA carboxylase
PGA1_c16810 fabI 1.3.1.9 enoyl-[acyl-carrier- protein] reductase (NADH) 1.00E-146
PGA1_c17930 fabG 1.1.1.100 3-oxoacyl-[acyl- carrier- protein] reductase 4.00E-094
PGA1_c17940 fabD 2.3.1.39 7.00E-102
PGA1_c30540 accA 6.4.1.2 acetyl-coenzyme A carboxylase carboxyl transferase subunit α 0
PGA1_c31690 accD 6.4.1.2 acetyl-coenzyme A carboxylase carboxyl transferase subunit β 0
Quorum sensing
PGA1_262p02120 2.7.13.3 histidine kinase 0
PGA1_262p02260 2.7.13.3 histidine kinase 1.00E-096
PGA1_c03880 luxR / pgaR transcriptional activator protein (LuxR)
PGA1_c03890 luxI / pgaI 3.00E-010 S
Nucleotide metabolism
PGA1_c06670 carA 6.3.5.5 carbamoyl-phosphate synthase (glutamine-hydrolysing) 0
PGA1_c12940 adk2 2.7.4.3 adenylate kinase 8.00E-091
PGA1_c23900 pyrG 6.3.4.2 CTP synthase 0
PGA1_c24560 carB 6.3.5.5 carbamoyl-phosphate synthase (large chain) 0
Polyhydroxybutanoate (PHB) – metabolism
PGA1_c03390 phaB 1.1.1.36 acetoacetyl-CoA reductase 1.00E-124
PGA1_c03400 phaA 2.3.1.9 acetyl-CoA acetyltransferase 0
PGA1_c20910 phaR PHA synthesis repressor protein
PGA1_c20920 phaP granule associated protein (phasin)
PGA1_c20930 phaC 2.3.1.- poly(3-hydroxyalkanoate) polymerase
PGA1_c20940 phaZ 3.1.1.75 poly(3-hydroxybutanoate) depolymerase
Amino acid biosynthesis
Aspartate / asparagine
PGA1_c20300 2.6.1.1 aspartate transaminase / aspartate aminotransferase 1.00E-071
PGA1_c21250 2.6.1.1 aspartate transaminase / aspartate aminotransferase 0
Gene 
name
E C 
number
sn -glycerol-3-phosphate-binding periplasmic protein [precursor]
sn -glycerol-3-phosphate transport system permease
[acyl-carrier- protein] S-malonyltransferase
acyl-homoserine lactone synthase (LuxI) 
(BlastP: Vibrio fischeri (strain ATCC 700601). Acc.-No.: P35328)
 Supplementary material xxix
S10: Selected enzymes and proteins of P. inhibens DSM 17395. (Continued)
Locus Tag Enzyme/protein function E-value
Cysteine / glycine / serine
PGA1_c11870 glyA 2.1.2.1 glycine hydroxymethyl transferase 0 M
PGA1_c13950 cysK 2.5.1.47 cysteine synthase 1.00E-106
PGA1_c17600 2.3.1.30 6.00E-040
PGA1_c17690 cysE 2.3.1.30 3.00E-095
PGA1_c36150 serC 2.6.1.52 phosphoserine aminotransferase 8.00E-163
PGA1_c36160 serB 3.1.3.3 phosphoserine phosphatase 1.00E-050
Histidine
PGA1_c09230 3.6.1.31 phosphoribosyl-ATP diphosphatase 2.00E-054
PGA1_c09330 hisB 4.2.1.19 imidazoleglycerol- phosphate dehydratase 1.00E-131
PGA1_c14400 cfa 3.5.4.19 phosphoribosyl-AMP cyclohydrolase 9.00E-072
PGA1_c17230 tktA 2.2.1.1 transketolase 0
PGA1_c17910 5.3.1.16 2.00E-130
PGA1_c25240 hisC 2.6.1.9 histidinol-phosphate transaminase 0
PGA1_c29870 2.4.2.17 ATP phosphoribosyl transferase 4.00E-107
PGA1_c31190 hisD4 1.1.1.23 histidinol dehydrogenase 0
Leucine
PGA1_c26470 leuA 2.3.3.13 2-isopropylmalate synthase 0
Tryptophan
PGA1_c04860 trpF 5.3.1.24 phosphoribosyl anthranilate isomerase 6.00E-099
PGA1_c04870 trpB 4.2.1.20 tryptophan synthase 0
PGA1_c16860 trpE 4.1.3.27 anthranilate synthase 0
PGA1_c16890 trpD 2.4.2.18 anthranilate phosphoribosyl transferase 0
PGA1_c16910 trpC 4.1.1.48 indole-3-glycerol- phosphate synthase 9.00E-126
Amino acid degradation
Alanine / glycine / serine / threonine
PGA1_78p00260 lpdA2 1.8.1.4 dihydrolipoyl dehydrogenase 1.00E-161
PGA1_78p00280 putative sodium/alanine symporter 
PGA1_78p00290 gcvT 2.1.2.10 aminomethyl transferase 1.00E-105
PGA1_78p00300 gcvH2 glycine cleavage system protein 
PGA1_78p00310 gcvP 1.4.4.2 glycine dehydrogenase (aminomethyl- transferring) 0
PGA1_c04590 4.3.1.19 threonine ammonia-lyase 2.00E-046
PGA1_c05560 gcvH1 glycine cleavage system protein 
PGA1_c07110 putative sodium/alanine symporter
PGA1_c11870 glyA 2.1.2.1 glycine hydroxymethyl transferase 0 M
PGA1_c11870 4.1.2.48 0 M
PGA1_c23770 tdcG 4.3.1.17 6.00E-153
PGA1_c25010 4.1.2.5 3.00E-008 S
PGA1_c30420 1.4.1.1 alanine dehydrogenase 1.00E-139
PGA1_c34320 tdh 1.1.1.103 threonine-3-dehydrogenase 0
PGA1_c34330 kbl 2.3.1.29 2.00E-179
PGA1_c34900 ilva 4.3.1.19 threonine ammonia-lyase / threonine dehydratase 3.00E-112
Arginine / ornithine / proline / glutamate
PGA1_c03800 4.1.1.17 ornithine decarboxylase 8.00E-048
PGA1_c11650 ldc 4.1.1.17 lysine/ornithine decarboxylase 6.00E-039
PGA1_c11750 pitA 1.5.5.2 proline dehydrogenase 0 M
PGA1_c11750 pitA 1.2.1.88 0 M
PGA1_c14470 speE 2.5.1.16 spermidine synthase 1.00E-173
PGA1_c16370 arcA 3.5.3.1 arginase 6.00E-124
PGA1_c16390 arcB 4.3.1.12 ornithine cyclodeaminase 0
Branched-chain amino acids (leucine, isoleucine, valine)
PGA1_c06200 scoB 2.8.3.5 succinyl-CoA:3-oxoacid-CoA transferase, subunit B 6.00E-098
PGA1_c06210 scoA 2.8.3.5 succinyl-CoA:3-oxoacid-CoA transferase, subunit A 1.00E-102
PGA1_c10280 ivd 1.3.8.4 isopentanoyl-CoA dehydrogenase 3.00E-165
PGA1_c10340 mvaB 4.1.3.4 hydroxymethylglutaryl-CoA lyase 3.00E-100
PGA1_c10360 mgh 4.2.1.18 methylglutaconyl-CoA hydratase 2.00E-018
PGA1_c11320 1.1.1.178 3-hydroxy-2- methylbutyryl-CoA dehydrogenase 3.00E-090 M
Gene 
name
E C 
number
serine O-acetyltransferase
serine O-acetyltransferase
1-(5-phospho ribosyl)- 5-[(5- phosphoribosylamino)  carboxamide 
isomerase]
low-specificity L-threonine aldolase
L-serine ammonia-lyase
L-threonine aldolase 
(BlastP: Candida albicans. Acc.-No.: O13427)
glycine C-acetyltransferase / 2-amino-3-oxobutanoate_CoA ligase
L-glutamate γ-semialdehyde dehydrogenase
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Locus Tag Enzyme/protein function E-value
PGA1_c12020 fadJ 1.1.1.35 fatty acid oxidation complex, α subunit 3.00E-123 M
PGA1_c12020 fadJ 4.2.1.17 fatty acid oxidation complex, α subunit 3.00E-123 M
PGA1_c17080 1.2.7.8 indolepyruvate ferredoxin oxidoreductase 1.00E-018
PGA1_c17300 mmsA 1.2.1.18 malonate-semialdehyde dehydrogenase (acetylating) 3.00E-144
PGA1_c17300 mmsA 1.2.1.27 methylmalonate-semialdehyde dehydrogenase 3.00E-151
PGA1_c17340 acdA1 1.3.99.12 2-methyacyl-CoA dehydrogenase
PGA1_c17350 hibch 3.1.2.4 3-Hydroxyisobutanoyl-CoA hydrolase 2.00E-064
PGA1_c17360 mmsB 1.1.1.31 3-Hydroxyisobutanoate dehydrogenase 7.00E-079
PGA1_c20500 ldh 1.4.1.9 leucine dehydrogenase 5.00E-103
PGA1_c21510 bhbA 5.4.99.2 methylmalonyl-CoA mutase 0
PGA1_c21540 pccA 6.4.1.3 propanonyl-CoA carboxylase, α subunit 0
PGA1_c21600 pccB 6.4.1.3 propanonyl-CoA carboxylase, β subunit 0
PGA1_c24490 mce 5.1.99.1 methylmalonyl-CoA epimerase 2.00E-052
PGA1_c33180 2.3.1.9 acetyl-CoA acetyltransferase 3.00E-118 M
PGA1_c33180 2.3.1.16 acetyl-CoA C-acyltransferase 1.00E-083 M
PGA1_c34110 ilvE 2.6.1.42 branched-chain- amino-acid transaminase 6.00E-075
PGA1_c34350 phbA 2.3.1.9 acetyl-CoA acetyltransferase 8.00E-160 M
PGA1_c34350 2.3.1.16 acetyl-CoA C-acyltransferase 8.00E-160 M
Various 1.2.1.3 aldehyde dehydrogenase (NAD+)
Various 1.2.1.4 aldehyde dehydrogenase (NADP+)
Histidine
PGA1_c08740 gluD 1.4.1.3 glutamate dehydrogenase 6.00E-147
PGA1_c36320 hutU 4.2.1.49 urocanate hydratase 0
PGA1_c36330 hutG 3.5.1.68 4.00E-109 T
PGA1_c36340 hutH 4.3.1.3 histidine ammonia-lyase 0
PGA1_c36350 hutI 3.5.2.7 imid azolonepropionase 0
PGA1_c36360 hutF 3.5.3.13 9.00E-128 T
? 1.14.13.- oxygenase/hydroxylase
Lysine
PGA1_c03390 phaB 1.1.1.36 acetoacetyl-CoA reductase 1.00E-124
PGA1_c03400 phaA 2.3.1.9 acetyl-CoA acetyltransferase 0
PGA1_c09350 2.6.1.- aminotransferase class-III
PGA1_c11650 ldc 4.1.1.17 lysine/ornithine decarboxylase 6.00E-039
PGA1_c12020 fadJ 1.1.1.35 3.00E-123 M
PGA1_c12020 fadJ 4.2.1.17 3.00E-123 M
PGA1_c15710 gcdH 1.3.8.6 glutaryl-CoA dehydrogenase 0
PGA1_c27870 2.8.3.16 formyl-CoA transferase 2.00E-045
PGA1_c27870 6.2.1.6 6.00E-023 T
PGA1_c33040 1.2.1.- aldehyde dehydrogenase 4.00E-144
PGA1_c33640 1.2.4.4 9.00E-041
PGA1_c34400 2.6.1.- aminotransferase class-III 3.00E-116
PGA1_c36500 fadJ / paaG 4.2.1.17 enoyl-CoA hydtratase/reductase 4.00E-108
PGA1_c36500 4.2.1.55 enoyl-CoA hydratase/isomerase
Methionine
PGA1_c16600 mdeA 4.4.1.11 0
PGA1_c21510 bhbA 5.4.99.2 methylmalonyl-CoA mutase 0
PGA1_c21540 pccA 6.4.1.3 0
PGA1_c21600 pccB 6.4.1.3 0
PGA1_c24490 mce 5.1.99.1 methylmalonyl-CoA epimerase 2.00E-052
PGA1_c27800 1.4.3.16 4.00E-161
Phenylalanine
PGA1_262p00800 paaZ2 Oxepin-CoA hydrolase 5.00E-110 M
PGA1_262p00800 paaZ2 1.17.1.7 3-oxo-5,6- dehydrosuberyl-CoA semialdehyde dehydrogenase 5.00E-110 M
PGA1_c01220 1.1.1.157 3-hydroxybutanoyl-CoA dehydrogenase 2.00E-146 M
PGA1_c01220 ? 1.1.1.35 3-hydroxyacyl-CoA dehydrogenase 3-hydroxyadipyl-CoA dehydrogenase M
PGA1_c04040 paaE 1.14.13.149 9.00E-091 S
Gene 
name
E C 
number
N-Formylglutamate deformylase 
(BlastP: Roseobacter denitrificans Och 114. Acc.-No.: Q162E1)
formimino-glutamate deiminase 
(BlastP: Pseudomonas fluorescens BRIP34879. Acc.-No.: L7H3A0)
Fatty acid oxidation complex, α subunit
Fatty acid oxidation complex, α subunit
putative glutarate-CoA ligase (BlastP: Renibacterium salmoninarum 
ATCC 33209. Acc.-No.: YP_001623353)
3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl- 
transferring)
methionine γ-lyase 
(BlastP: Pseudomonas putida .Acc.-No.: P13254)
propanonyl-CoA carboxylase, α subunit
propanonyl-CoA carboxylase, β subunit
L-aspartate oxidase
ring 1,2- phenylacetyl-CoA epoxidase, subunit E 
(BlastP: Escherichia coli K12 – substrain MG1655. Acc.-No.: P76081)
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PGA1_c04050 paaD 1.14.13.149 1.00E-050
PGA1_c04060 paaC 1.14.13.149 ring 1,2- phenylacetyl-CoA epoxidase, subunit C
PGA1_c04070 paaB 1.14.13.149 1.00E-039 S
PGA1_c04080 paaA 1.14.13.149 ring 1,2- phenylacetyl-CoA epoxidase, subunit A 3.00E-159
PGA1_c04090 paaJ 2.3.1.223 3-oxo-5,6- didehydrosuberyl-CoA thiolase 0
PGA1_c04090 paaJ 2.3.1.174 3-oxoadipyl-CoA thiolase 0
PGA1_c04490 iorAB 1.2.7.8 indolepyruvate ferredoxin oxidoreductase 4.00E-017
PGA1_c07610 hpd 1.13.11.27 4-hydroxyphenyl pyruvate dioxygenase 2.00E-117
PGA1_c26800 paaK1 6.2.1.30 phenylacetate CoA ligase 0
PGA1_c26810 paaI 3.1.2.- thioesterase (3.1.2.-)
PGA1_c26820 paaG 5.3.3.18 2.00E-078 S
PGA1_c26830 paaZ1 3.3.2.12 oxepin-CoA hydrolase 0 M
PGA1_c26830 paaZ1 1.17.1.7 3-oxo-5,6- dehydrosuberyl-CoA semialdehyde dehydrogenase 0 M
PGA1_c29420 tyrB 2.6.1.57 aromatic amino acid aminotransferase 0 M
PGA1_c31390 4.1.1.28 2.00E-104 M
PGA1_c31390 4.1.1.25 tyrosine decarboxylase 3.00E-109 M
PGA1_c36500 fadJ / paaG 4.2.1.17 enoyl-CoA hydtratase/reductase 4.00E-108 M
PGA1_c36500 4.2.1.55 enoyl-CoA hydratase/isomerase M
Tryptophan
PGA1_c09970 kynA 1.13.11.11 tryptophan 2,3-dioxygenase 7.00E-132
PGA1_c09980 kynU 3.7.1.3 kynureninase 4.00E-134
PGA1_c23440 6.2.1.32 0 T
PGA1_c23450 acdA2 1.3.8.1 short-chain acyl-CoA dehydrogenase 5.00E-063
PGA1_c23460 putative enoyl-CoA hydratase
PGA1_c23480 3-hydroxyacyl-CoA dehydrogenase
PGA1_c23490 1.14.13.40 0 T
PGA1_c29640 3.5.1.9 2.00E-078 T
Tyrosine
PGA1_c00380 5.2.1.2 maleylacetoacetate isomerase 8.00E-071
PGA1_c00430 fah 3.7.1.2 fumarylacetoacetase 1.00E-133
PGA1_c00440 hmgA 1.13.11.5 homogentisate 1,2-dioxygenase 0
PGA1_c07610 hpd 1.13.11.27 4-hydroxyphenylpyruvate dioxygenase 2.00E-117
PGA1_c07610 hpd 1.13.11.27 4-hydroxyphenyl pyruvate dioxygenase 2.00E-117
PGA1_c29420 tyrB 2.6.1.57 aromatic-amino-acid aminotransferase 0 M
PGA1_c29420 tyrB 2.6.1.5 tyrosine transaminase 9.00E-115 M
Glutamate metabolism / ammonium assimilation
PGA1_c08740 gluD 1.4.1.3 glutamate dehydrogenase 6.00E-147
PGA1_c18720 glnA 6.3.1.2 glutamine synthetase  / glutamate-ammonia ligase 0
PGA1_c36090 gltD 1.4.1.13 glutamate synthase (NADPH) small chain 0
PGA1_c36100 gtlB 1.4.1.13 glutamate synthase (NADPH) large chain M
PGA1_c36100 gtlB 2.6.1.16 glutamine-fructose-6-phosphate transaminase (isomerizing) M
Urea cycle
PGA1_c03450 argH 4.3.2.1 argininosuccinate lyase 0
PGA1_c03450 2.3.1.1 2.00E-128
PGA1_c06670 carA 6.3.5.5 carbamoyl-phosphate synthase (glutamine- hydrolysing) 0
PGA1_c16370 arcA 3.5.3.1 arginase 6.00E-124
PGA1_c24220 argF 2.1.3.3 ornithine carbamoyltransferase 0
PGA1_c24560 carB 6.3.5.5 carbamoyl-phosphate synthase large chain 0
PGA1_c34920 argG 6.3.4.5 argininosuccinate synthase 0
Carbohydrate degradation
Transport
PGA1_78p00530 putative Outer membrane protein
PGA1_262p00430 xylF xylose ABC transporter , periplasmic sugar-binding protein
PGA1_262p00440 xylH xylose ABC transporter , permease
Gene 
name
E C 
number
ring 1,2- phenylacetyl-CoA epoxidase, subunit D 
(BlastP: Escherichia coli SE11. Acc.-No.: YP_00229751)
ring 1,2- phenylacetyl-CoA epoxidase, subunit B 
(BlastP: Escherichia coli K12 –substrain MG1655. Acc.-No.: NP415907)
ring 1,2-epoxyphenylacetyl-CoA isomerase (oxepin-CoA forming) 
(BlastP: Escherichia coli K-12 – substrain MG1655. Acc.-No.: P77467)
aromatic-L- amino-acid decarboxylase
2-aminobenzoate-CoA ligase 
(BlastP: Azoarcus evansii. Acc.-No.: AAL02077)
2-aminobenzoyl-CoA monooxygenase/reductase 
(BlastP: Azoarcus evansii. Acc.-No.: AAL02063)
Arylformamidase 
(BlastP: Rhodobacter capsulatus SB 1003. Acc.-No.: YP_003576584)
amino-acid N-acetyltransferase
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PGA1_262p00450 xylG
PGA1_c07860 aglE alpha-glucoside ABC transporter, periplasmic sugar-binding protein
PGA1_c07870 aglF alpha-glucoside ABC transporter, permease
PGA1_c07880 aglG alpha-glucoside ABC transporter, permease
PGA1_c07900 aglK alpha-glucoside ABC transporter, permease
PGA1_c10290 outer membrane protein 
PGA1_c13180 smoK mannitol ABC transporter, ATP-binding protein
PGA1_c13190 mannitol ABC transporter, permease
PGA1_c13200 mannitol ABC transporter, permease
PGA1_c13210 mannitol ABC transporter, periplasmic sugar-binding protein
PGA1_c25180 outer membrane protein-like protein 
PGA1_c27930
PGA1_c27940
PGA1_c27950
PGA1_c27970
Peripheral carbohydrate degradation
PGA1_c05420 glk 2.7.1.2 glucokinase 9.00E-019
PGA1_c07890 aglA 3.2.1.20
PGA1_c12950 acs 6.2.1.1 Acetyl-coenzymeA synthetase 0
PGA1_c13160 mtlK 1.1.1.67 mannitol 2-dehydrogenase 1.00E-166
PGA1_c13170 polS 1.1.1.14 2.00E-130
PGA1_c14000 xylA 5.3.1.5 xylose isomerase 0
PGA1_c14010 xylB 2.7.1.17 xylulose kinase 9.00E-133
PGA1_c17230 tktA 2.2.1.1 transketolase 0
PGA1_c27880 nagA 3.5.1.25 2.00E-078
PGA1_c27890 nagB 2.6.1.16 glutamine- fructose-6- phosphate transaminase (isomerizing) 4.00E-039
PGA1_c27890 nagB 3.5.99.6 3.00E-148 T
PGA1_c27910 nagK 2.7.1.59 2.00E-048 T
PGA1_c27980 pgi 5.3.1.9 glucose-6-phosphate isomerase / Phosphoglucose isomerase 0
PGA1_c28020 frk 2.7.1.4 fruktokinase 2.00E-069
Pentose phosphate pathway
PGA1_c04170 rpe 5.1.3.1 ribulose-phosphate 3-epimerase 5.00E-135
PGA1_c05780 tal 2.2.1.2 transaldolase 2.00E-146
PGA1_c10730 rpiB 5.3.1.6 ribose-5-phosphate isomerase B 6.00E-039
PGA1_c17230 tktA 2.2.1.1 transketolase 0
PGA1_c23740 rpiA 5.3.1.6 ribose-5-phosphate isomerase A 1.00E-165
Entner-Doudoroff pathway and Embden-Meyerhof Parnas pathway
PGA1_c02770 gpmI 5.4.2.12 2,3-bisphosphoglycerate-independent phyosphoglycerate mutase 0
PGA1_c06970 pykA 2.7.1.40 pyruvate kinase 1.00E-163
PGA1_c11420 eno 4.2.1.11 phosphopyruvate hydratase 0
PGA1_c15170 pgl 3.1.1.31 6-phosphogluconolactonase 2.00E-031
PGA1_c17530 pgk 2.7.2.3 phosphoglycerate kinase 0
PGA1_c27490 gap 1.2.1.12 glyceraldehyde-3-phosphate dehydrogenase 1.00E-155
PGA1_c27990 zwf2 1.1.1.49 glucose-6-phosphate-1-dehydrogenase 0
PGA1_c28000 edd 4.2.1.12 phosphogluconate dehydratase 0
PGA1_c28010 eda 4.1.3.16 4-hydroxy-2- oxoglutarate aldolase 6.00E-061 M
PGA1_c28010 eda 4.1.2.14 2-dehydro-3-deoxy- phosphogluconate aldolase 6.00E-061 M
Pyruvate dehydrogenase complex
PGA1_c17390 lpdA1 1.8.1.4 dihydrolipoyl dehydrogenase 0
PGA1_c17550 pdhA 1.2.4.1 2.00E-159
PGA1_c17560 pdhB 1.2.4.1 0
PGA1_c17570 pdhC 2.3.1.12 2.00E-144
TCA cycle
PGA1_c03550 lpd2 1.8.1.4 dihydrolipoyl dehydrogenase 0
PGA1_c03590 sucA 2.3.1.61 1.00E-170
Gene 
name
E C 
number
xylose ABC transporter, ATP-binding protein 
N-Acetylglucosamine ABC transporter, permease 
N-Acetylglucosamine ABC transporter, permease 
N-Acetylglucosamine ABC transporter, permease 
N-Acetylglucosamine ABC transporter, ATP-binding protein 
α-glucosidase
L-iditol 2-dehydrogenase / sorbitol dehydrogenase
N-acetyl-glucosamine-6-phosphate deacetylase
glucosamine-6-phosphate deaminase 
(BlastP: Ruegeria sp. TW15. Acc.-No.: WP_010439364)
N-acetylglucosamine kinase 
(BlastP: Roseobacter denitrficans Och 114. Acc.-No.: YP_682036)
pyruvate dehydrogenase (acetyl- transferring) / pyruvate 
dehydrogenase, E1 α subunit
pyruvate dehydrogenase (acetyl- transferring) / pyruvate 
dehydrogenase, E1 β subunit
dihydrolipoyllysine- residue acetyltransferase / pyruvate 
dehydrogenase, E2
2-oxoglutarate dehydrogenase, E1 / dihydrolipoyllysine- residue 
succinyltransferase 
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PGA1_c03600 sucB 1.2.4.2 2-oxoglutarate dehydrogenase, E2 0
PGA1_c03610 sucD 6.2.1.5 succinyl-CoA ligase [ADP-forming], subunit α 5.00E-160
PGA1_c03630 sucC 6.2.1.5 succinyl-CoA ligase [ADP-forming], subunit β 0
PGA1_c03650 mdh 1.1.1.37 malate dehydrogenase 0
PGA1_c03740 sdhC
PGA1_c03750 sdhD succinate dehydrogenase hydrophobic membrane 
PGA1_c03760 sdhA 1.3.5.1 succinate dehydrogenase, flavoprotein subunit 0
PGA1_c03780 sdhB 1.3.5.1 succinate dehydrogenase, iron-sulfur subunit 5.00E-169
PGA1_c13520 fumC 4.2.1.2 fumarate hydratase class II 0
PGA1_c16970 gltA1 2.3.3.1 0 S
PGA1_c18830 acnA 4.2.1.3 aconitate hydratase 0
PGA1_c28340 Icd 1.1.1.42 isocitrate dehydrogenase [NADP] 0
Gluconeogenesis
PGA1_c08640 glpx 3.1.3.11 fructose-1,6-bisphosphate class 2 1.00E-087 M
PGA1_c08640 glpx 3.1.3.37 sedoheptulose- bisphosphatase 4.00E-073 M
PGA1_c10230 glmS 2.6.1.16 glutamine- fructose-6- phosphate transaminase (isomerizing) 0
PGA1_c17250 gapB 1.2.1.59 1.00E-104 S
PGA1_c20650 tpiA 5.3.1.1 triosephosphate isomerase 9.00E-119
PGA1_c23910 fda 4.1.2.13 fructose-bisphosphate aldolase class 1 5.00E-119
Anaplerotic reactions
PGA1_c01140 pckA 4.1.1.49 phosphoenolpyruvate carboxykinase (ATP) 0
PGA1_c03650 mdh 1.1.1.37 malate dehydrogenase 0
PGA1_c03650 mdh 1.1.1.82 malate dehydrogenase (NADP+) 2.00E-077
PGA1_c09420 pyc 6.4.1.1 pyruvate carboxylase 0
PGA1_c34990 1.1.1.40 malate dehydrogenase (oxaloacetate- decarboxylating) (NADP+) 0
Ethylmalonyl-CoA pathway
PGA1_c01110 1.3.8.- 0 T
PGA1_c03390 phaB 1.1.1.36 acetoacetyl-CoA reductase 1.00E-124
PGA1_c03400 phaA 2.3.1.9 acetyl-CoA C-acetyltransferase 0
PGA1_c03710 mch 4.2.1.148 2-methylfumaryl-CoA hydratase 0
PGA1_c03870 ccr 1.3.1.86 crotonyl-CoA reductase 0
PGA1_c09900 glcB 2.3.3.9 malate synthase 0
PGA1_c21510 bhbA 5.4.99.2 methylmalonyl-CoA mutase 0
PGA1_c21540 pccA 6.4.1.3 propanonyl-CoA carboxylase, α subunit 0
PGA1_c21600 pccB 6.4.1.3 propanonyl-CoA carboxylase, β subunit 0
PGA1_c24490 mce 5.1.99.1 methylmalonyl-CoA epimerase 2.00E-052
PGA1_c30490 mcl1 4.1.3.24 0
PGA1_c36500 fadJ / paaG 1.1.1.35 enoyl-CoA hydtratase/reductase
PGA1_c36500 fadJ / paaG 4.2.1.17 enoyl-CoA hydtratase/reductase 4.00E-108
? putative 2-methylfumaryl-CoA mutase
PGA1_c13520 fumC 4.2.1.2 fumarate hydratase class II 0
PGA1_c17990 4.1.1.73 tartrate decarboxylase 1.00E-138 M
PGA1_c17990 1.1.1.93 tartrate dehydrogenase 1.00E-138 M
PGA1_c17990 1.1.1.83 3.00E-142 M
PGA1_c27490 gap 1.2.1.12 glyceraldehyde-3-phosphate dehydrogenase 1.00E-155
Gene 
name
E C 
number
succinate dehydrogenase, cytochrome b   556 subunit
citrate synthase 
(BlastP: Escherichia coli K12. Acc.-No.: P0ABH7)
glyceraldehyde-3-phosphate dehydrogenase 2 
(BlastP: Bacillus subtilis strain 168. Acc-No.: O34425)
putative 2-mehtylfumaryl-CoA dehydrogenase 
(BlastP: Rhodobacter sphaeroides 2.4.1. Acc.-No.: Q3J5V7)
β-methylmalyl-CoA lyase
C4-carboxylates
D-malate dehydrogenase (decarboxylating)
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